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Abstract 
Introduction 
Chemotherapy-induced peripheral neuropathy [CIPN] is a significant debilitating side effect resulting 
from the administration of neurotoxic chemotherapy agents. It is estimated that a third of all patients 
undergoing chemotherapy experience CIPN, with a third of those progressing to a permanent 
neuropathy. Patients experiencing moderate to severe CIPN report reduced quality of life, chronic 
discomfort and disruption of physical abilities for general life activities, which can be temporary or 
permanent. Moreover, CIPN can lead to a dose reduction or possible cessation of treatment that may 
adversely impact disease outcomes.  
Methodology 
In a single blind randomised placebo-controlled trial, newly diagnosed patients undergoing 
chemotherapy treatment with paclitaxel, oxaliplatin or vincristine were assessed for the safety and 
efficacy of an oral B group vitamin to reduce the incidence of CIPN. The primary outcome was the 
Total Neuropathy Score and secondary outcomes included B vitamin pathology, EORTC quality of 
life questionnaire, Brief Pain Inventory and Patient Neurotoxicity Questionnaire [PNQ]. 
Discussion  
A total of 71 subjects were randomised from 121 evaluable patients (B vitamin n=38; placebo n=33). 
Participants between groups were matched for gender, chemotherapy agents, age and BMI. No 
statistical significance was found for the prevention of CIPN from vitamin B supplementation through 
total TNS score (p=0.73). On individual B vitamin analysis, Vitamin B12 was found to be statistically 
significant in reducing the onset and severity of CIPN (p=0.024) while vitamin B6 was not 
statistically significant (p=0.948). Statistical significance was recorded though for sensory peripheral 
neuropathy in the PNQ (12 weeks p=0.03; 24 weeks p=0.005; 36 weeks p=0.021). The risk estimate 
for the PNQ was also statistically significant with an OR=5.78, 95% CI = [1.63-20.5].  
Conclusions  
B vitamin supplementation throughout chemotherapy administration with neurotoxic agents was not 
superior to placebo (p>0.05) for the prevention of CIPN. Patient perception of reduced sensory 
peripheral neuropathy with B vitamin supplementation over placebo was statistically significant. 
Vitamin B12 was found to assist in reducing the onset and severity of CIPN. Furthermore, patients 
with moderate to severe CIPN may have a vitamin B12 deficiency that may lead to a worse 
symptomatic presentation.  
 
Trial number:   ACTRN12611000078954 
Protocol number: UH2010000749 
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1 CHAPTER 1  
1.1 PREFACE 
This thesis presents the results of a randomised placebo-controlled clinical trial assessing the safety 
and efficacy of a B complex vitamin supplement in reducing the incidence of chemotherapy-induced 
peripheral neuropathy [CIPN]. The background chapter of this thesis explores the aetiology of CIPN, 
the chemotherapeutic agents that cause CIPN, the current assessment and diagnostic tools and B 
vitamin background. 
 
1.2 INTRODUCTION 
CIPN is a debilitating clinical condition that represents a side effect from neurotoxic anti-neoplastic 
agents. It is estimated that one third of all patients who undergo chemotherapy experience CIPN [2]. 
Patients experiencing moderate to severe CIPN report a reduced quality of life [3], chronic discomfort 
[4] and disruption of physical abilities for general life activities, which can be temporary or permanent 
[3]. 
Current medical treatment for CIPN, including amifostine, anticonvulsants and antidepressants, has 
limited efficacy and can induce multiple adverse effects. These side effects include hypotension, 
nausea and vomiting, flushing, dehydration, fatigue, dyspepsia, myalgia, somnolence and allergic 
reactions [2, 5-8]. The referred pain commonly experienced with CIPN is often resistant to standard 
analgesics [9]. 
Moreover, CIPN can lead to a dose reduction of the chemotherapy agent or possible cessation of 
treatment, which may have an adverse impact on cancer treatment and disease outcomes [2].  It is 
hypothesised that effective application of therapeutic doses of B group vitamins1 will decrease the 
onset and severity of CIPN and may provide a significant benefit to cancer patients undergoing 
chemotherapy treatment.   
Chemotherapy agents [neurotoxic class of agents] that target the peripheral nervous system inducing 
CIPN include the platinum compounds and the anti-tubulin drugs such as the taxane class, vinca 
alkaloids and epothilones [2-4, 10]. Other drugs used for cancer that can cause CIPN include 
thalidomide [3, 11] and proteasome inhibitors such as bortezomib [3, 11]. The neurotoxic side effects 
                                                 
 1 B group vitamins are a group of water soluble vitamins that include vitamin B1 (thiamine), B2 (riboflavin), 
B3 (niacin), B5 (pantothenic acid), B6 (pyridoxial), folic acid and vitamin B12 (cynacobalmin). This group can 
also include inositol, choline and biotin which have been included in this thesis. 
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of these drugs target the peripheral nervous system. The highest incidence of CIPN has been found 
to be induced from the platinum drugs: cisplatin (60%) and oxaliplatin (80%); and anti-tubulin drugs 
paclitaxel (60%) and vincristine (75%) [2-4, 12-14]. 
1.2.1 Aims and Scope of Thesis 
1.2.1.1 Research Aim 
The aim of this research is to demonstrate that a B group vitamin complex can significantly reduce 
the incidence of CIPN over placebo.  
1.2.1.2 Research Hypotheses  
To expand on the aim of this project, the following hypotheses were developed.  
a) The delivery of an oral B vitamin complex will be efficacious in reducing the onset and 
severity of chemotherapy-induced peripheral neuropathy [CIPN]. 
b) Patients with low B vitamin status prior to chemotherapy administration will be at an 
increased risk of development and increased severity of CIPN. 
1.2.1.3 Research Objectives 
To assist in achieving the aims and hypotheses of this project, three trials have been completed. 
These include:  
a) Absorption Trial: Examining if the chosen B vitamin supplement shows absorption of 
vitamin B12 in healthy volunteers. 
b) Absorption and Interaction Trial: Examining the blood B vitamin status of patients 
undergoing chemotherapy over 72 hours compared to healthy controls.  
c) Main Clinical Trial: A randomised placebo-controlled clinical trial assessing the safety 
and efficacy of a B complex vitamin in reducing the incidence of CIPN. 
1.2.1.4 Significance and Scope of Thesis 
Current evidence states that approximately a third of all patients who undergo chemotherapy 
experience CIPN and of those a third will have neuropathy permanently [2]. The incidence of 
CIPN varies depending on the neurotoxic agent and the mechanism of action of these agents are 
diverse. The mechanisms include damage to neuronal cell bodies in the dorsal root ganglion, 
axonal toxicity via transport deficits, energy failure and axonal membrane ion channel 
dysfunction [10]. Although some of the underlying mechanisms are understood, further 
understanding of the pathophysiology of CIPN will assist in the development of neuroprotective 
strategies. The current prevention and management of CIPN remains a clinical challenge for 
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medical practitioners. Research into agents that may prevent this debilitating side effect is 
clinically relevant to assist clinicians in cancer management and care.  
1.2.1.5 Thesis Structure 
The overall structure of the thesis is as follows: 
Chapter 1: Covers background knowledge on CIPN, neurotoxic agents, current treatment and 
diagnostic methods; as well as B vitamins in relation to absorption, deficiency, toxicity and 
involvement with peripheral nerves.  
Chapter 2: Reviews the current international literature relating to CIPN prevention and treatment.  
Chapter 3: Examines two new diagnostic tools for CIPN.  
Chapter 4: Describes the methodology, study design, sample selection and analysis employed for 
all three trials used for this project.  
Chapter 5: Presents the results of Trial 1: Absorption Trial. 
Chapter 6: Presents the results of Trial 2: Absorption and Interaction Trial.  
Chapter 7: Presents the results of Trial 3: Main Clinical Trial. 
Chapter 8: Presents case studies relevant to the results from the main clinical trial.  
Chapter 9: Summarises the significant findings from the thesis, the limitations of the project, 
contributions to current knowledge, further recommendations and addresses future directions. All 
publications throughout this project, including publications still to be accepted, have been 
included in the appendices of this thesis.  
 
1.3 BACKGROUND 
1.3.1 Aetiology of CIPN 
CIPN has been defined as grade 2 or higher according to the National Cancer Institute Common 
Toxicity Criteria manual (v2, 1999). Grade 2 includes symptoms such as numbness, tingling, pain or 
burning in the peripheries as well as motor function impairment that interferes with daily living 
activities. To examine the meaning of these symptoms the aetiology of the peripheral nervous system 
needs to be examined.  
The peripheral nervous system (PNS) is the area where certain anti-neoplastic drugs accumulate.  The 
PNS involves input and output neurons. The input neurons consist of sensory or afferent neurons that 
conduct nerve impulses from sensory receptors throughout the body to the central nervous system 
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(CNS). The output neurons consist of motor or efferent neurons. The motor neurons originate from 
the CNS and conduct nerve impulses from the CNS to the muscles and glands. The PNS can be further 
subdivided into the somatic nervous system, which is voluntary; and the autonomic nervous system, 
which is involuntary [15]. 
For the peripheral nervous system to be affected, a chemotherapy drug must first cross the blood-
nerve barrier and, in addition, the nervous system must be sensitive to the drug.  Patients with 
predisposing conditions such as type II diabetes mellitus (T2DM), HIV/AIDs, alcoholism or who are 
deficient in B vitamins may be more prone to the side effects of the drug on the peripheral nervous 
system; thereby increasing the risk of developing CIPN [12, 16]. Given that cancer is a multi-factorial 
family of diseases, a differential diagnosis of peripheral neuropathy [PN] experienced by cancer 
patients is necessary to ascertain whether the PN is from the chemotherapy agent. [Table 1-1]  
 
Table 1-1:  The Differential Diagnosis of PN in Patients with Cancer [12]  
Cause Neurotoxic Affect 
Vitamin B12 deficiency Large nerve fibre injury 
Cachexia Diffuse weakness 
Chemotherapy Small and/or large nerve fibre injury, fast to occur, 
cumulative 
Charcot-Marie-Tooth disease Large nerve fibre injury 
T2DM Small nerve fibre injury, slow to occur 
Atherosclerotic ischemic disease Sensory neuropathy in lower extremities 
Paraneoplastic syndrome Distal sensory or sensorimotor deficit 
Thyroid dysfunction Proximal and distal weakness, carpal tunnel syndrome 
Alcoholic neuropathy Numbness, paraesthesias 
 
Peripheral nerve fibres are composed of small or large fibres. Small nerve fibres (SNF) are 
unmyelinated, comprised primarily of microtubules and have slow acting nerve impulses. SNF sense 
both pain and temperature. Large nerve fibres (LNF) are myelinated, composed mainly of 
neurofilaments that act as a framework for the axon and have fast acting nerve impulse.  LNF sense 
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position, vibration and motor control [12]. Both of these fibres are targeted by chemotherapy drugs, 
which may explain why patients experience a variety of symptoms. 
The symptoms of SNF CIPN include sensation of tingling, prickling, burning, decreased pin-prick, 
temperature and light-touch sensations. The symptoms of LNF CIPN include decreased vibratory 
sensation, proprioception, deep tendon reflexes and muscle strength [16]. 
The dorsal root ganglion [DRG] nerves, may also be affected by chemotherapy agents [3, 4, 12]. The 
DRG connect to either the dorsal column (large fibre) or spinothalamic tract (small fibre) in the spinal 
cord that acts to relay information to the sensory area of the brain [12]. 
Although each class of neurotoxic chemotherapy agents has a different effect on the nervous system, 
all induce a glove-stocking distribution of CIPN. This means that the point most distal from the trunk 
of the body is affected first e.g. fingers and toes, and then the sensations/pain progresses proximally 
towards the trunk [12]. Each agent has been found to specifically affect one type of fibre more than 
another. For example, cisplatin damages large fibres whereas paclitaxel and vincristine damages 
small fibres [12]. Figure 1-1 shows the locations on a nerve fibre where the neurotoxic agents 
accumulate and cause CIPN [10]. 
CIPN can be a temporary side effect from which a patient can take up to two years to experience full 
recovery.  However, in approximately one third of cases, it can be a permanent consequence of 
chemotherapy drug administration. Symptoms may occur within hours, days or weeks after the 
introduction of the chemotherapy agent(s) that induce CIPN, with cumulative doses increasing the 
severity and length of time the patient experiences the side effect [12]. Cisplatin differs to other 
neurotoxic agents as it can induce a delayed CIPN several months after the drug has been 
administered, rather than a more immediate response [4].  
The chemotherapy agents with the highest incidence rate of CIPN are oxaliplatin, paclitaxel and 
vincristine; consequently, these three agents have been selected for this pilot clinical trial [2-4, 12-
14]. These agents were chosen due to the beneficial in-vitro studies conducted on vitamin B6 for 
oxaliplatin [17, 18] and the high incidence of CIPN over a short period of exposure from paclitaxel 
and vincristine [2].  
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Figure 1-1: Diagrammatic Representation of a Nerve Cell with Sites of Chemotherapy-
Induced Neurotoxicity Highlighting where the Chemotherapy Drugs exhibit their Affect. 
Information and Figures Extracted from references [10, 19, 20]. 
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1.4 MECHANISM OF ACTION OF NEUROTOXIC CHEMOTHERAPY AGENTS 
Neurotoxic chemotherapy agents can be divided into four main categories: alkylating and anti-tubulin 
agents, thalidomide and proteasome inhibitors as shown in Table 1-2. A common feature of these 
drugs is that they are unable to cross the blood-brain barrier thereby protecting the CNS; however, 
the PNS has no protection barrier making it susceptible to neurotoxicity [3]. 
Table 1-2:   Neurotoxic Chemotherapy Agents and Incidence of CIPN 
 
Chemotherapy 
Category 
Chemotherapy Drug Incidence of CIPN 
Alkylating Agents 
 
Platinum 
compounds 
Cisplatin (Platinol®) 59-92%  [12-14] 
Carboplatin (Paraplatin®) 25% [4] 
Oxaliplatin (Eloxatin®) Acute:    80-90 % 
Chronic: 15-25%  
[3, 4, 12] 
Anti-tubulin Agents 
 
Taxane Class: 
Paclitaxel (Taxol®)  60% [2, 12, 21] 
Docetaxel (Taxotere®)  50% [2, 12] 
Abraxane™ 71% [22] 
Vinca 
Alkaloid 
Class: 
Vincristine (Onkovin®)  75% [2, 4, 23] 
Vinorelbine (Navelbine®)  25% [2, 4] 
Vindesine  
Vinorelbine 
 
Epothilones: 
Ixabepilone 60-71% [3, 24] 
Patupilone 
MBS-310705 
Epothilone D (KOS-862) 
Sagopilone (ZK-EPO) [25] 
Other Categories 
Proteasome 
inhibitors 
Bortezomib 35-50% [10, 11] 
Thalidomide Thalidomide 50-83% [11] 
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The following chemotherapy agents: the taxane class, oxaliplatin and vincristine were selected for 
the pilot trial conducted for this doctorate. This is due to the high incidence rate of CIPN experienced 
by patients who are exposed to these agents in addition to the fact that each agent has a different 
mechanism of action.  Three different chemotherapy agents were chosen to ascertain if B vitamins 
were more efficacious taken in conjunction with a particular type of chemotherapy agent. If a positive 
result was recorded for a particular chemotherapy agent, further phase II trials would be considered 
for that chemotherapy agent. The molecular weight of the chemotherapy agents and the B vitamins 
can be seen in Appendix 1.  
1.4.1 Platinum Compounds 
Platinum compounds are alkylating agents used for breast, colon, lung, testicular, bladder and ovarian 
cancer due to their wide range of activity.  These compounds include cisplatin, carboplatin and 
oxaliplatin [2]. The neurotoxicity from high doses of these drugs is reported to result from 
mechanisms that infiltrate the intra-cytoplasmic protein binding and ion channel interactions and 
neuronal apoptosis of the dorsal root ganglion [2, 3, 26]. Oxaliplatin has been chosen from these 
chemotherapy compounds due to its high incidence of CIPN [92%].  Furthermore, it was the 
chemotherapy agent used by Garg, et al [27] in vitro to test vitamin B6 and CIPN.  A recent study by 
Coriat, et al [18] tested a derivative of vitamin B6 mangafodipir, on CIPN from oxaliplatin in both 
mice and twenty-three cancer patients with grade 2 CIPN. The results found that mangafodipir may 
prevent and/or relieve oxaliplatin-IPN.  Results from both of these studies concluded that conducting 
clinical trials with vitamin B6 and oxaliplatin would be beneficial. 
1.4.1.1  Oxaliplatin 
The platinum compound, oxaliplatin has been found to have marked efficacy in the treatment of large 
bowel cancer when used in combination with 5-fluorouracil and leucovorin, also known as folinic 
acid (i.e. FOLFOX) [3]. The mechanism of action of oxaliplatin has been associated with several 
inter- and intra-strand cross links in DNA, especially two adjacent guanine or two adjacent guanine-
adenine bases [4]. Oxaliplatin activates metabolites and reacts with small proteins with sulfhydryl 
groups such as glutathione, cysteine and methionine. In addition, it also binds to larger molecular 
weight proteins such as albumin and gamma globulins [3].  
The neurotoxicity from oxaliplatin varies compared to the other platinum compounds. In addition to 
the cumulative dose neurotoxicity, oxaliplatin induces an acute neurotoxicity in approximately 80-
90% of patients.  This acute neurotoxicity can occur 30-60 minutes after administration [12] and 
includes dysaethesia and paraesthesia, predominately in the fingers, toes, pharyngolaryngeal tract, 
perioral and oral regions; furthermore, it is generally induced or aggravated by cold exposure [3, 4].  
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Most of these acute side effects resolve within a few hours or days. Some patients may also experience 
muscle cramps or spasms: with both the cramps and the acute neurotoxicity resulting from the drug-
related inhibition of sodium channels [3].  
The chronic neurotoxicity from oxaliplatin occurs in around 10-15% of patients after cumulative 
doses and normally resolves several months after oxaliplatin cessation. The symptoms of this CIPN 
include non-cold related dysesthesia; paraesthesias; superficial and deep sensory loss; and in some 
cases, sensory ataxia and functional impairment [3, 4].  Sural nerve biopsies in patients with this 
sensory neuropathy found evidence of axonal degeneration without any evidence of primary 
demyelination [3, 4]. [Figure 1-1] 
1.4.2 Taxane Class 
The taxane class consists of three drugs, paclitaxel, docetaxel and abraxane. All three chemotherapy 
agents are chemically similar [2]. The difference is that docetaxel is a semi-derived form of paclitaxel 
[4], whereas abraxane is paclitaxel biochemically attached to albumin as a base before administration 
[22]. The clinical features of the CIPN induced by paclitaxel, abraxane and docetaxel are qualitatively 
identical and the mechanism of action for all three agents is the same [2, 4]. Thus, the features of 
paclitaxel discussed below also refer to docetaxel and abraxane. 
The mechanism of action for paclitaxel is via suppression of microtubules inducing mitotic arrest in 
dividing cells. A similar effect on axonal microtubules can interfere with axonal transport, which 
results in neuropathy mostly affecting small sensory fibres. With higher doses, motor function can 
also be affected [28]. 
Paclitaxel preferentially localises to the dorsal root ganglia and induces neuronal damage via necrosis 
as a result of inhibition of microtubule axonal transport. Demyelination has also been found as a result 
of paclitaxel administration [2]. Axonal damage has been hypothesised to be the main pathological 
change that occurs [3]. 
The neurotoxicity induced by paclitaxel is typically sensory, with deep tendon reflex loss. This causes 
a distal, symmetrical hypaesthesia in the upper and lower extremities with a length dependent 
distribution.  Motor signs and symptoms may occur during treatment; however, these do not seem to 
be as clinically relevant as the sensory signs and symptoms experienced. Neuropathic pain very rarely 
occurs, although may still eventuate in certain individuals, with myalgia a frequent symptom in most 
patients [3]. The incidence of CIPN from paclitaxel is further increased with concurrent use of other 
neurotoxic agents such as carboplatin [2]. 
The CIPN induced by paclitaxel is mostly reversible, nevertheless in a minority of cases the 
neurotoxicity is persistent leading to permanent peripheral neuropathy [3]. [Figure 1-1] 
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1.4.3 Vinca Alkaloids 
The vinca alkaloid group are anti-tubulin agents that bind to microtubules inducing cell cycle arrest. 
However, their action is opposite to that of the taxanes. Vinca alkaloids disassemble normal 
microtubular structures as they inhibit axonal microtubule-mediated transport, resulting in axonal 
degeneration and loss of epidermal innervations [2, 4]. 
The CIPN symptoms induced by vincristine are mainly sensory and can begin two weeks after the 
first dose with cumulative doses increasing the risk. CIPN is the main dose-limiting factor that affects 
vincristine administration with symptoms resolving slowly after cessation of the drug (approximately 
one third of cases have reported a temporary worsening of effects after cessation) and in some cases, 
leaving permanent neuropathy [2-4]. 
Vinca alkaloids are similar to the other neurotoxic agents in that sensory signs and symptoms are 
predominately found in the majority of patients. These symptoms are caused by inhibition of 
anterograde and retrograde axonal transport by microtubule damage leading to degeneration and 
atrophy of the peripheral nerve fibres. Both small and large fibres are affected, however a stronger 
effect on small fibres has been reported [12].  
Mostly distal symmetrical hypaesthesia and dysesthesia involving all sensory modalities and both 
deep and superficial neuropathy have been reported with pain also noted [4]. Fifty-seven per cent of 
patients receiving vincristine reported paraesthesias in the hands or feet and 22-34% reported motor 
weakness or foot drop [23]. 
Myalgia or muscle cramps may occur in addition to reduced strength in the distal muscles, in those 
patients most severely affected by CIPN [3, 12]. Occasionally, severe impairment of motor function 
leading to tetraplegia has been reported in patients with pre-existing peripheral neuropathy [3]. There 
have also been rare reports of isolated peripheral nerve functional impairment associated with 
vincristine administration. [Figure 1-1] 
A recent study assessed nutrient deficiencies in children, with or without CIPN from vincristine 
administration, during acute lymphoblastic leukaemia (ALL) treatment [29]. Jain, et al [29] focused 
on vitamin E, B12 and folate. Of the 80 children tested electrophysiologically within the study, 
neuropathy was seen in 27 (33.75%). None of the children were found to be deficient in vitamin E; 
Moreover, the prevalence of a folate (p=0.48) and vitamin B12 (p=0.21) deficiency was not 
statistically significant. Although not statistically significant, a number of children were found 
deficient in folate and/or vitamin B12. However, no mention was provided regarding vitamin 
replacement and their current CIPN status. This would have been a clinically relevant finding if the 
CIPN status decreased after B12 and folate supplementation.  
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Further case studies on children with leukaemia treatment and CIPN have been conducted looking at 
vitamin B6 [30, 31]. Both studies used pyridoxine and pyridostigmine for treatment of vincristine-
IPN with success as all children had complete recovery between 1-2 weeks after commencing the 
intervention.  
 
1.5 CIPN CURRENT TREATMENT OPTIONS 
The prevention and management of CIPN is of major clinical importance to patients diagnosed with 
cancer and are undergoing therapy with neurotoxic chemotherapy agents. Several different substances 
for pharmacological neuro-protection have been tested e.g. Amifostine, but so far neither prophylactic 
strategies nor symptomatic treatments have proven useful [1, 4].  With the treatment of CIPN largely 
remaining ineffective, many patients undergo dose reduction of their chemotherapy treatment or cease 
treatment altogether putting them at risk for disease progression and treatment inefficacy [1].  
Figure 1-2 shows a flow chart for clinical evaluation of suspected CIPN. Clinicians supervising 
patients undergoing chemotherapy treatment with neurotoxic agents are required to monitor CIPN 
development throughout treatment. Guidelines for evaluation of CIPN are necessary for 
standardisation.  
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Symptoms (numbness, paraesthesias) or signs of 
peripheral neuropathy on examination by oncologist 
Path A: Worrisome features 
such as hyper-reflexia, bowel or 
bladder disturbances, sensory 
level on examination. 
Path B: Symptoms, history 
and examination all consistent 
with typical CIPN 
Path C: Symptoms and 
examination unclear 
Emergency neurologic 
evaluation 
Laboratory evaluation to 
include other potential 
contributing factors 
Neurology Evaluation 
Nerve Conduction Studies 
(NCS) / Electromyography 
(EMG) 
Adjust dose or drug using 
chemotherapy-specific 
guidelines NCS/EMG consistent with 
CIPN – return to Path B 
 
Other neurologic diagnosis – 
evaluate as appropriate 
Does patient require symptomatic treatment? 
1. If symptoms are mainly numbness, then defer pharmacologic 
treatment 
2. If symptoms of pain or discomfort, then initiate treatment with 
symptomatic agents. 
Remember to reassess frequently and discontinue medication 
when no longer needed. 
Figure 1-2: Clinical Evaluation of 
CIPN. [1] (Kaley TJ, DeAngelas 
LM. 2009) 
  
1-36 
 
1.6 CIPN DIAGNOSTIC TESTS AND ASSESSMENT OF CIPN 
The grading or assessment of CIPN is critical for accurate clinical and instrumental monitoring. There 
is no ‘gold standard’ measurement tool that is used in either clinical trials or medical monitoring [32]. 
The lack of standardisation and reporting mechanisms has resulted in contention of CIPN data leading 
to CIPN being relatively under-diagnosed [33]. 
Clinicians using common toxicity scales such as the National Cancer Institute – Common 
Toxicity Criteria (NCI-CTC), most commonly grade CIPN. However, these scales rarely provide 
the detailed information on clinical and pathological aspects of peripheral neuropathy that clinicians 
require for clinical trials. Other measurement tools such as the Total Neuropathy Score [TNS] involve 
more detailed information pertaining to motor, sensory and autonomic signs and symptoms, 
determination of vibration perception thresholds and electrophysiological examination [34, 35]. 
Of the current measurement tools available, it is recommended that a variety of standardised tools be 
used; including a peripheral neuropathy scale, quality of life questionnaire, pain scale and patient’s 
perspective questionnaire. The measurement tools recommended from the scientific literature 
include: TNS, EORTC quality of life questionnaire, a simple pain assessment and the Patients 
Neurotoxicity Questionnaire [34-36].  [Appendices 2, 3, 4 and 5.]  
1.7 STRENGTHS AND WEAKNESSES CIPN DIAGNOSTIC AND ASSESSMENT TOOLS 
 
As discussed, CIPN is generally assessed using the NCI-CTC scales however, it is known that 
significant inter-observer disagreements exist using these scales [34]. Table 1-3 outlines the available 
tools used to assess or measure CIPN, identifying their strengths, weaknesses, validation and 
psychometric properties. From the available literature, it is eveident the current existing scales are 
still limited when used individually for evaluating CIPN. The TNS and the FACT/GOG-Tnx have 
been found to be reliable, valid and relatively easy to use. However, there is limited information 
regarding physical limitations, symptom distress and effect on quality of life. Assessment for CIPN 
requires both objective and subjective data collected using both qualitative and quantitative methods. 
Moreover, it has been found that health-care professionals tend to underestimate and underreport the 
severity and frequency of CIPN. Hence, gaining information both from the patient and using a 
quantification tool conducted by a professional healthcare clinician is necessary to gather adequate 
information pertaining to CIPN detection and treatment. Therefore, further research into better 
instruments to assess and measure CIPN for clinical management needs to occur. The strengths and 
weaknesses of each assessment tool have been outlined in table 1-3. 
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Table 1-3    Assessment Tools for CIPN [34] 
Assessment Tool Strengths Weaknesses 
NCI-CTC 
- Quick to use 
- Easy to administer 
- Good for screening process to 
assess those patients requiring 
further testing 
- Subjective as it relies on observer’s 
opinion, therefore inter-observer 
disagreement occurs 
- No quantitative assessment 
World Health 
Organization 
(WHO) scale 
- Records patients baseline data 
and treatment-related toxicity 
- Easy to administer 
- Has never gained widespread use 
- No assignment of any clinical 
significance to each toxicity grade 
- Subjective rather than quantitative 
ECOG scales 
- Quick to use 
- Easy to administer 
- Subjective as it relies on observer’s 
opinion, therefore inter-observer 
disagreement occurs 
- No quantitative assessment 
Ajani scale 
- Included sensory and motor 
symptoms 
- Increased objective information 
- Introduced morbidity range 
- Subjective as it relies on observer’s 
opinion, therefore inter-observer 
disagreement occurs 
- No quantitative assessment 
FACT/GOG-Ntx2 
- Incorporates QoL questions 
- Gathers patient perception 
- Easy to administer 
- Focussed mainly on sensory 
function 
- Patient or self-reported 
- No quantitative assessment 
- Limited mixed functional, 
impairment and symptom items 
FACT-Taxane 
- Demonstrates internal 
consistency reliability  
- Gathers patient perception 
- Patient or self-reported 
- No quantitative assessment 
- Limited mixed functional, 
impairment and symptom items 
Peripheral 
Neuropathy Scale 
(PNS) 
- Gathers patient perception - Patient or self-reported 
- No quantitative assessment 
Oxaliplatin-
associated 
neuropathy 
questionnaires 
- Gathers patient perception - Patient or self-reported 
- No quantitative assessment 
- Interpretation of results difficult due 
to descriptive discrimination 
between acute and chronic toxicities 
SCIN3 
- Quick to use 
- Easy to administer 
- Single items summed up 
between a score of 0-6 
- Self-reported 
- Small scale divides into high (≥4) or 
low (≤3) 
- Limited to the occurrence of pain 
and tingling 
 
 
                                                 
2 Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group (GOG) – neurotoxicity (FACT/GOG-Ntx) 
3 SCIN - Scale for Chemotherapy-Induced Long Term Neurotoxicity 
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Assessment Tool Strengths Weaknesses 
Patient 
Neurotoxicity 
Questionnaire 
(PNQ) 
- Quick to use 
- Easy to administer 
- Gives patient perspective of 
CIPN 
- Self-reported 
- Small scale 
- Limited diagnostic tool 
EORTC QLQ-
CIPN204 
- Reliable, reproducible and 
consistent results on QoL 
- Easy to administer 
- Gives patient perspective 
- Self-reported 
 
Total Neuropathy 
Score (TNS) 
- Most comprehensive composite 
scale 
- Quantitative analysis by a 
neurologist 
- Indicates a higher sensitivity to 
CIPN 
- More accurate monitoring of 
detection and measurement of 
change 
- Incorporates nerve conduction 
studies 
- Incorporates both subjective 
and objective examinations 
- Inadequately assesses pain 
- Inadequately assesses severity of 
CIPN 
- Limited QoL data 
- Requires a qualified neurologist to 
conduct the assessment 
[37-39] 
 
Griffith KA et al., (2010) conducted a systematic review on psychometric properties of measures for 
CIPN.  [39]      Table 1-4 shows an adapted table of the results listed in the review indicating quality, 
grading and psychometric tests. Griffith KA et al., (2010) analysed the available literature using a 
tailored quality tool and individual assessments of other important aspects of measure for integrity, 
such as responsiveness.  The authors stated that both approaches were necessary to be able to 
differentiate measures scored in the higher range with the modified quality of diagnostic accuracy 
studies tool (QUADAS) [39]. 
The final outcomes from the evaluation of psychometric properties for measuring CIPN concluded 
that there were two well-tested, valid measures which scored moderately high that would be 
potentially useful in clinical trials and patient care. These were the FACT/GOG-Ntx and the TNS 
clinical versions. The FACT/GOG-Ntx was described as being a carefully developed subjective 
measure of CIPN-related quality of life measure and was considered important considering the high 
prevalence of this side effect. However, clinical measurement of CIPN is considered just as important. 
                                                 
4 European Organisation of Research and Treatment of Cancer (EORTC) quality of life (QLQ)- chemotherapy-induced 
peripheral neuropathy (CIPN)20 
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The authors of the systematic review [39] found the TNS clinical versions incorporated both objective 
and subjective times and are likely to represent a more sensitive measure of CIPN. For best results, it 
concluded that incorporating both the FACT/GOG-Ntx and a TNS clinical version would offer the 
most promising measure of CIPN.  
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Table 1-4 Psychometric Measures for CIPN [39] 
Study Quality 
Score 
Measure(s) 
evaluated 
Reliability 
/Type 
Validity / 
Type 
Responsiveness Results 
Forsythe et al. 
(1997) [40] 
4 QST - +/1 - Found no correlation between cumulative paclitaxel 
dose and ES or QST changes in both upper and lower 
limbs. 
Median cumulative paclitaxel dose and SS correlated 
(P<0.01) 
Postma et al. 
(1998) [41] 
4 WHO 
ECOG 
NCI-CTC 
Ajani 
+/2 - +/1 Inter-observer agreement ranged from 81.1% to 94% 
for dichotomised grade 0-2 vs 3 on all scales 
Inter-observer agreement using ICC ranged from 0.37 
(Ajani) to 0.75 (ECOG) 
Agreement on grade 3 ranged from 0% (WHO, Ajani) 
to 42% (ECOG, CTC) 
Cavaletti et al. 
(2003) [42] 
6 TNS 
TNSr 
- +/1 - TNS score had a high correlation with NCI-CTC 2.0, 
Ajani and ECOG scores. TNS more sensitive in severe 
cases of CIPN.  
Calhourn et al. 
(2003) [43] 
5 FACT/GOG-
Ntx 
+/1 +/1 +/2 Significant correlation post-chemo and 3 months’ post 
between FA/GOG-Ntx and reflexes and strength. 
P<0.05 for all. Cronbach’s α = 0.84- 0.90 
Cella et al. (2003) 
[44] 
3 FACT/Taxane +/1 +/1 +/1 Cronbach’s α = 0.82-0.86 depending on treatment time 
point. Mean score changed from baseline to week 12 of 
treatment was 7.0 (P<0.001) 
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Study Quality 
Score 
Measure(s) 
evaluated 
Reliability 
/Type 
Validity / 
Type 
Responsiveness Results 
Greimel et al. 
(2003) [45] 
3 QLQ-OV28 +/1 and 3 +1/ and 4 +/2 Cronbach’s α = 0.83. Peripheral neuropathy responsive 
from baseline to treatment (P<0.03).  
Test-retest reliability for chemotherapy group ICC = 
0.88  
Almadrones et al. 
(2004) [46] 
5 PNS +/1 +1 and 2 +/2 Cronbach’s α = 0.91. Clinical sensitivity from T1 to T2 
(P<0.05). The correlation between function and ICPN 
was P<0.05 
Kopec et al. (2006) 
[47] 
6 FACT/GOG-
Ntx 
+/1 +/1 +/1 Cronbach’s α = 0.85. Factor structure indicated uni-
dimensionality. Longitudinal score changes 
(P<0.0001). Correlated with NCI-Sanofi criteria 
Oldenburg et al. 
(2006) [48] 
7 SCIN +/1 and 5 +/5 - 
Cronbach’s α = 0.72. Factor structure indicated three 
dimensions. Sensorsymptom items discriminated 
between patients with cisplatin and those receiving 
alternate treatments (P≤ 0.02) 
Cavaletti et al. 
(2006) [49] 
6 TNS 
TNSr 
+/2 +/1 - Moderate to high correlation between TNSr/TNSc and 
NCI-CTC 2.1, ECOG motor and sensory items (P 
<0.0001 for all) 
Wampler et al. 
(2006) [50] 
5 TNS 
mTNS 
- +1 and 3 - TNS and mTNS correlated r = 0.99 (P<0.001). mTNS 
discriminated between groups, treatment vs control 
Huang et al. 
(2007) [51] 
5 FACT/GOG-
Ntx 
+/1 +/1 +/2 Cronbach’s α ≥ 0.80 prior to cycles 1-7. Sensory items 
attributed to 80% of treatment differences and 63% of 
longitudinal changes in subscale score 
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Study Quality 
Score 
Measure(s) 
evaluated 
Reliability 
/Type 
Validity / 
Type 
Responsiveness Results 
Cavaletti et al. 
(2007) [36] 
5 TNS 
TNSc 
+/1 +/1 +/2 TNS and TNSs correlated with NCI-CTC (P<0.001). 
Study 1 r =0.75, Study 2 r = 0.88 
Shimozuma et al. 
(2009) [52] 
4 PNQ - +/1 +/2 PNQ both sensory and motor scores correlated with 
FACT-GOG-ntx (r = 0.66 and 0.51 respectively). PNQ 
socres increased significantly with subsequent 
chemotherapy (P<0.0001) 
Smith et al. (2010) 
[53] 
5/5 TNSr/NPS +1 and 2 +/1 - Cronbach’s α = 0.56 for TNSr and 0.96 for NPS. TNSr 
items eliminated the following factor analysis i.e. pin 
sensibility; strength and reflexes due to low inter-item 
correlations 
NB: For reliability, validity and responsiveness: +, study tested this attribute; -, attribute not tested. For reliability type reported: 1 internal consistency; 2 inter-
observer; 3 intra-observer; 4 test-retest; 5 split half. For validity type reported: 1 construct; 2 content; 3 discriminant; and for responsiveness: 1 effect size; 2 other.  
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1.8 DIAGNOSTIC TOOLS SELECTED FOR THIS THESIS 
 
The measurement tools selected for this clinical trial were based on the literature suggesting a variety 
of measurement tools are required for accurate diagnosis, measurement and monitoring of CIPN 
development.  It is recommended that the tools selected should include a peripheral neuropathy scale, 
quality of life questionnaire, pain scale and patient’s perspective questionnaire. Hence, the TNS, 
EORTC Quality of Life Questionnaire, a simple pain assessment from MD Anderson used for cancer 
patients and the Patient Neurotoxicity Questionnaire were selected [34-36].   
CIPN has been defined as grade 2 or higher according to the National Cancer Institute Common 
Toxicity Criteria manual (v2, 1999). Therefore, for this thesis as well as the clinical trial, a diagnosis 
of CIPN must be conducted by professional medical personnel (i.e. Neurologist) who uses a validated 
measurement tool(s) that can quantify peripheral nerve damage due to a chemotherapy agent 
administration that causes numbness, pain, or tingling, which interferes with the physical abilities of 
the patient.  The major limiting issue of be able to diagnosis CIPN is that there is no defined 
standardisation approach to the diagnosis of CIPN. Hence, further quantification and standardisation 
of diagnosis needs to be confirmed. One group, CI-PERINOMS, are attempting to standardise the 
diagnosis of CIPN; however, further efforts are still required [54].  
 
1.9 B VITAMINS 
B vitamins are water-soluble vitamins that are required for a variety of functions within the human 
body, such as energy production from food and formation of red blood cells. Assessing the 
biochemistry and absorption of B vitamins is important when considering supplementation in 
compromised patients. The National Health and Medical Research Council’s [NHMRC] [55] daily 
recommended doses and the suggested recommended upper dose are detailed in Appendix 6.   
Currently, the B group vitamins encompass thiamine (vitamin B1), riboflavin (vitamin B2), niacin 
(vitamin B3), pantothenic acid (vitamin B5), pyridoxal (vitamin B6), folic acid and cobalamin 
(vitamin B12) and biotin [56]. Other vitamins that are similar and were traditionally included in the 
B vitamin group include choline and inositol [39]. Both choline and inositol can be produced by the 
human body but have been included the in the selected B group supplement due to traditional 
classification and their functionality [58-60]. 
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1.9.1 Mechanism of Action of B vitamins 
The vitamin B complex [vitamins B1, 2, 3, 5, 6, 12, folate, choline and biotin] functions as coenzymes 
in several intermediary metabolic pathways for energy generation, blood cell formation and energy 
metabolism.  Deficiencies in one or more of these B group vitamins may promote nerve dysfunction 
and nerve damage that can lead to peripheral neuropathy [61].  
Vu, et al [62] found that certain chemotherapeutic agents induced a temporary deficiency in vitamin 
B12 through evaluations of holotranscobalamin II levels (Holo TC) [62]. It is possible that 
chemotherapy agents induce a B vitamin deficiency or temporarily lowers the B vitamin status. This 
may be a major component of the development of CIPN in patients undergoing treatment with 
neurotoxic chemotherapy agents.  
Holo TC or active B12 test is an immunoassay that can be used for the detection of vitamin B12 
deficiency instead of or in conjunction with total serum vitamin B12. Vitamin B12 in blood is bound 
to two proteins specifically in serum, transcobalamin (TC) and haptocorrin (HC). The majority of 
circulating vitamin B12 is bound to HC (70-90%); however, it is considered to be biologically 
unavailable to most cells. The remaining 10-30% of vitamin B12 is bound to holotranscobalamin 
(holo TC), which delivers the vitamin into metabolising cells from its site of absorption [71, 72]. The 
measurement of holo TC has been found to be more diagnostically accurate for detecting early 
vitamin B12 deficiency compared to total serum vitamin B12, which measures both HC and TC levels 
[63]. 
It is hypothesised that patients who are low or deficient in B vitamins would be more susceptible to 
developing CIPN and that treatment with B vitamins will aid in reducing the onset and severity of 
CIPN as well as promoting recovery.  
 
1.9.2 Use of B vitamins in Cancer 
Vitamin supplementation has been controversial for many years with differing views on its usefulness 
in both daily diet and for medical treatment. Currently, it is estimated that over 47% of males and 
59% of females use dietary or vitamin supplementation for health benefits [64]. For decades now, 
numerous studies have reported that supplements do not have any health benefits or, alternatively, 
that they may trigger adverse health effects [64]. Nevertheless, many studies have also demonstrated 
the benefits of vitamin supplementation for certain conditions, for example using pre-natal folate 
supplementation to significantly decrease the incidence of foetal neural tube defects [65].  It is these 
equivocal and conflicting findings, regarding the administration of vitamin and dietary supplements 
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on health outcomes, that confuse consumers and clinicians alike. Vitamin supplementation in cancer 
is no different to any other health condition.  
Conflicting evidence has been found for certain B vitamins in cancer research [66-68]. Moreover, the 
role of vitamin supplementation in those diagnosed with cancer is still unclear. The two main B 
vitamins researched for cancer are folic acid and vitamin B6 [69, 70]. The use of a B complex 
supplement in cancer has been limited in human trials, although epidemiologic studies suggest cancer 
patients are regularly administering these supplements [71].  Both vitamin B6 and folate have had 
numerous studies conducted in vitro and in animal models with less studies conducted on humans 
[69]. There have also been safety issues that have been brought to the forefront concerning 
supplementation or fortification [70]. 
Vitamin B6 investigations began around 1950 with researchers looking at the influence of vitamin 
B6 on oncogenesis and tumour progression [69]. The majority of these initial studies included in vitro 
and animal studies on immune-deficient rodents. The general consensus was that vitamin B6 exerted 
anti-neoplastic activity. In 2012, vitamin B6 was reported to exhibit a synergistic effect with certain 
chemotherapeutic drugs [72]. Small participant number clinical studies were then conducted and 
subsequently expanded.  
The end-result found that cancer patients often manifest a decreased level of circulating P5P, or 
vitamin B6 vitamers, compared to age-matched healthy individuals. In addition, researchers also 
found that elevated circulating amounts of B6 vitamers in addition to high consumption of vitamin 
B6 correlated with a reduced incidence of several cancers. Furthermore, a high intra-tumoral 
expression level of pyridoxal kinase (PDXK – the enzyme that converts all forms of vitamin B6 to 
PLP) was reported to possibly improve disease outcome among lung cancer patients (NSCLC) [69].  
The molecular and cellular mechanism of action underlying these observations still needs to be 
elucidated. There have been a number of well-established relationships identified between vitamin 
B6 and cancer; these include that a proficient metabolism of vitamin B6 is required to sustain the 
anabolic requirements of highly proliferating cells, such as tumour cells and the immune system [72, 
74]. This assists in understanding why cancer patients can potentially suffer from a vitamin B6 
deficiency and, furthermore, that cancer-associated immunosuppression may partially be derived 
from a vitamin B6 deficiency [69].  
Vitamin B6 has been found to impinge on one-carbon metabolism and this may have an 
oncosuppressive activity by promoting DNA repair and genomic stability [75-77]. The metabolism 
of vitamin B6 has also been implicated in the adaptive response to a number of adverse conditions. 
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For example, multiple settings that malignant cells normally experience during tumour progression 
including nutrient deprivation and hypoxia [71].   
Therefore, vitamin B6 use has been clinically related to cancer on a number of levels. From the studies 
discussed, it would be adventitious for people with cancer to take a low dose supplement of vitamin 
B6, approximately 40 mg daily. Interactions with chemotherapeutic agents still require further 
investigation with studies showing beneficial effects when administered in conjunction with cisplatin 
[72].  However, considering that B6 has affected dose response when given in high doses, further 
studies assessing dose still need to be completed [78].  
Folic acid is the other B vitamin that has been extensively studied in relation to cancer [70]. The 
research on folate is more controversial compared to vitamin B6. A meta-analysis by Vollset, et al. 
[70] used individual participant data in a time-to-event analysis from large trials and found that there 
was no statistically significant excess risk from folate supplementation for any cancer. Vollset, et al. 
[70] state that any excess risk from folate supplementation found in prostate cancer patients was most 
likely a spurious exaggeration.   
A main concern with folate supplementation and fortification is the increased risk of colorectal cancer 
[79]. In geographical areas such as the UK, food fortification with folate has not occurred due to the 
perceived increased risk of colorectal cancer. This increased risk of malignancy stems from clinical 
data indicating an increased risk of colorectal cancer incidence in the USA and Canada from 1996-
98 when fortification of folate was introduced in those countries.  It was estimated that there was 
between four to six additional cases of colorectal cancer, per 100,000 of the population, post 
fortification with folate; moreover, that this fortification could have resulted in an acceleration of 
progression from adenoma to carcinoma [79]. However, a more recent prospective cohort study found 
that the level of folate fortification in the USA was not detrimental and did not increase the risk of 
colorectal cancer [80]. 
Overall, the human evidence regarding folic acid and the risk of cancer has not been substantiated. 
The meta-analysis by Vollset, et al. [70] concluded that the aggregate of trials provided no statistically 
significant evidence of short-term effects of folic acid supplementation on overall cancer incidence 
or on the increased risk for any type of cancer. Hence, it is currently suggested that folic acid 
supplementation and fortification is safe and does not prevent or increase the risk of any particular 
type of cancer.  
Recent research supports the use in low doses of B vitamin supplementation for patients diagnosed 
with cancer. Researchers suggest that dietary intake is a better form of consumption compared to 
supplementation.  
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1.9.3 B Vitamins Information and Research in Peripheral Neuropathy 
1.9.3.1 Thiamine (Vitamin B1) 
Thiamine, commonly designated as vitamin B1, was one of the first vitamins discovered and was 
identified as the dietary factor responsible for the development of beriberi. It is most commonly found 
in raw foods such as cereals, green vegetables, nuts, egg yolk and pork meat. Certain foods (e.g. 
breads, cereals and flours) are supplemented or fortified with thiamine, as heating destroys thiamine 
in foods [81]. Thiamine is decreased in the body by thyroid hormones, diabetes, ethanol, age and 
certain drugs such as 5-fluorouracil [81, 82]. The most common cause of a thiamine deficiency in 
affluent societies is chronic alcohol consumption leading to Wernicke-Korsakoff encephalopathy 
[83]. More recently, a link between thiamine deficiency and colon carcinogenesis [84] has also been 
reported.  
Thiamine’s chemical structure consists of a pyrimidine ring and a thiazole moiety linked by a 
methylene (CH2) bridge as seen in Figure 1-3. 
 
 
Figure 1-3: Chemical Structure of Thiamine [85] 
 
Digestion and Absorption of Thiamine 
Thiamine absorption primarily occurs in the jejunum or proximal small intestines. Thiamine 
predominately occurs in a nonphosphorylated form in plants and in a phosphorylated form such as 
thiamine diphosphate (TDP) in animal products [58]. In supplements, it is commonly found as 
thiamine hydrochloride and is hydrolysed by intestinal phosphatases to thiamine prior to absorption 
[58]. At low concentrations it requires transporters (i.e. THTR1 and THTR2 to cross the brush border) 
while at high concentration uptake occurs due to simple passive diffusion. The colon can also absorb 
thiamine through THTR1 transporters and thiamine/H+ exchange, which seems to be under the 
regulation of an intracellular calcium/cadmodulin mediated pathway. This could be the route of 
absorption from bacteria synthesised thiamine [81].  
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Absorption of thiamine is thought to be relatively high, however, there are certain anti-thiamine 
factors present in the diet that can interfere with thiamine’s absorption. For example, fish preparation 
methods will influence thiamine absorption as raw fish contain thiaminases (deactivated by cooking). 
Polyhydroxyphenols, such as tannic and caffeic acids, are found in tea, coffee, betel nuts, certain 
fruits and vegetables (e.g. blueberries, black currants, Brussels sprouts and red cabbage). The 
polyhydroxyphenols in these foods can be deactivated by cooking or heating [58].  
Within the mucosal cells, thiamine can be phosphorylated into a phosphate ester and transported 
across the basolateral border by active transport using both sodium and energy. Alcohol or ethanol 
ingestion interferes with the active transport of thiamine from the mucosal cells across the basolateral 
border but not the brush border thereby decreasing thiamine absorption [58]. Thiamine in the blood 
is mostly found in red blood cells (approximately 90%); and predominately exists as thiamine 
diphosphate (TDP) with small amounts of thiamine monophosphate (TMP). Whereas, in the plasma 
(approximately 10%) it is found in its free form, bound to albumin or as TMP [58].   
Tissue Storage of Thiamine 
A small amount of thiamine is stored in the body (approximately 30 mg per adult) with approximately 
40% of the stored thiamine found in muscles. Additional thiamine storage sites include the brain, 
heart, liver and kidney [81].  
Metabolism and Excretion of Thiamine 
Excess thiamine, intact or metabolised, is excreted via the urine. Both TDP and TMP are excreted in 
their enzymic forms. Degradation of thiamine begins with the cleavage of the molecule into its 
pyrimidine and thiazole moieties. These two rings are further metabolised generating 20 or more 
metabolites, which are excreted in the urine in addition to TDP and TMP [58].  
Function of Thiamine 
Thiamine plays a number of roles in the human body, for example, coenzymes, energy transformation 
(particularly metabolism of glucose), synthesis of pentoses and NADPH as well as assisting in 
membrane and nerve conduction [58]. In particular, it is highly active in the mitochondria as it is 
involved in the dehydrogenase reactions as a cofactor for pyruvate, α-ketoglutarate and branched-
chain ketoacid dehydrogenases. These enzymes catalyse the oxidative decarboxylation of α-ketoacids 
to release carbon dioxide; therefore, thiamine is central to mitochondrial energy production. Thiamine 
also acts as a cofactor for transketolase (TK), which is a reversible cytosolic enzyme that catalyzes 
the first and last step of the pentose phosphate pathway. This pathway plays a major role in cellular 
function, for example, the production of NADPH for maintaining cellular redox, glutathione (GSH) 
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levels, protein sulphydryl groups, fatty acid synthesis, and supplying ribose for nucleic acid synthesis 
[81].  
Another function of thiamine is involvement in nerve membranes whereby TTP is thought to activate 
ion transport, in particular, chlorine but also participation in nerve impulse transmission via sodium 
channel regulation and release of acetylcholine [58].  
Deficiency of Thiamine 
A thiamine deficiency is commonly known as Beriberi. The first symptoms of a thiamine deficiency 
are loss of appetite and weight loss. As the deficiency continues or worsens, cardiovascular symptoms 
such as hypertrophy and altered heart rate are diagnosed; neurological symptoms such as apathy, 
confusion, decreased short-term memory and irritability [58].  
There are three types of Beriberi that have been identified: 
1. Dry Beriberi: this is predominately found in older adults particularly if they are consuming 
a high carbohydrate diet. It is characterised by muscle weakness and wasting especially in 
the lower limbs. This form of Beriberi is associated with PN and is characterised by 
sensorimotor, distal and axonal peripheral neuropathy. It is often associated with calf 
cramps, muscle tenderness and burning feet [96-98]. 
2. Wet Beriberi: involves the cardiovascular system such as right-side heart failure leading 
to respiratory involvement with oedema.  
3. Acute Beriberi: is commonly observed in infants and has been primarily recorded in 
countries such as Japan [58]. 
As mentioned above, thiamine deficiencies have also been associated with high alcohol consumption 
and specific pharmaceutical drugs both of which can cause a peripheral neuropathy [81, 82]. In people 
with diabetes, a deficiency in thiamine has also been linked with multiple organ damage including 
diabetic peripheral neuropathy [86].  
Toxicity of Thiamine 
Currently, there are no reports of thiamine toxicity from oral ingestion of large doses of thiamine 
from supplementation i.e. 500mg daily for 1 month [87, 88]. However, headaches, convulsions, 
cardiac arrhythmias and anaphylactic shock have been associated with intravenous or intramuscular 
administration of thiamine [89]. The NHMRC has reported that there is no upper level or limit for 
oral thiamine and has not been documented as a health risk [90].  
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Assessment of Nutriture of Thiamine 
Body fluid measurement of thiamine has not been routinely assessed by clinicians. However, Sullivan 
Nicholaides Pathology (www.snp.com.au) conducts assays on levels of vitamin B1, B2 and B6, which 
will be utilised for this trial. Other assays used to measure thiamine include a serum assessment 
involving the measurement of erythrocyte transketolase activity [transketolase is the thiamine-
dependent enzyme of the hexose monophosphate shunt] or plasma thiamine pyrophosphokinase 1 
[thiamine pyrophosphate synthesis in eukaryotes, requires thiamine pyrophosphokinase (TPK), 
which catalyses the transfer of a pyrophosphate group from ATP to thiamine] [91]. Urinary thiamine 
can also be measured, as excretion of thiamine decreases with reduced thiamine status [58]. The most 
common thiamine measure in the plasma is thiamine diphosphate, which is the form that that was 
chosen to measure for this trial.  
Role of Thiamine in the Peripheral Nervous System 
A thiamine deficiency can cause a peripheral neuropathy called beriberi neuropathy [92]. Beriberi 
affects the central nervous system, peripheral nervous system and cardiovascular system as previously 
outlined [93-95]. The peripheral neuropathy that develops from thiamine occurs after a prolonged 
mild to moderate period of thiamine deficiency [95].  
Two studies conducted in Japan on beriberi neuropathy found that the neuropathy was due to axonal 
degeneration on large myelinated fibres rather than unmyelinated fibres. In addition, an accumulation 
of flattened sacs or tubuli in the axoplasm of large myelinated fibres was found [92, 96]. These PN 
changes were also displayed in thiamine deficient rats [97]. As a result of axonal degeneration from 
a thiamine deficiency, chromatolysis of DRG neurons and anterior horn cell neurons can occur [93]. 
The axonal degeneration from a beriberi neuropathy was comparable to that seen from vincristine 
sulphate, alcohol, triorthocresyl phosphate and acrylamide neuropathies [97]. Considering vincristine 
induces CIPN, a deficiency in thiamine displaying similar degeneration patterns may indicate the 
involvement of this nutrient. Active regeneration of peripheral nerves has been found in patients with 
a vitamin B1 deficiency receiving thiamine supplementation [97]. Consequently, it may assist in the 
regeneration of peripheral nerves from neurotoxic agents such as vincristine. 
Thiamine administration has also been found to suppress thermal hyperalgesia [increased sensitivity 
to pain] by reducing hyper-excitability and lessening alterations of sodium currents in injured DRG 
neurons in rats [98]. This may be correlated to the injury incurred by oxaliplatin in the DRG as it 
affects voltage-gate sodium currents and causes axonal degeneration without evidence of primary 
demyelination [3, 4]. Therefore, thiamine administration could aid in the regeneration of axons, 
reduce pain and aid in balancing sodium currents.   
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1.9.3.2 Riboflavin (Vitamin B2) 
Riboflavin, commonly known as vitamin B2 is the precursor to flavin adenine dinucleotide (FAD) 
and flavin mononucleotide (FMN); which are prosthetic groups essential for the activity of 
flavoenzymes, such as oxidases, reductases and dehyrodrogenases [81]. Riboflavin can be found in a 
number of foods especially those of animal origin. The major sources of riboflavin include eggs, lean 
meat, milk, broccoli, legumes and enriched bread and cereal products. Riboflavin can be destroyed 
by exposure to light [58, 81].  
The structure of riboflavin consists of a flavin or isoalloxazine ring, which is attached to a ribitol or 
sugar alcohol side chain. The structure of riboflavin can be seen in Figure 1-4.  
 
 
Figure 1-4: Chemical Structure of Riboflavin [99] 
 
Digestion and Absorption of Riboflavin 
Riboflavin is normally bound to proteins or found as FMN or FAD in foods. These protein bound 
riboflavins or flavoproteins, need to be released by stomach acid and gastric/intestinal proteases to 
free the riboflavin. The FMN and FAD foods forms or supplemental forms are hydrolyzed by FAD 
pyrophosphatase and FMN phosphatase on the brush border of the ileum enterocytes, which frees the 
riboflavin for transport into the enterocyte. Other enzymes may also assist in hydrolysing riboflavin 
from its attached phosphate such as nucleotide dephosphatase and alkaline phosphatase [81]. 
Small amounts of free riboflavin are absorbed into the enterocytes by saturable, energy-dependent 
carriers, primarily in the proximal small intestine; while large amounts found in supplemental 
administration are absorbed by diffusion. Once inside the enterocyte, it is phosphorylated to form 
FMN by flavokinases and requires ATP. Riboflavin then effluxes across the basolateral border and is 
transported to the liver by riboflavin transporters such as albumin. In the liver, riboflavin is converted 
to FMN and FAD. FAD is the predominant flavoenzyme transported to tissues. Before riboflavin can 
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transverse into most cells it must be converted to its free form, and then is phosphorylated inside the 
cell [58, 81].   
Tissue Storage of Riboflavin 
Approximately 50% of riboflavin is found in circulating plasma with 40% of it consisting of FAD 
and 10% FMN. Riboflavin is stored in small quantities in a variety of tissues with the greatest 
quantities found in the liver, kidney and the heart [58, 81].  
Metabolism and Excretion of Riboflavin 
Similar to thiamine, riboflavin and its metabolites are primarily excreted in the urine with only small 
amounts of unabsorbed riboflavin, or riboflavin metabolised by intestinal flora, excreted in faeces 
[58, 89]. Sixty to seventy percent of riboflavin is excreted into the urine intact, while the metabolites 
arise from tissue degradation of covalently bound flavins and the vitamin. This excretion can be seen 
in the urine a couple of hours after oral ingestion of a vitamin B2 supplement, as it is a fluorescent 
yellow compound. This is the noticeable change in colour of urine that individuals observe and report 
after taking a B vitamin supplement [58].  
Function of Riboflavin 
The flavoenzymes FMN and FAD function as coenzymes for a wide variety of enzyme reactions 
within the body. Both FMN and FAD act as an electron carrier, which plays an important role in 
mitochondrial energy production and cellular function.  
The main biochemical functions of flavoproteins include [58]: 
 in the electron transport chain as an electron carrier 
 in the oxidative decarboxylation of pyruvate and α-ketoglutarate as an electron carrier 
 as succinate dehydrogenase (a FAD flavoprotein) which removes electrons from succinate to 
form fumarate (forms FADH2 from FAD). Coenzyme Q10 then pass the electrons into the 
electron transport chain 
 as Sphinganine oxidase which requires FAD in sphingosine synthesis  
 as xanthine oxidase as it requires FAD as a coenzyme, which aids the transfer of electrons 
directly to oxygen forming hydrogen peroxide  
 as aldehyde oxidase as it requires FAD to convert aldehydes, such as pyridoxal (vitaminB6) 
to pyridoxic acid and retinal (vitamin A), to retinoic acid while passing electrons to oxygen 
and generating hydrogen peroxide  
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 for vitamin B6 metabolism as pyridoxine phosphate oxidase is dependent on FMN; this aids 
the conversion of pyridoxamine phosphate (PMP) and pyridoxine phosphate (PNP) to 
pyridoxal phosphate (PLP), which is the primary coenzyme form of vitamin B6.  
 for the synthesis of 5-methyl tetrahydrofolate (THF), the active form of folate requires 
FADH2. 
 kynureninase monooxygenase as it requires FAD, which is one of the steps in the synthesis of 
niacin from tryptophan.  
 choline metabolism as it requires FAD for several enzymes: such as choline dehydrogenase, 
dimethylglycine dehydrogenase and sarcosine (also called monomethylglycine 
dehydrogenase).  
 thioredoxin reductase as it is a flavoenzyme FAD  
 monoamine oxidase as it is a FAD dependent enzyme required for the metabolism of several 
neurotransmitters, such as dopamine and other amines e.g. tyramine and histamine 
glutathione reductase as it is a FAD dependent enzyme used in the reduction of the oxidised 
form of glutathione (GSSG) to its reduced form GSH.  
Deficiency of Riboflavin 
The deficiency of riboflavin is called ariboflavinosis and is rarely found in isolation as a 
deficiency state. In most cases it is accompanied by other nutrient deficiencies [58]. The most 
common symptoms of a riboflavin deficiency are inflammation of the lip (cheilosis), corners of 
the mouth (angular stomatitis), tongue (glossitis), redness or bloody (hyperaemia) and swollen 
(oedema) mouth/oral cavity. Other symptoms or conditions associated with a riboflavin 
deficiency include seborrhoea dermatitis, anaemia, and peripheral neuropathy [58 81].  
A severe deficiency of riboflavin may interfere with coenzyme and enzyme reactions that are 
dependent on riboflavin enzymes, such as the synthesis of vitamin B6 and niacin from tryptophan. 
Limited dietary intake without supplementation of riboflavin may cause a riboflavin deficiency 
in people with congenital heart disease, some cancers and those with an excessive alcohol intake 
[100]. Different conditions can also affect riboflavin status, such as thyroid disease, alters 
riboflavin metabolism and diabetes mellitus, trauma and stress increase excretion of riboflavin. A 
riboflavin deficiency may also be found in women taking the oral contraceptive pill compared to 
women who are not taking these drugs [58]. A deficiency in riboflavin can also affect iron 
metabolism. In a riboflavin deficient state heme formation in red blood cells is decreased, which 
results in normochromic and normocytic anaemia [101].  
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Toxicity of Riboflavin 
Currently no toxicity of high oral supplementation of riboflavin has been identified [58].  
Assessment of Nutriture of Riboflavin 
The assessment of riboflavin status is usually measured by the in vitro stimulation of favin adenine 
dinucleotide (FAD) of the erythrocyte enzyme, glutathione reductase [102].  
Role of Riboflavin in the Peripheral Nervous System 
Riboflavin is not normally correlated to peripheral neuropathy except in chickens [103]. The only 
association that riboflavin has in the peripheral nervous system is its requirement in the conversion 
of inactive pyridoxine to its active form, pyridoxal-5-phosphate [104]. The role of pyridoxine, or 
vitamin B6, is discussed below. 
 
1.9.3.3 Niacin/Nicotinamide/Nicotinic Acid (Vitamin B3) 
Niacin was first discovered due to its deficiency state. In humans this is called pellagra and is a similar 
condition to what occurs in dogs called black tongue [58]. Vitamin B3 can be found in three forms; 
niacin (which is the generic term for the other two forms), nicotinic acid and nicotinamide. There is 
only a slight difference in structure as nicotinic acid is pyridine 3-carboxylic acid and nicotinamide 
is nicotinic acid amide [58].  The structure of vitamin B3 is presented in Figure 1-5. 
   
Figure 1-5: Chemical Structures of Nicotinic acid, Nicotinamide and Niacin [87, 88]. 
 
The best sources of niacin are meat, poultry and fish, especially tuna or halibut. Cereal products or 
enriched cereals and bread products, whole grains, seeds, legumes as well as coffee and tea contain 
reasonable amounts of niacin. There is a lesser amount found in green vegetables [58, 81].  
In addition to being available in foods, niacin is synthesised by the liver and some other tissues from 
the amino acid tryptophan. Vitamin B2, B6 and iron are required for this reaction to occur in addition 
to adequate tryptophan consumption, as it is an essential amino acid.  Approximately 1mg of niacin 
is produced from 60mg of dietary tryptophan [58].  
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Digestion and Absorption of Vitamin B3 
Niacin exists as NAD+ and NADP+ in the majority of foods [81]. The digestion and absorption of 
niacin occurs due to NAD+ and NADP+ being hydrolysed by phyrophosphatases to release the 
phosphate bond and glycohydrolase to release free nicotinamide for absorption [58, 81].  
Small amounts of nicotinamide and nicotinic acid can be absorbed in the stomach. However, the 
majority is absorbed in the small intestine by sodium dependant carrier-mediated (or facilitated) 
diffusion. At higher concentrations, which occur due to oral supplementation, 
niacin/nicotinamide/nicotinic acid are all absorbed by simple or passive diffusion [58, 81].  
In the enterocytes, nicotinamide and nicotinic acid can be converted to NAD+ where required and the 
rest of the nicotinamide and nicotinic acid diffuses out of the cells into the portal blood. Once in the 
plasma, approximately one third is bound to plasma proteins and is transported to the liver. The 
nicotinamide and nicotinic acid can transport across cell membranes by simple diffusion except for 
kidney tubules and red blood cells whereby it requires a carrier, and in the brain where it is energy 
dependant [58, 81]. Nicotinamide is the primary precursor for NAD+ that can be synthesised in all 
tissues and cells. Nicotinic acid can also be synthesised to NAD+ but this primarily occurs in the liver 
[58].  
Tissue Storage of Vitamin B3 
Very small amounts of niacin are stored within the body. NAD+ or NADP+ (NADPH which is its 
reduced form) are stored in small amounts in the liver but are not bound to enzymes. The NAD+ and 
NADP+ in cells are trapped and used for enzyme reactions within the cell. All excess is either stored 
in the liver, as previously mentioned, or excreted in urine [58].  
Metabolism and Excretion of Vitamin B3 
NAD+ and NADP+ within the cells undergo degradation by glycohydrolase producing ADP-ribose 
and nicotinamide. The released nicotinamide is transported to the liver where it is than methylated 
and oxidised into metabolites, such as N’methyl nicotinamide, N’methyl 2-pyridone5-carboxamide 
and small amounts of N’methyl 4-pyridone carboxamide. Nicotinic acid is metabolised to N’methyl 
nicotinic acid and all metabolites are excreted in the urine. Free nicotinamide and nicotinic acid are 
not excreted in the urine as both are actively reabsorbed from the glomerular filtration [58]. 
Function of Vitamin B3 
Between 200 and 500 enzymes, primarily dehydrogenases, require the coenzyme forms of niacin 
NAD+ and NADP+. These compounds mainly act as a hydrogen donor or electron acceptor [58, 81]. 
Niacin coenzymes are essential for all of human energy production including [58, 81]: 
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 Glycolysis 
 Oxidative decarboxylation of pyruvate to acetyl-CoA 
 Oxidation of acetyl-CoA in the tricarboxylic acid cycle (TCA) 
 Β-oxidation of fatty acids. 
In addition to mitochondrial energy production, NAD+ and NADP+ are involved in the following [58, 
81]: 
 Oxidation of ethanol 
 Aldehyde dehydrogenase for catabolism of vitamin B6 from pyridoxal to pyridoxic acid 
 Pentose phosphate pathway 
 Mitochondrial membrane malate aspartate shuttle 
 Fatty acid synthesis 
 Cholesterol and steroid hormone synthesis 
 Proline synthesis 
 Deoxyribonucleotide synthesis 
 Glutathione, vitamin C and thioredoxin regeneration 
 Folate coenzyme synthesis (dihydrofolate [DHF], tetrahydrofolate [THF], 5-methyl THF, and 
5,10-methylene [THF]) 
 Donor of adenosine diphosphate ribose (ADP-ribose) for posttranslational modification of 
proteins associated with chromosomes and the formation of cyclic ADP-ribose 
 Other non-redox activity. 
Deficiency of Vitamin B3 
The term for the deficiency of niacin is pellagra. One of the signs and symptoms of pellagra is 
dermatitis. The dermatitis looks similar to sunburn at first and appears in areas exposed to the sun. 
The neurological signs and symptoms may include headaches, apathy, loss of memory, peripheral 
neuritis, paralysis of extremities, confusion, disorientation and dementia or delirium [58, 107].  
The gastrointestinal signs and symptoms include glossitis, cheilosis, angular stomatitis, nausea, 
vomiting and diarrhoea. Treatment for pellagra is administration of 500 mg of nicotinamide daily for 
several weeks. If pellagra is untreated then death can occur [58, 107]. 
Several drugs, malabsorption disorders and excessive alcohol intake have been found to decrease 
niacin status possibly leading to a deficiency state. Some of the medications that have been found to 
decrease niacin status include azathioprine [108], isoniasid, 5-fluoro-uracil, pyrazinamide 
ehtionamide, hydantoins, phenobarbital, chloramphenicol and mercaptopurine [107].  
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The malabsorption disorders include chronic diarrhoea, inflammatory bowel disease, some intestinal 
cancers and Hartnup disease [58, 107].  
Toxicity of Vitamin B3 
Side effects from niacin toxicity have been documented in doses above 1,000 micrograms per day 
[109]. These side effects include a vasodilatory ‘niacin flush’, which is partly due to a histamine 
release, causing an uncomfortable flush with redness, burning, itching, tingling and headaches. It can 
also affect the gastrointestinal tract causing heartburn, nausea and possible vomiting. In severe cases 
liver injury (hepatic toxicity), high uric acid levels (possibly gout) and high blood glucose 
concentrations may occur [58, 109]. 
Due to the side effects from niacin toxicity, the NHMRC have set an upper level for niacin at 900 mg 
a day for men and women [90]. The total amount each participant will be receiving for this trial per 
day is 200 mg (100 mg per capsule). 
Assessment of Nutriture of Vitamin B3 
There are several methods that have been used to assess niacin status.  In Australia, it is rarely 
assessed. Healthscope is the primary pathology company that conducts these tests/assays. 
Healthscope uses a 24-hour urine test to ascertain niacin levels, which seems to be the most common 
form of pathology assay undertaken for vitamin B3. Metabolites of the vitamin are tested in urine, 
such as N-methyl nicotinamide, as well as comparing N-methyl nicotinamide to creatinine ratio. This 
ratio has been criticised as being hard to interpret and normally just the metabolite is used. Red blood 
cell indicators may also be used to assess NAD concentrations in certain circumstances [58, 110].  
Role of Vitamin B3 in the Peripheral Nervous System 
Vitamin B3 has been related to a peripheral neuropathy associated with its deficiency state, namely 
pellagra and encephalopathy in alcoholics [111]. A retrospective study on 22 heavy alcoholics 
reported a post-mortem diffuse chromatolysis of neurons identical to that found in neurological 
pellagra [111]. Due to the fact that frequent co-existence of other alcoholic encephalopathies and 
neuropathies can be found in the same patient, pellagra encephalopathy that can cause a peripheral 
neuropathy can go unnoticed and treated with other nutrients such as thiamine (Vitamin B1) and 
pyridoxal (vitamin B6). In the case studies reported, fifteen patients were treated with thiamine and 
pyridoxine without niacin which appeared to aggravate their neurological state [111]. It is suggested 
that undetermined encephalopathy displaying peripheral neuropathy should be treated with niacin.  
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1.9.3.4 Pantothenic Acid (Vitamin B5) 
Pantothenic acid, or vitamin B5, is essentially known for its role as a precursor of coenzyme A (CoA). 
Coenzyme A is a molecule used in enzymatic reactions, such as TCA cycle, heme synthesis and lipid 
metabolism [58, 81].  
The structure consists of β-alanine and pantoic acid joined by a peptide bond or amide linkage as seen 
in Figure 1-6 [58]. 
 
  
Figure 1-6: Chemical Structure of Pantothenic Acid [112]   
 
Pantothenic acid is found widely within our foods and is present in virtually all plant and animal 
foods, therefore, making a deficiency unlikely. Some of the best sources of pantothenic acid include 
meats, particularly liver, egg yolk, and yoghurt, legumes including peanuts, whole-grain cereals, 
potatoes, mushrooms, broccoli, green leafy vegetables and avocadoes [58, 81].  
Digestion and Absorption of Pantothenic Acid 
Pantothenic acid found in foods is mainly found as CoA (approximately 85%) or in free form. To 
release the pantothenic acid from CoA, several steps are required during digestion to hydrolyse the 
CoA in the gastrointestinal tract. Phosphatases are firstly required to hydrolyse the CoA; 
pantetheinase, secreted by the intestinal mucosa, then splits the molecule to form pantothenic acid. It 
is then transported across the brush border by the sodium-dependent multivitamin transporter 
(SMVT). If ingested in high concentration, such as vitamin supplementation, it is absorbed by passive 
diffusion [58, 81]. 
After absorption it is transported to the liver where a certain percentage is converted to CoA. 
Pantothenic acid and CoA are both found in the blood. The same SMVT carrier is required to uptake 
the vitamin into cells throughout the body [58]. 
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Tissue Storage of Pantothenic Acid 
As most pantothenic acid in the body is used to synthesise CoA or resynthesise CoA, as well as be a 
component of 4’phosphopantetheine, it is mostly stored in these forms. These can be found in all cells 
due to mitochondrial activity, but is found primarily in high concentrations in the liver, adrenal gland, 
kidneys, brain and heart [58]. 
Metabolism and Excretion of Pantothenic Acid 
Pantothenic acid is primarily excreted intact in the urine, as it does not appear to undergo metabolism 
prior to excretion. A small amount is also excreted in the faeces, but at this stage no metabolites have 
been identified in either the urine or the faeces [58].  
Function of Pantothenic Acid 
The primary function of pantothenic acid in the body is as a component of the acylation factors, CoA 
and 4’phosphopantetheine. As such, pantothenic acids have the following function within the body 
[58]: 
As CoA [58]: 
 Participates extensively in nutrient metabolism – carbohydrates, lipids and proteins 
 Participates in the degradation reactions for energy production e.g. conversion of pyruvate to 
acetyl-CoA, the oxidative decarboxylation of α-ketoglutarate to succinyl-CoA 
 Are important in the synthesis of cholesterol, bile salts, ketone bodies, fatty acids and steroid 
hormones  
 Are involved in the synthetic reactions for the production of many vital compounds 
 Are involved in the acetylation (donation of long-chain fatty acids) of some proteins, sugars 
and some drugs.  
As Acyl Carrier Protein (ACP) [58]: 
 4’phosphopantetheine functions as the prosthetic group for acyl carrier protein which is a 
component of the fatty acid synthase complex 
 The sulfhydryl group in the 4’phosphopantetheine binds and transfers acyl groups to other 
sulfhydryl groups located in the enzyme complex, therefore assisting the acyl chain being 
synthesised.  
Deficiency of Pantothenic Acid 
A pantothenic acid deficiency is not normally seen as it is found in a variety of foods; however, a 
deficiency state has been identified called ‘Burning feet syndrome’. This is characterised by a 
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numbness of the toes and a sensation of burning in the feet. Warmth makes it worse and cold makes 
it feel better. Other deficiency symptoms may include vomiting, fatigue, weakness, restlessness and 
irritability [58]. 
This deficiency is normally found in conjunction with other nutrient deficiencies, for example, 
malnutrition or in conditions that may induce nutrient deficiencies such as alcoholism, diabetes 
mellitus or inflammatory bowel disease [58]. 
Toxicity of Pantothenic Acid 
No toxicity or adverse effects of oral pantothenic acid have been reported to date. As there are no 
reported cases of toxicity in humans or animals the NHMRC have set no upper levels for oral 
pantothenic acid [90].  
Assessment of Nutriture of Pantothenic Acid 
Both blood and urine pantothenic acid concentrations can be used to assess vitamin B5 status. Urinary 
pantothenic acid has been found to be a superior indicator of status, as blood concentrations do not 
correlate well with changes in dietary pantothenic acid intake [58].  
Role of Pantothenic acid in the Peripheral Nervous System 
The main involvement of pantothenic acid and the peripheral nervous system involves ‘burning feet 
syndrome’ [113]. There is a long history of burning feet syndrome going back as far as the first British 
Burmese war in 1823. It was not until the 1900s, when Gopalan [114] discovered that complete relief 
was found with calcium pantothenate, that the relationship was made between burning feet syndrome 
and vitamin B5 therapy (possibly due to a deficiency). His discovery was then further substantiated 
by mice studies [115]. As a pantothenic acid deficiency is rare today, it may only been found in 
disorders such as alcoholism [116]. 
 
1.9.3.5 Pyridoxine (Vitamin B6) 
The term pyridoxine or vitamin B6 incorporates the three forms pyridoxal, pyridoxine and 
pyridoxamine. These forms or vitamers are interchangeable as pyridoxine represents the alcohol 
form, pyridoxal the aldehyde form and pyridoxamine the amine form of vitamin B6. The phosphate 
bond form of all three vitamers is the major dietary source of the vitamin [58, 117]. 
The structure of pyridoxine is presented in Figure 1-7 [118]. 
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Figure 1-7: Chemical Structures of Vitamin B6 or Pyridoxine and Associated Metabolites 
[118]. 
 
Dietary sources of pyridoxine include meat, salmon, chicken, wholegrain products and vegetables as 
well as some fruits, for example, bananas, fortified cereals and nuts [58]. 
Digestion and Absorption of Pyridoxine 
Due to the food source of pyridoxine being bound to phosphates, vitamin B6 needs to be 
dephosphorylated by alkaline phosphatase (which is zinc dependant) and occasionally by other 
phosphatases at the intestinal brush border to free the vitamers. All pyridoxine vitamers are absorbed 
primarily in the jejunum by passive diffusion. If supplemental phosphorylated forms, such as 
pyridoxal-5-phosphate, are ingested in high concentrations they can also be absorbed by passive 
diffusion without being dephosphorylated [58]. 
The pyridoxine may be rephosphorylated in the enterocyte cells, however, little metabolism occurs 
here and the vitamers need to be dephosphorylated before entering the portal vein. The main 
metabolism of pyridoxine occurs in the liver where all vitamers are converted to pydridoxal-5-
phosphate (approximately 90% of total circulating vitamin B6). This conversion requires a FMN 
(vitamin B2) dependant enzyme, cytosolic pyridoxine phosphate oxidase [58, 117]. 
Tissue Storage of Pyridoxine 
The primary site for pyridoxine storage is in skeletal muscles (75-80%), which are bound to glycogen 
phosphorylase and range in content from 40-185mg. The liver stores approximately 5-10%; 
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additionally, small amounts can be stored in the brain, kidney and spleen normally bound to enzymes 
[58].  
Metabolism and Excretion of Pyridoxine 
Pyridoxine is primarily excreted in the urine with very small amounts excreted in the faeces. The 
major metabolite of pyridoxine is 4-pyridoxic acid, which results from the oxidation of pyridoxal by 
a NAD-dependent, aldehyde dehydrogenase (vitamin B3) or FAD-dependent aldehyde oxidases 
(vitamin B2), in the liver and kidneys. This metabolite if measured in the urine is representative of 
recent ingestion rather than stored pyridoxine levels. Large supplemental ingestion of pyridoxine 
(100mg or larger) can result in urinary excretion of intact pyridoxine or 5-pyridoxic acid and lower 
amounts of urinary 5-pyridoxic acid excretion [58]. 
Function of Pyridoxine 
The main function of the coenzyme form of pyridoxine is its role in enzyme activity, particularly with 
amino acids [58]. The main non-enzyme role of pyridoxine is its function in gene expression whereby 
it has been found to bind to DNA and, in some cases, modulate steroid hormone binding or 
transcription factor binding to regulatory regions on DNA [119].  
The coenzyme function of pyridoxine is involved in the following reactions [58]: 
 Transamination: Involves the transfer of an amino group (-NH2) from one amino acid to a α-
ketoacid. This is important for the synthesis of non-essential amino acids and the use of amino 
acid carbon skeletons for energy or glucose production. 
 Deamination: Is the reaction whereby an amino group is removed from a compound and 
releases ammonia or ammonium ion. 
 Decarboxylation: Involves the removal of a carboxy (COO-) group from an amino acid or 
other compound. 
 Transulfhydration: Pyridoxine is required for two enzymes catalysing reactions in which 
cysteine is synthesised from methionine.  
 Transelenation: Selenomethionine may be converted to selenocysteine, which requires a 
pyridoxine dependent enzyme, γ-lyase.  
 Cleavage: There are a number of cleavage reactions, however, an example of one that requires 
pyridoxine is the removal of the hydroxymethyl group from serine to tetrahydrofolate (THF) 
to form glycine.  
 Racemisation: Racemases that catalyse the interconversion of D- and L- amino acids require 
pyridoxine.  
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 Other Synthetic Reactions: Pyridoxine is also required as a coenzyme in the first step of heme 
synthesis, for animolevulinic acid synthetase, for sphingolipid synthesis, niacin synthesis and 
the synthesis of carnitine and taurine.  
 Glycogen degradation: Pyridoxine is required for glycogen phosphorylase activity.  
Deficiency of Pyridoxine 
A pyridoxine deficiency is considered rare but may occur occasionally; mainly occurring in selected 
groups such as the elderly, alcoholics, infants exposed to severe heat treatment of milk formulas and 
people on a variety of drugs therapies (e.g. Isoniazid, penicillamine, corticosteroids, anticonvulsants 
and the oral contraceptive pill) [58]. 
The signs and symptoms of a pyridoxine deficiency include a seborrheic rash on the face, neck, 
shoulders and buttocks; weakness; fatigue; cheilosis; glossitis; angular stomatitis; peripheral 
neuropathy; seizures and convulsions; microcytic anaemia and hyperhomocysteinemia. A deficiency 
is usually treated with 100mg or more of vitamin 6 daily [58].   
Toxicity of Pyridoxine 
Pharmacological doses of pyridoxine have been found to induce a toxicity of vitamin B6. Excessive 
ingestion of greater than 200 mg/day for more than 5-6 months has been found to cause a sensory 
peripheral neuropathy, including an unsteady gait, tingling in the extremities and impaired tendon 
reflex. Doses of 2 grams/day have been found to cause peripheral neuropathy (tingling and numbness) 
in the feet and hands as well as impaired motor control or ataxia (loss of voluntary muscle control). 
High doses over a period of time may also cause degeneration of neurons (dorsal root ganglia) in the 
spinal cord, loss of myelination and degeneration of sensory fibres in peripheral nerves [120].  
The upper level for adult men and women, as set by the NHMRC, is 50mg a day; which has been 
based on the results of studies involving long term oral administration of pyridoxine, as mentioned 
above. The dose prescribed in our clinical trial, being slightly higher than this upper level, was 60mg 
a day for between six to nine months. Participants were screened for both blood plasma levels of 
pyridoxine phosphate and peripheral neuropathy.  
This dose was chosen considering that the B vitamin complex selected for this trial was a government 
approved nutrient supplement (Therapeutic Goods Act) and can be bought in Australia. The dose of 
two capsules a day was based on the vitamin B12 level of 1,000 mcg a day to assist nerve 
regeneration. In this way, the dose of one capsule was equivalent to 30mg of vitamin B6 and two 
capsules was equivalent to 60 mg. This dose, although slightly higher than the upper limit recognised 
by NHMRC, would only be administered for a set period of time: six to nine months. The research 
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states that this dose and duration are not associated with peripheral neuropathy development from a 
vitamin B6 toxicity, therefore, it was deemed safe to administer.  
 
Assessment of Nutriture of Pyridoxine 
Pyridoxine can be measured by determining plasma, erythrocyte or total blood pyridoxal-phosphate 
(PLP) levels or by urinary pyridoxal excretion. Other tests that can assist in determining pyridoxine 
status are erythrocyte tryptophan catabolites levels, aspartate aminotransferase and alanine 
aminotransferase activities, or plasma homocysteine. A loading test of 2 grams of oral tryptophan 
measuring urinary 4-xanthurenic acid can also be used. Urinary cystathionine and plasma 
homocysteine levels can also be measured after a dose of 3grams of methionine [117]. Homocysteine 
can also be an indicator for folate and vitamin B12 status, so is not a reliable indicator of vitamin B6 
status [121]. The main pathology test utilised, clinically, is the plasma PLP test. A recent study on 
cancer utilised the sum of pyridoxial-5-phosphate, pyridoxal and 4-pyridoxic acid to define vitamin 
B6 status [122].  
Role of Pyridoxine in the Peripheral Nervous System 
Vitamin B6 directly affects the peripheral nervous system as both a deficiency and toxicity can cause 
peripheral neuropathy [123]. In relation to chemotherapy, two studies have been conducted with 
vitamin B6 and CIPN and positive results have been published [27, 78]. 
Wiernik, et al [78] conducted a clinical trial on low or moderate dose cisplatin and 
hexamethylmelamine in advanced ovarian carcinoma patients. Vitamin B6 was found to reduce CIPN 
[dose 100 mg of vitamin B6, pyridoxine hydrochloride, three times daily from days 1-21 of 
chemotherapy administration; equivalent to 300 mg/day]. However, it was also found to adversely 
affect response duration [78]. In 2010, Garg and Ackland found that vitamin B6 in cell culture 
examination was found to decrease CIPN associated with oxaliplatin administration, in the FOLFOX 
combination, without interfering with the anti-tumour activity [27]. It is recommended that further 
clinical trials be conducted on vitamin B6 and oxaliplatin administration for the prevention and 
treatment of CIPN.  
Two journal articles, looking at various case studies, have also been published on pyridoxine and 
pyridostigmine in children with vincristine-induced neuropathy [124, 125]. Another case study has 
been published on a neonate with vincristine-induced peripheral neuropathy [126]. All case studies 
on these babies and children showed positive benefit in reducing the vincristine CIPN, with further 
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research required. In addition, a case report on an adult with vincristine induced cranial 
polyneuropathy treated with pyridoxine reported complete recovery after 2 weeks [127]. 
In developed countries a clinical deficiency of vitamin B6 is uncommon; however, several studies 
have shown that approximately 10-20% of the population show biochemical evidence of inadequate 
vitamin B6 nutrition [110]. PN from vitamin deficiencies, due to inadequate food intake, can be found 
in underdeveloped countries, however, in developed countries the most common causes of PN are 
alcohol, diabetes and medication use [129]. 
The medications known to cause PN, due to their antagonism to vitamin B6, are isoniasid 
(tuberculosis medication), hydralazine (anti-hypertensive), cycloserine (antibiotic for tuberculosis) 
and penicillamine (chelating agent used for rheumatoid arthritis). Other neurological side effects 
evident from these drugs include hyperkinesis, irritability, sleep disorders and seizures. Vitamin B6 
administration has been found to reverse PN, and other neurological side effects from these drugs, 
without interfering with the efficacy of the medication [129]. 
The involvement of Vitamin B6 with peripheral nerves is through its role as a cofactor for neuronal 
protein synthesis [130]. The mechanism of action for pyridoxine on peripheral nerves is not 
confirmed, but it is known to be involved in numerous biochemical pathways of neural function. This 
includes neurotransmitter synthesis, amino acid metabolism and sphingolipid biosynthesis and 
degradation [131]. Similar to vitamin B1, the peripheral neuropathy related to a vitamin B6, 
deficiency occurs after an extended period of time [129]. 
A vitamin B6 toxicity has also been found to cause peripheral neuropathy [129, 131-135].  In 1983, 
Schaumburg et al [132] reported the development of PN in seven patients who were taking vitamin 
B6 in excess of 1g/day for several months. When the supplementation was ceased, the participants 
showed recovery of nerve function and reduced PN with a few patients experiencing persistent nerve 
damage. Further studies, with participants taking lower doses of vitamin B6 (90 mg-500 mg a day), 
also reported the development of sensory PN from vitamin B6 administration taken over one to five 
years. PN ceased once administration of B6 was discontinued, however, recovery took six months for 
most participants [133, 134].  
The toxicity from vitamin B6 was found to be detrimental to the dorsal root ganglia, with subsequent 
degeneration of the sensory peripheral nerves [129, 132]. These are the same neurological areas that 
the neurotoxic chemotherapy agents accumulate [2, 4, 10, 34].  
The dose that will be administered in this trial is 60 mg a day for nine months. According to the 
research, the administered dose for this trial is lower than the lowest reported dose to cause vitamin 
B6 induced PN (92 mg a day) and will be taken for less time (nine months versus one year).  
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The dose for this trial is also lower than the vitamin B6 administered in the Wiernik, et al [78] trial, 
which was 300 mg of vitamin B6 per day for 21 days after chemotherapy treatment. Although no 
toxicity from vitamin B6 was noted in Wiernik’s trial, and CIPN was reduced, the dose of vitamin 
B6 was found to adversely affect response duration [78]. Therefore, a lower dose of vitamin B6 
administration with chemotherapy treatment would be beneficial to trial for efficacy and safety.  
1.9.3.6 Folic Acid (Vitamin B9) 
The terms folic acid and folate are often used interchangeably, but are actually not interchangeable. 
Folic acid refers to the oxidised form found in supplements and fortified foods whereas folate refers 
to the reduced form found naturally in foods and biological tissue. Folate (pterolymonoglutamic acid 
or pterolglutamate) is composed of three parts, which are all required to be bound together for vitamin 
activity. These three parts include pteridine (2-NH2-4-OH-6-CH3 pterin), para-aminobenzoic acid 
(PABA) and glutamic acid. The primary pterolylmonoglutamates found in foods include 5-methyl 
tetrahydrofolate (THF) and 10-formyl THF, however, over 150 different forms of folate have been 
identified [58].  
The chemical structure of folate is presented in Figure 1-8. 
 
Figure 1-8: The Chemical Structure of Folate [136] 
 
The main food sources of folate include unprocessed grains, oranges, dried beans, peas, eggs, 
mushrooms as well as green vegetables such as spinach, Brussels sprouts, broccoli, asparagus. Other 
good sources of folate include legumes, such as peanuts and lentils, fruits and liver [58, 117]. 
Digestion and Absorption of Folate 
Folate found in foods is mostly bound to proteins and is required to be in its mono form or simple 
form for absorption. Consequently, polyglutamates cannot be absorbed without first being hydrolysed 
  
1-67 
 
by proteases to form monoglutamates. One of the main proteases found on the brush border that 
cleaves the polyglutamate into monoglutamine is called carboxypeptidase and is zinc dependent. A 
zinc deficiency has been found to impair folate absorption due to its requirement for this protease 
enzyme [58, 117].  
The primary absorption into intestinal cells occurs in the proximal jejunum via the transporter proton-
coupled folate transporter (PCFT) and 5-methyl THF. The PCFT is considered to be a high affinity 
folate carrier [137].  Inside the enterocyte, both folate and folic acid is converted to dihydrofolate 
(DHF), which is than reduced to generate THF. Transport across the basolateral border is active and 
carrier dependent, possibly involving multidrug resistance protein (MRP) 3. Folic acid can be found 
in the portal circulation as monoglutamates, not polyglutamates primarily as folate or 5-methyl THF 
with small amounts of dihydrofolate and formylated forms [137].  
In systemic blood, folate is found as monoglutamates (e.g. THF, 5-methyl THF, or 10-formyl THF), 
either in free form (1/3) or bound to proteins (2/3) such as albumin, α-2 macroglobulin and high-
affinity folate-binding protein. Red blood cells contain higher concentrations of folate than plasma; 
however, folate in red blood cells can only be obtained through erythropoiesis and is not taken up by 
mature red blood cells. Therefore, red cell folate pathology results represent long term folate status 
(approximately 2-3 months) compared to plasma [58]. 
Tissue Storage of Folate 
Storage of folic acid in the body ranges between 11 to 28 mg with approximately half of the storage 
of folate found in the liver. Folic acid is normally found in the cytosol and mitochondria of cells in 
the polyglutamate forms of THF and 5-methyl THF [58]. 
Metabolism and Excretion of Folate 
Folate excretion is through both urinary and faecal excretion. The body has the ability to retain needed 
folate via the kidneys by local folate binding proteins (FBPs) and tubular reabsorption. Excess folate 
is then excreted in the urine. Faecal excretion of folate is minimal [58].    
Function of Folate 
Folic acid functions as a coenzyme in both the mitochondria and cytosol as an acceptor of one carbon 
or single carbon groups. It is required for the synthesis of thymidylate, purines, methionine and other 
methylation related reactions. It is also required for the metabolism of amino acids, nucleotides 
(including pyrimidine synthesis) and metabolic pathways involving cell growth and survival, cell 
replication and DNA synthesis [58, 117].  
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There are certain genetic polymorphisms relating to folate-dependant enzymes that have mutations 
in the FAD-dependent methylene THF reductase enzyme (MTHFR – Methenyltetrahydrofolate 
receptor). These genetic polymorphisms can impair 5-methyl THF formation and, therefore, reduce 
the remethylation of homocysteine [58].  
These folate mutations are now being assessed as possible risk factors for certain cancers such as 
breast cancer. A recent case-controlled study evaluated the MTHFR mutations as possible risk factors 
for breast cancer [138]. Weiwei, et al [138] found that there was a significant association between 
MTHFR C667T polymorphism, folate intake, vitamin B6 and breast cancer risk. There was also a 
significant interaction observed between MTHFR C667T polymorphism and folate intake on the risk 
of breast cancer.  Although not assessed in this trial, further research into MTHFR, breast cancer and 
B vitamin supplementation is warranted.  
Vitamin B12 and folate have a synergistic relationship whereby without vitamin B12 the methyl 
group of 5-methyl THF cannot be removed and by this means is trapped. Adequate amounts of 
vitamin B12 need to present for the enzyme methionine synthase, as the methyl group of vitamin B12 
is required to convert homocysteine to methionine. In a low vitamin B12 status, it cannot accept the 
methyl group of 5-methyl THF and the folate is thus trapped. This means the cells have folate but not 
in a form they can use [58]. 
Deficiency of Folate 
A deficiency of folate results in megaloblastic macrocytic anaemia. This means that fewer red blood 
cells are released into circulation and those released are large and immature. The signs and symptoms 
of this condition include fatigue, weakness, headaches, irritability, difficulty concentrating, shortness 
of breath and heart palpitations [58].  
A diet devoid of folate can develop a folic acid deficiency within a month, with red blood cell folate 
concentrations diminishing after three to four months of low folate intake. Within approximately four 
to five months rapidly dividing cells become megaloblastic, the mean cell volume (MCV) increases, 
blood counts decrease and hyper segmentation of white blood cells occurs. The treatment for this 
deficiency is 1 to 5mg of folate daily [58].  
A deficiency of folate impairs DNA synthesis, which can be seen initially in rapidly dividing cells 
such as the gastrointestinal tract. Hence, the first signs of a folate deficiency may be a bright red 
tongue, impaired absorption (due to shortening of villi) and diarrhoea. There are also certain 
conditions associated with an increased requirement of folate, for example excessive alcohol 
consumption and malabsorption disorders such as inflammatory bowel diseases. Pregnancy also 
requires more folate as a deficiency can cause neural tube defects [58]. 
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Certain medications have also been found to affect folate status such as the diuretic furosemide, 
diphenylhydantoin or phenytoin (anticonvulsants), methotrexate (prevents THF synthesis), 
cholestyramine and sulfasalazine [58]. 
Toxicity of Folate 
The upper level for adult intake in Australia is 1,000 mcg per day, according to the NHMRC [90]. 
Although not a toxicity, folate supplementation has been found to ‘mask’ a vitamin B12 deficiency; 
folate supplementation can alleviate the megablastic anemia but the neurological damage caused by 
the B12 deficiency continues and can be irreversible [90]. However, this concern has decreased with 
awareness and the normal testing of folate and vitamin B12 being conducted together.  
Toxicity of folate supplementation with 15mg a day has been found to be associated with insomnia, 
malaise, irritability and gastrointestinal distress [90, 120, 139]. There have also been concerns that 
increased folic acid supplementation may accelerate the progression of pre-neoplastic lesions, which 
can increase the risk of colorectal cancer and possibly other forms of cancer in certain individuals 
[140-142]. 
There has also been a reported case of increased seizure frequency and activity with folic acid 
supplementation at a dosage of 800 mcg per day. The patient was on carbamazepine for symptomatic 
partial epilepsy with simple and complex seizures. The patient was planning to fall pregnant hence 
the folic acid supplementation; however, the paitent experienced generalised tonic-clonic seizures, 
for the first time, a few days after starting supplementation, which increased in frequency and severity 
[143].  
Assessment of Nutriture for Folate 
Folate status can be assessed by measuring plasma, serum or red blood cell folate concentrations. The 
plasma or serum folate concentrations reflect recent dietary intake, whereas the red blood cell folate 
concentrations reflect folate tissue status and are more representative of vitamin status [58]. 
Role of Folate in the Peripheral Nervous System 
Vitamin B12 and folate are closely linked with specific functions in the body. This includes co-
enzymatic one-carbon metabolism in the remethylation of homocysteine to methionine catalysed by 
the 5-methyltetrahydrofolate monoglutamate enzyme, activity in the nucleic acid pathways for the 
synthesis of thymidylate as well as purines and formation of methyl groups for biologic reactions 
[144, 145]. 
Deficiencies in either vitamin B12 or folate have been found to affect homocysteine levels due to 
their inter-relationship and the enzymes that are dependent on these vitamins [144-146]. Unlike 
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vitamin B12 deficiency, a folate deficiency does not cause primary peripheral neuropathy; however, 
it has been found to have a greater effect on cognitive abilities and the central nervous system rather 
than the peripheral nervous system [144-146]. Also, due to the inter-relationship between folate and 
vitamin B12, the neurologic manifestations displayed from a deficiency are indistinguishable between 
the two vitamins [93].  
One case study has been published on the significance of a folate deficiency in alcoholic and 
nutritional neuropathies [147]. A 33 year-old woman, with chronic alcoholism, presented with acute 
progressive glove-stocking sensorimotor polyneuropathy and underwent a comprehensive clinical 
screening. Pathology results indicated on admission that her folate levels were reduced (0.4 in a range 
of 3.6-12.9) while her thiamine (2.2 in range of 2-7.2), riboflavin (15.2 in a range of 11.9-20.4) and 
cobalamin levels (955 in a range of 233-914) were within range. Laboratory findings also revealed 
macrocytic anaemia and liver dysfunction, while neurological testing indicated axonal neuropathy 
[147]. 
Two years previously, a patient presented with a previous peripheral neuropathy. No folate levels 
were assessed at that time, only levels for vitamins B1, B2 and B12 and all were found to be in range. 
The treatment, for her second admission of peripheral neuropathy, was administration of a 
multivitamin and intravenous folic acid 15mg daily. The patient gradually recovered and, although 
being bed ridden on admission, could walk after 3 months [147]. Therefore, patients presenting with 
alcoholism and peripheral neuropathy should undergo full screening and supplementation of a 
complete B vitamin might be a better treatment option. This case indicated that folate may play a role 
in peripheral neuropathy; however, as discussed previously, it may be indistinguishable between 
vitamin B12 and a folate deficiency unless laboratory tests can differentiate. Either way, 
supplementation with both or all of the B vitamins should assist in a B vitamin induced peripheral 
neuropathy. 
 
1.9.3.7 Cobalamin (Vitamin B12) 
Vitamin B12, or cobalamin, is the generic name for a group of compounds called corrinoids due to 
their corrin nucleus. The compounds that make up vitamin B12 include cyanocobalamin, 
hydroxocobalamin, aquo- or hydrocobalamin, nitrocobalamin, 5’-deoxyadenosylcobalamin and 
methylcobalamin [58, 117]. 
The best dietary sources of vitamin B12 include: organ meats such as liver; red meat such as beef, 
lamb, kangaroo; white meat such as pork, poultry, fish, shellfish (especially clams and oysters); as 
well as eggs. Dairy products such as cheese, cottage cheese and yoghurt have smaller amounts of 
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vitamin B12. Some foods are also fortified with vitamin B12 [58, 117]. Only bacteria or 
microorganisms can synthesise cobalamin while animals and plants cannot and so require vitamin 
B12 from an external source [58].  
Bioavailability of vitamin B12 from food sources varies depending on the food and the age of the 
person; medication (such as antacids), surgery and digestive function. The range is approximately 40-
80%, however, this maybe reduced tremendously if there is an intrinsic factor antibody issue; lower 
bowel resection or damage of the ileum as seen in Crohn’s disease; atrophic gastritis; achlorhydria; 
metformin administration or chronic use of antacids. Other conditions that may interfere with vitamin 
B12 absorption include pancreatic insufficiency and Zollinger-Ellison syndrome, which results in a 
more acidic intestinal pH thereby impeding the release of vitamin B12 from the R proteins [58, 148-
152]. Parasitic infestation such as tapeworms may also cause a deficiency as the parasite uses vitamin 
B12 therefore limiting the absorption of B12 to the human incubator [58].  
The structure of vitamin B12, cyanocobalamin, which is the form found in most supplements is 
presented in Figure 1-9. The active forms, or coenzyme forms, of vitamin B12 in the body include 
methylcobalamin and adenosylcobalamin (5’-deoxyadensoyl-cobalamin) [58]. 
 
Figure 1-9: The Chemical Structure of Cyanocobalamin [153]  
 
Digestion and Absorption of Cobalamin 
The digestion and absorption of vitamin B12 is quite complex involving a number of steps in a 
particular sequence. Initially, the digestion requires the actions of gastric proteolytic enzymes, pepsin 
and hydrochloric acid, in the stomach to break the vitamin B12 away from amino acids. Next vitamin 
B12 binds to R proteins found in the saliva and gastric juices. The R proteins are said to protect and 
carry the vitamin away from bacterial use. Within the small intestine, the R protein-B12 complex is 
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hydrolysed by pancreatic protease which frees the vitamin B12. After B12 is released it then binds to 
intrinsic factor (IF) within the small intestine. The B12-IF complex travels from the duodenum to the 
ileum where it binds to a protein receptor called cubilin or IF receptor. If there are defects or damage 
to the receptors, this will result in vitamin B12 malabsorption as vitamin B12 is absorbed through the 
ileum [58, 154]. 
Inside the enterocyte, B12 is released from the B12-IF complex and is transported across the ileum’s 
basolateral membrane; it then binds to transcobalamin II, the transport protein for B12 [58].  
When vitamin B12 is given in pharmacological doses (1,000-2,000 µg) approximately 1-3% may be 
absorbed by passive diffusion [58].   The enterohepatic circulation of vitamin B12 is important as it 
accounts for part of the long half-life of the vitamin. Vitamin B12 is excreted in bile, however, once 
in the small intestine it can reattach to intrinsic factor and be re-absorbed. Therefore, malabsorption 
issues not only interfere with ingested vitamin B12 but also the enterohepatic reabsorption cycle. This 
may increase the amount of vitamin B12 needed for body requirements [58]. 
After absorption, vitamin B12 has been found to circulate for about 3 to 4 hours with peak levels of 
the vitamin occurring around 4 to 8 hours after ingestion. Vitamin B12 is circulated around the body 
by transport proteins called transcobalamin (TC) and haptocorrin (HC), like proteins [58]. Refer to 
the Holo TC section on page 37 for further information.  
A mutation in the TCII has been found whereby a substitution of cytosine for guanine at the base pair 
776 occurs. This substitution results in an insertion of arginine instead of proline, which decreases 
the ability of TCII to bind and transport vitamin B12 to tissues. It is estimated that approximately 
20% of the population is homozygous for the GG variant; this can result in low serum vitamin B12 
and high homocysteine levels, which is linked with an increased cardiovascular risk factor [155]. 
Tissue Storage of Cobalamin 
Unlike most B vitamins, vitamin B12 can be stored and retained in the body for long periods of time, 
consequently a deficiency may not appear for 3 to 5 years. Approximately 2 to 4 mg are stored in the 
body, mainly the liver (50%), with small amounts stored in the muscles, bone, kidneys, heart, brain 
and spleen [58]. 
Metabolism and Excretion of Cobalamin 
Little or no degradation of vitamin B12 occurs prior to excretion. The majority of vitamin B12 is 
excreted in bile, with only very small amounts lost in daily urine and trace amounts found in dermal 
losses [58]. 
Function of Cobalamin 
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Vitamin B12 has two enzymatic reactions that have been recognised in humans. One requires 
methylcobalamin and the other, adenosylcobalamin.  
1. Methylcobalamin is required for the conversion of homocysteine into methionine. 
Polymorphisms in this reaction have been linked with an increased risk of neural tube 
defects in people with suboptimal vitamin B12 status in conjunction with individuals who 
have the 5,10-methylene tetrahydrofolate reductase (MTHFR) mutation. This results in 
reduced methionine synthase activity and therefore decreased methionine production [58]. 
2.  Adensosylcobalamin is required for the methylmalonyl-CoA mutase conversation, which 
converts L-methylmalonyl-CoA to succinyl-CoA. A deficiency in vitamin B12 has been 
found to impair mutase activity, resulting in methylmalonyl-CoA and methyl malonic acid 
accumulating in the body. Methyl malonic acid status has been used to assist in 
determining vitamin B12 status, either deficiency or response to treatment [58]. 
Deficiency of Cobalamin 
The deficiency for vitamin B12 is similar to folate in that it results in megaloblastic macrocytic 
anaemia as described on page 61. In regards to a vitamin B12 deficiency, the manifestations occur in 
stages:  
1. Serum B12 concentrations decrease (serum B12 concentrations may remain normal until 
storage has been depleted). 
2. Cell concentrations of B12 diminish which affects the activity of both the B12 dependent 
enzymes.  
3. DNA synthesis decreases while plasma homocysteine and methyl malonic acid 
concentrations increase. 
4. Morphological and functional changes occur in blood cells resulting in megaloblastic 
macrocytic anaemia.  
The signs and symptoms of vitamin B12 deficiency affect the body’s hematologic and neurologic 
systems. The hematologic signs and symptoms include anaemia, low blood leukocyte and 
thrombocyte counts, skin pallor, fatigue, shortness of breath and palpitations. The neurological signs 
and symptoms, which may be irreversible, include peripheral neuropathy: numbness of extremities; 
abnormal gait; increased loss of coordination; loss of proprioception; loss of vibration senses or touch 
in the ankles and toes; swelling of myelinated fibres and demyelination; irritability; memory loss; 
disorientation; psychosis and dementia [58].  
Treatment of a B12 deficiency is administration of 1,000 mcg of vitamin B12 via either oral ingestion 
and/or intramuscular injections.  
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Toxicity of Cobalamin 
Currently there is no upper limit or toxicity noted for vitamin B12. There is no evidence to date that 
high amounts of vitamin B12 represents a health risk; with no adverse effects having been reported 
with excess vitamin B12 intake or supplementation. There is also no evidence to indicate that high 
levels of vitamin B12 are beneficial [90]. 
Assessment of Nutriture of Cobalamin 
There are a number of different pathological assessments that can be conducted to ascertain vitamin 
B12 status. These include: serum vitamin B12, holo Transcobalamin, homocysteine levels, methyl 
malonic acid levels and the Shillings test (rarely used now). At present, the laboratory tests used have 
limitations; due to technical issues or due to biological basis resulting in the inability to attain perfect 
sensitivity, specificity or predictive value [156, 157]. Further testing of intrinsic factor antibodies or 
parenteral cell antibodies is more indicative of a vitamin B12 deficiency but not functional 
considering other factors can also cause a B12 deficiency, as discussed before.  
1. Serum vitamin B12: A snapshot of total concentration in the blood (range 200-900 
pg/ml or pmol/ml) [58, 157]. 
2. Holo TC:  Measurement of holotranscobalamin, which is the metabolically active 
component of vitamin B12. It indicates the transport of vitamin B12 from the liver to 
the tissues and may detect an early B12 deficiency [157, 158].  
3. Homocysteine (HCY): Measurement of homocysteine in blood as a biomarker for 
vitamin B12. However, it is not specific as other vitamins, such as folate, vitamin B6 
and folate polymorphisms e.g. MTHFR, also affect it. High homocysteine levels do 
not always correlate with a B12 deficiency [157].  
4. Methylmalonylic acid (MMA): Measurement of MMA in the blood as a biomarker for 
vitamin B12. This is similar to HCY, however, is slightly more specific than HCY for 
a B12 deficiency [157]. 
5. Shillings test: A multistep assay involving the administration of radioactive vitamin 
B12, which is capable of assessing the aetiology of cobalamin malabsorption. As 
pernicious anaemia is the most common cause of cobalamin deficiency in Western 
populations, IF-blocking antibodies and antiparenteral cell antibody assays [157] have 
replaced this test.  
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Role of Cobalamin in the Peripheral Nervous System 
A vitamin B12 deficiency is known to cause primary demyelinating peripheral neuropathy without 
any other causal factors [159, 160]. A deficiency of vitamin B12 causes neuronal demyelination, 
axonal degeneration and reduced nerve conduction velocity in the peripheral nervous system; and, if 
not treated, will result in neuronal death and permanent damage [160-162]. 
The mechanism of action of vitamin B12 on peripheral nerves is based on its catalytic role. The 
biochemistry of vitamin B12 is associated with two enzymes that are cobalamin dependent.  
These include mitochondrial L-methymalonyl-coenzyme A (CoA) mutase and cytoplasmic 
homocysteine methyl transferase (also known as methionine synthase) [163, 164]. Reduced activities 
of these two enzymes alone have been linked to the neurological manifestations of a vitamin B12 
deficiency [163]. 
Cobalamin deficiency has neurological manifestations in the brain and peripheral nerves. Scalabrino, 
et al [163] reported that the severity of the neuropathological features of white matter in the spinal 
cord of totally gastrectomised rats does not correlate with the progressive accumulation of 
methylmalonylic acid (MMA) and homocysteine (HCY) in the serum or the spinal cord [162]. The 
authors hypothesised that the accumulation of these neurotoxic metabolites from chronic cobalamin 
deficiency was unlikely to be the main mechanism of action to cause the subacute combined 
degeneration like lesions. In addition, children who have an inherited mutation of the mitochondrial 
L-methylmalonyl CoA mutase enzyme, and as a result suffer from methyl malonic aciduria not due 
to cobalamin deficiency, do not express typical subacute combined degeneration lesions [165]. 
This indicates that there could be other underlying mechanisms that could affect both central and 
peripheral nerves, other than high MMA and HCY levels. Research into the mechanisms of action of 
these nerves has revealed that nerve damage from a vitamin B12 deficiency may be via its effect on 
glial cells (Schwann cells are the peripheral nerve glia cells) as well as the impact of certain cytokines 
and growth factors [163]. Nerve cells such as the glial cells synthesise and release certain cytokines 
and growth factors due to injury or following certain triggers. This neuroglial pattern of cytokine and 
growth factor production can lead to demyelination and phlogosis from cytokines such as tumour 
necrosis factor alpha (TNF-α) [163]. 
A cobalamin deficiency therefore causes an imbalance of cytokines and growth factors that can affect 
glial cells and nerve myelination. Abnormally high levels of TNF-α and abnormally low levels of 
epidermal growth factor (EGF) were found in serum and cerebrospinal fluid of humans who were 
cobalamin deficient.  
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It was concluded that this imbalance of TNF-α and EGF can cause demyelination leading to nerve 
damage from a vitamin B12 deficiency [163]. Figure 1-10 represents a vitamin B12 deficiency in 
adults due to an imbalance of TNF-α and EGF [163].  
 
 
 
 
 
 
 
 
Figure 1-10: Flow Chart of the Adverse Effect of a Vitamin B12 Deficiency in Adults [163] 
 
Other pathways involved in cobalamin deficiency that affect peripheral nerves includes the 
accumulation of Nέ-carboxymethyllysine (nCML) in sural nerves,  the receptors for advanced 
glycation end products (RAGE) pathway and its activation of the pro-inflammatory transcription 
factor NF-κB [162]. NF-κB proteins have also been found to regulate gene expression in various cell 
types in both acute and chronic inflammatory response [162].  
NF-κB activation can be related to the previous research of TNF-α production by glial cells. NF-κB 
is an important component when activated in the pathogenesis of inflammatory neuropathies. Its 
activation results in production of other pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 
[162]. nCML-induced RAGE-activation is also a non-self-limiting way to activate NF-κB and the 
inflammatory response [162]. 
A study addressing various types of peripheral neuropathies found that the perineurial cells in the 
peripheral nervous system contain significant amounts of nCML and moderate amounts of RAGE 
and NF-κB in a vitamin B12 deficiency. In addition, the mononuclear cells were found to have 
significantly high amounts of RAGE, nCML and NF-κB [162].  
Cobalamin Deficiency in 
adults 
↑ TNF-α 
synthesis 
↓ EGF 
synthesis 
Ineffective 
erythropoiesis 
Damage to myelin 
sheaths 
Epithelial damage of 
some portions of the 
alimentary tract 
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Although these findings were from a study with a small sample size (n=5) the results warrant further 
investigation, since they indicate that inflammation may play a major role in the development of 
peripheral neuropathy from a vitamin B12 deficiency. 
Furthermore, an in-vitro study found that neuroblastoma cells that were deficient in B12 showed 
slower proliferation, but faster differentiation. This was through interacting signalling pathways 
related to an increased expression of catalytic protein phosphatase 2A (PP2A), pro-nerve growth 
factor (proNGF) and two tumour necrosis factor alpha converting enzymes [166].  
Hence, cytokines and growth factors may play an important role in the development of peripheral 
neuropathy induced from a vitamin B12 deficiency. [Table 1-5] 
 
Table 1-5: The End Result of Enzymes from a B12 Deficiency on the Peripheral Nervous 
System: 
Cobalamin (Cbl) deficiency in Humans 
Biochemical abnormalities Cytokine and growth factor 
abnormalities 
Neurophysiological 
abnormalities 
↓ Cbl levels in serum 
↑Methylmalonylic acid (MMA) 
levels in serum 
↑ Homocysteine (HCY) levels in 
serum 
↑ N5-Carboxymethyllysine 
(nCML) 
↑Advanced glycation end product 
(RAGE) 
↑ Tumour necrosis factor 
alpha (TNF-α) levels in 
serum 
↓ Epidermal growth factor 
(EGF) levels in serum 
↑ Nuclear-factor kappa B 
(NFκB) 
↑Interleukin -1β (IL-1β) 
↓ Nerve conduction velocity 
in PNS 
Information adapted from [162-164, 166]       
Peripheral neuropathy that is caused by a deficit of vitamin B12 has been reported reversed or 
markedly improved by administration of vitamin B12 [160, 168-173]. Even in patients with other 
conditions that can cause peripheral neuropathy such as type II diabetes mellitus, administration of 
vitamin B12 has been beneficial for nerve regeneration and myelinogenesis [167]. 
In 1992 Yaqub, et al [167] conducted a double-blind randomised study on 50 diabetic patients (39 
were non-insulin dependent and 11 were insulin dependent) that displayed diabetic neuropathy [167]. 
The patients were randomised to receive either placebo or methylcobalamin 2 capsules 3 times a day 
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equivalent to 1500 µg a day (250 µg per capsule) for 4 months.  Evaluation was achieved via nerve 
conduction studies and a special scoring system adapted from the Peripheral Neurology Score (PNS). 
The results showed a significant improvement in somatic and autonomic symptoms in the 
supplemental group compared to placebo therefore showing efficacy in the treatment of diabetic 
neuropathy [167]. 
Another study compared oral versus intramuscular cobalamin treatment for megoblastic anaemia in 
a 90-day single-centre, prospective, randomised, open-label study [174]. Seventy patients (10 
dropped out) were randomised to receive either oral or intramuscular (IM) cyanocobalamin at 1mg 
each. For the first 10 days, they received 1 mg every day either orally or via IM. After the first 10 
days, both treatments were administered once a week for 4 weeks and then once a month for life. 
Serum B12 haematology tests were conducted at days 0 and 90, and complete blood counts were 
completed on days 0, 10 and 30. Results indicated that both oral and IM cobalamin treatment were 
equally effective for megablastic anaemia and cobalamin deficiency related conditions [174]. 
Therefore to achieve nerve regeneration and myelinogenesis, at least 1,000 µg of cyanocobalamin or 
methylcobalamin is required [167, 173, 174]. 
 
1.9.3.8 Choline 
Choline is one of the B vitamins that the body can manufacture in the liver without dietary intake 
although dietary intake is required to maintain choline status. Choline is manufactured from 
methylation of the amino acid serine using S-adenosyl methionine (SAMe). Choline can also be found 
in food but is mostly found as part of the phospholipid lecithin (phophatidyl choline) [58]. The 
structure of choline is presented in Figure 1-11. 
  
Figure 1-11: Chemical Structure of Choline [175].  
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Foods rich in choline include eggs, liver and other organ meats, muscle meats, shrimp, cod, salmon, 
wheat germ and legumes such as soybeans and peanuts. Lecithin is also available in shops which can 
be added to foods and is also used as an emulsifier in other foods [58]. 
Digestion and Absorption of Choline 
Digestion of choline from the diet as lecithin occurs in the small intestines where it is hydrolysed by 
intestinal mucosa to glycerophophoryl choline. The choline component is than absorbed in the small 
intestines via transporter proteins into the enterocyte with no other components found to be 
competitive for absorption. The liver takes up the majority of the absorbed choline with small 
amounts being transported to the peripheral tissues via intestinal lymphatics [176].   
Tissue Storage of Choline 
The majority of choline is stored within the liver as phosphatidylcholine and sphingomyelin. The 
kidney and the brain also store some choline with a specific transporter required to transport the 
choline across the blood brain barrier. Excess choline intake is then excreted in urine [176]. 
Function of Choline 
There are several functions of choline including [58]: 
 Is required for the synthesises of sphingomyelin and phosphatidyl choline 
 Is part of the neurotransmitter, acetylcholine 
 Assists as a methyl donor 
 Aids in the formation of platelet aggregating factor 
 Aids in the secretion of very-low-density lipoproteins from the liver 
Deficiency of Choline 
Diets that have found to be devoid of choline indicate a decrease in plasma choline and 
phosphatidylcholine concentrations in addition to alterations in some liver enzymes. Animal studies 
have shown that a diet devoid in choline increase the development of fatty liver accompanied by some 
hepatic necrosis. In addition, low intakes of choline and betaine have been linked with increased 
inflammation [58]. 
Toxicity of Choline 
Although no adverse events have been found, the NHMRC have set the upper level for adult male 
and females at 3,500 mg/day [90].  
Assessment of Nutriture of Choline 
  
1-80 
 
Choline assessment is not routinely conducted. However, for specific research and analysis, 
pathology tests have been used. As choline is a polar, non-volatile molecule, which lacks a 
chromophore, it cannot be assessed or measured by immunoassay due to its small size. Hence, other 
methods have been used such as homogeneous chemiluminescent enzyme assays and more 
importantly, liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods have been 
quantified [177,178].  
Role of Choline in the Peripheral Nervous System 
Choline’s role in the nervous system mainly revolves around its incorporation in the peripheral 
neurotransmitter, acetylcholine [58]. To date, choline has not been found to be involved with the 
development or treatment of peripheral neuropathy. Two studies on rats have assessed the topical 
application of cytidine-5’-diphophocholine (CDP-choline) to improve nerve regeneration and 
functional recovery of sciatic nerve injury [179, 180]. Both studies found that it was of benefit for 
nerve recovery and regeneration, however intra-application is not applicable to human nerves in 
regards to peripheral neuropathy. Nevertheless, CDP-choline maybe a potential treatment internally 
for nerve regeneration and recovery but further research is required. 
 
1.9.3.9 Biotin  
Biotin was first discovered after a link was established between raw eggs consumption and hair loss, 
dermatitis and various neuromuscular problems. A substance in liver, which was later found to be 
biotin was able to cure and prevent the problems caused by eating raw eggs [58]. 
The chemical structure of biotin or biotinyllysine is presented in Figure 1-12. 
 
 
Figure 1-12: Chemical Structure of Biotin [181] 
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Biotin sources can be found from both food and the manufacture from intestinal bacteria in the colon. 
The best sources of biotin include liver, soy beans, egg yolk, legumes, nuts, salmon and some cereals. 
The whites of raw eggs contain a component called avidin, which is a glycoprotein.  
Avidin can irreversibly bind to biotin in a tight noncovalent bond, which in turn prevents the 
absorption of biotin. Cooking of an egg or the white of an egg destabilises the avidin and it cannot 
bind to the biotin. The cooking process does not interfere with biotin so therefore, it can still be 
absorbed [58]. 
Digestion and Absorption of Biotin 
Biotin within the diet is usually found bound to protein therefore requires proteases in the small 
intestine to break the bond to assist with absorption. Biotinidase is an enzyme found on the surface 
of the brush border as well in pancreatic secretion. It assists with the hydrolysation of the biocytin to 
free biotin for absorption [58]. 
The absorption of biotin varies. The absorption of biotin from the diet across the brush border in the 
small intestines and colon as well into the liver is carrier mediated and sodium dependent while 
pharmacological doses is absorbed by passive diffusion. The biotin manufacture and absorption from 
the colon bacteria is not adequate to maintain the requirements of the body, so dietary intake is 
essential. Alcohol interferes with biotin absorption in the intestines [58].  
Tissue Storage of Biotin 
Small amounts of biotin is stored in the muscle, liver and brain [58]. 
Metabolism and Excretion of Biotin 
The metabolism or catabolism of biotin occurs due to proteases with only small amounts of 
metabolites formed. These metabolites are excreted in urine while unabsorbed intestinal bacteria 
synthesised biotin and unabsorbed dietary biotin is excreted in faeces [58]. Smoking has been found 
to increase the catabolism of biotin in women [182]. 
Function of Biotin 
Biotin functions as both a coenzyme and in non-coenzyme capacities which include cell proliferation 
and gene expression. The functions of biotin include [58]: 
Four Coenzyme Roles of Biotin [58, 183]: 
 1 and 2 Pyruvate carboxylase: a mitochondrial enzyme that catalyses the carboxylation of 
pyruvate to oxaloacetate 
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 Acetyl-CoA Carboxylase: Is the rate limiting enzyme involved in energy production from the 
fatty acid synthesis converting malonyl-CoA to acetyl-CoA 
 Propionyl-CoA Carboxylase: is another mitochondrial enzyme important for the catabolism 
of the amino acids isoleucine, threonine and methionine as well as odd-number-chain fatty 
acids (found in fish) to produce propionyl-CoA.  
 β-methylcrotonyl-CoA carboxylase: is an important enzyme in the catabolism of leucine 
Non-coenzyme Roles of Biotin [58, 183]: 
 Biotinylations of proteins and gene expression: Biotin has been found to influence multiple 
cellular functions through biotinylation of proteins, in particular nonhistone and histone 
proteins.  
 Cell cycle: Biotin is required for cells to progress normally through the cell cycle with a biotin 
deficiency appearing to cause cell arrest at the G1 phase. 
Deficiency of Biotin 
Biotin can be manufactured by gastrointestinal bacteria and subsequently absorbed [58], however 
human biotin requirements are still unknown, therefore a deficiency or sufficiency may be difficult 
to assess [183]. Nonetheless, deficiencies can occur due to genetic mutations (e.g. biotinidase and 
holocarboxylase synthetase), high raw egg intake, excessive chronic alcoholism and gastrointestinal 
disorders such as inflammatory bowel disease. Other states that may cause biotin status to decline 
include pregnancy and anticonvulsant medication (e.g. phenobarbital, phenytoin or carbamazepine) 
[58]. 
Deficiency signs and symptoms can include neurologic symptoms such as lethargy, paraesthesia in 
extremities (such as pins and needles), hypnotonia (reduced muscle tone), depression and 
hallucinations. Other signs and symptoms include a red, scaly dermatitis found around the eyes, nose 
and mouth, anorexia, nausea, alopecia (hair loss), and muscle pain. Death can occur if the biotin 
deficiency is not treated. Treatment is normally a therapeutic dose of biotin of 10 mg or more daily 
[58]. 
Toxicity of Biotin 
Currently the NHMRC has found that there is insufficient evidence of adverse effects or toxicity in 
both human and animal studies to set an upper level or limit [90].  
Assessment of Nutriture of Biotin 
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Both blood and urine can be used for the assessment of biotin. In blood analysis, biotinylated holo-
3-methylcrotonyl-CoA (holo-MCC) and holo-PCC from lymphocyte extracts are easily detectable in 
streptavidin blots and gel densitometry analysis and are reliable markers for biotin status.  
Urine excretion of biotin has been found to be beneficial in detecting biotin supplemented individuals 
however, it is not a good marker to distinguish a deficiency [183].  
 
 
Role of Biotin in the Peripheral Nervous System 
Currently, no research has been conducted on biotin and CIPN, but there has been studies conducted 
for uremic [184, 185] and diabetic neuropathy [186]. For uremic neuropathy, a small study conducted 
on nine patients undergoing dialysis that were suffering from PN were supplemented 10 mg of biotin 
in three divided doses for 1-4 years [184]. There was a marked improvement reported for paraesthesia, 
restless legs and difficulty walking in all patients within three months of supplementation. One patient 
who was unable to walk for three months improved significantly within six months of 
supplementation of biotin [184]. 
The same researchers who trialled the biotin treatment for dialysis patients, also began trying biotin 
for diabetic patients. A case report on three diabetic patients experiencing severe diabetic PN was 
treated with 10 mg of biotin via intramuscular injections daily for six weeks. This was followed up 
by injections three times a week for another six weeks and oral administration of 5 mg daily. All three 
patients noted improvements with 4-8 weeks although nerve conduction studies found that it had only 
slightly improved or not at all [186]. 
 
1.9.3.10     Inositol 
Inositol was originally thought of as a B vitamin although now it is considered to be an essential cell 
constituent. The human body has the ability to synthesis inositol so the need for external intake may 
not be necessary. Moreover, it can be found in nearly all plant and animal cells, both in free form and 
combined with other compounds [59, 60].  
The chemical structure of inositol is presented in Figure 1-13. 
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Figure 1-13: The Chemical Structure of Inositol [187] 
 
The main food sources of inositol include grains, beef liver, legumes, milk, fruits, nuts, organ meats, 
vegetables and brewer’s yeast.  
 
Absorption of Inositol 
As mentioned previously the body can produce inositol but we can also absorb it from our diet. The 
actual absorption pathway has not been completely documented however it is known that as a phytate 
it will block absorption of certain nutrients but as inositol it can aid the absorption of minerals such 
as zinc. A vitamin B complex also aids the absorption of inositol. Certain drinks such as alcohol, 
coffee, any caffeine drinks can all inhibit inositol absorption. Tobacco has also been found to inhibit 
inositol absorption [60].  
Tissue Storage of Inositol 
Inositol can be found in every cell in the body. Higher concentrations can be found in the brain, 
cerebrospinal fluid, skeletal and heart muscles, liver, kidneys and in the male reproductive organs, 
particularly the semen [60].  
Metabolism and Excretion of Inositol 
Inositol excretion is mainly through urine [188].  
Function of Inositol 
There are a number of functions that inositol plays within the body. These include [188]: 
1. As phosphatidylinositol in all cell membranes 
2. As a second messenger in cells 
3. Mediation of cell responses to stimuli 
4. Aiding nerve transmissions 
5. Aiding regulation of enzyme activity 
6. May also affect the function of lipid-transporting molecules 
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Deficiency of Inositol 
An inositol deficiency is considered rare due to the fact that humans can produce it within their 
bodies and its widespread availability in foods [60]. 
Toxicity of Inositol 
No toxicities have been reported related to inositol supplementation. Currently it is under review by 
the TGA with no negative studies being found on supplementation. One case report in 2010 [189] has 
documented a high dose of 3grams of inositol for 4 years to a 62 year female suffering from bipolar 
disorder for 30 years. It was found to be effective and safe [90].  
 
Assessment of Nutriture of Inositol 
The assessment method used will depend on which function of inositol is required. Both plasma and 
urine samples can be tested such as myo-inositol in plasma [190] and urine for inositol phosphoglycan 
P-type [191]. Inositol is not normally tested except for trials.  
Role of Inositol in the Peripheral Nervous System 
Inositol, in particular myo-inositol has been assessed for diabetic peripheral neuropathy. As 
mentioned in chapter one, myo-inositol is an important constituent of the phospholipids that make up 
cell membranes including nerve cells [192]. Nerve myo-inositol levels have been tested with 
numerous in vitro studies indicating reduced myo-inositol levels in diabetic peripheral neuropathy 
[193-197].  A rat study experimented with nerve myo-inositol levels and high glucose states [180]. 
They found that induced cellular myo-inositol depletion did occur in peripheral nerves without 
hyperglycaemia or insulin deficiency and this reproduced a biochemical, electrophysiological and 
structural defect that characterised early onset diabetic neuropathy. They still emphasised that this 
depletion was also in conjunction with other metabolic, vascular and neurotrophic insults that all 
contribute to the pathogenesis of diabetic neuropathy [198].  
A clinical trial on sural nerve biopsies was conducted on 30 males, n=10 with type 1 diabetes (5 with 
clinically diagnosed peripheral neuropathy), n=10 with impaired glucose tolerance and n=10 with 
normal glucose tolerance [199]. This study found that nerve myo-inositol levels were significantly 
lower in participants with diabetes who had neuropathy. In addition, participants with normal or 
impaired glucose tolerance who had high nerve myo-inositol levels were found to be associated with 
nerve regeneration due to increased nerve fibre density [199]. 
Two small clinical trials have been conducted on oral supplemental myo-inositol and diabetic 
neuropathy [200, 201]. A double-blind placebo-controlled RCT with 28 participants with diabetes 
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with early subclinical diabetic neuropathy were supplemented with 2 grams of oral myo-inositol or 
placebo three times daily for two months. The results found no significant changes in nerve 
conduction velocities, vibratory perception or amplitude of action potentials in either group. High 
blood and muscle tissue levels were found in the myo-inositol supplemented group but nerve myo-
inositol levels were not evaluated [200].  
The other trial was also a double-blind placebo-controlled RCT but on only 7 participants with clinical 
signs of diabetic neuropathy (n=3) or subclinical neurophysiological signs (n=4). These participants 
were supplemented with 500 mg of myo-inositol or placebo twice daily for 14 days, and then crossed-
over. Each group had 2 phases of the placebo (14 days = 1 phase) and 1 phase of myo-inositol. Results 
found no significant differences in the nerve conduction velocities during either placebo or myo-
inositol phases however, action potentials in the median, sural and popliteal nerves increased in 
amplitude by 76%, 160% and 40% respectively during the myo-inositol supplementation phase [201]. 
Although the initial potential to prevent or reverse diabetic peripheral neuropathy was seen, the 
clinical evidence is limited. Therefore it is hard to correlate if inositol would be beneficial or not for 
CIPN. No research has been conducted on CIPN and inositol to date and with the clinical research on 
diabetic PN not showing promise it may not be a selected nutrient for further research.  
 
1.10  Rationale: The Focus of the Study 
The relevance of CIPN is that it can affect chemotherapy dose and continuation of treatment, which 
is of clinical importance. Investigating agents that can assist with CIPN treatment and prevention has 
significant scientific merit. Several different substances hypothesised for pharmacological neuro-
protection (e.g. Amifostine) have been trialled, however, neither prophylactic strategies nor 
symptomatic treatments have proven useful [4, 28].  
The neurotoxic chemotherapy agents included in this clinical trial are oxaliplatin, paclitaxel and 
vincristine due to their high incidence of inducing CIPN. The consequence of developing CIPN from 
these drugs includes dose reduction, cessation of treatment and for approximately a third of patient’s 
permanent peripheral neuropathy, which can affect quality of life and physical functionality [2-4, 12].  
To date, no research on B group vitamins and CIPN has been undertaken. B group vitamins have the 
potential to decrease the onset and severity of CIPN. A deficiency or low status of B group vitamins 
may biochemically affect the health of nerve fibres and ganglia that neurotoxic chemotherapy agents 
can adversely modulate.  It is expected that the administration of a B group vitamin supplementation 
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will decrease the severity and onset of CIPN and therefore increase patient compliance and quality of 
life.  
A literature search to ascertain previous research on agents to prevent or treat CIPN has been 
conducted in Chapter 2. These include pharmaceutical, neutraceutical and other agents such as herbal 
medicine and acupuncture. A basis of current literature assists in giving a grounding knowledge in 
what has been trialled and the outcomes have been achieved.  
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2 CHAPTER 2 – LITERATURE REVIEW 
 
Modern cancer treatments have been reported to prolong life, however, treatment-related 
complications such as CIPN are detrimental for patients and increasing in frequency. Extensive 
clinical trials, epidemiological studies and standardised diagnostic criteria still have not produced 
established methods for prevention and/or treatment [202]. Listed below are the studies conducted on 
pharmaceutical agents, nutriceuticals and other complementary medicines trialled to assist in the 
prevention and/or treatment of CIPN. 
2.1 RESEARCH ON MEDICAL DRUGS FOR THE TREATMENT AND/OR PREVENTION OF 
CIPN 
Amifostine is a pharmaceutical agent that has had numerous studies conducted on it for the prevention 
of CIPN [6, 7, 203-215]. The results are contentious with two studies cancelled due to harmful side 
effects, for example. hypotension [209, 211]; while other studies reported an increased incidence of 
worsened nausea and vomiting and no improvement on quality of life [6, 207]. All other 
pharmaceutical agents showed negative or minimal prevention or treatment for CIPN.  
Results the current literature on pharmaceutical agents can be found in Table 2-1 Clinical Studies 
Investigating the Efficacy of Pharmaceuticals for the Prevention of CIPN. 
Methods 
A systematic search of the literature was conducted using PubMed, the Cochrane Library, Science 
Direct, Scopus, EMBASE, MEDLINE and CINAHL. 
Search Terms 
Articles were identified using the search terms, “chemotherapy” OR “Cisplatin” OR “Taxanes” OR 
“Paclitaxel” OR “Docetaxel” OR “Oxaliplatin” OR “Carboplatin” OR “Platinum compounds” OR 
“Proteasome inhibitors” AND “induced peripheral neuropathy” OR “CIPN” AND “Treatment” OR 
“Prevention”. 
The Inclusion criteria for this review were: 1) An RCT and/or cross-over clinical trial that used either 
a placebo comparator or current anti–CIPN treatment as a control; 2) Human participants diagnosed 
with a cancer and administered chemotherapy; 3) The use of a pharmaceutical agent as the main 
intervention and specifically investigating its effects on reducing the primary outcome i.e., CIPN; and 
4) The clinical study was published in English.  
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The overall body of evidence (based on a summary of the individual studies) (Table 2-3) evaluated 
within this review was assessed using a separate tool, the Australian National health and Medical 
Research Council’s (NHMRC) body of clinical evidence assessment matrix. This is an assessment 
tool that assigns a level/grade (Level I: strongest evidence to level IV: weakest evidence) based on 
the strength of the published study [216]. The consort diagram can be seen in figure 2-1.  
 354 Records identified from bibliographic databases 
 
                                                                                       261 Records excluded from further review  
          Study design not eligible 
           No relevant outcome 
         No relevant study group 
 
 93 Studies retrieved for relevant assessment 
 
 30 relevant studies assessed 
                                                                         0 study excluded due to  
                                                                     repeat publication of mid and final results 
 
 30 studies assessed qualitatively 
 
                    
                          0 studies excluded based on  
     negative study outcomes   
 
30 studies included 
 
Figure 2-1: Flow of information for systematic review on pharmaceutical agents. 
 
2.1.1 Pharmaceuticals and CIPN research 
2.1.1.1 Amifostine (WR2721) 
Fifteen trials have currently been conducted on Amifostine and CIPN [6, 7, 203-215] with mixed 
results. Of the trials conducted there was one pilot trial [206],  three non-randomised clinical trials 
[209, 210, 212],  six randomised controlled trials [7, 203-205, 211, 215], one phase II open label trial 
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[214], three phase II double-blind placebo-controlled clinical trials [6, 208, 213] and one multi-centre 
phase III trial [207].  
The types of chemotherapy varied amongst the trials with cisplatin resulting in minor protection for 
ototoxicity [7, 212] and general CIPN [204, 205, 214]. Oxaliplatin also showed minor protection for 
CIPN in one trial [206], which used subcutaneous administration of amifostine. Paclitaxel resulted in 
two negative responses [210, 213] indicating that it is not a clinical option for paclitaxel alone. 
Moreover, a trial conducted on paclitaxel and cisplatin was ceased due to the number of patients 
experiencing CIPN exceeded the pre-determined threshold [209]. However, the combination of 
paclitaxel and carboplatin indicated minor protection for severe CIPN [207, 211, 215] with one trial 
resulting in no benefit [6]. Only one trial on cisplatin administered for five consecutive days resulted 
in a significantly lower incidence of CIPN [203]. 
Most trials noted side effects including hypotension, nausea, vomiting, dizziness, flushing, anxiety, 
palpitations, and sneezing. Overall, the possible protective effect from amifostine is counteracted by 
its own side effects. 
2.1.1.2 Recombinant Human Leukaemia Inhibitory Factor (rhuLIF) 
One trial has been conducted on this compound with no benefit found for CIPN [217]. In addition, 
adverse reactions were noted including injection site reactions, light-headedness, rigor/chills, 
myocardial ischemia and hypotension [217]. 
2.1.1.3 Anticonvulsants  
Two anticonvulsants have been trialled for CIPN, carbamazepine and oxcarbazepine [218-221] for 
oxaliplatin-IPN. Two trials, one with 10 participants [218] and another with 32 participants [220] 
showed mild or possible prevention compared to two trials, which found no benefit [219, 221]. 
2.1.1.4 Gabapentin (Neurontin) 
Two trials have been conducted with gabapentin for the treatment of cancer and/or CIPN pain [5, 8]. 
Ross, et al. [8] found it may benefit cancer pain but was not specific for CIPN. Rao, et al. [5] who 
trialled gabapentin specifically for CIPN in 115 participants found that it failed to show any benefit 
for CIPN symptoms. 
2.1.1.5  Lamotrigine 
A phase III RCT has been conducted on lamotrigine [222] for the treatment of CIPN in 131 
participants. No difference was seen between the treatment and placebo arms and therefore was found 
to not be an effective agent for relieving neuropathic symptoms from CIPN. 
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2.1.1.6 Pregabalin 
An open label trial was conducted on pregabelin (Lyrica) [223] as a treatment for oxaliplatin induced 
peripheral neuropathy for 23 cancer patients.  The target dose of 150 mg three times a day (TDS) 
provided the most benefits (5/23 patients reached target dose) with improvements observed between 
two-six weeks of treatment.  
Forty-eight percent of patients CIPN improved by one to two grades bringing the authors to the 
conclusion that pregabalin can significantly reduce the severity of sensory peripheral neuropathy from 
oxaliplatin administration. Pregabalin has fewer side effects than gabapentin so may be better options 
for patients.  
2.1.1.7 Antidepressants 
A number of antidepressants have been trialled for the treatment of CIPN including tricyclic 
antidepressants such as amitriptyline [223] and nortriptyline [225], venlafaxine [226-228] and 
duloxetine [229, 230]. Three of the published papers on venlafaxine and one of the duloxetine papers 
were case studies [226-229] with most indicating some benefit. The tricyclic antidepressants [224, 
225] did not demonstrate improvement in CIPN particularly sensory neuropathic symptoms and 
participants also noted a number of side effects from these drugs. A recent phase III trial on duloxetine 
[230] assessing 231 participants for treatment of CIPN has been the first trial that has shown statistical 
significance for improving pain from CIPN compared to placebo. Further research to support this trial 
is warranted but it does show promise for patients experiencing CIPN pain from taxanes or 
oxaliplatin. 
2.1.1.8 Calcium Channel Blockers 
A retrospective study was conducted on 116 participants who underwent administration of FOLFOX6 
regime [231]. The data on these patients was assessed for acute CIPN development and calcium 
channel blocker concurrent administration. From the information obtained, it was hypothesised that 
calcium channel blockers may inhibit the development of CIPN but further research is required. To 
conduct a RCT would be difficult considering that these drugs lower blood pressure and not all 
patients undergoing chemotherapy have high blood pressure. If they do, they have normally been 
prescribed a specific drug or more which may not be a calcium channel blocker. Further research will 
most likely be more retrospective analysis on a larger population base.  
2.1.2 Strengths and Weaknesses and Gaps in the Research 
Clinical trials conducted on medical drugs involve a scientific study that involves patients and/or non-
patient volunteers. They confirm if a medicine is safe and effective to introduce as a new treatment 
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for a particular disease or condition [232]. One of the major problems with protective or treatment 
trials for CIPN is that each neurotoxic drug has a different mechanism of action and the actual cause 
of the neuropathy is unknown other than that fact that the chemotherapy agent accumulates in the 
peripheral nerves. In addition, the patients have or may have had cancer which in itself can present a 
myriad of other physiological and biochemical issues.  
The major weaknesses of the trials conducted on CIPN from medicinal drugs include the fact that the 
drugs themselves can induce their own side effects in addition to the side effects experienced by the 
chemotherapy agents. Moreover, most trials used the NCI-CTC as their measurement tool which is 
subjective rather than quantitative. The NCI-CTC is an assessment tool used by medical doctors or 
staff which is based on an examiner’s interpretation rather than a formal neurological evaluation. A 
study by Frigeni et al., (2011) examined the difference between the NCI-CTC and the Total 
Neuropathy Score (TNS) to identify any discrepancies in diagnosis of CIPN. The authors found that 
the NCI-CTC evaluation when performed by experienced examiners may overestimate the occurrence 
of motor neuropathy due to confounding factors such as fatigue, depression and cachexia. They 
concluded that a more formal neurological assessment of patients with CIPN is advised rather than 
using an examiner interpretation of the NCI-CTC [338].  
Considering that there are more cancer survivors and that these neurotoxic drugs can create a 
permanent consequence, it is important to see that further research is being conducted on both 
protection and treatment trials. One of the gaps in the research is that the drugs being trialled have 
been mostly used for other peripheral neuropathies which are different to CIPN. Other peripheral 
neuropathies such as diabetic, HIV or alcoholic induced peripheral neuropathy [12] are normally slow 
developing neuropathies whereas CIPN although accumulative can be a fast developing side effect 
[12]. Hence, the research gap is looking at different possible mechanisms of action that could be 
involved in the development or predisposition of CIPN.  One of these possibilities is the fact that a 
deficiency in certain B vitamins such as vitamin B1, B6 and B12 can cause a peripheral neuropathy. 
Therefore, if chemotherapy drugs and/or poor diet during chemotherapy lowers these vitamins into a 
deficiency or near deficiency state, it may predispose the patient to the development of CIPN. 
Another opportunity may involve prophylactic anti-inflammatory drugs. Although normal pain relief 
does not reduce the pain associated with CIPN, no specific anti-inflammatory drug has been trialled 
as a protective agent. This is one of the main mechanisms of action that has been identified in the 
nutrients and the herbs trialled for CIPN that have shown a possible beneficial protective effect [233-
246]. The anti-inflammatory component may or may not protect patients against CIPN but it would 
be an interesting aspect to investigate. Another aspect that may be interesting to research is the 
relationship between lower limb oedema and the incidence of CIPN.   
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2.1.3  Outcomes for Pharmaceutical Agents and CIPN 
From the trials conducted, no pharmaceutical agent has been found to prevent CIPN. Several agents 
have been found to have a limited benefit, for the treatment of CIPN however, further trials are 
required. Possible beneficial treatment options include duloxetine (Cymbalta) and other anti-
depressants such as venlafaxine (Effexor). Currently clinicians have also been using pregabalin 
(Lyrica) with some benefit although only one open label trial has been conducted on CIPN. 
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Table 2-1: Clinical Studies Investigating the Efficacy of Selected Pharmaceuticals for the Prevention of CIPN. 
 
Pharmaceuticals Study Type / 
Level of 
Evidence 
Level of 
Evidence 
Number 
of Pts5 
Chemotherapy and 
Duration 
Results 
Amifostine 
(WR2721) 
RCT [1203] 
 
Level III-1 
 
69 5 consecutive days of 
cisplatin 
WR 2721 had a significantly lower incidence of CIPN  
(incidence was 25% versus 49% ) 
NRCT Phase 1 
trial [212] 
Level III-2 
 
11 Cisplatin: duration not 
noted 
Possible protection for ototoxicity from cisplatin  
RCT [204] 
 
Level III-1 
 
242 6 cycles every 3 
weeks cisplatin/ CPP6 
Pre-treatment with amifostine showed a reduction in 
accumulative toxicities (p=0.029). 
RCT [205]  
 
Level III-1 
 
74 6 cycles weekly (3 
mth follow up)  of 
cisplatin 
Diminished incidence of subclinical CIPN in the amifostine 
arm (p=0.03) with no protection shown for renal or ototoxicity.  
RCT Phase II  
[213] 
Level III-1 40 3 cycles every 3 
weeks of taxol 
No differences observed in neurotoxicity  
Pilot trial [206]  
  
Level III-3 
 
15 Raltitrexed/OxP7 
every 3 wks 
Irinotecan/OxP given 
day 1,14 every 4 wks.  
Counteracted oxaliplatin CIPN as 10/15 patients had reduced 
the severity of CIPN. 
Phase II open 
label trial 
[214] 
Level III-2 
 
37 Cisplatin every 3 
weeks until disease 
progression 
No tumour protection or reduced toxicity  
Multi-centre 
Phase III 
RCT[207] 
 
Level III-1 
 
187 6 cycles every 3 
weeks of carbo/taxol8 
May be protective for grade 3 and 4 neurotoxicity (3.7% vs 
7.2%; P-0.02) 
                                                 
5 Pts - Participants 
6 CPP - cyclophosphamide 
7 OxP – oxaliplatin 
8 Carbo/Taxol is a combination of carboplatin and paclitaxel 
  
2-95 
 
DBRCT  [208] 
 
Level II 
 
60 2 cycles every 3 wks 
of carbo/taxol, then 
radiation, then 6 
weekly taxol 
No significant protective effects  
RCT [215] 
 
Level III-1 
 
38 6 cycles of carbo/taxol 
every 3 weeks 
May reduce the incidence of CIPN  
Multi-centre 
NRCT [209] 
Level III-2 
 
27 6 cycles of paclitaxel 
and cisplatin every 3 
weeks  
4/21 had grade 2-4 neurotoxicity, 3/21 had grade 3 CIPN – 
Study terminated 
NRCT [210] 
 
Level III-2 
 
31 Doxorubicin, 
paclitaxel and CPP 
over 9 days  
No significant effect was seen.    
RCT [211] 
 
Level III-1 
 
90 6 cycles every 3 
weeks of carbo/taxol  
Only minor protective effects  
DBRCT Phase 
II [6] 
Level II 
 
71 Carbo/taxol with or 
without epirubicin 
Found to improve sensory neuropathy according to the NCI-
CTC (P=0.0046) 
RCT [7] 
 
Level III-1 
 
97 4 cycles of cisplatin/ 
vincristine /CPP every 
3 weeks 
May significantly reduce the risk of severe ototoxicity 
Recombinant 
human leukaemia 
inhibitory factor 
(rhuLIF) 
DBRCT [217] 
 
Level II 
 
117 Carbo/taxol 4-6 cycles 
every 3 weeks  
No differences noted  
Anticonvulsants 
(carbamazepine/ 
oxcarbazepine) 
NRCT [218] 
 
Level III-3 
 
10 FOLFOX (OxP) 12 
cycles every 2 weeks  
Carbamazepine may provide a possible prevention  
NRCT [219] 
 
Level III-3 
 
25 FOLFOX (OxP) 12 
cycles every 2 weeks 
Carbamazepine did not provide symptomatic relief or 
prevention  
Open label 
RCT [220] 
Level III-2 
 
32 FOLFOX (OxP)  12 
cycles every 2 weeks 
Oxcarbazepine was lower than the control with 5/16 (31.2%) 
versus 12/16 (75%) getting CIPN 
RCT [221]  
 
Level III-1 
 
36 FOLFOX (OxP)  
6 weekly  
No major differences were found between the two groups. 
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Gabapentin 
(Neurontin) 
Open label 
NRCT [8] 
Level III-2 
 
62 15 days Only 2/25 had CIPN pain 
DBRCT multi-
centre [5] 
 
Level II 
 
115 CIPN >1 month  
Tx= 6 weeks plus a 2 
weeks washout  
Gabapentin failed to show any benefit to treat CIPN symptoms 
Lamotrigine RCT Phase III 
[222] 
 
Level II 
 
131 CIPN >1 month  
Tx = 10 weeks than 4 
week tapering off drug 
No differences seen in the two groups 
Pregabelin 
(lyrica) 
Open label 
[223] 
Level III-2 23 150mg TDS for 6 
weeks 
Significantly reduced the severity of oxaliplatin-induced 
sensory neuropathy in patients that reached target dose (22%) 
Antidepressants: 
 
1. Tricyclic 
antidepressants 
e.g. amitriptyline 
and nortriptyline. 
DBRCT cross 
over trial [225] 
Level II 
 
51 Cisplatin CIPN pain 
>1 mth: 4 weeks, 1 
week washout 
Very modest effect of nortriptyline on the relief of painful 
CIPN.  
DBRCT [224] Level II 44 CIPN 
8 weeks 
Amitriptyline did not demonstrate any improvement for sensory 
neuropathic symptoms 
2.Venlafaxine 
 
CS [227] 
 
Level VI 
 
1 CIPN from 
Carbo/Taxol 
60yo women developed CIPN after 3rd cycle.  
Venlafaxine reduced CIPN. 
CS [226] 
  
Level VI 
 
1 CIPN from OxP 
 
33yo patient developed CIPN after 3 cycles, exacerbated by 
cold. Venlafaxine reduced CIPN 
CS [228] 
 
Level VI 
 
2 CIPN from FOLFOX 
(OxP) 
82yo women: assisted quick recovery.  
53yo man: Venlafaxine had no beneficial effect.  
3. Duloxetine CS [229] Level VI 1  CIPN from paclitaxel 68yo man: decreased CIPN in 5 months. 
DBRCT cross 
over trial 
Phase III  
[230] 
Level II 
 
231 CIPN – treatment for 
12 weeks 
Statistically significant in improving pain from CIPN compared 
to placebo 
Calcium channel 
blockers 
Retrospective 
study [231] 
 
Level III-2 
 
116 Data analysed 
retrospectively from 
FOLFOX6 regime 
Had significantly lower incidence curve for acute CIPN but not 
for cumulative chronic CIPN. 
DBRCT: Double Blind Randomised Controlled Trial; SBRCT: Single Blinded Randomised Controlled Trial; RCT: Randomised Controlled Trial; NRCT: Non Randomised 
Clinical Trial; CS: Case Study; TNS: Total Neuropathy Score 
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2.2 RESEARCH ON NUTRACEUTICALS FOR THE TREATMENT AND/OR PREVENTION OF 
CIPN 
Twenty-four clinical trials examining a variety of agents on the prevention and symptomatic treatment 
of CIPN have been conducted.  To date, few nutraceuticals have proven successful in preventing 
CIPN development. One nutraceutical, acetyl-L-carnitine [247, 248] has shown promise in a 
preliminary trial as a neuroprotective agent for the treatment of CIPN after chemotherapy 
administration, but further studies are required. A new study looking at omega 3-fatty acids showed 
a statistically significant difference for paclitaxel induced neuropathy although further studies are 
required to confirm this finding [237]. 
Results of all the studies can be found in Table 2-3: Clinical Studies Investigating the Efficacy of 
Selected Nutraceuticals for the Prevention of CIPN. Information pertaining to this section has been 
published: Review: Nutraceuticals and Chemotherapy-Induced Peripheral Neuropathy (CIPN): a 
Systematic Literature Review. Schloss J, Colosimo M, Airey C, Vitetta L. Clin Nutr 2013: 32(6):888-
93 [249] 
2.2.1 Study Characteristics  
The studies selected for this review include randomised controlled trials, open label trials and one 
retrospective study. The randomised controlled trials identified are divided into eleven double blind 
placebo controlled trials, five randomised controlled trials including a randomised open label with a 
blind assessment plus two non-randomised controlled trials. Four open label trials were identified 
which did not contain a placebo component. 
The results of the included studies were mixed. Several nutraceuticals showed initial positive results 
in reducing CIPN however further studies found that they were either not significant or indicated 
possible interference with the chemotherapy agent’s response rate. No nutraceutical currently has 
been found to significantly show protection or treatment for CIPN. 
Methodology 
A systematic search of the literature was conducted using PubMed, the Cochrane Library, Science 
Direct, Scopus, EMBASE, MEDLINE and CINAHL. 
Search Terms 
Articles were identified using the search terms, “chemotherapy” OR “Cisplatin” OR “Taxanes” OR 
“Paclitaxel”  OR “Docetaxel” OR “Oxaliplatin” OR “Carboplatin” OR “Platinum compounds” OR 
“Proteasome inhibitors” AND “induced peripheral neuropathy” OR “CIPN” AND “nutrient” OR 
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“vitamin” OR “mineral” OR “Acetyl-L-Carnitine” OR “Glutamine” OR “Vitamin E” OR “Alpha 
Lipoic acid” OR “Magnesium” OR “Calcium” OR “Vitamin B6” OR “B vitamins” OR “Omega-3 
fatty acids”. 
The Inclusion criteria for this review were: 1) An RCT and/or cross-over clinical trial that used either 
a placebo comparator or current anti–CIPN treatment as a control; 2) Human participants diagnosed 
with a cancer and administered chemotherapy; 3) The use of a nutraceutical supplement as the main 
intervention and specifically investigating its effects on reducing the primary outcome i.e., CIPN; and 
4) The clinical study was published in English.  
The overall body of evidence (based on a summary of the individual studies) (Table 2-3) evaluated 
within this review was assessed using a separate tool, the Australian National health and Medical 
Research Council’s (NHMRC) body of clinical evidence assessment matrix. This is an assessment 
tool that assigns a level/grade (Level I: strongest evidence to level IV: weakest evidence) based on 
the strength of the published study [216]. The consort diagram can be seen in figure 2-2. 
   36 Records identified from bibliographic databases 
 
                                                                                         Records excluded from further review  
        1   Study design not eligible 
        0   No relevant outcome 
        11 No relevant study group 
 
24 Studies retrieved for relevant assessment 
 
24 relevant studies assessed 
                                                                         1 study excluded due to  
                                                                    repeat publication of mid and final results 
 
23 studies assessed qualitatively 
 
                    
                         0 studies excluded based on  
     negative study outcomes   
 
23 studies included 
Figure 2-2: Flow of information for systematic review on nutriceuticals. 
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2.2.2 Nutriceuticals and CIPN Research 
2.2.2.1 Magnesium and Calcium 
Magnesium and calcium infusions with oxaliplatin also showed initial positive results in a 
retrospective study [250]. Three clinical trials [251-253] reported that efficacy was not enhanced with 
one trial (n=174) being terminated due to the treatment group reporting a significant lower response 
rate compared to placebo [251].  
2.2.2.2 Vitamin E 
Vitamin E was demonstrated to have positive results in three RCT’s showing a significant reduction 
in the relative risk of cisplatin induced PN, especially ototoxicity [233-236, 254]. However, a phase 
III multi-centre trial combining vitamin E with taxanes, cisplatin, carboplatin, oxaliplatin or 
combination concluded that vitamin E did not appear to reduce the incidence of sensory neuropathy 
[254].   Vitamin E efficacy was limited to those patients administered cisplatin (only 8 from the 207 
cohort) during the phase III study.  Previous studies have indicated that vitamin E seems to be more 
protective for cisplatin ototoxicity compared to other neurotoxic agents [255].  
A recent pilot trial with oxaliplatin induced peripheral neuropathy also failed to show protective effect 
of vitamin E [256]. In contrast, this study showed an increased number of participants developing 
grade 1 and 2 acute CIPN from oxaliplatin. There was also a major confounding factor with this study 
as each patient (either on vitamin E or placebo) also received infusions of calcium and magnesium 
with each administration of chemotherapy. This may have played a key factor with possible 
interactions occurring with the vitamin E and could explain why the placebo (68% vs 83%) [256], 
experienced less CIPN considering previous trials on magnesium/calcium infusion and oxaliplatin 
[250].  
2.2.2.3 Lipoic Acid  
One open label study was conducted with alpha lipoic acid (n=15) co-administered with oxaliplatin 
[257]. This treatment combination showed a trend toward a reduction in the severity of oxaliplatin 
induced CIPN in 8 out of 15 patients but the trend was not statistically significant [257]. The second 
trial was a randomised, double-blind placebo-controlled trial (n=243) who were randomised to either 
600mg of alpha lipoic acid (n= 122) or placebo three times a day (n= 121). It was measured by the 
FACT/GOG-Ntx and the NCI-CTC.  Only 70 (29%) of the 243 participants completed the trial (24 
weeks) with both arms having comparable dropout rates. It was found that lipoic acid was not 
statistically significant in reducing neurotoxicity from cisplatin or oxaliplatin [258]. 
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2.2.2.4 N-Acetyl Cysteine 
N-acetyl cysteine (NAC) administration to cancer patients has been based on the assumption that 
NAC can increase glutathione production, an effect that may decrease cyto-toxicity [259].   
In a further study conducted with NAC no significant changes on electrophysiological testing on both 
sensory and motor nerves were found between the two groups [259]. 
2.2.2.5 Glutathione 
Glutathione has been reported to show positive results in reducing CIPN [260]. Intravenous 
glutathione administered before cisplatin administration reported promising outcomes for the 
prevention of cisplatin induced PN without reducing the anti-tumour activity of the chemotherapeutic 
agent [261-263]. A positive result was also found in two studies with oxaliplatin [264, 265]. Both 
studies reported a significant reduction in oxaliplatin induced PN, mainly relevant to sural sensory 
nerve reduction. These results present clinical data that indicates that glutathione administration may 
aid in the prevention of CIPN.  However, additional higher quality studies are required, as these trials 
were limited due to a high participant dropout rate and without long-term follow–up.  
2.2.2.6 Glutamine 
Two published clinical studies [266, 267] on the administration of glutamine with paclitaxel are the 
results from the same clinical trial. The first study is from an early publication of results [266] with 
final results being published in the second study [267].  These studies reported that the patients on 
glutamine tended to have fewer symptoms than those on placebo however the trend in the nerve 
conduction studies was not statistically significant. There was a drift in the results that indicated that 
glutamine decreased the severity of dysesthesia in the fingers and toes. An additional study [268] 
with glutamine and oxaliplatin co-administration reported that glutamine may reduce the incidence 
and severity of oxaliplatin induced CIPN. No significant differences were found between the two 
groups [268].  
2.2.2.7 Acetyl–L–Carnitine 
Two open label studies reported that acetyl–L–carnitine (ALC) may be a treatment option for 
paclitaxel and cisplatin induced CIPN [247, 269].  A phase III trial demonstrated that ALC did not 
provide a positive benefit for the prevention of CIPN [270].  The study concluded that patients should 
be discouraged from using ALC during treatment with taxane therapy.  Notwithstanding this 
recommendation it may be an option for the treatment of CIPN rather than prevention in patients that 
already may be experiencing CIPN. 
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2.2.2.8 Vitamin B6 
One DBRCT with vitamin B6 found that it significantly reduced CIPN from cisplatin and 
hexamtheylmelamin administration [78]. Furthermore the results indicated that the high dose vitamin 
B6 (100 mg) administered may affect response duration and that it requires further investigation [78]. 
A recent study on oxaliplatin used a derivative of vitamin B6, mangafodipir [18] which found it 
beneficial in preventing or alleviating oxaliplatin-IPN.  
2.2.2.9 Omega–3 Fatty Acids 
A recent DBRCT investigating the effect of omega–3 fatty acids on paclitaxel induced peripheral 
neuropathy found that it significantly reduced the incidence of CIPN from paclitaxel by 70% [237]. 
The results of the reduced TNS found that 21 out of 30 patients (70%) did not develop CIPN while 9 
patients (30%) did develop CIPN in the omega 3 fatty acid supplemented group. In the placebo group 
out of 11 out of 26 patients (40.7%) did not develop CIPN.  The only statistical significance found in 
the NCS parameters was the sural nerve conduction test. A significant difference was observed for 
the sural a-SAP score between the omega-3 supplemented group compared to placebo (p=0.015). A 
sharp decrease of the sural a-SAP as seen in the placebo group compared to the intervention group. 
Further testing in larger randomised clinical trials is required however omega–3 fatty acids do show 
promise for protection against paclitaxel induced peripheral neuropathy [237]. 
2.2.3 Adverse Events and Adherence 
There were limited adverse events noted from the nutraceuticals trialled for CIPN. The reported 
adverse events were from the use of acetyl-l-carnitine. Two patients reported acetyl-l-carnitine 
induced mild nausea [247] and one patient reported insomnia related to acetyl-l-carnitine treatment 
[271]. 
The nutraceuticals trialled were generally well tolerated according to the journal articles with only 
one study stating that two participants stopped their vitamin E supplementation after one month [272]. 
No reason was given as to why they had stopped taking the vitamin E.  
2.2.4 Confounding Factors for Research on Nutraceuticals and CIPN 
All studies indicated but did not state confounding factors associated with the clinical trials. These 
may have been listed under why patients didn’t complete the trial or why they withdrew or other 
toxicities associated with the chemotherapy administration. All of these factors may have implications 
on the nutraceutical administration by affecting absorption, metabolism or compliance. One study 
reported the difficulty in reproducing or quantifying peripheral neuropathy as a confounding factor 
[263]. 
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The main confounding factors reported in the studies from Table 2-3 are presented in Table 2-2  
Table 2-2: Reported Confounding Factors in Studies on Nutraceuticals and CIPN. 
 
Confounding Factors n 
Grade 3 or 4 nausea and vomiting 4 
Grade 3 or 4 diarrhoea 3 
Haematological toxicity (including transient hepatic failure)  2 
Stomatitis 2 
If the treatment was first, second or third line treatment 2 
Cardiac and/or neurocerebellar adverse events  2 
Use of Alternative treatments  1 
 
2.2.5 Possible Drug-Interactions with High Doses of Nutraceuticals 
Three studies found that there could be possible drug interactions with high dose nutraceuticals. The 
intravenous magnesium and calcium trial with FOLFOX regime was terminated due to the fact that 
the treatment group reported a significant lower response rate compared to placebo [251]. The authors 
concluded that a possible drug interaction occurred between the chemotherapy regime and the 
magnesium and calcium infusions however no further investigations were continued to ascertain the 
mechanism of action. 
One study on glutamine stated that there could have been a protective effect from the glutamine on 
the tumour from the cytotoxic effects from the paclitaxel although no decrease in response rate was 
noted in the trial [266]. Again, no further testing was undertaken to ascertain this variable.  
The study on vitamin B6 did show a significant decrease in the response rate with cisplatin and HMM 
[78]. Authors stated that this was directly due to the vitamin B6 supplementation as it occurred in all 
participants administered the high dose of vitamin B6. However, it also showed that vitamin B6 
reduced response rate. No investigations were undertaken to ascertain how this occurred or the 
possible mechanism of action although the authors stated that further investigations were warranted. 
2.2.6 Review Limitations 
Several limitations have been identified within the selected studies. Limitations identified in the 
retrospective study [250] include no randomisation of patients, no blinding and patients, medical and 
nursing staff may have been biased in their reporting or assessment of signs and symptoms. All studies 
that did not include a placebo noted the limitation of not having a placebo-effect. 
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Assessment of CIPN is varied amongst all studies. This makes it difficult when comparing studies 
and results. There is no “gold standard assessment” of CIPN therefore clinical trials use a variety of 
assessment tools to quantify CIPN development and severity. These include the National Cancer 
Institute Common Toxicity Criteria (NCI-CTC), total neuropathy score (TNS), nerve conduction 
studies and/or electrophysiological investigations and quality of life questionnaires.  Refer to chapter 
1 section 1.7, p 1-37 for further evaluation of assessment tools.  
The NCI-CTC is a clinician-based grading scale whereby the assessor may mix impairment, disability 
and quality of life measures which can lead to different interpretations of results and demonstrates 
observer objectivity and possible bias [34]. The NCI-CTC is the most commonly used assessment 
tool in the selected studies. The TNS is stated to be the most comprehensive assessment tool available 
at this time [273] with only one study using this assessment tool as their main measurement of results 
[256]. The nerve conduction studies and electrophysiological investigations are the other main 
assessment tool used within these studies. These provide information on compound action potential 
amplitude and conduction velocity but do not provide information regarding ion channel function or 
resting membrane potential and are still dependent on the skill of the neurologist conducting the 
assessment [274].   
Another limitation involves the activities of daily living (ADL) or assessment of ADL.  This is 
because the level of symptoms or interference of daily activity is generally subjective and signs on a 
physical examination may not always be predictive of whether ADL is affected or if it is important 
for that patient’s life.  
2.2.7 Discussion on Outcomes on Nutraceuticals and CIPN 
Currently there are no established neuroprotective nutraceuticals or treatment options for CIPN. 
Results are inconsistent requiring further investigation to confirm efficacy and safety. There are 
several nutraceuticals which have shown promise for selective neurotoxic chemotherapy agents such 
as vitamin E with cisplatin, intravenous glutathione for oxaliplatin administration, vitamin B6 with 
HMM and cisplatin although it did interfere with response rate and omega-3 fatty acids for paclitaxel. 
Acetyl-L-carnitine has also shown promise as a treatment option for CIPN with further research 
required in large randomised controlled trials. 
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Table 2-3: Clinical Studies Investigating the Efficacy of Selected Nutraceuticals for the Prevention of CIPN. 
 
Nutraceuticals Study Type  Level of 
Evidence 
Number 
of Pts 
Duration Results 
Magnesium / 
Calcium 
Retrospective 
study [250]   
Level III-2 161 3 cycles of FOLFOX every 2 weeks Grade 3 or 4 CIPN in Ca/Mg group recovered 
significantly quicker  
 DBRCT  [251]  
 
Level II 174 8 cycles of FOLFOX plus 
bevacizumab every two weeks 
Trial was terminated  
 Open label [252]  Level III-3 14 FOLFOX 12 cycles every two 
weeks 
CIPN occurred in 8 participants (57.1%)  
 DBRCT [253]     
 
Level II 35 FOLFOX6 12 cycles given every 
two weeks 
Not significant 
Vitamin E DBRCT [233]    
 
Level II 
 
47 Cisplatin 6 cycles and 3 months 
after  
Significantly lower incidence of CIPN  [vitamin E 
group 30.7% vs control group 85.7] 
RCT  [234]   
Open label blind 
assessment 
Level III-1 40 6 cycles of cisplatin, paclitaxel or 
combination plus 3 months after  
CIPN developed in 4/16 (25%) of vitamin E group 
compared to 11/15 (73.3%) of control group. 
 RCT  [235]  
Open label blind 
assessment  
Level III-1 
 
35 6 cycles of cumulative cisplatin 
based regimes 
This study includes the final results of the 
published 2005 paper  
 DBRCT [236]   
 
Level II 
 
108 Cisplatin – given before, during and 
3 months after chemotherapy 
Significantly lower incidence of CIPN [vitamin E 
5.9% vs placebo 41.9%] 
 DBRCT  [254]  
Multi-centre 
Level II 
 
207 4 days after chemotherapy, during 
and 1 month after 
No significant differences found 
RCT [256] 
 
Level III-1 34 OxP 12 cycles every 2 weeks  No significant decrease in the incidence of acute 
CIPN  
Alpha Lipoic 
Acid 
Open label [257] 
 
Level III-3 
 
15 ≥grade 2 CIPN after 6 cycles of 
OxP till recovery 
Reduced severity of CIPN in 8/15(53%)  
DBRCT [258] Level II 243 Oxaliplatin or cisplatin: stratified to 
no prior exposure to platinum 
compounds, prior exposure to 
<399mg/m2 cisplatin or <750mg/m2 
oxaliplatin lastly exposure to 
Was found ineffective in preventing neurotoxicity 
from oxaliplatin and cisplatin 
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>400mg/m2 of cisplatin or 
>750mg/m2 of oxaliplatin 
N-acetyl 
cysteine (NAC) 
RCT [259] 
 
Level III-1 
 
14 FOLFOX 12 cycles every 2 weeks  No significant change. 
Glutathione DBRCT [261]  
 
Level II 
 
50 Weekly cisplatin for 15 weeks A trend towards prevention of CIPN  
RCT [262]  
 
Level III-1 
 
33 Weekly cisplatin for 9 weeks No major differences observed, trend towards 
neuroprotection 
 DBRCT  [263] 
 
Level II 
 
151 Cisplatin every 3 weeks for 6 
cycles 
Not significant  
 DBRCT [264]  
 
Level II 52 Oxaliplatin every 2 weeks for 12 
cycles 
Not statistically significant but was for placebo 
sural nerve conduction 
 RCT [265]   
 
Level III-1 27 Oxaliplatin every 2 weeks for 12 
cycles 
Statistically significant reduction of neurotoxicity 
(P=0.0037). 
Glutamine NRCT [266, 267]   
 
Level III-2 47 Given orally for 4 days starting 24 
hours after paclitaxel completion 
Not statistically significant 
RCT [268]  
 
Level III-1 88 6 cycles FOLFOX regime over 6 
months 
May reduced severity of CIPN 
Acetyl-L-
Carntine (ALC) 
Open label [247] Level III-2 25 8 weeks  May provide an option for treatment of CIPN 
 Open label [269] Level III-2 26 10 days Slight improvement in CIPN 
 DBRCT [270] 
multi-centre 
Level II 
 
409 24 weeks No evidence of a positive impact  
Vitamin B6 DBRCT [78] 
 
Level II 
 
248 Between 1-70 months 
 
Significantly reduced CIPN however adversely 
affect response duration.  
Open label [18] Level III-1 23 Treatment for 8 cycles of 
oxaliplatin (16 weeks) 
May prevent and/or relieve oxaliplatin-IPN 
Omega 3 Fatty 
Acids (Omega 
3FA) 
DBRCT [237] 
 
Level II 
 
69 Paclitaxel every 3 week for 4 cycles 
and one month after 
Statistically significant protection of CIPN  
DBRCT: Double Blind Randomised Controlled Trial; SBRCT: Single Blinded Randomised Controlled Trial; RCT: Randomised Controlled Trial; 
NRCT: Non Randomised Clinical Trial; CS: Case Study; TNS: Total Neuropathy Score 
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2.3 OTHER COMPLEMENTARY THERAPIES FOR CIPN 
A number of complementary therapies other than nutraceuticals have been tested for CIPN. These 
include acupuncture [275], herbal medicine [276] and contact needle therapy [277]. Acupuncture has 
the most clinical trials whilst herbal medicine has limited research mainly based on in vitro and animal 
studies. The contact needle therapy is one pilot trial with more research needed.  
2.3.1 Acupuncture and CIPN 
A 2013 systemic review on experimental and clinical acupuncture in CIPN [275] identified 3989 
articles on acupuncture, however only 98 were relevant to CIPN. Of those, there were only 7 clinical 
trials [278-284] and 1 experimental study [285] which was a rat study. The overall conclusion from 
the systemic review [275] was that acupuncture generally had positive effects on CIPN by reducing 
the pain score in most studies. The limitations identified in the trials reviewed include small sample 
size, poor controls or no controls, poor randomisation and lack of blinding. Further studies are 
required to confirm benefit from acupuncture but they require more rigorous randomised controlled 
clinical trials. 
One paper has been published on contact needle therapy and CIPN which involves case studies on 6 
patients [277]. Contact needle therapy (CNT) is a form of traditional Japanese acupuncture. It uses 
disposable needles that are not inserted but only settle on the acupuncture point to perform the least 
stimulus compared to other forms of acupuncture which insert the fine needles through the skin. The 
latter is used to unblock the meridian and improve the patients’ condition no matter what the disease 
by regulating the flow of Qi [277]. 
The results of the CNT case studies found that all patients displayed some improvement with 4/6 
patients showing apparent improvement in pain [277]. To confirm these preliminary results, well-
designed clinical trials with adequate power and sample size are required.  
A recent RCT on electroacupuncture found that the electroacupunture point’s trialled were not 
superior to placebo and no significant differences were seen in sensory nerve conduction studies or 
quality of life [286]. The authors concluded that as other acupuncture studies have found benefit 
contrary to their findings, the effect of acupuncture remains unclear with further trials required.  
2.3.2 Herbal Medicine and CIPN 
A total of 5614 journal articles were identified (1543 in English and 1997 in Chinese or Japanese). 
These were retrieved through electronic search and examination of references in reviews. 
Dissemination of the articles and abstracts decreased the total of articles from 3540 to 34 relevant 
journal articles. These results found 6 single herbs [238, 245, 287-296], one extract [297], one 
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receptor agonist [298, 299] and 8 combinations of herbs [300-318].  All studies were analysed for 
common scientific characteristics however lower levels of evidence was used as rigorous randomised 
clinical trials were limited. The majority of the journal articles identified were animal studies [n=17]. 
Human trials consisted of one multi-centre, randomised double-blind placebo-controlled trial, six 
randomised trials, six retrospective studies, one uncontrolled study and three case reports found, (see 
Table 2-4). Information pertaining to the herbs reported for CIPN has been accepted in Critical 
Reviews in Food Science and Nutrition. Herbal Medicines and Chemotherapy-Induced Peripheral 
Neuropathy (CIPN): a Critical Literature Review. Schloss J, Colosimo M, Vitetta L. [319]    
The main problem with research involving herbal extracts or medicinal herbs is the understanding of 
the mechanism of actions and the fact that the herbs contain a number of active compounds. 
Moreover, Asian herbal therapies contain a combination of multiple herbs, which adds to the 
complexity of study analysis, data interpretation and an assessment of benefit. Isolation of one extract 
which is common in scientific research is unable to be conducted with herbal medicine research in 
most situations as the combination of compounds or combination of herbs such as Asian herbal 
therapies are seen to work in synergy. 
Therefore, the studies conducted on herbal medicines and CIPN to date have not yielded clinical 
evidence to support the use of herbal medicines in the prevention or treatment of CIPN.  However, 
some herbal medicines and combination of herbs such as Goshajinkigan (Japanese Kampo medicine) 
show promise with further research required. 
 
Methodology 
Selection Criteria 
The Inclusion criteria for this review were:  
1) Any type of human trial e.g. RCT, retrospective, case study;  
2) Animal studies;  
3) The use of a herb or combination of herbs as the main intervention and specifically investigating 
its effects on reducing the primary outcome i.e. CIPN; and  
4) The journal article or abstract must be written in English (a number of Asian journal articles 
had the abstract in English but the journal article in their language i.e. Japanese or Chinese.) 
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Databases 
The following databases were used to retrieve journal articles: PubMed, the Cochrane Library, 
Science Direct, Scopus, EMBASE, MEDLINE, CNKI, CINAHL and Google Scholar.  
Search Terms 
Electronic databases were searched using the following  search terms, “chemotherapy-induced 
peripheral neuropathy” OR “Cisplatin” OR “Taxanes” OR “Paclitaxel” OR “Docetaxel” OR 
“Oxaliplatin” OR “Carboplatin” OR “Platinum compounds” OR “Proteasome inhibitors” AND 
“peripheral neuropathy” OR “CIPN” AND “herb” OR “cannabis” OR “chamomile” OR “ginkgo” 
OR “sweet bee venom” OR “turmeric” OR “sage” OR “hypericum” OR “herbal medicines” OR 
“Chinese herbal medicines” OR “ayurvedic herbal medicines”. 
The overall body of evidence evaluated within this review was primarily assessed using a separate 
tool, the Australian National Health and Medical Research Council’s (NHMRC) body of clinical 
evidence assessment matrix. This is an assessment tool that assigns a level/grade (Level I: strongest 
evidence to level IV: weakest evidence) based on the strength of the published study [216]. 
Supportive evidence was obtained from animal studies. 
 
Risk bias assessment 
The risk bias of both animal and human studies was assessed using the Cochrane Risk of Bias 
Assessment tool (http://handbook.cochrane.org/, part 2, Chapter 8). All studies were reviewed by two 
researchers.  
 
Data Synthesis 
All human clinical trial data (excluding case studies) was analysed using RevMan version 5.2.7 to 
quantify and compare the efficacy outcomes of the intervention versus control.  
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Figure 2-3: Flow chart of study selection for herbal medicines. 
 
 
2.3.2.1 Single Herbal Medicines on Human Studies and CIPN 
2.3.2.1.1 Ginkgo biloba (EGb 761) 
One retrospective study has been conducted on human beings administered oxaliplatin [292]. The 
retrospective analysis was conducted on 17 colorectal patients who were being treated with either 
FOLFOX or CAPEOX chemotherapy regimens for either adjuvant or metastatic treatment. Gingko 
biloba 120mg b.i.d was given orally either after cycle 1 or 2 of treatment. They concluded that Gingko 
biloba appeared to decrease the intensity and duration of the acute dysesthesias caused by oxaliplatin 
Studies identified through 
database search 
n = 5614 
Number of studies after 
duplicates removed 
n = 1347 
Number of studies after 
screening 
n = 92 
Studies that met the inclusion 
criteria 
n = 34 
Final number of studies 
selected for the literature 
review 
n = 34 
Final number of animal 
studies 
n = 18 
Final number of human 
studies 
n = 17 
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and have initiated a phase II RCT to confirm results. To date, no results have been published from 
this phase II trial which apparently started in 2004 [292]. 
2.3.2.1.2 Sweet Bee Venom (Pharmacopuncture) 
Two journal articles outlining case studies using sweet bee venom for CIPN have been found with 
the agent used being identified as melittin, an extracted active ingredient from the bee venom that has 
the allergens removed such as phospholipase A2 (PLA2), hyaluronidase and histamine. Melittin is a 
low molecular weight peptide and is reported to have analgesic, anti-inflammatory and anti-cancer 
effects [240, 242, 246]. 
The first article outlined five case reports receiving a one week course of treatment with sweet bee 
venom pharmacopuncture. No side effects were experienced and results indicated clinical 
improvement of CIPN [294]. Another case series on 11 patients were treated for three weeks with six 
sweet bee venom pharmacopuncture treatments. Results showed a reduction in the WHO CIPN grade 
and PNQ score indicating a reduction in CIPN [295]. Further studies are required to confirm their 
findings. 
2.3.2.2 Combination Herbal Medicine on Human Studies and CIPN 
Many of the combination herbal formulas used in this literature review have been obtained from 
Chinese journals which only have an abstract printed in English. Obtaining the complete information 
pertaining to the clinical trial or observation has been limited due to inability to read Chinese. 
Therefore, conclusions on the results of some of the trials have been obtained from the authors without 
being able to quantify their conclusions. This has also limited access to statistical analysis, 
measurement tools, analysis and how they measured their primary outcomes. This is a major 
limitation and makes all results recorded from abstracts biased due to the author’s perspective with 
no ability to clarify their conclusions. 
2.3.2.2.1 Bu Yang Huan Wu (Chinese) 
This formula consists of Astragulus membranaceus radix, Angelica sinesis radix, Prunus persicae 
semen, Paeoniae rubra radix, Ligustici chuanxiong rhizome, Lumbricus terrestris, Spatholobi caulis, 
Curcuma radix, Chaenomeles lagenaria fructus and Achyranthes bidentatae radix. In traditional 
Chinese medicine (TCM) it is said to tonify the yang and restore the five-tenths decoction [320]. This 
decoction was used in an RCT of 84 participants (intervention n=44, control n=40) for the treatment 
of CIPN after oxaliplatin administration. Results indicated that Bu Yang Huan Wu reduced the 
development of CIPN in the treatment group. Due to the main journal article being written in Chinese 
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rather than English, statistical analysis and measurement tools to ascertain this positive result are 
unable to be quantified. The information obtained was from an abstract written in English [314]. 
2.3.2.2.2 Modified Bu Yang Huan Wu (Chinese) 
The modified formula used was Bu Yang Huan Wu plus Liuwei Di Huang which contains the herbs: 
Astragulus membranaceus radix, Ligustrum lucidum fructus, Paeoniae rubra radix, Lumbricus 
terrestris, Prunus persicae semen, Rehmanniae viride radix, Corni officinalis fructus, Dioscorea 
opposite radix, Alismatis rhizome, Poria alba, Spatholobi caulis, Scolopendra, Mori fructus, 
Glycyrrhizae radix, Dipsaci fructus, Lycii fructus, Coicis semen, Atractylodis Rhizome, Phellodendri 
cortex, Scorpio, Moi ramulus and Cyathula officinalis.  
A RCT was conducted using this decoction on 32 patients with existing CIPN from various 
chemotherapy agents. The treatment was compared to 32 patients who were treated daily with 2500 
µg of vitamin B1 orally in addition to intramuscular injections of 100 mg of vitamin B1. The Chinese 
herbal formula was found to be significantly more effective compared to the vitamin B1 treatment 
(P<0.05) [301]. Information pertaining to this observation was from an abstract as the main journal 
article was published in Chinese. Therefore measurement techniques and the magnitude of the 
differences seen in the results are unable to be expanded on.  
2.3.2.2.3 Modified Chai Hu Long Gu Mu Li Wan (Chinese) 
This modified Chinese oral combination of herbs consists of Psuedostellaria heterophylla, Pinelliae 
rhizome, Glycyrrhizae radix, Scutellaria baicalensis radix, Bupleuri radix, Fossiliaossis mastoid, 
Ostreae concha, Rubia cordifolia radix, Scutellariae barbatae herba and Fritillariae thunbergia 
bulbi. This combination was used in a RCT of 48 patients with ovarian cancer undergoing paclitaxel 
administration. They were divided into a control group of paclitaxel only or a treatment group of 
paclitaxel plus a combination of the oral Chinese herbal decoction and an external washing of the feet 
with Chinese herbs (Astragulus membranaceus radix, Angelica sinensis radix, Paeoniae radix, 
lumbricus terrestris, Ligustici chuanxiong Rhizome, Prunus persicae semen and Carthami flos.) 
Results indicated that the incidence rate of CIPN in the treatment group was nearly half compared to 
the paclitaxel only group. Therefore according to the authors this Chinese formula may help in 
preventing paclitaxel CIPN [311]. Further information pertaining to the clinical trial is unavailable 
due to the main journal article being written in Chinese. 
2.3.2.2.4 Geramii Herba plus Aconiti Radix 
A RCT was conducted on 58 patients experiencing CIPN from oxalipatin, taxol or capecitabine. 30 
patients were assigned to the treatment group and 28 to the control group. After one week of 
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treatment, the external application of the two herbs was found to reduce pain, paraesthesia and 
swelling. The authors concluded that Geramii herba plus Aconiti radix may relieve neuropathy and 
improve quality of life. No species of these two herbs were mentioned in the abstract nor any 
statistical significance [313]. The main journal article was written in Chinese hence, further 
information is difficult to ascertain. 
2.3.2.2.5 Goshajinkigan (Japan), Niu Che Sen Qi Wan (Chinese), Pilula renales plantaginis et 
achyranthis (Lat.) 
Six human trials have been conducted on Goshajinkigan [GJG]. Firstly, GJG was invested in a non-
controlled trail on 14 patients receiving oxaliplatin. GJG was administered every day after the first 
oxaliplatin infusion and results indicated that it seemed to prevent acute oxaliplatin-IPN [312]. Two 
retrospective studies were conducted on FOLFOX (oxaliplatin) and GJG [308, 310]. The first trial 
was conducted on 45 patients with 22 patients receiving GJG with their FOLFOX regime compared 
to 23 who did not receive GJG.  
They found that the incidence of grade 3 CIPN in the GJG group was significantly lower than in the 
control group (P<0.01, log-rank test [310]. 
The second study investigated 90 patients undergoing FOLFOX for metastatic colorectal cancer. 
There were four groups: 1) FOLFOX plus GJG; 2) FOLFOX plus GJG plus Ca2+/Mg2+; 3) FOLFOX 
plus Ca2+/Mg2+; 4) FOLFOX only. Results included the incidence rate for each group which were 
91% for FOLFOX only, 100% in FOLFOX plus Ca2+/Mg2+, 79% in FOLFOX plus GJG plus 
Ca2+/Mg2+ and 50% in FOLFOX plus GJG. The authors concluded that GJG reduced the 
neurotoxicity of oxaliplatin without affecting the response rate [308].  
In another retrospective trial, GJG was investigated for paclitaxel-IPN in 82 breast and 
gynaecological cancer patients. The investigators concluded that GJG was possibly effective for the 
treatment and the prevention of paclitaxel-IPN was seemed more effective if administered at the 
beginning of chemotherapy treatment [318]. Another human trial on GJG involved a prospective RCT 
on paclitaxel/carboplatin treatment for 29 ovarian or endometrial cancer patients. They were divided 
into two groups; 1) 14 patients received vitamin B12; 2) 15 patients received vitamin B12 and GJG 
and were given treatment for six weeks. Grade 3 CIPN was observed in 2/14 patients receiving 
vitamin B12 compared to 0/15 receiving vitamin B12/GJG. It was concluded that GJG inhibits the 
progression of CIPN but further trials are warranted [307]. 
A recent phase II multi-centre, randomised, double-blind, placebo-controlled trial was conducted and 
published on GJG and oxaliplatin-induced PN [321]. In this trial, patients undergoing FOLFOX for 
colorectal cancer was randomised to either receive oral GJG (7.5 g) or matching placebo daily. The 
  
2-113 
 
severity of CIPN was assessed, using the common toxicity criteria for adverse events, every two 
weeks until the 8th cycle and then every 4 weeks thereafter. The primary endpoint was the incidence 
of grade 2 CIPN or greater before the 8th cycle. The incidence of grade 2 or greater CIPN was 39% 
in the GJG arm and 51% in the placebo arm. The authors concluded that GJG shows promise in 
delaying the onset of grade 2 or greater CIPN without impairing FOLFOX efficacy [321]. 
2.3.2.2.6 Keishikajutsubuto (Japanese), Gui Zhi Jia Shu Fu Tang (Chinese), Decoctum 
ramulorum cassia cum atractylodis macrocephae et aconite (Lat) 
This oriental formula contains Cinamomi cortex, Aconiti lateralis praeparata tuber, Zingiberis 
rhizome, Jujubae fructus, Glycyrrhizae radix and Atracylodis macrocephalae rhizome. A non-
controlled trial was conducted investigating this herbal formula on 11 patients with metastatic 
colorectal cancer undergoing FOLFOX administration. A reduction of CIPN was observed in 5 cases 
(45.5%) after cessation of chemotherapy [317].  
2.3.2.2.7 Ogikeishigomotsuto (Japanese), Huang Qi Wu Wu Tang (Chinese), Decotum 
quinque medicamentorum cum astragalo (Lat.), Astragulus and Cinnamon Five 
herb combination (English) 
This oriental herbal combination contains Astragalus membranaceus radix, cinnamomi cortex, 
Paeonia alba radix, Jujubae fructus and Zingiberis Rhizome. A single case study was published using 
this formula for neuropathic pain induced by oxaliplatin. It showed a positive effect in reducing the 
pain and the patient was allowed to continue chemotherapy treatment with oxaliplatin [315]. 
2.3.2.2.8 Shakuyakukanzoto (Japanese), Shao Yao Gan Cao Tang (Chinese), Formula 
glycyrrhizae et paeonia (Lat), Peony and Licorice Decoction (English) 
Two studies human studies have been conducted on this formula, a retrospective case analysis [302] 
and a retrospective clinical trial comparison [306]. The retrospective case analysis investigated 23 
patients with paclitaxel-IPN and observed that this combination had a positive effect on the 
neuropathic pain experienced by these ovarian cancer patients [302]. Lastly the retrospective clinical 
trial compared Shakuyakukanzoto (peony and licorice) to Goshajinkigan (GJG). This was a 
preventive study and investigated 20 metastatic colorectal cancer patients administered 
Shakuyakukanzoto in conjunction with FOLFOX compared to 24 patients administered GJG. The 
Shakuyakukanzoto group was found to prevent 65% CIPN compared to 50% in the GJG group. It 
was concluded that both formulas may prevent oxaliplatin-IPN [306]. 
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Table 2-4: Human Clinical Studies with Herbal Medicines for the Treatment and or Prevention of CIPN 
 
Medicinal Herb Study Type No 
Pts9 
T10 C11 NHMRC 
Rating 
Chemotherapy 
Agent  
Results 
Single Medicinal Herbs 
Ginkgo biloba RS [292] 17 N/A12 N/A Level IIIb Oxaliplatin  Possible neuroprotection 
Sweet bee venom 
(pharmacopuncture) 
Case series [294]  5 N/A N/A Level IV Taxol, 
carbo/taxol13  
Injecting into the acupoint decreased pain and 
neuropathy (treatment) 
Case series [295]   11 N/A N/A Level IV Taxol, 
carbo/taxol  
Injecting into the acupoint decreased pain and 
neuropathy (treatment) 
Combination Herbal Studies 
Bu Yang Huan Wu 
(Chinese)  
RCT [314]  84 44 40 Level II Oxaliplatin  Reduced development of CIPN 
Modified Bu yang 
Huan Wu (Chinese)  
RCT [301]  64 32 32 Level IIIa Different 
chemotherapies  
Reduced development of CIPN 
Modified Chai Hu 
Long Gu Mu Li Wan 
(Chinese) 
RCT [311]  48 N/A N/A Level II Paclitaxel  Possible neuroprotection 
Geramii herba plus 
Aconiti radix 
RCT prospective  
[313]  
58 30 28 Level II Oxaliplatin  Reduced neuropathic pain 
 
                                                 
9 Pts: Participants 
10 T: Treatment group 
11 C: Control group or placebo 
12 N/A: Not applicable 
13 Carbo/Taxol: Carboplatin and Paclitaxol chemotherapy combination 
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Medicinal Herb Study Type No 
Pts 
T C NHMRC 
Rating 
Chemotherapy 
Agent  
Results 
Goshajinkigan  
GJG (Japan) 
 
NRCT [312]  14 N/A N/A Level IIIb Oxaliplatin  Reduced acute neurotoxicity 
RS [310] 45 22 23 Level IIIa Folfox  Possible neuroprotection 
RS [308] 90 11 44 Level IIIa Folfox  Possible neuroprotection, no change of anticancer 
activity 
 CaMg14 
= 21 
CaMg 
= 14 
RS [318] 82 N/A N/A Level IIIb Paclitaxel  Possible neuroprotection, better when 
administered early 
RCT prospective 
study [307]  
29 Vit 
B12 + I 
= 15 
Vit 
B12 
= 14 
Level IIIa Carbo/Taxol  Less severe neurotoxicity, better in combined 
group 
DBRCT [321]  89 44 45 Level II Folfox  Acceptable safety margin and indicates a delay in 
onset of grade 2 or higher CIPN without 
impairing FOLFOX efficacy. 
Keishikajutsubuto 
(Japanese) 
Uncontrolled 
study [317] 
11 N/A N/A Level IIIb Folfox  76.6% mean improvement 
Ogikeishigomotsuto 
(Japanese) 
Case report [315]  1 N/A N/A Level IV Oxaliplatin  Reduced neuropathic pain 
Shakuyakukanzoto 
(Japanese) 
Peony and Licorice 
Decoction (English) 
Retrospective 
case analysis 
[302]  
23 N/A N/A Level IV Paclitaxel  
 
Reduced neuropathic pain 
RS comparison 
[306] 
44 
 
20 
(SKK) 
24 
(GJG) 
Level IIIa Folfox  50% response in Shakuyu-kanzoto and 65% in 
Goshajinkigan on prevention of neurotoxicity. 
DBRCT: Double Blind Randomised Controlled Trial; SBRCT: Single Blinded Randomised Controlled Trial; RCT: Randomised Controlled Trial; NRCT: Non Randomised Clinical 
Trial; CS: Case Study; TNS: Total Neuropathy Score; RS: Retrospective Study 
                                                 
14 CaMg: Calcium and magnesium infusion 
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2.3.2.3 Discussion on Outcomes on Herbal Medicine and CIPN 
Current improvements in the detection and treatment of cancer strongly correlates with increases 
survival rates of those patients diagnosed with a malignant disease [322]. With an increased survival 
rate, long-term side effects from chemotherapy and other medical treatments has raised significant 
awareness as it can affect quality of life and clinical outcomes [2, 3, 229]. CIPN is an important side 
effect that can affect quality of life and can be a permanent consequence of treatment [2-4]. Currently, 
there are no standard recommended treatments or prophylactic options for CIPN that employ 
pharmacologicals, nutraceuticals or herbal medicines.  Agents that have shown promise such as 
duloxetine [229, 230], vitamin E [233, 234, 236, 323], omega 3 fatty acids [237] and Asian herbal 
medicines in particular Goshajinkigan [300, 303, 304, 307-310, 312, 316, 318]  require further 
research, however, in order to assess the strength of efficacy.  
Traditional scientific research is based on a single agent or active compound; herbal medicines though 
can be comprised of numerous active compounds with synergistic efficacy. For example in the use 
of Asian herbal medicines, a combination of herbs can be employed [309]. This combination may 
give a multi-targeted approach that complicates the identification and elucidation of the active 
compound and the mechanism of action. Nevertheless, warranted research on single herbal extracts 
and compounds through validated clinical studies can still provide useful data.  
Investigations carried out with herbal medicines for CIPN found no neuroprotection or treatment 
when a single compound or herb was studied. Animal models provide basic research for further 
studies but do not guarantee that the herb or compound will be efficacious in human clinical trials. 
Herbal medicines such as Ginkgo biloba [292] and curcumin [238] warrant further research as they 
have reported a positive clinical likelihood from animal studies.  
An important and common mechanism of action within the identified medicinal herbs trialled for 
CIPN is their anti-inflammatory activity [237-246]. The anti-inflammatory activity of the herbs may 
be a plausible mechanism of action that assists with the protection and treatment of CIPN. Medical 
treatment of peripheral neuropathy has involved non-steroidal anti-inflammatory drugs for the 
inflammation and pain associated with this condition [1]. This potential mechanism of action warrants 
further research, which may attribute to other herbal remedies, nutrients or pharmaceuticals being 
trialled for CIPN. 
The Asian herbal combination remedies investigated for CIPN were difficult to analysis as a number 
of the journal articles were written in their Asian language rather than English. Therefore, the 
information obtained for twelve out of the nineteen herbal combinations journal articles was extracted 
from abstracts. From these Asian herbal combinations, Goshajinkigan (GJG) is the herbal medicine 
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that has been trialled extensively through animal and human clinical trials [300, 303, 304, 307-310, 
312, 316, 318]. Of the clinical trials, three were retrospective studies using controls for Folfox and 
paclitaxel administration [308, 310, 318], one RCT [307] comparing vitamin B12 administration with 
the herbal combination and a recent phase II multi-centre, randomised, double-blind, placebo-
controlled trial conducted as an adjuvant treatment with FOLFOX [309]. All studies concluded that 
this herbal combination may provide neuroprotection however, as this is a Japanese combination and 
has been trialled in Japan, it may be difficult to transfer into other countries depending on their 
National regulatory body. Another limitation with GJG is that not all details of its mechanism of 
action have been clearly identified and for certain herbs, their effects are unknown [276].  
All other trials with the Asian combination herbs were animal models, case studies, retrospective 
studies and limited RCT’s so the quality of evidence is very low. Without further randomised clinical 
trials that are written in English and well established, they are not recommended for use.  
Two herbal treatments have been investigated for peripheral neuropathy that may be considered for 
use in CIPN. These include St John’s wort and capsaicin cream. St John’s Wort (Hypericum 
perforaturn) was selected to trial for PN as tricyclic antidepressant medication is used medically for 
its treatment. In a crossover DBRCT, 54 patients with or without diabetes were investigated for 
treatment with St John’s Wort (SJW) for diabetic PN. Participants were randomly assigned to either 
SJW (900mcg hypericin/tablet) or placebo for five weeks. They were then crossed over to the other 
treatment for an additional five weeks. No statistical significant was found in pain indexes however 
a trend was noted for an improved overall pain score [324].  
Capsaicin has been investigated as a topical application for diabetic [325-329] and HIV peripheral 
neuropathy [330-332]. The majority of studies have been conducted on diabetes PN with most 
resulting in statistical significance [325-329]. The results indicate that capsaicin cream may provide 
relief for chronic, intractable pain and reduce dependence on opioids however the main side effect of 
burning at the site of application may be of concern [329]. It is recommended that it is not used as a 
monotherapy but in combination with oral medication to assist this condition.  
Herbal treatments may offer a different aspect to assisting CIPN however the main problems with 
research involving herbal extracts or medicinal herbs is the understanding of the mechanism of 
actions and the fact that the herbs contain a number of active compounds. Moreover, Asian herbal 
therapies contain a combination of multiple herbs, which adds to the complexity of trying to analysis 
the results and what was beneficial. Isolation of one extract which is common in scientific research 
is unable to be conducted with herbal medicine research as the combination of compounds or 
combination of herbs such as Asian herbal therapies are seen to work in synergy. 
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2.4 CONCLUSION 
Currently, no pharmaceutical, neutraceutical or complementary agent has been found beneficial in 
preventing or treating CIPN.  Certain pharmaceutical agents have shown potential for the treatment 
of CIPN pain as with duloxetine (Cymbalta) and other anti-depressants such as venlafaxine (Effexor) 
although Effexor was case study based. Pregabalin is the pharmaceutical drug of choice for clinicians 
at present based on an open label trial. This has been chosen due to lower dose and less side effects 
compared to gabapentin.   
For nutraceuticals, vitamin E shows potential for prevention of cisplatin-induced ototoxicity, 
intravenous glutathione for oxaliplatin administration, vitamin B6 for both oxaliplatin and cisplatin 
and omega three fatty acids for paclitaxel administration. Acetyl-L-carnitine may provide some relief 
as a treatment option for CIPN but should not be used as a preventative agent. Acupuncture may be 
of benefit for some patients and Goshajinkigan may be of benefit for protection of oxaliplatin-IPN 
for patients in Japan.  
Another option for clinicians includes topical application. A combination of baclofen 10 mg, 
amitriptyline HCL 40 mg (3%) and ketamine 20 mg (1.5%) in a base of pluronic lecithin organogel 
and was found to be beneficial for sensory neuropathy over placebo (p=0.053) and decreased motor 
neuropathy symptoms (p=0.021) [333]. However, a phase III RCT trial on 462 patients with CIPN 
found no difference in six weeks of treatment with 2% ketamine and 4% amitriptyline cream 
(p=0.363) [334].   Recent case studies on menthol topically (1%) have found it beneficial for 
bortezomib [335] and carboplatin CIPN [336]. Moreover, as mentioned, high dose topical capsaicin 
cream may show benefit although no studies for CIPN have been conducted.  
Clinicians and researchers also have no gold standard diagnosis technique for CIPN. The true 
incidence and severity of CIPN in clinical trials has been questioned and could be masked by non-
standardised reporting [337]. New techniques in diagnosing and reporting CIPN require further 
investigation. Chapter three examines two new techniques that maybe beneficial for diagnosing and 
reporting CIPN development.  
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3 CHAPTER 3 – OTHER POSSIBLE TECHNIQUES TO MEASURE 
CIPN 
 
The oncologists, haematologist oncologists or medical practitioners, using the National Cancer 
Institute Common Toxicity Criteria (NCI-CTC) scale [338], commonly diagnose CIPN. As discussed 
in chapter 1, page 36, this assessment tool is subjective depending on the medical practitioner’s 
perception.  This chapter explores two possible techniques that could be incorporated into a CIPN 
diagnosis or used as an assessment tool. These include a corneal confocal microscopy (CCM) and 
two analytical techniques, nuclear magnetic resonance (NMR) and mass spectrometry (MS). A 
collaboration was formed between the researchers of the B vitamin and CIPN trial and 
ophthalmologist researchers from QUT. It was decided that a group of participants from the B vitamin 
trial be tested to find any correlation between the neurologists CIPN assessment and the 
ophthalmologists results.  
3.1 CORNEAL CONFOCAL MICROSCOPY  
The corneal confocal microscopy (CCM) is a technique used by ophthalmologist’s that can be used 
to estimate the overall density of the corneal innervation [339]. This is achieved by assessing the 
nerve fibre length (NFL) and nerve fibre density (NFD) in the Bowman’s layer. The tortuosity 
coefficient is a dimensionless measurement that reflects the nerve irregularity or curving and aims to 
assess the corneal nerve structure [339].  Basically the CCM is a high magnification microscope that 
can be used to look at the nerves in the front of the eye.  This technique has been validated as a 
neuropathic diagnostic tool particularly for diabetic patients [340] and has been selected to trial for 
CIPN assessment. 
3.1.1 Ophthalmic Markers for the Possible Diagnosis of CIPN 
A collaboration was formed with the Queensland University of Technology involving Dr Nicola 
Pritchard, Dr Katie Edwards and Professor Nathan Efron who have been working on the LANDMark 
study for diabetes [341]. It was proposed that the CCM and the ocular coherence tomography (OCT) 
which is used to assess the nerves and tissues at the back of the eye [342] might be able to detect 
small nerve damage from chemotherapy similar to what they are finding for diabetic patients. As the 
nerve conduction studies that the neurologist uses assess large nerves, the only assessment of small 
nerve damage is the pin sensibility test which is not quantitative as it’s based on what the patient can 
feel, therefore subjective. Validating a quantitative method of assessing small nerve damage such as 
the CCM or OCT would be of assistance for medical practitioners treating CIPN. 
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3.1.2 Rationale 
CIPN [3] may reveal corresponding ocular changes in the corneal [340, 341] and nerve layers of the 
retina [342] similar to the nerve damage seen in diabetes.  Conducing CCM and OCT assessments 
may allow researchers to investigate the relationship between the nerves of the eye and the peripheral 
nerves of the body in patients who undergo chemotherapy with neurotoxic agents.  The measures of 
nerves made by these techniques may be related to the damage of nerves in the peripheral limbs 
therefore quantifying small nerve damage associated with CIPN. 
In collaboration with the LANDMark study and the B vitamin and CIPN trial, it was aimed to 
investigate the following:  
• Changes in corneal (front of eye) nerve counts before and after chemotherapy 
• Changes in retinal (back of eye) nerve layer thickness before and after chemotherapy 
The results of this pilot study were aimed at developing a better understanding of small fibre 
peripheral nerves in the arms and legs in patients suffering from nerve damage, and hoped to 
determine the extent to which these changes are associated with the clinical signs and symptoms of 
the condition.  The significance of this pilot study was that it should reveal the potential for these eye 
tests to serve as sensitive, rapid, repeatable, ‘patient-friendly’ eye tests for the detection, diagnosis 
and monitoring of the progression of nerve damage. Understanding these aspects of the nerves may 
provide healthcare professionals with a quick, simple, cost-effective and repeatable means to identify 
patients at risk, anticipate and monitor deterioration, and assess new treatments for nerve damage.   
3.1.3 Hypotheses 
1. Corneal and retinal nerve parameters are reduced in individual who have undergone 
chemotherapy. 
2. The amount of nerve tissue reduces as severity of impairment increases.  
3. Corneal and retinal nerve parameters are associated with established measures of neuropathy.  
3.1.4 Study Population 
The participants in this pilot study were recruited from patients attending a chemotherapy-induced 
neuropathy study at the Princess Alexandra Hospital in Brisbane, Australia. It was estimated that 20 
individuals who were undergoing chemotherapy would participate in this extended research, 
however, a sample of only three presented to participate for the study. Ophthalmologist researchers 
evaluating the number of participants required to meet statistical relevance for the B vitamin study 
(90 plus 50% attrition rate) statically determined the study sample. As this is a pilot trial to see if there 
is relevance in using this technique to analysis small nerve cell damage, a study size of 20% of the B 
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vitamin group was determined which is equivalent to 18-27 people including the attrition calculation. 
Therefore, an estimation of 20 patients were determined to be recruited from the B vitamin trial.   
3.1.5 Study Design 
This was a cross-sectional, observational, unmasked study.  The ophthalmic researcher was aware of 
the status of the participant. Relevant medical and ocular history and demographic measures were 
ascertained and participants were asked to undergo corneal confocal microscopy (CCM) and, in some 
instances, ocular coherence tomography (OCT). Patients with ocular disease, for example, glaucoma 
or a peripheral neuropathy due to another disease were not eligible.  The participant was assessed 
prior to commencing chemotherapy (or as close to this date as possible), and 6 and 12 weeks post-
treatment.   
The primary objective was to establish pilot data exploring the hypothesis that morphology of corneal 
and retinal nerves are altered in patients with CIPN.  An estimate of association between the structural 
measures and standard tests of neuropathy was explored. The two primary structural outcome markers 
are morphometric measures obtained from:  
1.  Corneal nerve fibre length (CNFL) – length of nerves/mm2 of corneal tissue from CCM 
images of the corneal sub-basal nerve plexus. 
2.  Retinal nerve fibre layer, ganglion cell complex and overall retinal thickness (µ) using OCT 
of the retinal layers.  
The measures of CIPN include nerve conduction studies (NCS), neuropathy disability score and 
neuropathy symptom score. The secondary objectives of the study were to determine the effect size 
to establish if progression of CIPN could be monitored, the sensitivity, specificity of CCM and OCT 
in CIPN and identify risk factors of CIPN associated with corneal and retinal nerve damage, observed 
using CCM and OCT. 
 
3.1.6 Methods 
All tests were carried out according to the LANDMark standard operating procedures manual. 
3.1.6.1 Corneal Confocal Microscopy (CCM) 
Participants were first examined with a slit lamp biomicroscope to ensure the anterior eye was 
healthy.  After anesthetising the cornea, images of the sub-basal nerve plexus was captured from one 
eye of each participant using a commercially available laser scanning CCM, the Heidelberg HRT III 
with Rostock Cornea Module.  Images were captured using the section capture mode of the CCM, 
while fixates a stationary target with the contralateral eye.  Corneal nerve morphology was determined 
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using automated software:  the amount of nerve tissue (corneal nerve fibre length mm/mm2) and 
corneal nerve branch density (#/mm2) were assessed in the 400 x 400 um image. 
3.1.6.2 Optical Coherence Tomography (OCT) 
Optical coherence tomography (OCT) is a non-invasive and reliable technique allowing quantitative 
analysis of retinal morphology and is generally used to qualitatively assess retinal pathology or to 
measure retinal layer thicknesses. High axial and transverse resolution and rapid image capture 
capacity enable accurate identification and thickness measurement of individual retinal layers.  The 
RTVue 100 (Optovue Inc, USA) is a Fourier domain OCT, which was used to collect data for all 
participants in this study. It has an axial resolution of 5 micron and a transverse resolution of 15 
micron. Separate macula, optic nerve head and peri papillary scans were obtained, providing 
quantitative data for RNFL, ganglion cell layer and full retinal thickness at multiple sites, as well as 
(optic nerve head) neuro-retinal rim, and cup area and volume data.  . 
3.1.6.3 Neuropathy Measures 
A qualified electrophysiology technician at IHBI measured the peroneal and sural nerve conduction 
velocity, amplitude and latencies.  Neuropathy disability score involves sensation to heat, cold, 
vibration and reflex testing.   These tests took approximately 15 minutes to perform. 
3.1.7 Results 
Participant sample results are presented in the form of case summaries in Table 3-1. Neuropathy 
symptoms were reported after chemotherapy had started in two of the three participants; neuropathy 
measures from the CCM did not support the symptoms the patients were experiencing. Corneal nerve 
fibre length did not vary between the three visits (paired t-test p=0.61 and 0.69 for pre-chemo vs. 6-
week post and pre-chemo vs. 12 week post, respectively). The only clinically relevant change noted 
was in patient PA070LxW where a change of 5 mm.mm2 and 3.3 mm/mm2 was seen from baseline 
to the 6 weeks post-chemotherapy examination. The QUT researcher’s unpublished research from 
the LANDMARK study assessing diabetes neuropathy established that less than 14 mm/mm2 is 
indicative of neuropathy in diabetic patients [343]. The CNFL is calculated by the sum of the blue 
and red lines from baseline to the next measurement point.  
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Table 3-1: Case Summaries using CCM on Three Participants Pre- and Post-Chemotherapy 
 
ID: PA034 PTE Pre-chemo 6 weeks post-chemo 12 weeks post-chemo 
69 year old male Consent dated 27/6/12   
Sample raw CCM 
imagea 
   
Sample processed 
CCM image 
   
Corneal nerve 
fibre length 
mm/mm2 b 
20.0 ± 0.4 16.3 ± 4.8 18.1 ± 2.9 
Neuropathy 
measures 
Nil symptoms reported 
Sural 53.4 m/s (normal) 
NDSd 1 (normal) 
Nil symptoms reported 
NDSd 1 (normal) 
Nil symptoms reported 
Sural nerve CVf 56.9 
m/s (normal) 
ID: PA067 DxH Pre-chemo 6 weeks post-chemo 12 weeks post-chemo 
54 year old female Consent dated 18/3/13   
Sample raw CCM 
imagea 
   
 
Sample processed 
CCM image 
   
Corneal nerve 
fibre length 
mm/mm2 b 
18.0 ± 1.4 21.4 ± 1.2 19.0 ± 3.3 
Neuropathy  Nil symptoms reported Symptoms reported Symptoms reported 
DNSSe 4 (abnormal) 
Sural nerve CVf 
45.3m/s (normal) 
 
Legend 
 White lines represent nerves 
 Blue line represents nerve branches 
 Red line represents nerve trunks 
 Green dots represent nerve bifurcations 
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Table 3-1 continued 
ID PA070 LxW Pre-chemo 6 weeks post-chemo 12 weeks post-chemo 
58 year old female Consent dated 23/4/13   
Sample raw CCM 
imagea 
  
No visit 
Sample processed 
CCM image 
  
No visit 
Corneal nerve fibre 
length mm/mm2 b 
17.7 ± 2.3 
 
14.4 ± 3.2 No visit 
Neuropathy  Nil symptoms reported Symptoms reported 
Sural nerve CVf 40.9 
m/s (abnormal) 
No visit 
b average of 8 central images 
d NDS = neuropathy disability score, 0 (nil) to 10 (severe) 
e DNSS = diabetic neuropathy symptom score, 0 (nil) – 4 (severe) 
f CV = conduction velocity 
 
ID PA070 LxW pre-chemotherapy also had her OCT conducted showing her ocular fundus which 
can be seen in Figure 3-1. The tomography report is reported in Figure 3-2. 
 
Figure 3-1:  PA079 LxW Pre-Chemotherapy Ocular Fundus Picture using OCT.  
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Figure 3-2: Ocular Coherence Tomography Report for PA070 LxW 
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3.1.8 Conclusion on CCM and OCT for CIPN Diagnosis 
Because only three participants from the B vitamin study participated in this collaboration, few 
conclusions can be drawn from this pilot work.  The main obstacle found for patients not participating 
in this collaboration was the fact that they had to physically go to Kelvin Grove, a suburb on the other 
side of Brisbane from The Princess Alexandra Hospital before their chemotherapy regime 
commenced. Although this may not be a major obstacle to some, certain factors need to be considered.  
Participants in the B vitamin trial were recruited from a public hospital. This meant that a number of 
patient’s have difficulty with transport, as either they didn’t drive or were unable to drive. Moreover, 
they may not be able to drive due to surgery. In addition before commencing chemotherapy the 
patients have a number of medical tests, and appointments that they need to attend and it is common 
that patients may experience anxiety before commencing chemotherapy. Lastly, most of the 
participants lived on the south side of Brisbane rather than the north side, which was prohibitive. 
These factors need to be considered if further research is to be conducted.  
For the conclusions of this pilot work, the QUT researchers were unable to determine if corneal nerve 
mass was reduced in participants who underwent chemotherapy. Anecdotally, it did not appear that 
the amount of nerve tissue reduced was as severe an impairment, nor were corneal nerve parameters 
associated with established measures of neuropathy. Further investigation in a larger number of 
participants is required to establish the goals for this pilot study.   
 
3.2 MASS SPECTROMETRY AND NUCLEAR MAGNETIC RESONANCE (NMR) 
ANALYSIS OF B VITAMINS 
Nuclear magnetic resonance (NMR) spectrometry is an analytical technique for determining the 
structure of organic compounds [344]. There are a number of spectroscopic methods but only NMR 
has the ability to do a complete analysis and interpretation of the entire spectrum. NMR observes the 
specific quantum mechanical magnetic properties of nuclei of atoms. All nuclei have a magnetic field 
which absorbs and re-emits electromagnetic radiation and this energy resonates at a particular 
frequency which depends on the strength of the magnetic field and its properties [344] 
Mass spectrometry (MS) is another analytical technique that produces a spectra of a mass of 
molecules from a sample i.e. solid, liquid or gas such as urine, plasma or food [345]. To measure the 
characteristics of individual molecules, a MS converts them into ions that can move around and be 
manipulated by an external electric and magnetic field.  
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Three essential functions of a MS involves [345]: 
1. Ion source: A small sample is ionised (usually to cations due to a loss of an electron). 
2. Mass Analyser: Ions are sorted and separated according to their mass and charge 
3. The Detector: Separated ions are then measured and results displayed on a chart usually 
represented by bars.  
The technique of NMR and MS were planned for this thesis but time prevented their completion. The 
samples collected will be used in future analysis of correlation between B vitamins and CIPN. To 
assess the current literature on these techniques, studies that have been conducted on B vitamins and 
patients with CIPN have been collated. 
 
3.2.1 B Vitamins and Mass Spectrometry 
3.2.1.1 B vitamin Complex 
Five studies have been conducted on B vitamins or a selection of B vitamins using mass spectrometry 
[346-350]. The substances they were tested on include nutritional yeast [346], nutritional supplements 
[347], human milk [348] and infant formula [349]. The last article was a review comparing various 
mass spectrometry methods [350]. All studies found that mass spectrometry could achieve 
quantification of B vitamins. The greatest challenge found was the interference by other compounds 
in the samples and that the LC-MS/MS means more expensive equipment and requires experienced 
personnel. 
3.2.1.2 Vitamin B6  
Five studies have been conducted on vitamin B6 using different mass spectrometry machines and 
samples. The first study was also used in the B vitamin mix from human breast milk [348] which 
could quantify each vitamin from the sample. The blood samples that were assessed by NMR and 
Tandem MS could only detect certain metabolites in people with a vitamin B6 deficiency [351]. 
Plasma, urine and CSF was found to be a good sample to ascertain certain B6 metabolite’s such as α-
aminodipic semialdehyde in urine and pepecolic acid in plasma and cerebral spinal fluid [352, 353]. 
Whole blood was found to be the best sample to detect pyridoxal phosphate (PLP) [354]. 
3.2.1.3 Folate 
Only two studies using mass spectrometry were found. It was determined that both were fast, reliable 
and sensitive for folate vitamers, homocysteine and methyl malonic acid [355, 356].  
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3.2.1.4 Vitamin B12 
Five studies have been conducted using different forms of mass spectrometry machines to detect 
different forms and metabolites of vitamin B12. All studies concluded that mass spectrometry was an 
effective method to detect vitamin B12 in all forms in addition to homocysteine and methyl malonic 
acid [357-361]. Depending on what determinates were being examined determined what type of 
sample was used but all were found to be appropriate samples to detect the vitamin B12 they were 
assessing. 
3.2.1.5 Betaine (Choline) 
Only one study has been conducted on choline, which used urine and blood as samples and the LC-
MS/MS machine. This method was found to be reliable and accurate in quantifying choline [362].  
 
3.2.2 Discussion on Outcomes on NMR and MS and B vitamins 
The literature search found a number of studies that have been conducted using MS to assess B 
vitamins; however, only four studies were found on NMR and B vitamin status [351, 363-365]. Two 
of the four studies were useful for assisting us for techniques linked with B vitamin identification 
using NMR [351, 365]. One study which was conducted in 1974, focused on the spectra for the 
vitamin B6 group looking at pyridoxal, pyridoxal 5’-phosphate, pyridoxamine, pyridoxamine 5’-
phosphate and pyridoxine [365]. The other study also assessed vitamin B6 and found that NMR was 
effective in classifying samples according to vitamin B6 status and identifying discriminating features 
[351]. This indicates that NMR analysis should observe all forms of vitamin B6 in the analysis 
however no other information has been found for other B vitamins using NMR.  
A number of studies using MS for B vitamin analysis were identified as mentioned above. Four 
studies addressing various samples was conducted on vitamin B complexes [346-349], a review on 
folate, vitamin B6 and B12 was conducted on methods for analysis in humans [350], four studies 
were conducted on vitamin B6 [351-354], two on folate [355, 356], five on vitamin B12 [357-361] 
and one on betaine (from choline) [362]. These studies have been outlined below in Table 3-2. 
According to the research on mass spectrometry and NMR, these methods should be able to detect 
peaks indicated by B vitamin supplementation and their vitamirs as well as bi-products, metabolite’s 
and other related compounds. 
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Table 3-2: Mass Spectrometry Analysis on B Vitamins 
 
Vitamin Samples 
Used for 
Analysis 
Type of Mass 
Spectrometry 
Efficacy 
B complex 
vitamins 
[346]  
Nutritional 
Yeast 
LC/MS – TOF15 
 
Fine separation of peaks of all studied vitamins 
was achieved. NAD+ and CoA could not be 
achieved with any of the studied enzyme 
preparations. 
B vitamins 
[347] 
Nutritional 
supplements 
Flow-injection 
ESI-Ms/MS16 
B vitamins down to the nanogram per gram level 
could be achieved.  
B Vitamins 
[348] 
Human milk UPLC-MS/MS17 Quantitation of all vitamins was achieved even 
in human milk from severely depleted women.  
B vitamins 
[349] 
Infant formula LC-MS/MS18 The accuracy was demonstrated and achieved a 
good spike recovery of the vitamins (100+/- 6%) 
Vitamin 
B12, B6 
and folate 
[350] 
Review MA19, CI or ELI20, 
LC with UV, 
fluorescence or 
electrochemical 
detection, LC-
MS/MS, (GC)- 
MS21 
Long term, LC-MS/MS have the potential to 
replace the ‘automated methods’ of 
chemiluminescent and immunoassays which 
often under report and require the establishment 
of method specific reference ranges for correct 
data interpretation. 
Vitamin B6 
[351] 
Blood 
samples 
NMR, Tandem MS Certain metabolites may be detected connected 
with a vitamin B6 deficiency.  
Vitamin B6 
[352] 
Plasma LC-MS/MS LC-MS/MS was used to analysis compounds 
relevant to one-carbon metabolism after a 
vitamin B6 restriction (diet)  
Vitamin B6 
[353] 
Urine and 
plasma, 
cerebrospinal 
fluid 
LC-MS/MS and 
(HPLC)/MS/MS22 
LC-MS/MS can measure the presence of α-
aminoadipic semialdehyde in urine. 
(HPLC)/MS/MS can measure pepecolic acid in 
plasma and/or cerebrospinal fluid 
Vitamin B6 
[354] 
Whole blood LC-ESI-MS/MS An appropriate method to determine PLP in 
whole blood 
Folate [355] Plasma LC-MS/MS LC-MS/MS was used to measure concentrations 
of homocysteine and methyl malonic acid 
Folate [356] Whole blood UPLC-MS/MS A fast, reliable and sensitive assay using UPLC-
MS/MS for the folate vitamers 
                                                 
15 LC/MS – TOF - Liquid chromatography with mass spectrometry – time of flight and stable isotope assay 
16
  Flow-injection ESI-Ms/MS - Flow-injection electrospray ionization tandem mass spectrometry  
17 UPLC-MS/MS - Ultra-performance liquid chromatography tandem mass-spectrometry 
18 LC-MS/MS - Liquid chromatography/tandem mass spectrometry 
19 MA- Microbiological assay 
20
  CI or ELI - Chemiluminescent or enzyme-linked immunoassay 
21 (GC)- MS - Gas chromatography mass spectrometry 
22 (HPLC)/MS/MS – High Performance Liquid chromatography tandem mass spectrometry 
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Vitamin 
B12 [357] 
Plasma and 
serum 
HPLC-MS/MS, 
 (GC)-MS 
IM B12 causes swift and significant changes in 
plasma aminothiols  
Vitamin 
B12 [358] 
Plasma LC/MS/MS Found to be an accurate and precise method to 
measure hydroxycobalamin and 
cyanocobalamin. 
Vitamin 
B12 [359] 
Urine, Blood (GS)-MS, LC-
MS/MS 
Both methods provided accurate and precise 
information 
Vitamin 
B12 [360] 
Blood, serum LC-MS/MS MMA has been considered a gold standard in 
the diagnosis of metabolic vitamin B12 
diagnosis so was used to validate the Holo TC 
accuracy 
Vitamin 
B12 [361] 
Serum UPLC-MS/MS This method can be used to detect MMA in 
neonates and infants using lower amounts of 
serum  
Betaine 
(choline) 
[362] 
Urine, blood LC-MS/MS This method provided reliable, accurate and 
precise information. 
 
3.2.3 Mass spectrometry and NMR analysis of CIPN 
To date, no studies have been conducted on patients who are experiencing CIPN using mass 
spectrometry or NMR analysis.  
3.2.4 Conclusion on NMR and MS for CIPN and B Vitamins 
NMR and MS analysis are valid and have been found to be accurate in measuring samples for B 
vitamins and chemotherapy agents. These techniques are suggested for further research in this area.  
The following trials have been conducted without examining samples using NMR and MS due to 
time restraints. The methodology for the three trials has been explained in Chapter 4.  
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4 CHAPTER 4 – RESEARCH PLAN AND METHODOLOGY 
OVERVIEW 
 
4.1 PURPOSE OF STUDY AND OBJECTIVES 
4.1.1 Purpose 
The main purpose of this thesis was to evaluate the efficacy and safety of supplemental B group 
vitamins to reduce the incidence and severity of chemotherapy-induced peripheral neuropathy.  
4.1.2 Hypothesis 
To investigate the therapeutic efficacy and safety of an oral B vitamin complex to assist in reducing 
the onset and severity of chemotherapy-induced peripheral neuropathy [CIPN]. CIPN will be defined 
as grade 2 or higher according to the National Cancer Institute Common Toxicity Criteria manual 
(v2, 1999) or a score higher than 22 on the TNS. This means numbness, tingling, pain or burning in 
the peripheries in addition motor function impairment that interferes with daily living activities. 
 
4.1.3 Aims 
1. To demonstrate that a B group vitamin complex can significantly reduce the incidence of CIPN 
over placebo. 
2. To document the status of B group vitamins in patients diagnosed with cancer that undergoes 
chemotherapy. 
4.2 OUTCOMES 
4.2.1 Primary Outcomes for main trial 
 Total neuropathy score (TNS) is a validated test to assess CIPN that is conducted by an 
independent Neurologist. The comparison of this measure between the B vitamin group and 
the placebo group is the primary outcome.   
4.2.2 Secondary Outcomes for main trial 
 MD Anderson Brief Pain Inventory  
 EORTC Quality of Life Questionnaire  
 Patient Neurotoxicity Questionnaire and patient diaries 
 Blood pathology of B vitamin status (vitamin B1, B2, B6, B12 and folate) 
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The comparison between the B vitamin and the placebo arms using these measurement outcomes 
comprises the secondary outcomes.  
4.3 INVESTIGATIONAL PLAN 
4.3.1 Overall Study Design 
This study was a single-blinded, randomised, placebo-controlled trial. Outcomes were assessed 
before, after and 3 months’ post-chemotherapy administration.   
4.3.2 Study Sites 
The trial was conducted at the Princess Alexandra Hospital, Brisbane, Australia. 
4.3.3 Trial Conduct 
Conduct of all researchers, investigators and personnel involved in the study were in line with the 
National Statement on Ethical Conduct in Research Involving Humans and the Declaration of 
Helsinki. 
4.3.4 Population 
The population for this trial were newly diagnosed cancer patients undergoing chemotherapy 
treatment and who were between the ages of 18 and 80. No restriction were given to ethnicity, social, 
and financial background. People who were excluded from the trial131 included pregnant and breast 
feeding ladies, people who had established cognitive impairment, alcoholism, intellectual disability 
or severe mental illness. All subjects were required to sign a written consent form before participation 
in the clinical trial(s). 
4.3.5 Eligibility Criteria 
4.3.5.1 Inclusion Criteria 
1. Newly diagnosed with a neoplastic disease;  
2. Prescribed chemotherapy treatment with oxaliplatin, taxanes or vincristine. 
3. Aged 18 years old or older. 
4.3.5.2 Exclusion Criteria 
1. Participants prescribed any other concurrent  investigational product  
2. Participants who were currently experiencing peripheral neuropathy  
3. Had undergone chemotherapy treatment before with a neurotoxic agent  
4. Had undergone chemotherapy treatment within the last 5 years  
5. Pregnant or breast feeding women 
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6. Any patient with established cognitive impairment, diagnosed alcoholism, intellectual disability 
or severe mental illness 
7. Any patient found to be deficient in vitamin B12 or folic acid 
8. Any patients taking concurrent multivitamins, nutritional and herbal supplements or fish oils 
4.3.6 Study Treatment 
4.3.6.1 Vitamin B Complex 
The investigational product was a registered product with the Therapeutic Goods Act [TGA] of 
Australia. The dose regime was one capsule after/with breakfast and dinner. The dose per day was 
equivalent to 2 capsules administered daily. The combined daily dose can be seen in Table 4-1.  
 
Table 4-1: B Vitamin Supplement which is Equivalent to Two Capsules Taken Daily.  
B Vitamin Amount 
 Biotin 1000 µg 
 Calcium folinate (folinic acid) 1000 µg 
 Calcium pantothenate (vitamin B5) 327.4 mg 
 Choline bitartrate 200 mg 
 Cyanocobalamin (vitamin B12) 1000 µg 
 Inositol 1000 µg 
 Nicotinamide (vitamin B3) 160 mg 
 Nicotinic acid (vitamin B3) 40 mg 
 Pyridoxal-5-phosphate (vitamin B6) 20 mg 
 Pyridoxal hydrochloride (vitamin B6) 40 mg 
 Riboflavin 5-phosphate (vitamin B2) 40 mg 
 Thiamine hydrochloride (vitamin B1) 100 mg 
 
The dose for this trial was based on research conducted on deficiency states of vitamin B1, B6 and 
B12 and administered dosages required to correct these deficiencies [161, 162, 164-168]. Due to the 
fact that a toxicity of vitamin B6 may cause a peripheral neuropathy (dose above 95 mg a day for 
over a year) and that a high dose of 300 mg a day was found to interfere with tumour duration [159], 
the dose of vitamin B6 was suggested to be below 70 mg a day (dose in this trial is 60 mg a day). 
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Oral administration was selected over intra muscular injections as it included the entire B group 
vitamins rather than just vitamin B12. As these vitamins are water soluble, separating the dose to one 
capsule after breakfast and one capsule after dinner was required to maintain saturation levels. 
Patients were advised   to take the capsules after or with food to decrease the risk of flushing and 
irritation on the digestive system which could have been sensitive due to chemotherapy 
administration.  
The dosage period of three months after chemotherapy cessation was selected as delayed peripheral 
neuropathy or ‘coasting’ has been found to develop in some patients, particularly those receiving 
platinum drugs [169, 170].  
4.3.6.2 Placebo 
The placebo capsules were identical to the B vitamin capsules in appearance. They contained 
microcrystalline cellulose with a small amount of beta-carotene for colour.  
4.3.7 Concomitant Treatment 
All medically prescribed medications was allowed prior and throughout the trial period and recorded 
in the case report form and in the participant diaries. Any rescue medications or changes in medication 
was permitted and recorded in both the case report form and participant diaries.  
Other complementary medications or trial medications were not permitted one week before and 
during the trial period. The only complementary therapy permitted supplement wise was a vitamin or 
mineral the patient had been found deficient in such as vitamin D. If a participant wanted to engage 
in other therapies, researchers had to have consented. Therapies such as acupuncture were not 
permitted, however massage, physiotherapy, occupational therapy, psychology or counseling were 
permitted throughout the trial period.  
4.3.8 Medication 
All participants received chemotherapy agents and adjunct medication. Each participant varied in 
regards to what chemotherapy agents they were administered and what adjunct medication they were 
given. All chemotherapy and adjunct medication was recorded on the participant’s case file and 
diaries. Any changes in medication were recorded in the participant diaries and case file.  
Current medication that participants had been prescribed was continued throughout the trial unless 
changed by their medical practitioners. 
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4.3.9 Withdrawal Criteria 
Participants in this trial were considered ‘high risk patients’ as they have been diagnosed with a 
potentially life threatening disease and had undergone treatment with chemotherapy agents known to 
cause toxicity. Therefore, participants could have withdrawn from the trial due to disabling or life-
threatening events, death, the clinical opinion of the treating doctor that discontinuation from the trial 
would be in the best interests of the patient, and by voluntary participant withdrawal.   
A potential 50% withdrawal rate has been accounted for however the attrition rate at the end of trial 
was 14%. People did withdraw due to reactions to chemotherapy, death and disease progression. 
These have been listed in chapter 7, tables 7-1, 7-2. 
If participants decided to withdraw from the study, they were asked to notify a member of the research 
team before they withdrew. This notice allowed the person or the research supervisor to inform them 
if there were any special requirements linked to withdrawing. Abrupt termination of the study 
supplement was unlikely to cause any adverse health effects. 
All data collected was utilised as ‘intention to treat’. If a participant withdrew or was lost to follow 
up, all data collected at the point of withdrawal including personal, health information and testing 
was kept by the researchers. Survival data on all participants withdrawn or lost to follow-up was 
obtained. If a change in chemotherapy treatment or adverse reaction occurred, participants were asked 
to finish their participation with the last blood pathology test and a neurology test after their 
chemotherapy regime had been completed. Participants were contacted by phone, or next of kin were 
contacted by phone up to four times before being truly lost to follow up. Participants who passed 
away were not contacted. 
4.3.10 Study Duration 
Participants were required to have signed a consent form to participant in   this study prior to their 
chemotherapy administration, during their chemotherapy regime and three months’ post-
chemotherapy. This entailed either six or nine months in total per participant.  
4.3.11 Treatment Assignment and Randomisation 
An independent statistician, using a computer generated randomisation sequence, conducted 
randomisation. Due to the trial analysing three different chemotherapy drugs, a three-block 
randomisation on two variables was conducted with the overall number of intervention and placebo 
allocations found to be as close as possible. The statistician with study investigators kept blinded by 
the sequence allocated the randomisation sequence. See Figure 4-1 for allocation of participants.  
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4.3.12 Discontinuation 
Discontinuation of the trial occurred due to ethical and university time requirements and length of 
time of recruitment. The trial from start of recruitment to the finish of the last participant was two and 
half years.  
Due to the small numbers recruited for this trial, no outside monitoring of interim analysis was 
organised. This trial was monitored from governance from the Princess Alexandra Hospital Human 
Research Ethics Committee twice throughout the recruitment of this trial.  Results were also assessed 
after twenty-five participants had been completed.  
 
 
Oncologists/Haematologists/Cancer Care Coordinator refers 
patient to researchers 
Assessed for 
Eligibility 
Excluded: 
1. Did not meet inclusion and 
exclusion criteria 
2. Elected not to participate 
Randomised by Statistician 
Chemotherapy Plus  
Oral Vitamin B complex 
N = 45 
[Plus 50% attrition rate] 
Chemotherapy Plus  
Placebo 
N = 45 
[Plus 50% attrition rate] 
Figure 4-1: Flow Chart of Allocation of Participants 
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Ethical and Statistical implications included: 
1. Number of participants experiencing severe CIPN in either group. If over 50% were 
experiencing severe CIPN ((a score of over 22 from the TNS results quantified as severe CIPN 
the trial would have been terminated. 
The statistical analysis utilised to confirm these results were: 
a) Proportion percentage of severe CIPN reported comparing B vitamin arm versus placebo 
arm. If there were over 50% of the number participants experiencing CIPN and there was a 
similar percent proportions between the two arms than the trial would have been terminated. 
b) An interim analysis of the data was conducted. The mean primary outcome score [TNS] 
was used to measure if there was a beneficial, harmful or null trend at participant 
recruitment points of n=25 for the B group vitamin intervention over placebo. The baseline 
TNS score of a ± 25% change on the primary outcome was assessed.  The researcher group 
agreed that the null hypothesis for this clinical trial would refer to a default position and 
would indicate that there is no difference between the two treatments (namely, B vitamins 
versus placebo). This then indicated that the potential medical treatment with B group 
vitamins would have had no effect. The net effect would have resulted in the clinical trial 
cessation for a null or harmful outcome of the interim analysis. 
2. Disease progression, adverse events and number of deaths were recorded and analysed to 
confirm if they were related to the intervention being trialed. 
Safety concerns included: 
1. If data or results indicated patient safety was at risk or that there was interference with the 
chemotherapy agent, the trial would have been terminated. 
2. If patient medical treatment was deemed to be compromised, the trial would have been 
terminated. 
Recruitment: 
1. Due to the complexity of the inclusion and exclusion criteria, the potential participants 
emotional state of being newly diagnosed with cancer and having to undergo treatment, other 
research trials requiring similar patients and the referral of patients from oncologists/hospital 
staff, the trial was discontinued after 70 participants had been recruited due to time restraints. 
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4.3.13 Data Identification 
All data was de-identified. All participants were given a trial number e.g. PA045 paperwork included 
the participant’s initials and trial number. Not all publications and educational information/material 
pertaining to the trial identified any subject participating in this trial. Every effort was made to conceal 
the patient’s identity and maintain anonymity and confidentiality of their personal details. 
Any information obtained in connection with this research project that can identify a participant 
remained confidential and was only used for the purpose of this research project. It will only be 
disclosed with the participant’s permission, except as required by law. Notification of involvement in 
this trial was given to the participant’s oncologist and the signed consent form, blood pathology 
results and neurology test results were included in the participants hospital health file. 
 
4.4 STUDY METHODOLOGY 
4.4.1 Clinical Trials 
Three aspects of the trial were required to support the pilot trial. These include: 
1. Absorption study:  to ascertain absorption of vitamin B12 from selected B vitamin complex. 
(Chapter 5) 
2. Absorption/interaction study: B group vitamin status directly after administration of 
chemotherapy with or without B group vitamin administration. (Chapter 6) 
3. Main clinical trial:  Randomised clinical trial (Chapter 7) 
4.4.2 Study Schedule for Main Trial 
The patient flow chart can be seen on Figure 4-2, which outlines the flow of patients from recruitment.  
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Patient consults with Oncologist/Haematologist 
Prescribed chemotherapy treatment  
Researchers contact patient and confirm that 
they want to be involved in the study  
Patient not included in the 
study 
Researchers check 
inclusion and exclusion 
criteria 
Patient DOES NOT meet 
inclusion and exclusion 
criteria - excluded from the 
study 
Patient meets inclusion and 
exclusion criteria: patient is sent 
pathology request form for B 
vitamin status or blood 
pathology conducted at the PAH. 
Deficient in B1, B2, B6, B12 or folate: 
Excluded from the study and doctors are 
advised of deficiency. Patient is 
recommended advice and supplementation 
In normal range for B vitamins: 
included in the study and arrange 
first meeting. 
SEE NEXT PAGE 
Patient’s details forwarded to the researchers of this Study 
NO 
YES 
NO 
YES 
Figure 4-2: Patient Flow Chart for Main Trial (con’t next page) 
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Patient Initial Meeting:  
 Patient to read and sign the 
Information and Consent form. 
 Complete case report form 
 Complete questionnaires and 
TNS 
 Randomize for trial 
 Distribute diary and B 
vitamins or Placebo 
 Organise date for next meeting 
Neurologist to 
assess TNS  
Chemotherapy treatment 
starts 
Patient to complete diary 
and randomised intervention 
(B vitamin or placebo) 
Second meeting: 3 months 
 Complete questionnaires 
 Return diary and unused 
capsules 
 Verbally check compliance 
 Receive new diary and 
supplements 
 Organise date for next meeting  
 
Neurologist to assess 
TNS if finished 
chemotherapy 
Oncologist to assess 
CIPN score 
Blood samples to be 
collected if finishing 
chemotherapy treatment 
Third meeting: 6 months 
 Complete questionnaires  
 Return diary and unused 
capsules 
 Verbally check compliance 
 Receive new diary and 
supplements 
 Organise next meeting 
Patient to complete diary 
Neurologist to assess 
TNS if finished 
chemotherapy 
Oncologist to assess 
CIPN score 
Final meeting: 9 months 
 Complete questionnaires 
 Return diary and unused 
capsules 
 Verbally check compliance 
Neurologist to assess 
TNS  
Patient to complete diary 
Blood samples to be 
collected if finishing 
chemotherapy treatment 
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4.4.3 Screening 
Participants were recruited through selected oncologists, haematologists and cancer care coordinators 
at The Princess Alexandra Hospital and various other hospitals located in Brisbane. Possible 
participants contact details were forwarded to the researchers from the doctors and cancer care 
coordinators via email, phone or in person or hospital’s record system. The researchers contacted the 
possible participant to screen the patient (inclusion and exclusion criteria) and confirm participation. 
If participants meet inclusion and exclusion criteria and were interested in participating, a blood test 
for B vitamin status was conducted and they were asked to read through the participant information 
sheet thoroughly. They were given the opportunity to ask any questions in regards to the trial and 
were asked if they understood the requirements and information given.   
From the blood test results, if a participant was found to be deficient in either vitamin B12 or folate, 
the participant was excluded from the study. If a prospective participant’s vitamin B12 or folate were 
found to be within normal range, then inclusion in the study was satisfied and consent provided. 
Screening and neurology testing was subsequently organised. One participant was excluded to 
excessive high vitamin B6 levels although not on the exclusion list, this was a risk of peripheral 
neuropathy due to high vitamin B6. Two consent forms were signed upon full comprehension of the 
study. A copy of the consent form was provided to the participant, and the original document was 
retained and filed by the researchers. A copy of the signed consent form was put in the patients 
hospital file to indicate their involvement in this trial. 
Participation in this research project was voluntary. Participants had the right to not participate or 
withdraw at any stage. Participation or withdrawal did not affect their treatment or their relationship 
with their medical practitioners. 
4.4.4 Neurology Testing 
Participants underwent a neurological test from an independent neurologist. The tests included a 
validated neuropathy score called the TNS see Appendix 2 in addition to nerve conduction studies. 
This incorporated qualitative and quantitative information regarding sensory and motor neuropathy, 
pin prick test, vibration testing, reflexes, motor and sensory nerves including the sural nerve and 
peroneal nerve and autonomic nerve system functioning.  
4.4.5 Questionnaires Conducted  
4.4.5.1 Patient Neurotoxicity Questionnaire (PNQ) 
The Patient Neurotoxicity Questionnaire (PNQ) is a validated questionnaire developed to assess the 
incidence and severity of CIPN as reported directly by patients rather than physicians.  
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The PNQ consists of two items involving sensory and motor function and was initially developed for 
use in registration trials of potential neuroprotective agents as a measure of CIPN as a clinically 
significant end point. Physicians usually under report and under estimate the severity of CIPN 
symptoms compared with patients so it is important to support the view of patients undergoing 
chemotherapy with neurotoxic agents. See Appendix 3. 
4.4.5.2 EORTC Quality of Life Questionnaire (QLQ) - C30 (version 3) 
The EORTC QLQ-C30 is a quality of life questionnaire specifically designed to assess cancer 
patients.  The EORTC QLQ-C30 is a copy write instrument and the version 3 is the most recent, 
version, which is to be used for all new studies. As CIPN can affect a patient’s quality of life, this is 
an important aspect that requires monitoring. See Appendix 4. 
4.4.5.3 MD Anderson Brief Pain Inventory (BPI) 
The brief pain inventory was selected as pain has been reported from CIPN patients and it is not 
recorded in other assessment tools used. The BPI short form is a validated tool used in clinical trials 
to assess the severity of pain and impact of pain on daily functions. It also assesses the severity of 
pain, impact of pain on daily function and location of pain in addition to pain medications and amount 
of pain relief in the past 24 hours. See Appendix 5. 
4.4.6 Blood Analysis 
Blood samples from participants in the main trial were used to investigate their vitamin B1 (thiamin 
diphosphate), B2 (FAD), B6 (P5P), B12 (Holotranscobalamin- Holo TC) and folate (red cell folate) 
status on two occasions: before and after chemotherapy. Participants had blood taken before they 
commenced chemotherapy and supplementation and two to three weeks after chemotherapy has 
ceased. Participants were asked to abstain from alcohol, cigarettes, tea and coffee for 24 hours before 
sample collection.  
Licensed phlebotomists collected blood from the Princess Alexandra Hospital or Sullivan Nicolaides 
pathology in Brisbane, Australia. For each participant at both venipunctures session, a lithium heparin 
tube (no gel) of blood was collected in addition to standard blood collection tubes for B vitamin 
analysis (heparin, ETDA and serum). The blood samples were centrifuged, 2 tubes were kept at room 
temperature and the plasma from the others were aliquoted and frozen at -20ºC by Princess Alexandra 
Hospital and/or Sullivan Nicolaides pathology staff. A research assistant collected the samples and 
brought to the Princess Alexandra Hospital for metabolomics experiments (the analysis will now 
occur in Sydney after thesis submission therefore samples will be packed accordingly and posted). 
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Staff from Sullivan Nicolaides Pathology Group performed additional pathology assays. The assays 
used by Sullivan Nicolaides are presented in Appendix 6.    
4.4.7 Monitoring of Participant Compliance 
Participant compliance was self-recorded in a participant diary (completed daily). The researchers 
counted the remaining capsules at each interview appointment to calculate the number of doses 
missed. B vitamin status was determined after chemotherapy has ceased through blood tests as a 
measure of adherence to the investigational product. 
4.4.8 Timeline 
Details of the study procedure are detailed below in chronological order. Each visit consisted of the 
following: 
Visit 1 – Baseline and Beginning of Treatment 
The first visit was conducted a week or more before the first cycle of chemotherapy treatment 
commenced. During this visit, written informed consent to participate in the study was collected. A 
blood test was performed to determine B vitamin status, a case report was filled out and 3 
questionnaires regarding quality of life, pain and perception of neurotoxicity was completed. A 
registered neurologist conducted a neurology test that included the TNS. Study medication was 
provided to the participant and all information was recorded in a study diary given to the participant. 
A further appointment was made twelve weeks later depending on treatment cycles 
Visit 2 – Mid Treatment (week 12) 
The second visit involved the collection of any unused study medication and the participant receiving 
new study medication, retrieving the first diary and distributing a new diary, completing the same 
three questionnaires on quality of life, pain and perception of neurotoxicity and recording any health 
conditions or changes in medication from their treatment over the last three months. If the participant 
had completed their chemotherapy regime, blood was drawn to determine B vitamin status and the 
neurologist conducted the neurology tests including the TNS. A further appointment was made twelve 
weeks later depending on treatment cycles. 
Visit 3 – Mid Treatment (week 24) 
The third visit involved the collection of any unused study medication and the participant receiving 
new study medication, retrieving the second diary and distributing a new diary, completing the same 
three questionnaires on quality of life, pain and perception of neurotoxicity and recording any health 
conditions or changes in medication from their treatment over the last three months. If the participant 
had completed their chemotherapy regime, blood was drawn to determine B vitamin status and the 
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neurologist conducted the neurology tests including the TNS. A further appointment was made twelve 
weeks later if appropriate. 
Visit 4 – End of Treatment (week 36) 
The last visit involved the collection of any unused study medication, retrieving the last diary, 
completing the same three questionnaires on quality of life, pain and perception of neurotoxicity and 
recording any health conditions or changes in medication over the last three months. A neurology test 
was conducted by the neurologist and included the TNS. Follow up six months later occurred if 
possible in regards to survival, cancer re-occurrence and CIPN. 
4.4.9 Invitation to Participate in Related Research 
Twenty people were invited to assist with a new diagnostic test for CIPN.  It is commercially available 
technology used to examine the nerves in the eyes, namely a corneal confocal microscope (CCM) 
and an ocular coherence tomography (OCT) that are being investigated for assessing and diagnosing 
peripheral neuropathy in diabetes. See chapter 3 for rationale and explanation.  
The requirements for the twenty participants involved them attending three testing appointments at 
the Queensland University of Technology [QUT] Institute of Health & Biomedical Innovation [IHBI] 
at Kelvin Grove. The appointments were approximately 30 minutes in duration and were conducted 
at: 
1. Baseline – before chemotherapy 
2. After chemotherapy cessation 
3. Three months after chemotherapy cessation 
 
4.5 STATISTICAL ANALYSIS 
All available data was treated as an intention-to-treat analysis. Due to the nature of the dependent 
variables the statistical analysis was based on t-tests, analysis of variance and multiple logistic 
regression. All analysis was conducted with software from STATA for Windows version 11.0 
[College Station, Texas] and IBM SPSS Statistics 20 (SPSS Inc, Chicago). 
The statistical analysis incorporated the following: 
1. Comparison of Participants who experienced CIPN: B vitamins versus Placebo. This was 
analysed using the test of proportions of people experiencing CIPN between the treatment groups. 
A univariate analysis using Fisher’s exact test was used due to the small sample size. 
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2. Comparison of Participants with Severe CIPN: B vitamins versus Placebo. Independent 
Samples t-test (or Mann-Whitney U test if data is non-normal) was used to compare severity of 
CIPN between treatment groups. 
3. Scores of the TNS/Electro Neurology Tests before chemotherapy, after chemotherapy and three 
months’ post-chemotherapy was compared between B vitamin and placebo groups. Mixed Effects 
Model was used for sub scores and the total score of the TNS. 
4. Scores of the Pain Questionnaire before chemotherapy, three, six and nine months was 
compared between B vitamin and placebo groups. A score of pain and a score of pain interference 
will be calculated at each interval. Independent Samples t-test and mixed effects model was 
utilised for the analysis. Pain medication was recorded and a graphical comparison between 
treatment groups was generated. Differentiation was made between cancer pain and CIPN pain. 
5. Scores of the Quality of Life Questionnaire before chemotherapy, three, six and nine months 
was compared between B vitamin and placebo groups in general. A sub group analysis of those 
participants who developed CIPN and those who didn’t. An Independent Samples t-test and 
Mixed Effects Model was utilised for analysis on the general QLQ scores.  
6. Scores of the Patient Neurotoxicity Questionnaire before chemotherapy, three, six and nine 
months was compared between B vitamin and placebo groups. Independent Samples t-test and 
Mixed Effects Model was used to compare between treatment groups at each time point. 
7. Comparison of Treatment Groups for Each Chemotherapy Drug was generated for those 
participants who developed CIPN compared to those who did not. A Test of proportions between 
the treatment groups was used for analysis in addition to Fisher’s exact test. 
8. Chemotherapy Dose Reduction was assessed. A test of proportions between the treatment 
groups was used for analysis if required. Allergy response to the chemotherapy agents or other 
reasons will be identified if the cause of dose reduction or cessation is not due to CIPN.  
9. B Vitamin Status before and after chemotherapy was assessed. Each B vitamin (vitamin B1, B2, 
B6, folate and B12) was compared to baseline between treatment groups. Either an Independent 
Samples t-test was utilised for analysis. Separate analysis occurred for interaction/absorption trial 
comparing hourly time points of B vitamin status between chemotherapy patients and healthy 
controls.  
10. B Vitamin Prophylaxis Effect on Tumour Response Rate. Analysis of tumour response rate 
was conducted comparing B vitamin versus Placebo arms. The landmark approach will be utilised 
for 6 months after the end of intervention (end of the trial). The log rank test was used.  
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NB: Additional statistical analysis was conducted on data at the end of the trial as seen appropriate. 
4.5.1 Subject Population(s) for Analysis 
The subject population(s) whose data was used for analysis included: 
 All-randomised population:  Any participant who was randomised into the study, regardless of 
whether they received the investigation product or the placebo. 
 All-treated population:  Any participant randomised into the study that received at least 3 
months of the investigational product or placebo. 
4.5.2 Significance 
The criterion of significance for this trial is set at 0.05.  
4.5.3 Power Calculation for Sample Size 
For the sample size of this research project, there are no published data on B group vitamins and 
CIPN. The calculation for our sample size was obtained from published studies on other nutraceutical 
and pharmaceutical agents such as magnesium/calcium infusions, acetyl-L-carnitine, glutathione, 
vitamin E, glutamine, amifositine and other drugs that have been conducted for CIPN.  
Out of 52 human studies published, 7 were eligible to be used for the calculation of sample size.  
Calculations were based on comparison of two independent proportions of patients expected to have 
CIPN. Only 1 study used the TNS score as their measurement tool [215], the others used the National 
Cancer Institute – Common Toxicity Criteria. Research states that the TNS is the best measurement 
tool for CIPN. 
Results: The power of our study was set at 80% and the significance level at 0.05 and the alpha is two 
sided.  
The statistical calculator used is:  http://www.stat.ubc.ca/~rollin/stats/ssize/ 
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Table 4-2: Power Analysis and Sample Size for B vitamin and CIPN Trial 
Author and Year Intervention group Placebo group Chemotherapy 
Assessed 
Argyriou.,  et al. 
(2005) [215] 
N = 16 
25%  
N=15 
73.3%  
Cisplatin, Paclitaxel 
or combination 
Wang.,  et al. (2007) 
[247] 
N=42 
Grade 1:  16.7% 
Grade 3-4:  11.9% 
N=44 
Grade 1:  38.6% 
Grade 3-4:  31.8% 
Oxaliplatin 
Pace.,  et al. (2010) 
[217] 
N=17 
5.9%  
N=24 
41.7%  
Cisplatin 
Argyriou., et al. 
(2006) [216] 
N=14 
21.4% 
N=16 
68.5% 
Cisplatin 
Gamelin., et al. 
(2004) [230] 
N=96 
Grade 3:  7% 
Total:  20% 
N=65 
Grade 3: 26% 
Total:  45% 
Oxaliplatin 
Gedlicka., et al. 
(2002) [237] 
N=15 
53% 
 Oxaliplatin 
Milla., et al. (2009) 
[244] 
N=14 
Grade 1:  50% 
Grade 2:  50% 
N=13 
Grade 2:  69.2% 
Grade 3:  30.7% 
Oxaliplatin 
 
The average participant numbers from the studies cited above for: 
Grade 1   N=30 
Grade 2-4   N=35 
We are predicting that the proportion of patients expected to develop no CIPN, Grade 1 CIPN and 
Grade 2-4 CIPN to be approximately 38% [n=13.3≈13], 42% [n=14.7≈15], and 20% [n=7] 
respectively.  These calculations were based on average proportion percentages from the 7 studies 
above. 
Hence, the requisite number for this pilot trial was 90 participants plus 50% attrition rate equating to 
135 participants. The study endeavored to recruit an equal number of participants per group.   
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4.6 DISCUSSION 
This clinical trial was designed to evaluate the efficacy and safety of B group vitamins in the 
prevention and treatment of CIPN development. By decreasing the incidence of this chemotherapy-
induced side effect, it was anticipated that the patient’s chemotherapy treatment regime, expected 
outcome, quality of life and physical ability for general life would be improved.  
It was hypothesised that participants low in B vitamins before the commencement of chemotherapy 
treatment were at an increased risk of developing CIPN and that administration of B group vitamins 
could decrease CIPN incidence and/or severity. In addition, it was thought that the chemotherapy 
agents may lower the patients B group vitamin status therefore making them susceptible to the 
development of CIPN. That only occurred in one patient (refer to chapter 8) and final blood pathology 
results indicate only a slight decrease in certain B vitamins.  
Limitations for this clinical trial included adverse reactions to chemotherapy agents that were not 
CIPN related, emotional/mental/physical exertion and stress involved with cancer diagnosis and 
treatment, mucositis associated with chemotherapy treatment that may alter B vitamin absorption and 
the mortality rate of high-risk cancer patients. An example of a non-related CIPN reaction includes 
allergic or hypersensitive reactions [366, 367] or significant myelosuppression [368] that may affect 
chemotherapy dose and treatment continuation. Two patients had quite adverse reactions to the 
chemotherapy. One developed Sweet’s syndrome and the other had pulmonary artery spasms. 
Approximately eight participants had mild allergic reactions to the chemotherapy agents. 
B group vitamins were assumed to have the potential to decrease the onset and severity of CIPN as a 
deficiency of B vitamins biochemically affects the health of nerve fibres and ganglia that neurotoxic 
chemotherapy agents can further adversely modulate. Reducing this chemotherapy-induced side 
effect is clinically relevant for disease outcome and quality of life.  
The results of each trial can be seen in chapter 5, 6 and 7.  
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5 CHAPTER 5 – STUDY 1: ABSORPTION STUDY 
5.1  INTRODUCTION 
A majority of vitamin supplements in Australia, although approved by the Therapeutics Goods Act 
(TGA - Australia’s governing body), are not externally tested for absorption. To ascertain if the B 
vitamin supplement chosen for this clinical trial was absorbed, an absorption study was devised. 
Initially the study focused on vitamin B12 as being the major B vitamin that could potentially decrease 
the incidence of CIPN. Hence, this pilot study tested serum vitamin B12 levels. Additionally, vitamin 
B12 has the potential to be poorly absorbed due to the complexity required for its absorption and 
utilisation (see chapter 1, page 64-65).  
Initially a small absorption study was conducted on two healthy volunteers to ascertain the vitamin 
B12 status after administration. The first 24 hours with the two volunteers also included red cell 
folate, however only serum vitamin B12 was assessed for this pilot study for the rest of the volunteers 
due to availability of the assay.  
Two participants were not enough to guarantee the selected supplement showed absorption or indicate 
significance. A further eight healthy volunteers underwent testing to quantify the absorption of the 
supplement giving a total of ten participants.  
5.2 METHODS 
5.2.1 Purpose  
To ascertain the absorption of vitamin B12 from the selected B group vitamin supplement.  
5.2.2 Design 
The masking of this trial was open with the study duration being 3 weeks for each person. The end-
point classification was the serum vitamin B12 status comparing baseline to 3 weeks after 
supplementation of B vitamins equivalent to 1,000 µg of vitamin B12 daily.  
5.2.3 Participants 
Ten generally healthy volunteers consisting of 5 male and 5 females were selected that meet the 
following inclusion and exclusion criteria: 
5.2.3.1 Key Inclusion Criteria 
1. Over the age of 18 years old 
2. Healthy with no known acute illness (chronic illnesses such as diabetes, cardiovascular 
disease and arthritis are allowed if managed or in a stable situation.) 
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5.2.3.2 Key Exclusion Criteria 
1. Participants who have been prescribed any other concurrent investigational product such as a 
vitamin, mineral or pharmaceutical agent for another trial. 
2. Currently experiencing peripheral neuropathy 
3. Have undergone previous chemotherapy treatment 
4. Pregnant or breast feeding women 
5. Any participant with established cognitive impairment, diagnosed alcoholism, intellectual 
disability or severe mental illness. 
6. Any participant taking concurrent multivitamins, nutritional and/or herbal supplements or fish 
oils 
5.2.3.3 Recruitment 
Recruitment of health volunteers was established through the University of Queensland, School 
of Medicine students and staff located at the Princess Alexandra Hospital, Translational Research 
Institute. Recruitment was through word of mouth and researchers contacting staff and students.  
5.2.4 Dose and Duration of Supplementation 
Each participant had fasting blood drawn from a phlebotomist from the University of Queensland or 
the Princess Alexandra Hospital before supplementation for baseline vitamin B12 status. One capsule 
was then administered after breakfast, which was equivalent to 500 µg of both vitamin B12 and folate 
(as folinic acid). Bloods were then taken 3 hours, 6 hours and 24 hours after the initial administration 
of the B vitamin capsule. The last blood request was taken three weeks after the initial 24 hours. Each 
participant was administered one capsule twice a day after food equivalent to 1,000 µg/day of vitamin 
B12. Bloods are then drawn again to ascertain vitamin B12 status after administration.  
During the first 24 hours a diet that restricted vitamin B12 was implemented. See Appendix 8.  
5.2.5 Study Site and Ethics Approval 
The study site was the University of Queensland and the Princess Alexandra Hospital, Brisbane, 
Australia. The University of Queensland Ethics Committee (UH 2010000749) approved the ethics 
for this project. 
5.2.6 Study Outcomes 
The primary end-point was the comparison of the baseline serum vitamin B12 status compared to the 
3-week serum B12 status. 
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5.3 RESULTS 
The demographics of the healthy volunteers seen in Table 5-1 showed an equal number of males to 
females. Their average age was 38 years old and they were in a generally healthy weight range and 
BMI (healthy BMI = 23-27). They had minimal caffeine and alcohol intake and none of the volunteers 
smoked.  
 
Table 5-1: Demographics of Healthy Volunteers for the B12 Absorption Study 
 
Healthy Volunteers Demographics 
Gender Females x 5      Males x 5 
Age (years) Mean ± SD       38 ± 12.45 
Weight (kg) Mean ± SD       76.5 ± 13.52 
BMI Mean ± SD       24.38 ± 2.84 
Caffeine intake (per day) Median ± SD       1.5 cups ± 1.16 
Alcohol intake (per week) Median ± SD       3 standard drinks ± 1.77 
Smoking (per day) Median ± SD       0 ± 0 
 
 
Table 5-2 contains the full results of the samples collected from the healthy volunteers. Levels varied 
over the twenty-four period however, all participants increased from baseline in the three week period 
of supplementation except participant PO5. This is the only participant that was vegetarian. 
Considering there is a higher prevalence of a vitamin B12 deficiency found in vegetarians [369] the 
initial baseline result of 750 pmol/L may represent a false result or reading considering the vitamin 
B12 status decreased after supplementation was commenced (500 µg). One capsule was taken after 
breakfast the same day as noted by researchers and the results three, six and twenty-four hours after 
were all lower than the baseline result. The results of PO5 after three weeks of supplementation can 
be surmised that the participant was not being compliant with taking the recommended dose although 
they stated that they were approximately 73% compliant. 
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Table 5-2: Results from the B12 Absorption Study including Vitamin B12 and Folate 
 
Patient Tests Baseline 3 hours 
 
6 hours 
 
24 hours 
 
3 weeks taking 
B vitamins 
P01 Serum B12 212  216  216  208  657  
P02 Serum B12 500  603  620  693  819  
PO3 Serum B12 318 368 358 314 790 
PO4 Serum B12 401 426 466 456 900 
PO5 Serum B12 750 570 580 610 570 
PO6 Serum B12 256 321 303 366 640 
PO7 Serum B12 285 282 303 312 520 
PO08 Serum B12 191 194 208 177 272 
PO09 Serum B12 263 269 280 357 425 
PO10 Serum B12 311 279 335 347 414 
Patient Tests Baseline 3 hours 
 
6 hours 
 
24 hours 
 
3 weeks taking 
B vitamins 
P01 RCF 14.85  13.55  13.65  13.82  N/A 
P02 RCF 25.22  22.94  23.18  23.53  N/A 
The blood results of the red cell folate collected for the two initial healthy volunteers as seen in 
Figure 5-1 showed no difference after 500 µg of folinic acid was ingested. No further testing was 
conducted on folate for the remainder of the pilot study.  
 
 
Figure 5-1: Red Cell Folate (RCF) Results from 2 Participants over 24 hours. 
 
0
5
10
15
20
25
30
0 3 6 24
R
C
F 
(N
M
O
L/
L)
TIME (HOURS)
Absorption Study Red Blood Cell Folate 
from Folinic Acid Suplementation
PO1 PO2
  
5-153 
 
The final-results of the absorption study seen in Figure 5-2 shows that the selected oral B vitamin 
supplement does increase serum vitamin B12 levels in healthy volunteers after three weeks of 
supplementation of two capsules a day (equivalent to 1,000 µg/day). Minimal absorption of vitamin 
B12 was seen in blood results over twenty-four hours after 500 µg was ingested. 
 
 
Figure 5-2: Vitamin B12 Results over Three Week Supplementation 
 
5.4 DISCUSSION 
Ten healthy volunteers commenced and completed the absorption study. The demographics of these 
volunteers can be seen in Table 5-1. There were equal male and female participants with an average 
age of 38 years old. All were within an adequate BMI of around 24 so therefore were not overweight 
and consumed on average one to two cups of coffee a day and around 2 to 4 standard alcoholic drinks 
a week. No participants used tobacco products and only two participants had been prescribed 
medications. One participant was a type 1 diabetic and the thyroid had been removed. The medication 
this participant was taking included humalin NPH (20 units x 2), Humalog (8 units x 2) and Oroxine 
(200 mcg/day). Another participant had the two genetic mutations of methylenetetrahydrofolate 
reductase (MTHFR: C677T and A1298C mutations) and had been diagnosed with high blood pressure 
and cardiovascular disease.  
The medication for this participant included Karvea (150 mcg/day) and Norvasc (5 mg) for 
hypertension.  One participant, PO5 was a vegetarian but still consumed fish and seafood while all 
other participants consumed animal meats on a regular basis.  
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In regards to the vitamin B12 results, there was some variation among the participants in regards to 
ranges. The range for the serum vitamin B12 assay is 133 to 680 pmol/L for the Princess Alexandra 
Hospital. It should be noted that reference ranges vary depending on the laboratory. However, it has 
been reported that this reference range is not correct, as many people in the population will exhibit 
neurological symptoms of a deficiency at a much higher concentration compared to 133 pmol/L [370, 
348]. Researchers vary in opinion as to the lowest concentration that should be considered. The 
consensus is that a low value of 221 pmol/L is an acceptable ‘normal’ bottom line [370].  
As such the agreement on the lowest normal range indicates that two of the participants would be 
considered deficient at baseline (PO1=212 pmol/L and PO8=191 pmol/L). One participant was over 
range PO5=750 pmol/L. Over the 24 hour period, minor increases in range were reported at 3, 6 and 
24 hours with the mean increasing slightly from baseline (348.7 pmpl/L) 4.1 pmol/L at 3 hours, 18.2 
pmol/L at 6 hours and 35.3 pmol/L at 24 hours (see Figure 5-2).  At the three-week interval, the mean 
went from 348.7 pmol/L at baseline to 600.7 pmol/L (252 pmol/L difference). This indicates a 58% 
increase with no participants considered deficient at the conclusion of the trial.  
One participant, P05 was the only participant who reported a decrease in B12 from baseline (750 
pmol/L at baseline to 570 pmol/L at 3 weeks). This variation may have occurred due to poor 
compliance, a false reading at baseline (as all other results were around the 570 pmol/L: 750=baseline, 
570=3h, 580=6h, 610=24h and 570=3 weeks) or previous unreported vitamin B12 administration 
prior to the trial. The participant had reported missing a number of doses of the B vitamin over the 
three-week period but was found to be 73% compliant.  
In regards to the participants that were sub-clinically deficient at baseline, both participants reported 
an increase in vitamin B12. PO2 increased from 212 pmol/L to 657 pmol/L within the 3 weeks. PO08 
did not have a dramatic increase in B12 and actually had a further decrease at 24 hours. This 
participant’s range decreased from 191 pmol/L to 177 pmol/L at 24 hours and to 272 pmol/L at 3 
weeks. Although this result may indicate poor compliance over the 3-week period, the participant 
however was found to be 82% compliant. 
Participant PO08 had the genetic double MTHFR polymorphisms. These polymorphisms may have 
an impact on this participant’s vitamin B12 status, although this has not been proven [372]. Other 
possible reasons that may be involved with the slight increase include intrinsic factor antibodies (not 
tested, awaiting results), stress (the participant was in a particularly high acute stress situation during 
testing), impaired digestion or inadequate utilisation [371].  These confounding factors may have 
been involved with the end result with the intrinsic factor antibody status still pending.  
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5.5 CONCLUSION 
The results of this small clinical trial indicate a trend that the B vitamin supplement chosen was 
adequate for vitamin B12 absorption in healthy volunteers, the supplementation outcome was not 
significant. Taking into consideration that this supplement will be administered to cancer patients 
undergoing chemotherapy, there will be a number of confounding factors that may interfere with 
vitamin B12 absorption. Hence, the few confounders found in this study are reasonable indicators 
that the supplement may still be absorbed despite certain factors. To expand on this trial, an absorption 
and interaction trial was developed to ascertain the B vitamin status of other B vitamins and the B 
vitamin status after chemotherapy administration.  
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6 CHAPTER 6 – STUDY 2:   INTERACTION/ABSORPTION STUDY 
6.1 INTRODUCTION 
The hypothesis for this thesis incorporated two themes.  The first of premise was to substantiate 
whether patients with low B vitamin status prior to chemotherapy administration may be at an 
increased risk of developing CIPN and the level of severity experienced. To examine this theme, B 
vitamin status was assessed during chemotherapy administration to ascertain if chemotherapeutic 
interventions change a patient’s B vitamin status. It is posited that a decrease in B vitamins such as 
vitamin B1, B6 and B12 from specific chemotherapy agents may predispose a patient diagnosed with 
cancer to the development of CIPN.  
To test this concept, an absorption and interaction pilot clinical trial was developed. A small cohort 
of six participants undergoing chemotherapy was chosen from the main clinical trial. All subjects 
undergoing chemotherapy agreed and consented to being part of the absorption and interaction trial. 
All six subjects were undergoing chemotherapy at the time of testing for the absorption/interaction 
trial and had been taking the selected B vitamin supplement or placebo [see Chapter 4 for B vitamin 
complex breakdown on page 154].  The subjects continued to take the given supplement throughout 
this trial, during the entire chemotherapy regime and three months’ post-chemotherapy. To assist in 
clarifying the B vitamin response, six healthy volunteers with similar demographics to the 
chemotherapy participants were selected to investigate if there was a difference in the blood B group 
vitamin status with the same supplementation of B vitamins. 
The healthy volunteers were given the B vitamin to ascertain if there was an increase in blood B 
vitamin status over the seventy-two hours without chemotherapy administration. Therefore, as half 
of the chemotherapy patients were also taking the B vitamin prior and during the 
absorption/interaction trial, a comparison could be made if chemotherapy administration made a 
difference in the B vitamin status of patients. The three chemotherapy patients taking the placebo 
were selected in order to determine the effects that would be observed in B vitamin status after 
chemotherapy administration with no B vitamin supplementation.  
The three chemotherapy agents that were selected for the main trial (vincristine, oxaliplatin and 
taxane class) were used in this pilot clinical trial to test the B group vitamin status response to each 
agent.  This decision was made rather than testing one agent as all three were being used in the main 
clinical trial study. Even though each agent has a different mechanism of action, the general B group 
vitamin status could still be monitored.  
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6.2 METHODS 
6.2.1 Purpose:  
To assess and compare the absorption and status of the B group vitamins in patients undergoing 
chemotherapy with either vincristine, docetaxel or oxaliplatin who were taking an oral B vitamin 
supplement or placebo; and further compared to the healthy volunteers who were taking the same B 
vitamin supplement.  
6.2.2 Design 
Six participants enrolled in the main clinical trial consented to be part of the pilot clinical trial 
assessing absorption and interaction. From the six participants who were receiving chemotherapy 
there were three participants that were taking the B vitamin supplement and three that were taking 
the placebo (microcrystine cellulose). A blood sample was collected prior to the administration of 
chemotherapy (baseline value), and then twenty-four and seventy-two hours. Six healthy volunteers 
who also had blood samples taken at baseline, then post administered one capsule of B group vitamins 
twice a day (same as the main clinical study). A blood sample was then collected at twenty-four and 
seventy-two hours after B group vitamin administration. 
The blood sample analysis consisted of vitamin B1 (thiamine diphosphate), vitamin B2 (flavin 
adenine dinucleotide), vitamin B6 (pyridoxal-5-phosphate), red cell folate and vitamin B12 
(holotranscobalamin).  These samples were analysed by Sullivan Nicolaides Pathology. The technical 
equipment and assays used are listed in Appendix 6. 
6.2.3 Participants 
1. Six patients diagnosed with cancer undergoing chemotherapy treatment (mixture of males and 
females). The selected cancer patients were already enrolled in the main clinical trial and had 
been randomised to either the B vitamin or placebo arm. Hence, the patients were taking the 
selected B vitamin complex or placebo prior to testing for the absorption/interaction trial.  
2. Six healthy volunteers (mixture of males and females) not taking any B vitamin supplements 
prior to testing. 
6.2.4 Key Inclusion Criteria 
For the patients diagnosed with cancer:  
1.   Newly diagnosed with a neoplastic disease 
2. Had been prescribed chemotherapy treatment with oxaliplatin, the taxane class or vincristine 
and had commenced their chemotherapy regime.  
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3. Aged 18 years old or older. 
4. Had been enrolled in the main clinical trial assessing B vitamin supplementation in the 
prevention of CIPN and were taking either the B vitamin supplement or placebo.  
For the healthy volunteers:  
1.   Aged 18 years old or older 
2. Relatively healthy – no known acute disease. Volunteers who had a chronic illness such as 
diabetes, cardiovascular disease, arthritis were included unless they were experiencing an 
acute stage of their illness. No volunteers were enrolled if they had chronic liver, digestive 
(including bowel resections) or kidney disease.  
6.2.5 Key Exclusion Criteria 
1. Participants who had been prescribed any other concurrent investigational products in another 
trial such as vitamins, minerals or pharmaceutical agents (drugs).  
2. Currently experienced peripheral neuropathy.  
3. Had undergone previous chemotherapy treatment with a neurotoxic agent.  
4. Women who were pregnant or breast-feeding 
5. Any patient who had established cognitive impairment, diagnosed alcoholism, intellectual 
disability or severe mental illness. 
6. Any patient taking concurrent multivitamins, nutritional and/or herbal supplements or fish oils. 
6.2.6 Dose and Duration of Supplements 
Cancer patients were randomised to a B group vitamin (1 capsule b.i.d) or placebo (1 capsule b.i.d) 
after meals in the main clinical trial. Cancer patients were undergoing chemotherapy at the time of 
testing for this absorption/interaction trial with concurrent administration of the B vitamin supplement 
or placebo.  Healthy volunteers did not undergo chemotherapy treatment and were given a B group 
vitamin (1 capsule b.i.d). Healthy volunteers were not randomised. 
6.2.7 Study Site and Ethics Approval 
The study sites were the University of Queensland and the Princess Alexandra Hospital, Brisbane, 
Australia. The University of Queensland Ethics Committee (UH 2010000749) and the Princess 
Alexandra Hospital Ethics Committee (HREC/10/QPAH/140) approved ethics for this project. 
  
6-159 
 
6.2.8 Statistical Analysis 
The data was recorded and statistical analysis conducted using the Excel program. The participant 
numbers for this trial were too small to use SPSS. The concept of this trial was to observe any change 
in projection from chemotherapy administration in patients supplemented with B vitamins or placebo. 
Therefore the most effective way of analysing the data was to assess the difference in projection 
through a line graph and noting any differences observed.   The scholar/researcher carried out and 
completed the analysis.  
6.3 STUDY OUTCOMES 
6.3.1 Descriptive Statistics 
Data for descriptive statistics of the groups are presented in Table 6-1. The healthy volunteers were 
equal number of males and females and of similar age to the group that was administered 
chemotherapy. The average weight and BMI of the healthy volunteers was in the range 23-28 Kg/m2 
(deemed healthy). The chemotherapy group had more females than males (4:2) and was equally 
divided for each chemotherapy agent with one participant on placebo and one participant on the test 
intervention.  There was only one oxaliplatin participant due to the main clinical trial ceasing 
recruitment of this chemotherapy agent. The average weight and BMI of the chemotherapy 
participants was overweight (30 Kg/m2).   
Table 6-1: Descriptive Statistics of Participants in Absorption/Interaction Pilot Trial 
 
 Chemotherapy Participants Healthy Volunteers 
Gender             Male 2 3 
Female 4 3 
Age 38.5 ± 15.3 years 
Mean ± SD 
39 ± 13.7 years 
Mean ± SD 
Weight 99.7 ± 32.65 kg 
Mean ± SD 
68.05 ± 8.48 kg 
Mean ± SD 
BMI 29.9 ± 9.33 kg/m
2 
Mean ± SD 
23.6 ± 2.09 kg/m
2 
Mean ± SD 
Chemotherapy 
Agents 
  
Docetaxel 3 
Oxaliplatin 2 
Vincristine 1 
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6.3.2 B Vitamin Blood Results 
6.3.2.1 Vitamin B1 
The results for vitamin B1 are mixed in regards to the chemotherapy patients as seen in Table 6-2  
and Figure 6-1. The healthy volunteers showed a general increase over the seventy-two hours (18%). 
The chemotherapy patients who were supplemented with B vitamins in comparison showed a 
decrease in vitamin B1 status twenty-four hours after chemotherapy (15%) administration was begun 
and then increased above baseline at seventy-two hours (12%). The placebo arm showed a slight 
increase twenty-four hours after chemotherapy (8%) then a 40% increase from baseline seventy-two 
hours after chemotherapy administration.  
 
Table 6-2: Vitamin B1 Results for Absorption/Interaction Pilot Trial  
Vitamin B1  (ref 66-200 nmol/L)  Vitamin B1  (ref 66-200 nmol/L) 
Allocation 
No Baseline 24 hour 72 hour 
 Allocation no Baseline 24 hour 72 hour 
AT1 DxS 170 220 220  PA015AJM - VB 220 220 190 
AT2 SxC 160 180 190  PA009BJS - DB 210 170  
AT3 BxG 130 150 160  PA043MME-AB 230 170 310 
AT4 NCB 170 200 220  Average B vits 220 186.66 250 
AT5 NxP 150 170 180  SD 10 28.86 84.85 
AT6 AxB 160 170 180 
 PA011GMB – 
VP 
170 160 290 
Average 156.66 181.66 191.66  PA012EBS - OP 140 190 130 
SD 15.05 24.83 24.01 
 PA049EMD – 
DP 
150 150 340 
     Average Placebo 153.33 166.66 253.33 
     SD 15.27 20.81 109.69 
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Figure 6-1: Vitamin B1 Results for Absorption/Interaction Pilot Trial 
 
6.3.2.2 Vitamin B2 
Data are presented in Table 6-3 and Figure 6-2. Vitamin B2 showed a noticable decrease at 24 hours 
(18%) with the B vitamin supplemented chemotherapy group versus the placebo (4%), however, both 
groups showed an increase at 72 hours (B vitamin arm=15%; placebo arm= 9%). The healthy controls 
indicated a normal increase over the 72 hours (11%). 
Table 6-3: Vitamin B2 Results for Absorption/Interaction Pilot Trial 
 
Vitamin B2 (ref 180-470 nmol/L)  Vitamin B2 (ref 180-470 nmol/L) 
Allocation 
No Baseline 24 hour 72 hour 
 Allocation No Baseline 24 hours 72 hours 
AT1 DxS 320 350 360  PA015AJM - VB 320 310 290 
AT2 SxC 340 360 370  PA009BJS - DB 350 220  
AT3 BxG 310 340 340  PA043MME-AB 290 260 330 
AT4 NCB 290 310 320  Average B vits 320 263.33 310 
AT5 NxP 250 280 320  SD 30 45.09 28.28 
AT6 AxB 290 310 320  PA011GMB - VP 280 240 240 
Average 300 325 338.33  PA012EBS - OP 260 280 250 
SD 30.98 30.16 22.28  PA049EMD - DP 270 260 370 
     Average Placebo 270 260 286.66 
     SD 10 20 72.34 
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Figure 6-2: Results of Vitamin B2 in Absorption/Interaction Pilot Trial 
 
6.3.2.3 Vitamin B6 
Data for this section are presented in Table 6-4 and Figure 6-3. The results of vitamin B6 
demonstrated a marked increase in circulating pyridoxal-5-phospate (P5P) the active form of vitamin 
B6 with 40 mg of vitamin B6 daily. The healthy individuals all showed an increased response to 
supplementation, with an average increase between 5 to 12 fold. Whereas only one subject showed a 
two fold increase. The chemotherapy patients showed that the B vitamin supplement group had a 
decline (65%) and then a marked increase (79%) over the 24 hour and 72 hour time points 
respectively. Alternatively the placebo group showed minimal difference over the 72 hours compared 
to the B vitamin supplemented arm (24 hour decrease 9%; 72 hours increase by 12.6%).  
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Table 6-4: Vitamin B6 Results in Absorption/Interaction Pilot Trial 
 
Vitamin B6 (ref 35-10 nmol/L)  Vitamin B6 (ref 35-10 nmol/L) 
Allocation 
No Baseline 24 hour 72 hour 
 Allocation no Baseline 24 hour 72 hour 
AT1 DxS 350 1840 2160 
 PA015AJM-VB 950 500 480 
AT2 SxC 200 440 920  PA009BJS - DB 200 100  
AT3 BxG 330 520 690  PA043MME-AB 880 310 1450 
AT4 NCB 130 370 690  Average B Vits 676.66 303.33 965 
AT5 NxP 85 400 690  SD 414.28 200.08 685.89 
AT6 AxB 130 1280 1580  PA011GMB - VP 90 85 110 
Average 204.16 808.33 1121.66  PA012EBS - OP 90 80 65 
SD 111.64 610.65 614.47  PA049EMD - DP 50 45 90 
  
  
 Average Placebo 76.66 70 88.33 
     SD 23.09 21.79 22.54 
 
 
 
Figure 6-3: Vitamin B6 Results for Absorption/Interaction Pilot Trial  
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6.3.2.4 Folate 
 
The overall B group vitamin status in blood of all participants including the healthy controls were all 
within optimal range indicating a generally favourable absorption of folic acid as seen in Table 6-5  
and Figure  6-4. This may in part be due to the fortification of foods in Australia [373]. The healthy 
controls increased their folate status by 9% over the seventy-two hours of supplementation. The B 
vitamin supplemented chemotherapy group (including the patient on oxaliplatin as they have folinic 
acid as part of their chemotherapy combination) had a 2% increase over twenty-four hours and went 
back to baseline at seventy-two hours. The placebo group had a 8.5% decrease in red cell folate 
seventy-two hours after chemotherapy administration.  
 
Table 6-5: Folate Results for Absorption/Interaction Pilot Trial 
 
Folic Acid (ref >900 nmol/L)  Folic Acid (ref >900 nmol/L) 
Allocation 
No Baseline 24 hour 72 hour 
 Allocation No Baseline 24 hour 72 hour 
AT1 DxS 2452 1999 2507  PA015AJM-VB 3369 3004 2916 
AT2 SxC 2146 2667 2374  PA009BJS - DB 2968 2600  
AT3 BxG 1580 1682 1741  PA012EBS - OP 2881 3513 3386 
AT4 NCB 1528 1471 1600  PA043MME-AB 2261 2589 2289 
AT5 NxP 1478 1498 1442  Average B Vits 2869.75 2926.5 2863.66 
AT6 AxB 1501 1773 2033  SD 458.11 436.07 550.36 
Average 1780.83 1848.33 1949.5 
 PA011GMB - 
VP 
2502 2023 2273 
SD 414.26 445.28 429.22 
 PA049EMD - 
DP 
2321 2420 2095 
     Average Placebo 2411.5 2221.5 2184 
     SD 127.98 280.72 125.86 
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Figure 6-4: Folate Results for the Absorption/Interaction Pilot Trial 
 
6.3.2.5 Vitamin B12 
An unknown factor that the test chosen for vitamin B12, the Holo TC is only measured to 128 pmol/L 
was not discovered until this study was conducted. The company, Sullivan Nicolaides Pathology who 
conducted the assays did not communicate this fact to us, nor did the researchers ask. So, the results 
of this study are impaired as the true increase cannot be seen. There are no results higher than 128 
pmol/L. Therefore, the healthy controls showed that supplementation over 72 hours reached 
maximum result capacity as seen in Table 6-6 and Figure 6-5. The chemotherapy participants had 
mixed results. The B vitamin arm decreased their vitamin B12 status by 3.5% twenty-four hours after 
chemotherapy and then increased 14% by seventy-two hours. The placebo arm increased their vitamin 
B12 status twenty-four hours after chemotherapy by 12% and then decreased 25% by seventy-two 
hours.   
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Table 6-6: Vitamin B12 Results for Absorption/Interaction Pilot Trial 
 
Vitamin B12 (Holo TC)  ( ref >35 pmol/L)  Vitamin B12 (Holo TC)  (ref >35 pmol/L) 
Allocation 
No Baseline 24 hour 72 hour 
 Allocation No Baseline 24 Hours 72 Hours 
AT1 DxS 128 128 128  PA015AJM - VB 128 128 128 
AT2 SxC 128 128 128  PA009BJS - DB 92 96  
AT3 BxG 97 128 128  PA043MME-AB 122 106 128 
AT4 NCB 76 121 128  Average B Vits 114 110 128 
AT5 NxP 72 123 128  SD 19.28 16.37 0 
AT6 AxB 82 128 128  PA011GMB - VP 128 128 78 
Average 97.16 126 128  PA012EBS - OP 112 128 127 
SD 25.34 3.16 0  PA049EMD - DP 85 113 72 
     Average Placebo 108.33 123 92.33 
     SD 21.73 8.66 30.17 
 
 
 
Figure 6-5: Vitamin B12 Results for Absorption/Interaction Trial 
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6.4 DISCUSSION  
The absorption/interaction study before discussing the data does not indicate any results due to the 
low number of participants and the fact there was no healthy controls on placebo. Thi is a major 
weakness within the pilot trial and further more substantial trials are required to substantiate any 
information obtained from this trial. The low number of participants was due to ethic clearance and 
their concern of further venous puncture on patients who are already receiving numerous blood test 
and needle interventions. The healthy controls in retrospect should have been divided into two groups, 
one B vitamin and one placebo to ascertain any differences. The orginal decision for the healthy 
volunteers to all take the B vitamin oral supplement was due to the low numbers of participants. By 
having all healthy volunteers taking the B vitamin, it was surmised to give a better median result than 
only two to three people in one group.  
Each B vitamin had varing results. Vitamin B1 blood levels increased over the seventy-two hours for 
the healthy volunteers (18%) which was expected, however it was hypothesised that the vitamin B1 
status would decrease after chemotherapy. This occurred with the B group vitamin arm (decreased 
15% by 24 hours) however the placebo arm increased at 24 hours after the chemotherapy 
administration (8%) and further still at 72 hours (40%). The increase seen in the placebo arm may be 
due to the glucose release by the liver after chemotherapy administration.  
The cofactor of Vitamin B1, TDP, acts as a cofactor for transketolase and for pyruvate dehydrogenase 
and α-ketoglutarate dehydrogenase complexes as discussed in chapter 1 [374]  page 41-42. All of 
these enzymes play a fundamental role in intracellular glucose metabolism. As seen in diabetic 
patients, an increased requirement for these enzymes has been found in high blood glucose status 
[374].  Therefore, this may explain the increase of TDP in the serum in the placebo arm. The body 
adapted to the higher requirement, wllhereas it is assumed that the B group vitamin arm may have 
had a higher saturation level in the tissues, therefore the body did not have to increase its production 
of TDP to adapt to the high blood glucose requirement. The blood tests of the study participants 
before and after chemotherapy as seen in Figure 6-1 indicates that the placebo group did decrease its 
thiamine level after chemotherapy thereby depleting the vitamin B1 status, whereas the B vitamin 
arm increased from baseline.  
For vitamin B2, a decrease in vitamin B2 was seen in the B vitamin supplemented chemotheapy arm 
(18%) compared to placebo (4%) and then both arms increased in blood status over seventy hours (B 
vitamin=15%; placebo=9%). This slight increase in both placebo and B vitamin groups indicates no 
changes in this B vitamin after chemotherapy administration.  
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Comparing the results with the final blood results of the main trial seen in Figure 6-2, both B vitamin 
and placebo groups showed a decrease in vitamin B2 status from the commencement of chemotherapy 
to the completion of chemotherapy. It was expected that vitamin B2 levels would have increased with 
supplementation, however this was not the case. The reason for this may lie with vitamin B6. Vitamin 
B2 is the main cofactor for the enzyme pyridoxine phosphate oxidase which is the enzyme that 
converts the inactive vitamin B6 to the active form in the liver [58]. The results of the vitamin B6 
assays showed a marked increase of circulatory pyridoxal-5-phosphate (P5P) which his the active 
form of vitamin B6 [58]. This dramatic increase of vitamin B6 and the use of vitamin B2 to assist in 
this activation may be why the vitamin B2 levels decreased.  
Also, this may explain why the vitamin B2 increased at 72 hours after chemotherapy as it had a higher 
requirement. In addition, its role in other co-enzymes such as glutathione reductase, thioredoxin 
reductase, monoamine oxide, and its involvement with the electron transport chain, choline 
metabolism and 5-methyl tetrahydofolate [58] may also play a key role in the explaination of the B2 
status. 
Interpreting the high levels of vitamin B6 seen in Table 6-4, perhaps excess circulating vitamin B6 
due to supplementation is temporarily decreased, whereas if the circulating levels are only reaching 
adequate amounts of vitamin B6 as seen in the placebo arm then no difference in circulating P5P 
(vitamin B6) levels are noted. A number of reasons for this occuring include the chemotherapy agent 
binding to the circulating P5P or interferance with the molecule in the blood however a plausible 
explanation for this is beyond the scope of this study at present. An answer may be found with the 
NMR completion studies that will be conducted in the future. Overall, supplementation throughout 
chemotherapy and at the completion of chemotherapy has a marked increase in P5P.  
For folate status, all participants were found to have adequate amount of circulating folate. All 
chemotherapy participants had a higher baseline than the general healthy volunteers (B vitamins= 
38% higher; placebo=26% higher). The end results of the study seen in Figure 6-4 found that the 
overall baseline for cancer patients was similar to the healthy controls, therefore it may have been the 
patients selected for this trial that had a higher baseline folate status. The placebo participants also 
showed a minor decrease after chemotherapy administration (8.5%) however overall, the final blood 
B group vitamin results indicated very little difference from baseline to after completion of 
chemotherapy course. The B vitamin group showed no significant differences during chemotherapy 
administration although increased in the final blood results by approximately 500 nmol/L. High folate 
intake has been linked with health concerns such as reduced cognitive function [375] and colon cancer 
[376, 377]. Continual supplementation with folic acid is not suggested, so considering the high initial 
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levels of folic acid, patients who consume a multi-vitamin or vitamin B complex regularly should be 
careful of high folic acid status.  
The assay for Vitamin B12 as stated did not exceed 128 pmol/L, which means the true vitamin B12 
status of patients and healthy volunteers were unable to be obtained. However, changes in vitamin 
B12 status were seen in Figure 6-5. According to Vu’s [62] study in 1993, it was expected that vitamin 
B12 would be temporarily decreased with chemotherapy administration. The B vitamin group showed 
a small decrease after chemotherapy administration (3.5%) than an increase due to supplementation 
(14%). The placebo group however, showed an increase after chemotherapy (12%) than a marked 
decrease within 72 hours (25%). This response may be due to the impact on the liver from the 
chemotherapy. It has been found that liver damage or disease may release stored vitamin B12 
therefore showing high vitamin B12 levels [378, 379].  Hence, the increase 24 hours after 
chemotherapy administration may indicate liver damage than the decrease at 72 hours is the actual 
status of vitamin B12. Overall, the final blood results do not show any significant changes in vitamin 
B12 status after chemotherapy administration.  
In summary, a slight decrease in vitamin B1, B2 and B12 blood levels and a marked decrease in 
vitamin B6 were seen over twenty-four hours for patients supplemented with B vitamins undergoing 
chemotherapy compared to healthy volunteers. For the patients on placebo, a slight decrease was seen 
in vitamin B6 and folate after chemotherapy with vitamin B1 and B12 status increasing twenty-four 
hours after chemotherapy administration. Vitamin B1 continued to increase seventy-two hours after 
chemotherapy administration while vitamin B12 levels dropped for patients on placebo.  
Overall, no information of substance can be extracted from the information obtained from this pilot 
trial. The small number of participants and the small amount of changes noted makes it impossible to 
interpret correctly and give any substantial findings.  
Limitations were noted for this pilot trial and the results may not be a true indication of what occurs 
for patients B vitamin status after chemotherapy administration as stated above as it may only be a 
chance finding due to the following limitations identified.  
The limitations include: 
a. Low number of participants (no power analysis was conducted. The decision on the 
number is due to ethical clearance.) 
b. More than one chemotherapy agent (in retrospect to test only one chemotherapy agent for 
this pilot clinical study would have been more scientifically meaningful.) 
c. The Holo TC as the vitamin B12 pathology test as the assay is stopped at 128. Using serum 
vitamin B12 would have been a better choice for this study.  
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d. The healthy volunteers were not randomised. In retrospect, it would have been beneficial 
to randomise the healthy volunteers to three receiving the B vitamin supplement and three 
receiving the placebo. Or if ethically approved, an increase number of both chemotherapy 
patients and the healthy volunteers to be able to conduct statistical analysis on the data 
collected.  
If the researchers could do this study over again, ideally it would have been better to test only one 
chemotherapy agent with 20 participants at a particular time during their chemotherapy treatment. 
This may have been at the beginning and at the last chemotherapy administration to see a comparison. 
As this is not the case, the researchers assessed the results as stated.  
The results of this study do not answer the question of the hypothesis regarding B vitamin status 
during chemotherapy but do give a snap shot as to what may be occurring for some chemotherapy 
patients. B vitamin status may potentially be compromised by chemotherapy administration. 
However, further research is required.  
 
6.5  CONCLUSION 
In summary, no specific information can be obtained from the data collected from this pilot trial due 
to the low participant numbers and changes noted. The results show only a snap shot of a small 
number of chemotherapy patients B vitamin status after one chemotherapy administration. Further 
information on B vitamin status for chemotherapy patients will have more statistical power in the 
main trial seen in chapter 7.  
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7 CHAPTER 7 – STUDY 3:  MAIN RESEARCH PROJECT 
 
7.1 INTRODUCTION 
The main clinical trial was conducted to assess the efficacy and safety of an oral vitamin B complex 
formulation over placebo that was posited to reduce the development of CIPN.  The aim was to recruit 
between ninety and one hundred and thirty-five participants however, due to the complexity of 
recruitment and time restraints of completing a post doctorate this clinical trial was ceased after 71 
participants were recruited. The reduced number of participants lowered the power of the study but 
still gave a result.  
 
7.2 METHODS 
7.2.1 Purpose 
The purpose of the clinical trial was to evaluate the efficacy and safety of a vitamin B complex to 
reduce the incidence and severity of oxaliplatin-induced; the taxane class-induced; and vincristine-
induced CIPN. 
7.2.2 Design 
The design of the clinical study was a single-blinded placebo-controlled randomised clinical trial 
(RCT). The main purpose of the RCT was to assess the prevention of CIPN through oral 
supplementation of a vitamin B complex. The end-point classification was efficacy and safety. All 
participants that adhered to the inclusion and exclusion criteria and signed an informed consent were 
then randomised before the commencement of any chemotherapy cycle. The subjects continued till 
the completion of the chemotherapy treatment regimens and were then followed three months’ post-
chemotherapy. The follow up assessment post-chemotherapy was to evaluate the possibility that 
participants in the clinical study may have developed a delayed CIPN from certain chemotherapy 
agents (i.e. the Taxane class, vincristine and oxaliplatin) [380]. The complete time of involvement for 
participants who consented for this clinical trial varied between six to nine months in duration 
depending on their chemotherapy regimen.   
7.2.3 Primary Outcome 
The primary outcome for this clinical trial was the occurrence of peripheral sensory and motor 
neuropathy as defined by changes in the TNS, which is a measurement tool for the development of 
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CIPN. The TNS measurement tool can be found in Appendix 2. An independent neurologist at the 
PA hospital, who was blinded to the allocation of the participants, conducted the TNS examination. 
The same neurologist conducted all neurology tests on all participants.  
7.2.4 Secondary Outcomes 
There were four secondary outcome measures used, namely the MD Anderson Brief Pain Inventory, 
EORTC Quality of Life Questionnaire, Patient Neurotoxicity Questionnaire and patient diaries. In 
addition, blood pathology tests were conducted before and after chemotherapy for each participant 
and included the serum levels of vitamins B1, B2, B6, folate and vitamin B12. The questionnaires 
were completed at baseline, three months, six months and nine months depending on the participant’s 
chemotherapy regimen. All subjects completed participant diaries throughout the administration of 
their chemotherapy cycles, and three months’ post-chemotherapy cessation. The patient neurotoxicity 
questionnaire was completed by the participants and entered into their diaries every second week as 
shown in Appendix 3. The comparison of results between the two arms addressing the occurrence of 
CIPN, pain and changes in blood status are the secondary outcomes. 
7.2.5 Participants 
Following a power and sample size analysis (section 4.5.3 and table 4-2), the aim of the clinical trial 
was to recruit ninety participants [plus 50% attrition rate]. This equated to one hundred and thirty-
five subjects. Participants were a mixture of males and females recruited primarily from the Princess 
Alexandra Hospital in Brisbane, Australia from selected oncologists, haematology oncologists and 
cancer care coordinators. The participants were randomised into two groups: 
         Group 1: Chemotherapy plus oral vitamin B complex 
Group 2: Chemotherapy plus placebo (microcrystalline cellulose plus 1% of beta-carotene for 
colour) 
Recruitment was ceased after seventy-one participants had been inducted due to time constraints 
imposed for completion of a post doctorate degree. The recruitment of patients was slow due to I) the 
stringent/tight inclusion and exclusion criteria; ii) the number of patients prescribed the selected 
chemotherapy regimens; iii) the willingness of subject participation in the clinical trial; iv) subjects’ 
transport issues to and from the PA Hospital; v) access to the patients who were prescribed the 
chemotherapy agents in time to arrange testing for the clinical trial and; vi) the mental state of the 
prospective participants following the diagnosis of cancer and having to undergo chemotherapy (e.g. 
feelings of being too overwhelmed). 
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7.2.6 Key Inclusion Criteria 
1. Participants who were newly diagnosed with a neoplastic disease and chemotherapy 
naïve;  
2. Participants who were prescribed chemotherapy treatment with oxaliplatin, the taxane 
class or vincristine.  
7.2.7 Key Exclusion Criteria 
1. Participants who had been prescribed any other concurrent investigational products;  
2. Participants who currently experienced peripheral neuropathy; 
3. Participants who had undergone chemotherapy treatment previously with a neurotoxic 
agent; 
4. Participants who were pregnant or breast feeding; 
5. Any participant that had established cognitive impairment, diagnosed alcoholism, 
intellectual disability or severe mental illness; 
6. Any participants that were taking concurrent natural supplements such as multivitamins, 
nutritional and/or herbal supplements or fish oil formulations. 
7.2.8 Dose and Duration of Supplements 
Participants were randomised to a B group vitamin [1 capsules x b.i.d] or placebo [1 capsules x b.i.d] 
taken with or after meals. Duration of the intervention was either six or nine months starting at the 
commencement of chemotherapy, throughout the participant’s chemotherapy regime and three 
months’ post-chemotherapy completion. 
7.2.9 Study Site and Ethics Approval 
The study sites were the University of Queensland and the Princess Alexandra Hospital, Brisbane, 
Australia. The University of Queensland Ethics Committee (UH 2010000749) and the Princess 
Alexandra Hospital Ethics Committee (HREC/10/QPAH/140) granted ethical approval for this 
project. The trial was registered with the TGA for clinical trial notification (CTN form) and with the 
Australian New Zealand clinical trial registry (ACTRN12611000078954). Furthermore, the RCT trial 
was audited twice from the Princess Alexandra hospital ethics governance committee during the 
course of 2.5 years. 
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7.3 RESULTS AND OVERVIEW 
In total, one hundred and twenty-one participants were screened for eligibility and fifty of the subjects 
were excluded due to not meeting the inclusion and exclusion criteria, or for being too overwhelmed 
with diagnosis of a cancer. The full list of details for exclusion have been presented in Table 7-1. 
 Seventy-one participants were randomised to either the vitamin B complex arm or placebo. Thirty-
eight participants were randomised to the vitamin B complex arm and thirty-three to the placebo arm. 
Of the participants randomised, three were excluded from the vitamin B complex arm and six from 
the placebo group leaving thirty-five participants to receive the vitamin B complex and twenty-seven 
to receive placebo; that is a total of sixty-two evaluable subjects.   
Additional drop outs were recorded at three-months follow up.  At this time point there were twenty-
seven participants available for assessment in the vitamin B complex and twenty-three in the placebo 
arm, for a total of fifty evaluable subjects.  Eight subjects were not available due to drop out or other 
reasons in the vitamin B complex arm and four in the placebo arm. The full list of reasons for drop 
out can be seen in Table 7-2. By the six-month follow up review, twenty-six participants were 
available for assessment in the vitamin B complex arm with eleven participants finishing the trial at 
this time point. Twenty-two participants were available for assessment in the placebo arm with eleven 
completing the trial. At nine-months there were fourteen participants available for assessment in the 
vitamin B complex arm and eleven in the placebo arm. Therefore, forty-seven participants (66.2%) 
completed the clinical trial from randomisation. The final attrition rate was 14%. A diagrammatic 
representation of the RCT trial is presented in Figure 7-1. 
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71 Randomised for inclusion 
      50 Participants Excluded 
38 Allocated to receive B vitamins 
3 excluded (1 too sick, 2  
chemotherapy brought forward) 
35 Received 
 27 Follow up 3 months 
8 Lost due to Chemotherapy 
reactions (2),  
couldn’t take Vitamins (5),  
too sick  (1) 
 26 Follow up 6 months 
11 Finished trial 
1 Lost due to disease progression 
 14 Follow up 9 months 
1 Lost to follow up 
33 Allocated to receive Placebo 
6 Excluded (1 alcoholic, 5 chemotherapy 
brought forward) 
27 Received 
 23 Follow up 3 months 
4 Lost due to patient death (1), bone 
marrow transplant (1), couldn’t take 
tablets (2) 
 22 Follow up 6 months 
11 Finished trial 
1 Lost to disease progression 
 11 Follow up 9 months 
0 Lost 
Figure 7-1: Diagrammatic View of the RCT for B Vitamins in the Protection of CIPN. 
121 Participants Screened for Eligibility 
47 participants completed the trial 
(66.2%) 
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Table 7-1: Reason for Exclusion 
 
Number Reason for Exclusion 
21 Did not meet inclusion/exclusion criteria 
• 11 had their chemotherapy brought forward before our testing 
• 2 declined chemotherapy 
• 3 had peripheral neuropathy 
• 1 had chemotherapy before 
• 2 alcoholics and/or used recreational drugs 
• 2 in another study – Vitamin D 
14 Too overwhelmed with diagnosis 
6 Transport issues 
4 Said they didn’t want to be in the study 
3 Poor English – didn’t understand trial 
2 Didn’t turn up for testing 
 
Table 7-2 Reason for Withdrawn or Drop Out 
 
Participants Reason 
9 Excluded (2 due to B12 deficiency, 4 failed Neurology test, 2 too sick to get 
neurology test completed- in patients, 1 too high in vitamin B6 levels) 
7 Withdrew due to not being able to take the capsules  
1 Died 
2 Disease progression after chemotherapy  
2 Reacted to their chemotherapy regime and their chemotherapy were ceased. 
I.e. Sweet’s syndrome and pulmonary artery spasms with increased risk of 
heart attack  
1 Now getting bone marrow transplant 
1 Too sick to get to neurology test after chemotherapy completed 
1 Lost to follow up for 9 month (last follow-up) – had skin cancer cut out of 
his face and had developed dementia – couldn’t remember his appointments 
 
 
7.3.1 Descriptive Statistics 
The descriptive statistics have been divided up into the total cohort of the trial and comparied the 
results of the vitamin B complex arm to the placebo arm. 
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7.3.1.1 Total Cohort Demographics 
There were more female participants than males (67.6% vs 32.4%) and the taxane class was the most 
common chemotherapeutic agent administered (66.2%).  Due to poor recruitment of colorectal cancer 
patients administered oxaliplatin (5.6%), recruitment for this demographic group of subjects was 
ceased after 6 months. This was decided as a statistical significant investigation for oxaliplatin 
administration in the RCT was deemed not achievable.  Therefore, the RCT focused on recruiting 
breast and lymphoma patients. Lung cancer patient recruitment was ceased after one and half years 
into the RCT trial due to the poor survival rate experienced by patients inducted into the RCT (note: 
one patient died during treatment from chemotherapy toxicity and radiation; and two had disease 
progression after treatment).  
The average age of subjects inducted into the study was approximately 55 years of age and the 
majority of participants were over-weight or obese (average BMI 30). The majority of participants 
were still very active (67.8% ECOG performance score) with limitations mainly due to recent surgery, 
particularly breast cancer patients or lymphoma impingement. Two participants with a score of 3 on 
the Eastern Cooperative Oncology Group (ECOG) performance scale were excluded from the trial. 
The ECOG23 performance score is a set of scales and criteria that is used by clinicians and researchers 
to assess how a patient’s disease is progressing or how the disease is affecting the patient’s daily 
living ability [381].  
The main race of participants was Caucasian (81.7%), 14% of patients were still continuing to smoke 
(lung and breast cancer participants), 47.9% consumed alcohol on a weekly basis and just over 90% 
consumed caffeine daily. No subjects stated that they were vegans on this clinical trial or history of 
                                                 
23 ECOG – Is the Eastern Cooperative Oncology Group which as presented a set of scales and criteria that is used by 
doctors and researchers to assess how a patient’s disease is progressing or how the disease is affecting their daily living 
ability.  
ECOG PERFORMANCE STATUS* 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. 
light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of 
waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
* As published in Am. J. Clin. Oncol.  
358. Oken MM., C.R., Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP, Toxicity And Response Criteria Of The 
Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982. 5:649-655. 
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being a vegan. One participant was a current vegetarian and one subject stated they had been a 
vegetarian previously for twenty years but were not now. This data was collected to focus on vitamin 
B12 as vitamin B12 can only be obtained from animal foods. A long history of being a vegan or a 
vegetarian indicates the participant could have low stores of vitamin B12 or could be deficient in 
vitamin B12. The subject who was a current vegetarian was found to have adequate vitamin B12 
levels (PA 042 NCB Vitamin B12=58 pmol/L at baseline and >128 pmol/L after chemotherapy with 
ref >35). This dietary information substantiated that the cohort was consuming adequate amounts of 
vitamin B12. 
PA042 NCB who stated that they were a current vegetarian was randomised to the B vitamin arm and 
did develop a delayed CIPN. The baseline TNS score was 2, which was due to decreased reflexes, no 
sensory or motor nerve peripheral neuropathy. After chemotherapy, the participants TNS score was 
5, which entailed a score of 1 for sensory peripheral neuropathy (mild) and 4 for reflexes indicating 
no reflexes. At three months follow up post-chemotherapy, the TNS score for PA042 NCB was 14. 
This consisted of 1 for sensory peripheral neuropathy, 1 for pin sensibility, 1 for vibration, 4 for 
reflexes, 4 for sural nerve and 3 for peroneal nerve. Therefore, the neurologist was unable to locate 
sural nerve activity and found limited nerve activity in the participant’s peroneal nerve.  
This delayed CIPN cannot be attributed to low vitamin B12 as the participant’s B12 levels were in 
normal range before and after chemotherapy administration. The subject’s vitamin B6 status was 
elevated post-chemotherapy (1880 nmol/L in ref 35-110 nmol/L). Elevated vitamin B6 has been 
associated with the development of peripheral neuropathy although normally from a high 
supplemental dose (>500 mg) over nine months to a year [102]. Further discussion on vitamin B6 can 
be seen on pages 199 and 220.  
The full demographics of the total cohort is presented in Table 7-3:     
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Table 7-3: Descriptive Statistics of Total Cohort 
 
Chemotherapy Patients Demographics of Total Cohort 
Variable Number (%) 
Age  54 ± 12 years 
Mean ± SD       
Weight  85 ± 21.5 kg 
Mean ± SD       
BMI  
30 ± 7 kg/m
2 
Mean ± SD       
Gender Males  
Females  
23 (32%) 
48 (68%) 
Chemotherapy agents Vincristine  
Oxaliplatin  
Taxanes     
20 (28%) 
4   (6%) 
47 (66%) 
Types of Cancer Breast  
Lymphoma  
Lung  
Large Bowel  
Prostate  
Endometrial  
36 (51%) 
20 (28%) 
9 (13%) 
4 (7%) 
1 (1%) 
1 (1%) 
ECOG 
 
0  
1  
2  
3  
46 (65%) 
20 (28%) 
3 (4%) 
2 (3%) 
Race Caucasian  
NZ Maori  
Sri Lankan)           
Italian                      
Indigenous                
American Samoan  
Chilean           
58 (82%) 
5 (7%) 
1 (1% 
1 (1%) 
2 (3%) 
1 (1%) 
1 (1%) 
Smokers 14%                2.7 ± 7.1 / day 
Alcohol consumption 48%             3.6 ± 9.5 / week 
Caffeine consumption 90%            3.5 ± 2.9 / day 
Vegetarians 1.6%  
History of vegetarian 1.6%   
Red meat consumption 97%            3.1 ± 1.8 per week 
White meat consumption 97%             2.6 ± 1.4 per week 
Fish and seafood consumption 70%             1.4 ± 1.5 per week 
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7.3.1.2 Demographics/Descriptive Statistics for Group A and B 
The two research groups were randomised and appropriately matched at baseline. However, due to 
early recruitment termination, more participants were randomised to the vitamin B complex group 
rather than the placebo group. Females comprised 78.7% of the participants’ randomised to the 
vitamin B complex arm of the study compared to 60.6% in the placebo arm. The distribution of 
chemotherapy agents were well matched with the taxanes being the main chemotherapeutic agent 
assessed. The vitamin B complex arm versus placebo for taxanes consisted of 68.4% versus 63.6% 
of the participants respectively. Of those, the majority were docetaxel administrations in both groups 
(50% versus 36.4% respectively).  
For vincristine and oxaliplatin, there were equal numbers for each arm (10 vincristine and 2 
oxaliplatin in each arm). Breast cancer was the major type of cancer in both arms (20 vs 16 subjects), 
lymphoma had equal numbers (10 in each arm), lung cancer consisted of 4 subjects in the vitamin B 
complex arm and 5 in the placebo arm and there were 2 in each arm for subjects diagnosed with large 
bowel cancer. Additional participants included a subject diagnosed with prostate cancer and another 
with endometrial cancer. The prostate cancer patient was included as he received ten administrations 
of docetaxel and the endometrial cancer patient was included as she received six administrations of 
docetaxel combined with carboplatin.  
Age, weight and BMI were similar in each arm as were smoking habits. Alcohol consumption was 
found to be much higher in the vitamin B complex group compared to placebo (63.2% vs 30.3% 
respectively) and caffeine consumption was slightly higher in the vitamin B complex group (94.7% 
vs 84.9%). These differences may be due to the slightly higher participant numbers in the vitamin B 
complex arm. As mentioned, there was only one vegetarian so the majority in both arms consumed 
adequate amounts of animal protein for vitamin B12 consumption.  
Table 7-4 provides an overview of the descriptive statistics for group A and B.  
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Table 7-4: Descriptive Statistics of Group A and B 
 
 
Group A: B Vitamins 
N=38 
Group B: Placebo 
N=33 
Gender Female 28 74% Female 20 61% 
Male 10 26% Male 13 39% 
Chemotherapy 
Agent 
Taxanes 26 68% Taxanes 21 64% 
a) Docetaxel 19 50% a) Docetaxel 12 36% 
b) Paclitaxel 7 18% c) Paclitaxel 9 27% 
Vincristine 10 26% Vincristine 10 30% 
Oxaliplatin 2 5% Oxaliplatin 2 6% 
Types of 
cancer 
Breast cancer 20 53% Breast 16 49% 
Lymphoma 10 26% Lymphoma 10 30% 
Lung 4 11% Lung 5 15% 
Colon 2 5% Colon 2 6% 
Prostate 1 3%    
Endometrial 1 3%    
ECOG 0 24 63% 0 21 63% 
1 12 31% 1 9 27% 
2 2 5% 2 1 3% 
3 0 0% 3 2 6% 
Age 53.8 ± 12.6  55.2 ± 12  
Weight 82.6 ± 17.6 87.1 ± 25.4 
BMI 29.4 ± 6.3 31.1 ± 7.2   
Smoking 13.2%  
2.8 ± 7.7 per day 
Median ± SD    
15.15%  
2.6 ± 6.4 per day 
Median ± SD    
Alcohol 
consumption 
63.2%   
3.3 ± 5.5 per week 
Median ± SD   
30.3%   
4 ± 12.8 per week 
Median ± SD   
Caffeine 
consumption 
94.74%  
3.5 ± 3.3 per day 
Median ± SD   
84.8%  
3.4 ± 2.4 per day 
Median ± SD   
Vegetarian 2.6% 0%  
History of 
vegan 
2.6% 3% 
Red meat 
consumption 
97.4%  
2.81 ± 1.6 per week 
Median ± SD   
97%  
3.33 ± 2.04 per week 
Median ± SD   
White meat 
consumption 
97.4% 
2.44 ± 1.24 per week 
Median ± SD   
94%  
2.66 ± 1.53 per week 
Median ± SD   
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Fish and 
seafood 
consumption 
63.2% 
1.13 ± 1.29 per week 
Median ± SD   
78.8%  
1.75 ± 1.56 per week 
Median ± SD   
The demographics of the participants in each group were similar with the majority in both groups 
being Caucasian (81.6% vs 81.8%) and married (60.5% vs 60.6%). There were similar childhood 
diseases in both arms and allergies were found more prevalent in the vitamin B complex arm 
compared to placebo (52.1% vs 29.6%). Full descriptions of the history of participants can be seen in 
Table 7-5.  
Table 7-5:  History of Group A and B 
 Criteria Group A: B Vitamins 
N=38 
Group B: Placebo 
N=33 
Race Caucasian 31 (81.6%) 27 (81.8%) 
New Zealand 2 (5.3%) 3 (9.1%) 
Indigenous 2 (5.3%) 0 
Italian 1 (2.6%) 0 
Asian 1 (2.6%) 1 (3%) 
American Samoan 0 1 (3%) 
Chilean 1 (2.6%) 0 
Social History Married 23 (60.5%) 20 (60.6%) 
Divorced 5 (13.2%) 5 (15.2%) 
Widowed 5 (13.2%) 1 (3%) 
Significant Other 3 (7.9%) 2 (6.1%) 
Engaged 1 (2.6%) 0 
Single 1 (2.6%) 5 (15.2%) 
Childhood 
illnesses 
Measles 22 (57.9%) 17 (51.5%) 
Mumps 12 (31.6%) 12 (36.4%) 
Chicken pox 20 (52.6%) 18 (54.5%) 
Other Sandy fly eye infect  = 1 
TIA = 1 
German measles = 2 
Fainted = 1 
Hepatitis = 2 
Tonsillitis = 1 
Yellow fever = 1 
Allergies Drugs 20 (52.6%) 15 (45.5%) 
Environment 9 (23.7%) 4 (12.1%) 
Food/Beverages 8 (21.1%) 2 (6.1%) 
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The participants in this clinical trial had a number of other co-morbidities. The main adult disease 
that both groups experienced was cardiovascular disease, with approximately 36% in each arm being 
treated for hypertension. Asthma and respiratory problems had a high prevalence with 36.8% in the 
vitamin B complex arm and 39.4% in the placebo arm. Patients with diabetes are known to experience 
peripheral neuropathy [341] and if they have been diagnosed with a cancer they have also been 
simulataneously administered chemotherapy [382].  Subjects who had been diagnosed with diabetes 
were included in the RCT if no current or previous peripheral neuropathy was known.  Subjects that 
were assessed by a neurologist and had no neuropathy were then subsequently inducted into the 
clinical trial if they adhered to all other inclusion and exclusion criteria.  Overall, two participants in 
the vitamin B complex arm and four in the placebo arm had diabetes and three borderline diabetics 
in the placebo group were allowed to participate in the RCT.  
Two of six participants in the clinical trial who were diagnosed with diabetes on inclusion, 
subsequently developed CIPN.  Both were in the vitamin B complex group and a borderline diabetic 
in the placebo group also developed mild CIPN.  Not all other participants with diabetes developed 
CIPN. Although these were only small subject numbers, it indicated that vitamin B complex did not 
prevent CIPN in subjects who have been diagnosed with diabetes and were undergoing chemotherapy 
with a neurotoxic agent. There may be a potential to develop CIPN if a patient with diabetes is 
prescribed a vitamin B complex.   
A potential confounder that could have interfered with the neurology assessment for nerve status was 
arthritis.  In the vitamin B complex arm 36.9% of participants and 39.3% in the placebo arm 
experienced arthritis, or had accidents leaving physical discomfort. Arthritis particularly in the knee 
and lower extremities, as well the hands, interfered with ECS scores as the neurologist was unable to 
detect nerve function due to possible damage from the arthritis. Therefore, baseline for sural nerve 
activity in particular was difficult, although after chemotherapy and follow up had the same result. 
Arthritis or damage from accidents does not predispose the patient to CIPN like diabetes, but it does 
interfere with research quantifying nerve function. Table 7-6 shows the full list of adult diseases that 
the participants experienced. 
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Table 7-6: Adult Illnesses of Group A and B 
 
Adult Illnesses Criteria Group A – B Vitamins 
N=38 
Group B – Placebo 
N=33 
Cardiovascular 
disease 
Hypertension 14 (37%) 12 (36%) 
Hypercholesteremia 6 (16%) 5 (13%) 
Chronic heart disease 4 (10%) 4 (12%) 
Other 7 (18%) 0 
Respiratory 
problems 
Asthma 7 (18%) 7 (21%) 
Other 7 (18%) 6 (18%) 
Digestive problems Indigestion/GORD 2 (5%) 5 (13%) 
Other 5 (13%) 3 (9%) 
Diabetes T2DM 2 (5%) 4 (12%) 
Borderline diabetes 0 3 (9%) 
Bone problems Osteoarthritis 6 (16%) 8 (24%) 
Rheumatoid arthritis 2 (5%) 0 
Accidents 1 (3%) 4 (12%) 
Other 5 (13%) 1 (3%) 
Other Acne rosacea 0 1 (3%) 
Alcohol foetal syndrome 0 1 (3%) 
Anaemia 1 (7%) 0 
Arachnoid cysts 0 1 (3%) 
Bladder prolapse 0 1 (3%) 
Breast cancer 2 (5%) 0 
Carpel tunnel syndrome 0 3 (9%) 
Clubbing of fingers 0 1 (3%) 
Conn’s syndrome 0 1 (3%) 
Depression/Anxiety 3 (8%) 3 (9%) 
Endometriosis 1 (3%) 0 
Eye problems 2 (5%) 1 (3%) 
Headaches 1 (3%) 0 
Hernia 0 1 (3%) 
Kidney stones 1 (3%) 0 
Migraines 1 (3%) 3 (9%) 
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 NAFLD 0 1 (3%) 
Obesity 1 (3%) 3 (9%) 
Restless legs / cramping 1 (3%) 1 (3%) 
Skin problems 4 3 (9.1%) 
SLE 1 (3%) 0 
Sleep apnoea 1 (3%) 1 (3%) 
Stroke/TIAs 1 (3%) 2 (6%) 
Telangiectasia around 
mouth 
0 1 (3%) 
Thyroid problems 4 (10%) 4 (12%) 
Vertigo 0 1 (3%) 
Viruses 18 (47%) 8 (24%) 
 
Similar to adult illness and diseases, this cohort has undergone a number of surgical interventions. 
For the breast cancer and colorectal participants, they all had tumour removal surgical interventions 
related to their cancer before chemotherapy was commenced. Female patients who had no children 
had been encouraged to undergo in vitro fertilisation (IVF) to cryopreserve embryos before 
chemotherapy commencement.  Three of the participants inducted into the clinical trial had 
undergone IVF prior to chemotherapy for this reason. 
PA019 MJW who was diagnosed with lung cancer had a history of two previous breast cancer 
associated lumpectomies. This participant was chemotherapy naïve and as such was included in the 
clinical trial and inducted as a lung cancer subject with the associated chemotherapy regime for this 
cancer type. PA015 AJM was a lymphoma participant who had a history of a prostatectomy for 
prostate cancer and who was also chemotherapy naïve and as such was also inducted into the clinical 
trial. A complete list of all surgical interventions from both the vitamin B complex and placebo arms 
has been presented in Table 7-7.  
 
Table 7-7:  Past Surgery of Group A and B 
 
Surgery Criteria Group A:  
B Vitamins 
N=38 
Group B: 
 Placebo 
N=33 
Breast Lumpectomy  22 (58%) 7 (21%) 
Mastectomy 10 (26%) 6 (18%) 
Fibrous adenoma 2 (5%) 0 
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Breast implants 1 (3%) 0 
Gynaecological Hysterectomy 6 (16%) 1 (3%) 
Cone biopsy 4 (10%) 1 (3%) 
Caesarean 3 (8%) 4 (12%) 
Laparoscopy 2 (5%) 2 (6%) 
Tubal ligation 2 (5%) 1 (3%) 
Egg harvest / IVF 4 (10%) 1 (3%) 
Cysts on ovary 1 (3%) 0 
Fibroid 0 1 (3%) 
Male  Prostate removal 1 (3%) 0 
Testacies (orchandectomy) 2 (5%) 2 (6%) 
Digestion Biopsy 0 3 (9%) 
Bowel resection 3 (8%) 1 (3%) 
Lap band 1 (3%) 2 (6%) 
Gall bladder removed 5 (13%) 8 (24%) 
Laparotomy 2 (5%) 0 
Tummy tuck 1 (3%) 0 
Appendectomy 7 (18%) 6 (18%) 
Hernia 3 (8%) 3 (9%) 
Colonoscopy 1 (3%) 0 
Skeletal Accidents 7 (18%) 3 (9%) 
Knee 5 (13%) 2 (6%) 
Upper limbs 3 (8%) 3 (9%) 
Back fusion 2 (5%) 0 
Hips 1 (3%) 0 
Carpel tunnel 0 2 (6%) 
CVD Open heart surgery 0 2 (6%) 
Stents 3 (8%) 0 
Pacemaker 0 1 (3%) 
Other Tonsils 2 (5%) 7 (21%) 
Lipomas 2 (5%) 1 (3%) 
Kidney donation 2 (5%) 0 
Skin cancers 1 (3%) 3 (9%) 
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Eye operations 0 4 (12%) 
Veins stripped 0 3 (9%) 
Lung operations 0 3 (9%) 
Ear operations 0 3 (9%) 
Teeth extractions 1 (3%) 1 (3%) 
Cysts 1 (3%) 1 (3%) 
Facial 2 (5%) 0 
Pheochromotcytoma 0 1 (3%) 
Spleen 0 1 (3%) 
Thyroid 0 1 (3%) 
The prescription medications documented in this trial detailed in Table 7-8 is representative of the 
number of adult illnesses and diseases the participants expressed. It was important to identify 
medications that could interfere with the absorption of an oral vitamin B complex. Medications such 
as protein pump inhibitors have previously been reported to cause a vitamin B12 and iron deficiency 
[383]. Metformin has also been associated with a vitamin B12 deficiency [384, 385]. The participants 
who were diagnosed with diabetes and were participating in this clinical trial had all been prescribed 
metformin (2 in vitamin B complex arm and 4 in the placebo arm).  Research reports have shown that 
only long-term administration of metformin have been associated with metformin-induced vitamin 
B12 deficiency [384, 385].  As such, all subjects participating in the clinical trial and who were taking 
metformin, were found to have an adequate vitamin B12 status.  
Table 7-8: Current Medication of Groups A and B 
 
Current 
Medication 
Criteria Group A: 
 B Vitamins  N=38 
Group B: Placebo 
N=33 
Digestion Proton pump inhibitor 5 10 
Maxalon 1 0 
Movicol 2 1 
Coloxyl 2 1 
Sulfasalazine 1  
Nausea 0 2 
Bentyl 0 1 
Sleep / Anxiety Tamazapam 3 4 
Valium 2 1 
Oxazepam 1 0 
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Restavit 1 0 
Depression Anti-depressant 5 10 
Hypertension Beta Blocker 3 5 
Calcium channel blocker 1 3 
ACE inhibitor 3 1 
Angiotensin II receptor 
blocker 
4 8 
Anti-angina 2 0 
 Vasodilator 0 1 
 Aldosterone inhibitor 0 1 
 Diuretic 0 2 
Respiratory Bronchodilator 2 7 
Spiriva 1 2 
Israel 0 1 
Salbutamol plus 0 1 
Nasal Spray 1 0 
Pain Endone 1 0 
OxyContin 1 0 
Nurofen 1 0 
Paracetamol 2 5 
Endep 1 0 
Mersyndol 1 0 
Inza 0 1 
Fentanyl 0 1 
CorVel 0 1 
Tramadol 0 1 
Cholesterol Statins 8 6 
Infections Antibiotics 4 1 
Ear Sofradex 1 0 
Eye Glaucoma drops 1 0 
Anticoagulants Aspirin 5 7 
Warfarin 2 0 
Thyroid Oroxine 1 3 
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Neomercazole 0 1 
Diabetic 
medication 
Metformin 2 4 
Gliclazade 0 1 
Diamicron 0 1 
Glucobay 1 0 
Glycade 1 0 
Other Allopurinol 1 0 
 Anti-histamine 0 1 
 Epilium 0 1 
 Femara 1 0 
 Fluticasonel/Salmeterol 1 0 
 Golgout 0 1 
 Hydrochlorothiazide 1 0 
 Imigrine 0 1 
 Mirina 0 1 
 Paraven 1 0 
 Prednisolone 1 2 
 Suboxane 0 1 
 
7.3.2 Statistics Results for the Main trial 
The statistics for this trial were analysed using SPSS statistics software with the assistance of 
statistician Ms Helen Gramotnev and A/Prof Luis Vitetta. The statistical analysis was based on an 
intention to treat analysis. All statistical tests and graphics were generated using SPSS version 17.0 
or Excel software. The criterion for significance was set at p<0.05. The odds ratio was calculated on 
both the total incidence of CIPN and the subject’s perception (PNQ). 
Not all statistical analysis for the primary and secondary outcomes assessing both paired T scores and 
P score using a Mixed Effects Model (MEM) were statistically significant, see Table 7-9. The only 
time point that was statistically significant was the differences in time on the P score indicating that 
there was a significant difference in time for the development of CIPN, a known fact as CIPN is a 
cumulative side effect [10]. 
No difference was observed between vitamin B complex and placebo groups in the prevention of 
CIPN. The TNS sensory and motor neuropathy sections, which were tested by the independent 
neurologist did not show any statistical differences between the treatment groups except for motor 
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neuropathy at baseline. This was more probable due to the type of cancer subjects had been diagnosed 
with, such as a lymphoma, lung cancer or from surgical intervention for a breast cancer. The actual 
test for neuropathy was assessable post-chemotherapy and three months’ post-chemotherapy. Neither 
sensory nor motor neuropathy through the TNS assessment was statistically significant as 
summarised in Table 7-10 using Chi-squared and Fisher exact tests. An independent t-test and Mann 
Whitney test was conducted on the TNS, which was reported in Table 7-11 with no statistical 
significance noted.  Therefore, an oral vitamin B complex was not statistically significant in 
preventing CIPN in this clinical trial.  
 
Table 7-9: Statistics for Primary and Secondary Outcomes 
 
Mixed Effects Model 
Outcomes 
 
Placebo v B vitamins 
 
Differences in Time 
 
Placebo v B vitamins over 
3 time points 
 
 Scores T Score P score T score P score T score P score 
Primary Outcome 
TNS 1.24 0.22 2.41 0.02 -0.35 0.73 
Secondary Outcomes 
NPQ Sensory 0.85 0.4 0.61 0.55 0.84 0.4 
NPQ Motor 0.73 0.47 0.51 0.61 0.48 0.63 
NPQ Other -0.05 0.96 -1.43 0.16 1.13 0.26 
EORTC QoL 0.74 0.46 -0.67 0.5 0.28 0.78 
Total Pain Score -0.12 0.9 -0.35 0.73 0.56 0.58 
Total Pain 
Interference -0.9 0.37 -1.21 0.23 1.51 0.13 
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Table 7-10: Neurologists Assessment of Sensory and Motor Nerve Function through TNS of 
the B Vitamin Arm compared to the Placebo Arm  
 
Y/N results: p values 
 Chi-sq Fisher 
Before 
Chemotherapy 
Sensory 0.551 0.42 
Motor 0.002 0.003 
Post-
Chemotherapy 
Sensory 0.11 0.094 
Motor 0.797 0.508 
Three weeks 
Post-
Chemotherapy 
completion 
Sensory 0.961 0.596 
Motor 0.464 0.334 
 
 
 
Table 7-11: Independent Samples T-test and Mann Whitney Test for TNS of the B Vitamin 
Arm compared to the Placebo Arm 
  
Independent samples t-test for total TNS scores 
 t-score p value 
Before Chemotherapy -1.412 0.163 
Post-Chemotherapy -0.893 0.376 
Three weeks Post-Chemotherapy -0.559 0.579 
 
Mann Whitney for TNS scores:  p values 
Before Chemotherapy 0.15 
Post-Chemotherapy 0.329 
Three weeks Post-Chemotherapy 0.424 
 
7.3.2.1 Primary Outcome Results 
The TNS score before chemotherapy to post-chemotherapy between the B vitamin and placebo arms 
was the primary outcome for this study. As seen in Figure 7-2, no differences were noted. Although 
the vitamin B complex group started slightly below the placebo group, both had a similar 
development of neuropathy and decreased at the three-month follow-up.  
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Total TNS 
  Baseline After Chemo 3 mths f/u 
B vitamins 3.05 ± 3.25 9.86 ± 5.08 7.12 ± 4.67 
Placebo 5.5 ± 6.02 11 ± 3.96 8.14 ± 4.29 
 
Figure 7-2: Results of the Total TNS score for Vitamin B Complex and Placebo Arms at 
Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy.  
 
CIPN is represented by both sensory and motor nerve damage, although predominately sensory is 
reported from neurotoxic chemotherapy agents [386]. Sensory neuropathy is experienced by 
numbness, tingling, burning or pain in the fingers, and toes and then progresses up the arms or legs 
[387, 388]. The vitamin B complex showed a very minor trend in decreasing the development of 
sensory neuropathy during chemotherapy administration, but by the three-month follow-up, both 
placebo and vitamin B complex arms had exactly the same sensory measure of nerve function as seen 
in Figure 7-3. Therefore, it was possible that there was some decrease in discomfort during 
chemotherapy administration but overall it showed no improvement over placebo after completion of 
chemotherapy cycles.  
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Sensory  
  Baseline After Chemo 3 mths f/u 
B vitamins 0.08 ± 0.28 0.71 ± 0.76 0.69 ± 0.97 
Placebo 0.2 ± 0.55 1.08 ± 0.93 0.68 ± 0.94 
 
Figure 7-3: Final Sensory Neuropathy Score from the TNS for Vitamin B Complex and 
Placebo Arms at Baseline, After Chemotherapy Cessation and Three Months Post-
Chemotherapy. 
 
Motor nerve impairment is defined as the inability of a patient to pick up objects or the inability to 
use their fingers or hands normally. Moreover, it is about strength, so individuals may drop objects 
or may demonstrate difficulty walking [388]. The motor component started lower in the vitamin B 
complex arm at baseline compared to the placebo arm. However, the vitamin B complex arm had a 
slightly higher trajectory during chemotherapy treatment and decreased less at the three-month time 
point, possibly indicating that a vitamin B complex is of no assistance in decreasing motor nerve 
damage or motor function as seen in Figure 7-4. The “post-chemotherapy and follow up” results were 
important for the end-result. 
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Motor 
  Baseline After Chemo 3 mths f/u 
B vitamins 0.02 ± 0.16 0.75 ± 0.93 0.36 ± 0.65 
Placebo 0.37 ± 0.71 0.91 ± 0.93 0.42 ± 0.74 
 
Figure 7-4: Final Motor Neuropathy Score from TNS for Vitamin B Complex and Placebo 
Arms at Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
 
Pin sensibility is a pinprick test on the fingers and the toes, and if the participant cannot feel the pin-
prick, the neurologist continues up the hand/arm and feet/leg respectively until the subject responds 
that a sensation can be felt.  Pinprick sensibility has been reported to be a test for small nerve fibre 
damage [273]. The results of this test showed that a vitamin B complex did not prevent small nerve 
damage as seen in Figure 7-5. The participants on placebo showed that pin-prick sensation was back 
to baseline three months’ post-chemotherapy administration, the vitamin B complex arm sensation 
however remained similar to post-chemotherapy. This indicated that a vitamin B complex did not 
prevent small nerve damage in this clinical trial. 
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Pin Sensibility 
  Baseline After Chemo 3 mths f/u 
B vitamins 0.34 ± 0.08 0.78 ± 0.68 0.73 ± 0.82 
Placebo 0.43 ± 1.07 0.92 ± 0.83 0.45 ± 0.67 
 
Figure 7-5:  Pin Sensibility Score from the TNS for Vitamin B Complex and Placebo Arms at 
Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
 
The vibration test showed no differences between vitamin complex and placebo as seen in Figure 7-
6.  
 
 
 
Vibration 
  Baseline After Chemo 3 mths f/u 
B vitamins 0.45 ± 0.81 0.75 ± 1 0.77 ± 1.03 
Placebo 0.5 ± 1.17 0.87 ± 1.07 0.77 ± 1.06 
 
Figure 7-6:   Vibration Results from TNS for Vitamin B Complex and Placebo Arms at 
Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
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The results from the autonomic nervous system were equivocal.  The autonomic nervous system was 
assessed by the neurologist, by querying the participants regarding symptoms such as sweating and 
changes in bowel habits (diarrhoea to constipation or vice versa).  The neurologist acknowledged the 
subjective nature of this interpretation of the investigation given that cancer itself causes autonomic 
NS changes. These included sweating, in addition to chemotherapy causing constipation or diarrhoea 
depending on the agent administered. All of the breast cancer participants experienced hot flushes 
after chemotherapy administration due to menopausal symptoms [389]. Lymphoma can also cause 
sweating [390] and therefore assessing autonomic nervous system activity and its relevance to 
neuropathy is a challenge.     
The results indicated that there was no difference between vitamin B complex and placebo as seen in 
Figure 7-7. The placebo arm was noted to have a higher response than the vitamin B complex arm at 
baseline or before chemotherapy, which was due to the lymphoma and breast cancer patients’ 
experiencing increased sweating. Therefore, this information was not a true representation of CIPN 
symptoms.   
 
 
 
Autonomic NS 
  Baseline After Chemo 3 mths f/u 
B vitamins 0.28 ± 0.57 0.78 ± 0.83 0.65 ± 0.84 
Placebo 1.06 ± 0.98 0.79 ± 0.83 0.79 ± 1.02 
 
Figure 7-7:  Autonomic Nervous System Score from TNS for Vitamin B Complex and Placebo 
Arms at Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
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Ninety percent of all of the participants had no reflexes after administration of chemotherapy (85.7% 
in vitamin B complex arm and 95.8% in the placebo arm) as seen in Figure 7-8. At three months’ 
post-chemotherapy, twenty-five percent of all participants were able to demonstrate reflex ability 
(34.6% in vitamin B complex arm and 13.6% in the placebo arm). This was related to CIPN and nerve 
damage reiterating that the vitamin B complex did not prevent CIPN development.  However, 
participants in the vitamin B complex arm recovered their reflexes slightly faster (albeit minimally) 
than those in the placebo arm after three months (41.3% improvement in vitamin B complex arm 
compared to 30.9% improvement in placebo arm).  
 
 
 
Reflexes 
  Baseline After Chemo 3 mths f/u 
B vitamins 0.54 ± 1 2.82 ± 1.47 1.92 ± 1.67 
Placebo 1.53 ± 1.93 3.21 ± 1.14 2.63 ± 1.33 
 
Figure 7-8:  Reflex Scores from the TNS for Vitamin B Complex and Placebo Arms at 
Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
 
No differences were observed between the vitamin B complex and placebo arms for strength testing 
post-chemotherapy, nor at the three-month follow up, as depicted in Figure 7-9. This indicates 
minimal motor nerve damage in participants from both groups, with the exception of outlier data from 
four participants [see error bars on the graph]. The participants who experienced strength changes 
also presented with muscle weakness deemed from the effects of chemotherapy and other conditions, 
such as rheumatoid arthritis or restless leg syndrome.  
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Strength 
  Baseline After Chemo 3 mths f/u 
B vitamins 0.02 ± 0.16 0.03 ± 0.18 0.07 ± 0.39 
Placebo 0.6 ± 0.25 0.07 ± 0.28 0.18 ± 0.85 
 
Figure 7-9: Strength Score from TNS for Vitamin B Complex and Placebo Arms at Baseline, 
After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
 
The sural nerve was assessed by the neurologist utilising the ECS. The neurologist noted that in older 
subjects and those with arthritis present in the lower extremities, the sural nerve was difficult to locate. 
In addition, a number of participants presented with oedema of the feet and ankles post-chemotherapy 
(PA027 CxB presented with seeping oedema as the skin had broken, as well as with disease 
progression post-chemotherapy and is now deceased). The oedema, which is an adverse outcome of 
chemotherapy administration [368] made it difficult to obtain an accurate sural nerve assessment. 
This result affected both arms of the study, hence no difference was observed between the two groups 
in relation to sural nerve scores as presented in Figure 7-10. 
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Sural Nerve 
  Baseline After Chemo 3 mths f/u 
B vitamins 1 ± 1.7 2.07 ± 1.92 1.31 ± 1.76 
Placebo 0.2 ± 0.55 2.26 ± 2.02 1.47 ± 1.89 
 
Figure 7-10: Sural Nerve Score from TNS for Vitamin B Complex and Placebo Arms at 
Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
 
The neurologist, utilising the ECS, also assessed the peroneal nerve. No difference was observed in 
the peroneal nerve scores as shown in Figure 7-11. The vitamin B complex arm had a slightly worse 
projection from baseline; however, minimal difference was observed between the treatment groups.  
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Peroneal Nerve 
  Baseline After Chemo 3 mths f/u 
B vitamins 0.28 ± 0.89 1.14 ± 1.21 0.57 ± 1.17 
Placebo 0.43 ± 0.93 1.04 ± 1.55 0.54 ± 1.1 
Figure 7-11: Peroneal Scores from TNS for Vitamin B Complex and Placebo Arms at 
Baseline, After Chemotherapy Cessation and Three Months Post-Chemotherapy. 
 
7.3.2.2 Secondary Outcomes  
7.3.2.2.1 Blood Results 
All participants in the vitamin B complex arm responded to supplementation with the exception for 
the vitamin B2 levels, as shown in Table 7-13 and Figure 7-12. The intervention group blood analysis 
post-chemotherapy demonstrated a significant difference for all the vitamin B complex (see Table 7-
14), except vitamin B2. The decrease in vitamin B2 pathology post-chemotherapy for both arms could 
be due to increased urine output and utilisation within the cells. It can be postulated that vitamin B2 
decreased as it is the main co-factor for pyridoxine phosphate oxidase, which is the enzyme that 
converts the different types of vitamin B6 to pyridoxal phosphate [58]. However, vitamin B2 has 
many functions as described in chapter 1, and with supplementation, the expectation would have been 
to see it increase in blood serum.  
Vitamin B1 blood pathology results increased above the average reference range for the vitamin B 
complex arm compared to placebo, which decreased by 7% (155.31 to 144.8 nmol/L) from baseline. 
All standard deviations for each of the B vitamins were in the high range due to the variation of blood 
results. Blood vitamin B6 levels in particular, was observed to vary extensively. As seen in chapter 6 
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from the interaction and absorption pilot trial, blood levels of P5P (vitamin B6) was very responsive 
to supplementation. The same result was observed in the final data seen in Figure 7-12. Four 
participants in the vitamin B complex arm had blood vitamin B6 results over 1,000 nmol/L (ref 35-
110 nmol/L), this was over ten times higher than the reference range shown in Table 7-12. All four 
participants experienced mild to moderate CIPN.  
Given that vitamin B6 toxicity can cause peripheral neuropathy, it is plausible that the increased 
vitamin B6 blood levels (>1,100 nmol/L) post-chemotherapy may be related to the development of 
CIPN in these participants. It has been reported that peripheral neuropathy from high dose vitamin 
B6 supplementation (500-5,000 mg daily for 1-3 years) may give rise to a slow onset peripheral 
neuropathy [129] compared to the fast onset peripheral neuropathy experienced by chemotherapy. 
Vitamin B6 has been found to be beneficial for oxaliplatin triggered CIPN [17, 18], cisplatin [78] and 
vincristine in children [30, 125]. The participants in this RCT trial with high vitamin B6 blood levels 
post-chemotherapy had been administered taxanes and vincristine. As no research regarding blood 
vitamin B6 levels post-chemotherapy have been conducted in relation to peripheral neuropathy, and 
although definitive conclusions are difficult from the data from only four patients, further research is 
certainly warranted. 
Table 7-12: After Chemotherapy Scores for Participants over 1,000 nmol/L of Vitamin B6 
Participant Total TNS 
score  
Sensory 
Neuropathy 
Motor 
Neuropathy 
Pin 
Sensibility 
Vitamin B6 
nmol/L 
 BC AC BC AC BC AC BC AC BC AC 
PA016 GDT 6 11 0 1 0 1 0 1 530 1,290 
PA042 NCB 
2 14 0 1 0 0 0 0 50 1,880 
PA058 MJM 
1 17 0 1 0 1 0 2 80 1,560 
PA062 GMA 0 21 0 2 0 1 0 1 100 1,080 
NB: BC = Before chemotherapy; AC = After chemotherapy 
Increasing blood vitamin B12 to reduce the incidence of CIPN was the initial investigative focus for 
this clinical trial. The blood results post-chemotherapy administration indicated that those participants 
supplemented with a vitamin B complex increased blood B12 status compared to those randomised 
to the placebo (Wilcoxon 0.0 vs 0.602; the vitamin B complex arm increased on average by 14 pmol/L 
and placebo decreased on average by 5 pmol/L). While the vitamin B12 blood levels cannot be 
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correlated with CIPN development, the result obtained confirms the data from Vu, et al’s [62] study 
which concluded that chemotherapy may cause a temporary deficiency of vitamin B12 in patients 
undergoing chemotherapy.  
The results for blood folate levels also demonstrated that a vitamin B complex increases red blood 
cell levels of folate post-chemotherapy compared to placebo, see Figure 7-12. Levels of blood folate 
in the participants recruited for this clinical trial presented with a blood saturation level of folate prior 
to chemotherapy administration, which may represent the folate fortification status for foods in 
Australia [392].  
Overall, blood levels for the vitamin B complex showed that supplementation with a vitamin B 
complex during chemotherapy administration increased blood levels of vitamin B1, B6, B12 and 
folate compared to placebo. 
 
Table 7-13: Pathology Blood Results for All Participants 
  
B vitamin Arm Placebo Arm 
Ref 
Range 
  
Before Chemo After Chemo 
Before 
Chemo 
After Chemo nmol/L 
B1 174.2 ± 34.3 203.9 ± 55.1 155.3 ± 28.4 144.8 ± 38.7 66-200 
B2 321 ± 56.5 301.4 ± 43.9 291.9 ± 43.6 264.2 ± 42.3 180-470 
B6 167.8 ± 201.9 656.9 ± 428.9 191.1 ±  624 148.1 ± 253.8 35-110 
B12 86.8 ± 23.2 101 ± 14.8 80.9 ± 25.5 76.4 ± 25 
>35 
pmol/L 
Folate 1873.3 ± 612.4 2456.6 ± 515.1 1870 ± 477.6 1814.4 ± 588.3 >900 
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Figure 7-12:    Graphic Pictures of Differences in B group Vitamin Results 
 
 Table 7-14: Statistics for Blood Pathology Results  
 
Normality Tests:  p values 
 
Wilcoxon Placebo 
 
Treatment 
 Mann Whitney 
U test:  p values 
  Baseline 
After 
Chemo 
 
B12 0.602 
 
0 
 
B12 0.004 
B12 0.005 0  B1 0.129  0.001  B1 0.001 
B1 0 0  Folate 0.648  0  Folate 0.002 
Folate 0.2 0.044  B2 0.019  0.196  B2 0.645 
B2 0.001 0.095  B6 0.845  0  B6 0 
B6 0 0         
 
7.3.2.2.2 Comparing Blood Pathology to TNS Results 
 
A comparison between the blood pathology results to the TNS final results was an important outcome 
measure for this clinical trial. This was to ascertain whether the administration of a vitamin B complex 
was an efficacious intervention in the prevention or an adverse outcome in promoting CIPN. Vitamin 
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B12 and B6 data were individually assessed for comparison to the TNS before and after chemotherapy 
administration. These two B vitamins were chosen due to the pathology results obtained in Table 7-
13 and the statistics on the pathology blood levels seen in Table 7-14.  
To ascertain normal or non-normal distribution of variables, a Stem-and-Leaf plot was developed for 
baseline and post-chemotherapy for the variables TNS, vitamin B12 and vitamin B6. The data was 
found to be not normally distributed as seen in Figure 7-13 to Figure 7-16.  
 
               
   
Figure 7-13: Stem-and-Leaf Plot for TNS Final Results at Baseline and Post-Chemotherapy.  
               
 
Figure 7-14: Stem-and-Leaf Plot for Vitamin B12 Pathology Results at Baseline and Post-
Chemotherapy.  
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Figure 7-15: Stem-and-Leaf Plot for Vitamin B6 Pathology Results at Baseline and Post-
Chemotherapy.  
 
As the data was not normally distributed, a non-parametric statistical approach was required. A non-
parametric Levene’s test was used to verify the equality of variances in the samples (from the vitamin 
B complex and placebo groups), therefore providing a homogeneity of variance (p=>0.05) [370, 371].  
The results of the analysis have been presented in Table 7-15 to Table 7-20. The results found that 
the TNS at baseline and post-chemotherapy were not statistically significant (p=0.760; p=0.300 
respectively).. 
The vitamin B12 results when compared to the TNS results showed that at baseline there was no 
statistically significant differences (p=0.770), however the post-chemotherapy result was statistically 
significant (p=0.024). This data indicates that vitamin B12 statistically correlates to CIPN 
development. Therefore, it can be surmised that vitamin B12 may have a significant role to play as 
an important preventative factor in the onset and severity of CIPN development. Vitamin B6 was not 
found to be statistically significant before or post-chemotherapy (p=0.938; p=0.948 respectively). A 
possible explanation for this may be due to the high standard deviation found in the blood vitamin B6 
results obtained (for the total cohort: baseline SD=513.19; Post-chemotherapy SD=442.29 indicated 
by normality tests).  
From this analysis, administration of vitamin B12 demonstrated a statistically significant impact in 
decreasing the onset and severity of CIPN development. Vitamin B6 was not found to be statistically 
significant. The vitamin B12 result was found to be clinically significant for one of the participants 
who was reported to be deficient in vitamin B12 post-chemotherapy. PA032 PMP who was 
randomised to the placebo arm presented with moderate to severe CIPN post-chemotherapy and her 
blood result showed a moderate deficiency in vitamin B12. The participant was supplemented with 
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vitamin B12 and given an intramuscular injection of vitamin B12 by the oncologist. The CIPN was 
reduced to a mild deficiency two months’ post-supplementation and injection. Further expansion on 
this participant is presented in Chapter 8.  
 
Table 7-15: TNS at Baseline 
 TNS at Baseline Descriptive 
Groups No Mean SD Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
 
B 
vitamin 
38 17.48 8.72 1.41 14.61 20.35 2.57 34.57 
Placebo 32 16.80 9.76 1.72 13.28 20.32 3.17 30.33 
Total 70 17.17 9.15 1.09 14.99 19.35 2.57 34.57 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
Between Groups 8.014 1 8.014 .094 .760 
Within Groups 5769.012 68 84.838   
Total 5777.026 69    
 
 
Table 7-16: TNS Post-Chemotherapy 
 
TNS Post-Chemotherapy Descriptive 
Groups No Mean SD Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
B 
vitamin 
28 13.67 8.56 1.61 10.35 16.99 .89 27.39 
Placebo 24 11.39 6.80 1.38 8.52 14.27 2.29 24.71 
Total 52 12.62 7.80 1.08 10.44 14.79 .89 27.39 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
Between Groups 66.686 1 66.686 1.096 .300 
Within Groups 3043.445 50 60.869   
Total 3110.131 51    
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Table 7-17: Vitamin B12 at Baseline 
 
Vitamin B12 at Baseline Descriptive 
Groups N Mean SD Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
B 
vitamin 
38 17.13 8.75 1.41 14.25 20.00 .12 32.12 
Placebo 32 17.78 9.89 1.74 14.21 21.35 .80 31.30 
Total 70 17.42 9.22 1.10 15.22 19.62 .12 32.12 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
Between Groups 7.414 1 7.414 .086 .770 
Within Groups 5867.525 68 86.287   
Total 5874.939 69    
 
 
Table 7-18: Vitamin B12 Post-Chemotherapy 
 
Vitamin B12 Post-Chemotherapy Descriptive 
Groups N Mean SD Std. Error 95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
B 
vitamins 
27 6.62 4.93 .95 4.67 8.57 4.26 20.24 
Placebo 24 10.60 7.14 1.45 7.58 13.61 .73 21.77 
Total 51 8.49 6.33 .88 6.71 10.27 .73 21.77 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
Between Groups 200.779 1 200.779 5.442 .024 
Within Groups 1807.951 49 36.897   
Total 2008.730 50    
 
  
  
7-208 
 
Table 7-19: Vitamin B6 at Baseline 
 
Vitamin B6 Baseline Descriptive 
Groups N Mean SD Std. Error 95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
B 
vitamins 
38 17.04 10.00 1.62 13.75 20.33 .80 37.30 
Placebo 32 17.22 8.67 1.53 14.09 20.34 .80 39.20 
Total 70 17.12 9.35 1.11 14.89 19.35 .80 39.20 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
Between Groups .542 1 .542 .006 .938 
Within Groups 6035.204 68 88.753   
Total 6035.747 69    
 
Table 7-20: Vitamin B6 Post-Chemotherapy 
 
Vitamin B6 Post-Chemotherapy Descriptive 
Groups N Mean SD Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
B 
vitamins 
28 8.13 5.63 1.06 5.95 10.31 .61 26.61 
Placebo 24 8.01 7.38 1.50 4.89 11.13 .79 34.29 
Total 52 8.08 6.43 .89 6.28 9.87 .61 34.29 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
Between Groups .179 1 .179 .004 .948 
Within Groups 2110.380 50 42.208   
Total 2110.559 51    
 
7.3.2.2.3 Quality of Life Questionnaire 
No differences were observed for quality of life between arms as presented in Figure 7-16. The best 
obtainable score for this questionnaire was 42 and the worst score was 114, hence the lower the score 
the better the quality of life experienced. The graph is expressed as the total score for the QoL.  
Vitamin B complex supplementation has been linked with energy production [58], and could have 
had an impact on the patient’s quality of life but the results of this QoL questionnaire did not support 
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this result. The projections indicate that the participant’s quality of life was similar for each arm and 
continually improved post-chemotherapy.   
 
 
 
EORTC QoL 
 N Baseline N 12 weeks N 24 weeks N 36 weeks 
B vitamins 38 57.5 ± 13.2 28 57.9 ± 11.9 27 56.1 ± 10 14 51.7 ± 10.5 
Placebo 32 58.8 ± 11.6 24 64.3 ± 14 22 59.5 ± 11.9 11 54 ± 11.9 
 
Figure 7-16:  Results for the EORTC Quality of Life Questionnaire. 
 
7.3.2.2.4 Pain Score 
The pain score was the first section of the MD Anderson Brief Pain Inventory (see Appendix 5) where 
the participants indicated the pain they had experienced in the last 24 hours. From the results seen in 
Figure 7-17, the placebo arm experienced slightly more pain, however it was not statistically 
significant. The projection showed that in both arms the pain was still increased at three months’ post-
chemotherapy cessation. The pain experienced was not always linked with CIPN, as the pain 
questionnaire is a general pain score that does not distinguish the origin of pain. The pain documented 
from participants included general knee or joint pain and those undergoing radiation therapy had 
radiation associated pain.  
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Pain Score 
  N Baseline N 12 weeks N 24 weeks N 36 weeks 
B vitamins 38 4.8 ± 6.1 28 3.7 ± 5.6 27 4. ± 10 14 5.4 ± 7.1 
Placebo 32 5.3 ± 7.4 24 3.3 ± 6 22 6.6 ± 8.2 11 6.6 ± 9.7 
 
Figure 7-17:  Results for the Pain Scores 
 
7.3.2.2.5 Pain Interference Score 
The pain interference score consists of the second part of the MD Anderson Brief Pain Inventory (see 
Appendix 5).  This indicated how pain interfered with a subject’s general life and activities over the 
past 24 hours. The outcome of this analysis presented in Figure 7-18 indicated that the vitamin B 
complex group had less interference with general activities due to pain compared to the placebo 
group. The continued projection showed a major difference in direction. Vitamin B complex 
supplementation cannot be solely attributed to this projection difference but may have played a part 
in the outcome.  
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Pain Interference Score 
  N Baseline N 12 weeks N 24 weeks N 36 weeks 
B vitamins 38 9.9 ± 18 28 9.8 ± 16.8 27 8.3 ± 16 14 6.8 ± 12.3 
Placebo 32 9 ± 13.8 24 7.7 ± 17.4 22 12.9 ± 17.8 11 12.9 ± 18 
 
Figure 7-18: Results for the Pain Interference Scores 
 
7.3.2.2.6 Patient Neurotoxicity Questionnaire (PNQ) 
The statistics for the PNQ was assessed as a risk estimate (odds ratio)and P values using Chi squared 
and Fischer’s exact test, as presented in Table 7-21.  The odds ratio was analysed by addressing 
sensory and motor function at each time point or at an interview. Statistical significance was observed 
for sensory neuropathy at 24 weeks (OR=5.78, 95% CI = [1.63-20.5]) and at 36 weeks (OR=.8.1, 
95% CI = [1.23-53.2]) between the control and the intervention arms. Therefore, there was a 
statistically significant effect as perceived by the subjects regarding the prevention of sensory 
neuropathy through supplementation. 
This was validated using the Chi-square and Fisher’s exact test.  Statistical significant was found for 
sensory peripheral neuropathy in the PNQ (12 weeks p=0.03; 24 weeks p=0.005; 36 weeks p=0.021) 
as seen in Table 7-21. The motor nerve function was statistically significant at baseline (p=0.004), 
however, this was due to a participant’s cancer site and complications that ensue such as after surgical 
interventions for breast cancer.  
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The questionnaire used a linear scale and the participants were asked if they felt any numbness, 
tingling, burning or pain in their fingers or toes for the sensory perception. Appendix 3 shows the full 
questionnaire that was utilised at baseline and every second week throughout the clinical trial.  
It has been stated that CIPN is generally under reported by clinicians [34], however, these results 
show a participant’s perception under reported sensory neuropathy compared to the neurologist’s 
analysis. The participants’ overall felt that sensory neuropathy was not as prevalent for them 
compared to the neurologist’s analysis using the TNS. Therefore, it is important when assessing CIPN 
to obtain both a clinical diagnosis and the patient’s perception for a comparative view and further 
understanding of the neurotoxicity diagnosed.    
 
Table 7-21: PNQ Assessment of CIPN at Each Time Point.  
 
Y/N results: Patient Neurotoxicity Questionnaire: p values 
 Chi-square Fisher 
Baseline Sensory  0.077 0.082 
Motor  0.004 0.005 
Other  0.526 0.389 
    
12 Weeks Sensory  0.03 0.029 
Motor  0.477 0.336 
Other  0.53 0.385 
    
24 Weeks Sensory  0.005 0.005 
Motor  0.656 0.437 
Other  0.127 0.133 
    
36 Weeks Sensory  0.021 0.027 
Motor  0.383 0.325 
Other  0.096 0.183 
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7.3.3 Results for Each Cancer 
7.3.3.1 Breast Cancer 
No statistical significance in TNS was found between the control and intervention arms in the 
subgroup of participants with breast cancer. There was a minor trend in decreased motor function 
disturbances for the vitamin B complex group over the placebo group, but no differences where 
observed between the groups for the total TNS or sensory neuropathy. Results have been presented 
in Figure 7-19.   
      
 
 
 
Figure 7-19: Breast Cancer Participant’s Outcome from the TNS score 
7.3.3.2 Lymphoma 
In participants diagnosed with a lymphoma, the total TNS indicated an increase in CIPN development 
post-chemotherapy in the vitamin B complex arm of the study as compared to the placebo group 
(trend presented in Figure 7-20). For the participants in this clinical trial with lymphoma diagnosis, 
the chemotherapy regime wasR-CHOP24, with the exception of four participants who were 
                                                 
24 R-CHOP is a chemotherapy regime that involves the administration of rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisolone.  372. Mian M, A.F., Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle 
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administered additional intrathecal methotrexate. These participants received either 6 or 8 cycles 
administered either two or three weekly. As these results included all participants, a further 
breakdown can be seen in Figure 7-21, which compares the participants who received 6 cycles versus 
those that received 8 cycles either two or three weekly.  
The intervention arm was found to be statistically significant for the TNS sensory neuropathy 
compared to placebo post-chemotherapy.  By the three months’ follow-up, the two arms were very 
similar in the TNS sensory neuropathy scores. This indicated that the vitamin B complex group may 
have achieved some protection for the sensory nerves during chemotherapy administration, thereby 
allowing the participants to complete the chemotherapy regimen. However, the sensory neuropathy 
three months’ post-chemotherapy showed no difference. Considering the results of the total TNS and 
the motor neuropathy scores for the patients diagnosed with a lymphoma, B vitamin supplementation 
would need further research to be justified. 
  
 
 
Figure 7-20: Lymphoma Participant Outcomes from the TNS 
                                                 
H, Schreieck S, Schnallinger M, Fiegl M., A success story: how a single targeted-therapy molecule impacted on 
treatment and outcome of diffuse large B-cell lymphoma. Anticancer Res., 2014. 34(5): p. 2559-64. 
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Subdividing the patients diagnosed with lymphoma according to the number of cycles administered, 
how often they received the chemotherapy regimen and the addition of intrathecal methotrexate 
provided an overview of the impact of dose duration and accumulation. The participants who 
underwent eight cycles of R-CHOP all received chemotherapy every three weeks. All participants 
who underwent six cycles of R-CHOP, except for one subject (three weekly) had chemotherapy 
administered every two weeks. The participants who received the intrathecal methotrexate in addition 
to R-CHOP were administered chemotherapy every two weeks for six cycles. One participant 
received two extra weeks of just R-CHOP (participant in vitamin B complex arm).  
The participants represented in the Figures 7-21-7.23 consisted of all participants that had completed 
all TNS evaluations, except one participant who completed baseline and post-chemotherapy (follow 
up was not continued due to disease progression and kidney failure). Not all subjects who were tested 
at baseline but did not have any further neurological evaluations were included. Although this trial 
was an RCT with an intention to treat analysis for the data, the stratification of participants diagnosed 
with a lymphoma was changed to those that were assessed to ascertain a better observation of results. 
The total TNS score shown in Figure 7-18 demonstrated that all participants experienced CIPN. The 
participants who received eight cycles of R-CHOP three weekly (R-CHOP x 8) had similar increases 
in TNS scores post-chemotherapy. However, three months’ post-chemotherapy the vitamin B 
complex arm (3 participants) had reversed their TNS score back to baseline. The placebo arm (2 
participants) remained relatively high with little reversal of CIPN development. This indicated that 
although the vitamin B complex did not prevent the development of CIPN, it may have assisted in 
the treatment of CIPN for these participants. 
The participants randomised to the vitamin B complex arm who received six cycles of R-CHOP two 
weekly (R-CHOP x 6) all had high TNS scores post-chemotherapy administration. Both arms (3 
participants in each arm) improved their nerve function after three months with no statistical 
difference noted. The participants who received intrathecal methotrexate consisted of one participant 
per group. Two other participants recruited also received intrathecal methotrexate, however they 
withdrew from the study due to not being able to consume the capsules (1 placebo, 1 vitamin B 
complex).  Both of the participant’s TNS scores increased post-chemotherapy. The participant in the 
vitamin B complex arm received two extra administrations of R-CHOP two weekly after the initial 6 
cycles of R-CHOP+M. This meant that the subject was exposed to a longer duration and accumulation 
of vincristine.  
As presented in Figure 7-18, the R-CHOP+M participant in the vitamin B complex arm had a 
progressively worse presentation of CIPN post-chemotherapy and at three months’ follow-up. This 
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patient was diagnosed with rheumatoid arthritis post-chemotherapy, which may have impacted his 
CIPN score. All RCT participants that received intrathecal methotrexate experienced CIPN that 
progressed post-chemotherapy administration.  
Although intrathecal methotrexate does not directly cause peripheral neuropathy, it is well 
documented for neurotoxicity of diverse clinical manifestations in addition to myelopathy [396]. It is 
possible that the neurotoxicity from the intrathecal methotrexate was the reason the participants 
receiving R-CHOP+M experienced moderate CIPN with worsening symptoms post-chemotherapy 
cessation.   
 
 
 
TNS Score 
 
R-CHOP 
x 8 B 
R-CHOP 
x 8 P 
R-CHOP 
x 6 B 
R-CHOP 
x 6 P 
R-CHOP+M 
x 6 B 
R-
CHOP+M 
x 6 P 
Baseline 
 
Average 4.3 6 2 1 8 2 
St Dev 4.7 8.5 1.7 0   
After chemo 
 
Average 11.3 13 14 12 14 9 
St Dev 4.2 1.4 3.6 2.6   
3mth Follow 
up 
Average 4.7 11 6.7 3.7 19 11 
St Dev 3.2 1.4 3 4     
Figure 7-21: The Total TNS Scores for Lymphoma Participants who Received 6 versus 8 
Cycles of R-CHOP and the Participants who Received Intrathecal Methotrexate (R-
CHOP+M).25  NB: No standard deviation for R-CHOP+M as only 1 person in each. 
 
                                                 
25 Index for figure: 8 = 8 cycles administered three weekly, 6 = 6 cycles administered two weekly, B= B vitamin arm, P= 
placebo arm 
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The total cohort of lymphoma patients showed a trend for vitamin B complex supplementation for 
sensory peripheral neuropathy compared to placebo post-chemotherapy. Breaking the participant data 
into dose and weekly administration shows a different perspective as presented in Figure 7-22.  
The participants that received eight cycles of R-CHOP plus oral vitamin B complex had minimal 
development of sensory PN with no sensory neuropathy at three months’ follow-up. The participants 
who received R-CHOP plus placebo developed sensory neuropathy post-chemotherapy with minimal 
reduction of symptoms by three-months follow up.  The participants who received six cycles received 
less exposure to vincristine compared to participants who were administered eight cycles, however 
the chemotherapy was administered every two weeks compared to every three. This increased dose 
accumulation could impact CIPN development. 
Therefore, it seems that both dose and accumulation play an important role in the development of 
CIPN for patients administered vincristine.  The supplementation of vitamin B complex did not 
prevent the delayed sensory neuropathy experienced by participants receiving R-CHOP two weekly 
but may be beneficial for patients receiving R-CHOP three weekly. 
 
Sensory Nerve 
Assessment from TNS 
R-CHOP 
x 8 B 
R-CHOP 
x 8 P 
R-CHOP 
x 6 B 
R-CHOP 
x 6 P 
R-
CHOP+M 
x 6 B 
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CHOP+M x 
6 P 
Baseline 
 
Average 0 0.5 0 0 0 0 
St Dev 0 0.7 0 0   
After 
chemo 
 
Average 0.3 1 0.7 1 1 1 
St Dev 
0.6 1.4 0.6 0   
3mth 
Follow up 
Average 0 0 1.3 1.5 2 0 
St Dev 0 0 2.3 0.7     
Figure 7-22: The Sensory Neuropathy Scores from the TNS for Lymphoma Participants who 
Received 6 versus 8 cycles of R-CHOP and the Participants who Received Intrathecal 
Methotrexate.  
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Motor nerve function for the subdivided patients diagnosed with lymphoma shown in Figure 7-23 
found that participants who received vitamin B complex and eight cycles of R-CHOP three-weekly 
developed motor neuropathy during chemotherapy administration. However, this dissipated by three-
months follow-up. The participants on placebo and eight cycles of R-CHOP did not develop motor 
neuropathy at any time during or post-administration of chemotherapy.  
All participants who received 6 cycles of R-CHOP two-weekly developed motor neuropathy post- 
chemotherapy however, the placebo arm’s motor neuropathy disappeared completely by three 
months’ follow-up, whereas the vitamin B complex arm still reported minimal motor neuropathy. 
Both patients who received R-CHOP+M developed moderate motor neuropathy, which did was not 
reduced after three-months. Similarly, to the sensory neuropathy, the methotrexate could have had an 
impact on the motor neuropathy development in conjunction with the vincristine. Therefore, a vitamin 
B complex was not beneficial for preventing motor neuropathy experienced by those patients 
diagnosed with a lymphoma and may potentially increase the risk of CIPN development. Intrathecal 
methotrexate may increase the development of motor neuropathy in conjunction with vincristine 
administration.  
 
Motor Nerves 
Assessment from the 
TNS 
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After 
chemo 
 
Average 1 0 1 1 2 2 
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3mth 
Follow up 
Average 0 0 0.3 0 2 2 
St Dev 0 0 0.6 0     
 
Figure 7-23: The Motor Neuropathy Scores from the TNS for Lymphoma Participants who 
Received 6 versus 8 Cycles of R-CHOP and the Participants who Received Intrathecal 
Methotrexate.  
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7.3.3.3 Lung Cancer 
Nine patients recruited in this clinical trial had been diagnosed with lung cancer. This small cohort 
was not representative of a large population of patients with lung cancer, however all participants 
received weekly carboplatin and paclitaxel in conjunction with radiation. This provided a group of 
participants who were administered the same treatment regime. The results are presented in Figure 7-
24    
The results for these participants in this clinical trial showed that a vitamin B complex was beneficial 
for the prevention of sensory neuropathy. Moreover, it also showed a trend in prevention for total 
CIPN during chemotherapy, but was noted to have a worse presentation three-months’ post-
chemotherapy.  Two patients randomised to the placebo arm have deceased and one patient 
randomised to the vitamin B complex had disease progression after chemotherapy and is currently 
still well. 
 
             
 
 
 
Figure 7-24: Lung Cancer Participant Results from the TNS. 
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7.4 DISCUSSION 
This placebo-controlled randomised clinical trial investigating the efficacy of a vitamin B complex 
to reduce the incidence of CIPN over placebo recorded a large heterogeneous set of data. In total, one 
hundred and twenty-one participants were screened for eligibility and fifty of the subjects were 
excluded. Seventy-one participants were than randomised to either the vitamin B complex arm or 
placebo. Thirty-eight participants were randomised to the vitamin B complex arm and thirty-three to 
the placebo arm. Of the participants randomised, three were excluded from the vitamin B complex 
arm and six from the placebo arm leaving thirty-five participants to receive the vitamin B complex 
during chemotherapy treatment and twenty-seven to receive placebo for a total of 62 potentially 
evaluable participants. By completion, forty-seven participants (66.2%) had completed all 
requirements for this study with an attrition rate of 14%.  
The medical treatment for the development of CIPN during chemotherapy administration is to reduce 
the dose or cease administration of the chemotherapy agent [2]. Four participants in this RCT trial 
had their neurotoxic chemotherapy dose reduced or ceased due to the development of CIPN. These 
included from the placebo arm: PA003 RxT who had weekly taxol ceased after nine administrations 
from the allocated twelve cycles to be administered. PA038 JRW had the vincristine dose reduced by 
50% for the fifth administration and then ceased for the sixth cycle. PA055 MJM had the vincristine 
administration ceased after the fourth administration (6 cycles completed).  From the vitamin B 
complex arm only one participant had a dose reduction. PA070 NLW had the taxol administration 
decreased by 20% after the second cycle due to CIPN development. This meant that three participants 
in the placebo had their chemotherapy agent ceased due to CIPN and only one participant in the 
vitamin B complex arm had a dose reduction of 20%, nevertheless completed the prescribed 
chemotherapy regimen. These findings build a hypothesis  that a vitamin B complex may potentially 
decrease the onset and severity of CIPN development. Or may assist in the completion of the 
prescribed chemotherapy regimen, thereby assisting treatment outcomes. 
The final-results of the clinical trial reported no statistical significance for the vitamin B complex to 
prevent CIPN. The primary outcome was based on the TNS scores, which through a Mixed Effects 
Model (MEM) reported a T score of 0.22 for placebo compared to the vitamin B complex arm with 
a T score of 1.24.  When the placebo arm was compared to the vitamin B complex arm over the three 
time points of neurological assessments, no statistical significance was found (p=0.73; T score = -
0.35). A statistical significance from the TNS (primary outcome) was found for the difference in time 
points of the neurological assessments (p=0.02). This indicated that neurological changes were seen 
from the total cohort between each neurological assessment. CIPN is known to be an accumulative 
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side effect, which can occur during or after chemotherapy administration from a neurotoxic agent 
[12]. All other analysis from the MEM scores for secondary outcomes found no statistical 
significance.  
Other statistical analysis of sensory and motor functions from the TNS results using Chi-squared and 
Fisher’s exact tests found no statistical significance (24 weeks: sensory p=0.11 motor p=0.79; 36 
weeks: sensory p=0.96 motor p=0.46). Statistical significance was calculated at baseline for motor 
function (p=0.002), however this has no relevance on the outcome as it was representative of the 
patients’ cancer and cancer related surgical interventions. Independent samples t-test and the Mann 
Whitney test were also conducted for the TNS with no statistical significance found (Independent 
samples t-test: 24 weeks p=0.376, t-score=-0.89; 36 weeks p=0.579, t-score=-0.559; Mann Whitney: 
24 weeks p=0.329; 36 weeks p=0.424).  
A statistically significant result was observed in the patient neurotoxicity questionnaire results for 
sensory neuropathy (12 weeks p=0.03; 24 weeks p=0.005; 36 weeks p=0.021). In addition, the risk 
estimate for the PNQ was also statistically significant at both 24 weeks OR=5.78, 95% CI = [1.63-
20.5] and 36 weeks OR= 8.1, 95% CI = [1.23-53.2]. Therefore, B vitamin supplementation was found 
to be statistically significant for the participant’s perception of sensory peripheral neuropathy 
prevention.  
Additional relevant results included the small nerve damage encountered with chemotherapy 
administration that vitamin B supplementation did not reverse. Reflexes were lost in ninety percent 
of all participants with seventy-five percent still exhibiting no reflexes by three-months of follow-up. 
Blood pathology results demonstrated that supplementation with a vitamin B complex during 
administration of chemotherapy increased blood levels of vitamins B1, B6, B12 and folate compared 
to placebo.  
The only B vitamin that was found to be statistically significant in potentially preventing the onset 
and severity of CIPN was vitamin B12. In addition, a participant (i.e., PA032 PMP) that was found 
to be deficient in vitamin B12 post-chemotherapy administration presented with moderate to severe 
CIPN development. After supplementation with vitamin B12, CIPN was significantly reduced. 
Further expansion on the results of this participant can be found in Chapter 8.  
High vitamin B6 blood pathology results were found in four participants in the vitamin B complex 
arm who presented with mild to moderate CIPN after chemotherapy treatment. It remains to be 
elucidated if the high vitamin B6 blood levels (over 1,000 nmol/L) encountered was associated with 
the CIPN development in these participants.  
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Pain scores did not show a statistical significance and no differences were seen between the two arms 
except for the projection of pain interference. It was observed that in the vitamin B complex arm of 
the study, if the projection continued it would have led to significantly less pain interference in these 
participants than in those randomised to the placebo arm. These results cannot conclusively 
demonstrate that vitamin B complex supplementation was solely responsible for the reduction of pain 
and its interference with daily activities.  
Examining the data from individual participants regarding cancer types, no benefit was found for 
breast cancer patients, but possible sensory neuropathy benefits may have been observed for patients 
diagnosed with a lymphoma undergoing R-CHOP for eight cycles’ three weekly and patients 
diagnosed with a lung cancer undergoing paclitaxel and carboplatin weekly.  
 
7.5 CONCLUSION 
Whilst a vitamin B complex was not statistically efficacious when compared to placebo in decreasing 
the incidence of CIPN, vitamin B12 was observed to correlate in preventing the onset and severity of 
CIPN development. Participant perception for the prevention of sensory neuropathy with a vitamin 
B complex was statistically significant, as was the odds ratio for post-chemotherapy and follow up. 
A vitamin B complex may be beneficial in preventing sensory neuropathy for patients diagnosed with 
a lymphoma who are to be administered chemotherapy with R-CHOP for eight cycles every three 
weeks and for those patients diagnosed with lung cancer who receive weekly paclitaxel and 
carboplatin.  A vitamin B complex may play a role in decreasing pain interference for daily activities. 
One patient who presented with moderate to severe CIPN was found deficient in vitamin B12 post-
chemotherapy and benefited from vitamin B12 administration. This was clinically relevant and 
further information on this participant (i.e., PA032 PMP) is presented in Chapter 8. The overall 
impression from this clinical study is that patients diagnosed with a cancer who will be administered 
chemotherapy and who may be at risk of developing moderate to severe CIPN, could benefit from 
either vitamin B12 or a vitamin B complex, but further research is required. In addition, patients 
undergoing chemotherapy with a neurotoxic agent should have their vitamin B12 pathologically 
tested either prior to chemotherapy administration or on presentation of moderate to severe CIPN. 
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8 CHAPTER 8:  CASE STUDIES DOCUMENTING CIPN DUE TO 
VITAMIN B12 DEFICIENCIES 
8.1 INTRODUCTION 
CIPN is emerging as a major concern for oncology specialists considering the increasing number of 
cancer survivors and the lack of standardised prevention strategies and treatments [397]. The 
incidence of CIPN depends on the chemotherapy agent administered with an estimated prevalence of 
one third of all patients that undertake a chemotherapy regimen [3]. As previously discussed, patients 
experiencing moderate to severe CIPN report a reduced quality of life [12], chronic discomfort [2], 
and disruption of physical abilities for general life activities, which can be temporary or permanent 
[12]. Currently in clinical oncology practice, CIPN is assessed using the common toxicity scales 
however, this relies heavily on the patient’s subjective reports rather than quantitative testing [398]. 
CIPN is a potentially reversible side effect although reversibility may be dependent on early detection 
or identification and modification of chemotherapy treatment as symptoms appear [398]. Permanent 
CIPN continues to be reported, especially sensory symptoms in the lower extremities among patients 
treated with oxaliplatin even up to 11 years after treatment [399]. Early differential diagnosis and 
prevention of permanent CIPN needs to be a priority benefiting the quality of life of cancer patients. 
A history of blood vitamin B12 deficiency has been identified as a predisposing factor that may 
increase the risk of CIPN development [12]. However, patients who have had no previous history of 
blood vitamin B12 deficits may not be tested before chemotherapy commences in order to assess 
blood vitamin B12 status. Moreover, a potential blood vitamin B12 deficiency may develop during 
the chemotherapy treatment [44], therefore potentially subjecting the patient to be predisposed to the 
development of CIPN and/or the delayed progression of CIPN.  
A case report of a cancer patient that participated in this B vitamin clinical trial and who developed 
CIPN is described below. The participant was found vitamin B12 deficit after the chemotherapy 
regime had been completed and upon vitamin B12 administration, the severity of CIPN decreased. 
This allowed the patient more functional ability in daily activities including walking. Another case 
report has been documented for a participant who was excluded from this clinical trial due to a vitamin 
B12 deficiency and consented to being followed throughout chemotherapy and after cessation. One 
other case report provides noteworthy findings from the subject’s diaries and has been included to 
further expand discussions.  
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8.2 PA032 PMP CASE REPORT ONE 
8.2.1 PA032 PMP Details and Results 
A 53-year-old female (PA032 PMP) was enrolled in the main clinical trial and was randomised to the 
placebo group. Initial vitamin B group status pathology bloods, a neurological exam involving the 
TNS and electro-neurological examination in addition to other history and questionnaires was 
conducted prior to the commencement of chemotherapy. The same independent neurologist following 
chemotherapy administration conducted the neurological examination and TNS and blood B group 
vitamin status was established.  This subject’s case report details and results are documented in Table 
8-1.  
Table 8-1: Medical Details of Participant PA032 PMP 
 
PA 032 PMP Details 
DOB 17/06/59 
Diagnosed Breast Cancer in March, 2012 
Surgery PA Hospital 27/3/2012 – right breast lumpectomy and axillary 
clearance. 
Previous surgery:  Appendectomy, cholecystectomy, basal cell 
carcinoma on nose    (flap repair)  
Results Grade II IDC and DCIS – Oestrogen and Progesterone positive, 
HER2 negative 
Nodes positive/removed:   0/9 
Recruited for study 2/6/2012 
Race Caucasian 
Marital Status Married 
Other medical 
considerations 
Psoriasis, hypothyroidism, osteoarthritis, reactive arthritis, asthma 
(late onset), osteopenia, obesity 
Medications Thyroxin 100 mcg daily 
Allergies Codeine, pethidine 
Diet history No history of being a vegan or vegetarian. Normally consumes red 
meat (beef, lamb, kangaroo) 3-4 times a week, chicken or pork 2-3 
times a week and fish or seafood approximately 3-4 times a week. 
She does drink caffeine, approximately 4-5 cups a day (tea), rarely 
drinks alcohol, doesn’t smoke or take recreational drugs. 
Height 162cm 
Weight 129kg 
BMI 49.2 
Chemotherapy regime Carboplatin and docetaxel (TC) 4 times every three weeks 
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PA032 PMP is generally healthy, although overweight. The subject has been diagnosed with arthritis 
with increased difficulty in walking, which adds to this subject’s weight issue. This participant works 
in an office and has a generally sedentary life.  
8.2.2 Blood Pathology Results for PA032 PMP 
The blood pathology tests for this participant showed that vitamin B12 status had changed and was 
deficient after chemotherapy administration, as seen in Table 8-2. After supplementation with a B 
group vitamin complex (equivalent to 1,000 µg/day) and receiving one intramuscular vitamin B12 
(dose 1,000 µg), the blood vitamin B12 level reverted back to baseline. All other bloods were similar 
except for blood levels of vitamin B6, which had increased after supplementation with the oral B 
vitamin complex. However, this was expected when assessing previous pilot clinical trial results (see 
Chapter 5). This suggests that vitamin B12 may be a contributing factor linked with peripheral 
neuropathy presenting in this participant.  
 
Table 8-2: PA032 PMP Blood Pathology Results 
 
Blood Pathology Baseline 
5/6/2012 
After 
Chemo 
25/09/2012 
Last follow up 
8/12/2012 
Ref Range 
Vitamin B1 (TDP) 140 140 180 66-200 nmol/L 
Vitamin B2 (FAD) 280 310 230 180-470 nmol/L 
Vitamin B6 (P5P) 95 90 250 H 35-110 nmol/L 
Red cell folate 2249 2163 2170 >900 nmol/L 
Holo TC (Vitamin 
B12) 
107 29 L 106 >35 pmol/L 
 
 
8.2.3 Neurological Testing Results for PA032 PMP 
8.2.3.1 Total Neuropathy Score (TNS) used in the Trial 
The neurological test results in Table 8-3 showed that the participant’s peripheral sensory and motor 
nerve function decreased after chemotherapy administration. The participant at baseline showed no 
numbness, tingling or pain in the hands or feet. All motor functions in the hands and feet were 
preserved, although arthritis did impair some ambulatory walking. The participant had just applied 
copious amounts of a moisturiser just before arriving at the appointment, and this interfered with the 
electronic testing therefore showing a mild impairment in the motor function of the test. The sural 
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nerve was unable to be found due to the arthritis and the moisturiser application.  After chemotherapy 
administration, sensory peripheral nerves and motor nerves were noticeably affected. Level 2 
indicates numbness, tingling and neuropathic pain up to the ankle and the wrist.  
The pin sensibility is the test for small nerve damage and post-chemotherapy administration was 
noted past the wrist and ankle in this subject. In addition, there was loss of tendon reflexes, which 
was observed in many participants in this clinical trial and is also representative of nerve damage. 
The sural nerve was not unable to be detected after chemotherapy administration, however this time 
there was not copious amounts of moisturiser applied beforehand. Therefore, peripheral neuropathy 
was detected affecting the sural nerve function and leading to the inability of the nerve being detected 
by the electrical testing procedure.  
After receiving vitamin B12 intramuscularly (dose 1,000 µg) and orally administering the vitamin B 
group complex (2 capsules a day equivalent to 1,000 µg a day), retesting was conducted three months 
later. Sensory nerve function returned to the fingers and toes (level 1).  Motor function remained 
unchanged after chemotherapy administration and pin sensibility was still present to the wrists and 
ankles. The sural nerve was positively detected in this test, and it is possible that the patients baseline 
reading could have been similar if the moisturiser hadn’t interfered with the test.  Alternatively, it is 
possible that her sural nerve improved with B vitamin complex administration. As the participant was 
now in menopause, hot flushes were increased in severity indicating autonomic nervous function 
involvement.  
  
  
8-227 
 
Table 8-3: TNS Results of PA032 PMP 
Total Neuropathy Score (TNS) 
Item Baseline Score 
02/06/2012 
After 
Chemotherapy 
25/08/2012 
 
Three months later 
17/11/2012  
(2 months after 
beginning of B12 
supplementation) 
Sensory symptoms 0 2 1 
Motor symptoms 1 (right hand 
sweating reduced 
testing) 
2 2 
Autonomic symptoms 1 (sweating) 1 2 (menopause post-
chemo) 
Pin sensibility 0 2 2 
Vibration sensibility 0 0 0 
Strength 0 0 0 
Tendon reflexes 0 4 2 
Sural amplitude score 4 4 2 
Peroneal amplitude score 0 0 0 
Total 7 15 11 
 
8.2.3.2 Neurological Conduction Studies (NCS) 
The neurologist conducted extra nerve conduction tests in addition to the tests required for the TNS. 
These electrical tests assess large nerve activity. The nerve conduction study (NCS) normal values 
were ascertained from the University of Michigan Medical School [400]. The NCS conducted on 
PA032 PMP indicate that nerve damage occurred after chemotherapy administration. The main areas 
affected were the hands (palms), wrists, sural nerve and the peroneal only slightly after chemotherapy. 
The sural nerve at baseline was unable to be found due to a large amount of moisturiser applied by 
the patient prior to testing. This makes it difficult to ascertain if damage did occur or if the sural 
activity was low before chemotherapy administration. Considering the fact that the sural activity had 
improved by the last neurological test, it can be assumed there may have been some activity prior to 
chemotherapy. Except for the amplitude of the peroneal after chemotherapy on the 25/8/2012 which 
is a motor nerve, all nerve damage was sensory. This is congruent with the symptoms displayed by 
the patient.  
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Table 8-4: PA032 PMP NCS Study Results 
 
 Sensory NCS 
Nerve/Sites Rec Site Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl 
µV 
 2/6/2012 25/08/2012 17/11/2012 
R MEDIAN  
   Palm 
III 1.30 4.3 2.8 10.2 2.85 4.9 
L MEDIAN 
   Palm 
III   2.70 12.0 3.30 5.0 
L ULNAR –  
   Wrist 
Digit V 1.95 19.5     
R ULNAR –  
     Wrist 
Dorsum of 
Hand 
1.30 26.1 1.65 1.5 1.85 3.1 
L ULNAR –  
     Wrist 
Dorsum of 
Hand 
1.65 13.2 1.70 3.6 1.65 3.9 
R SURAL –  
     Calf 
Lat Malleolus   2.65 6.7 2.35 5.1 
 
NB: First baseline tests were difficult due to moisturiser used by patient 
 
 
Motor NCS 
Nerve/Sites 
Rec Site 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak Ampl 
µV 
 2/6/2012 25/08/2012 17/11/2012 
L MEDIAN – APB   
    Wrist  
5.10 7.7 4.45 8.0 3.80 7.7 
    Elbow 9.45 7.8 9.05 7.3 9.35 7.8 
R COMM PERONEAL – 
EDB 
    Ankle 
4.05 2.9 3.15 3.3 4.05 2.2 
    Fib Head 9.65 4.8 10.55 0.7 10.15 2.3 
R TIBIAL (KNEE) – AH 
     Ankle 
5.05 10.4 3.55 8.3 4.65 3.7 
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8.2.3.3 Patient Neurotoxicity Questionnaire for PA032 PMP Results 
This is a linear scale and indicates the level of CIPN that the patient has experienced in the past week. 
The results of PA032 PMP’s patient neurotoxicity questionnaire can be seen in Table 8-5.  
 On the 25/8/12, subject PA032 PMP was having difficulties with buttoning clothes, zippers, typing 
on a keyboard, writing, walking, putting on jewellery, knitting, sewing, working and dialling or using 
a telephone. By the 17/11/12, all of these issues were resolved and no further difficulties were reported 
aside from some shortness of breath.  
On the 2/10/12 the patient presented at the PA hospital breast cancer clinic following receipt of blood 
results.  Holo TC was reported as 29 (ref >35) indicating a deficit in blood vitamin B12. The 
oncologist was informed and administered vitamin B12 intramuscularly (dose 1,000 µg). The subject 
was than provided 3 bottles of the vitamin B complex from the manufactures and advised to take 1 
capsule twice daily with food, morning and night. At this visit point, the patient reported that 
numbness was present up to the hips in both legs and from the wrists to the elbows (considered Grade 
3 to 4 CIPN). The subject was referred to a physiotherapist at the PA hospital for the numbness and 
the lymphoedema that was being experienced.  
One week later 9/10/12, the patient reported experiencing a major positive difference. On the 
17/11/12, the patient described numbness in the toes to be approximately 50% and on the tips of the 
fingers.  
 
Table 8-5: PA032 PMP Patient Neurotoxicity Questionnaire Results 
 
Items Baseline 3 mths 6 mths 
 2/6/12 25/8/12 17/11/12 
Numbness, Pain, burning or tingling 0/4 3/4 1/4 
Weakness in arms and legs 1/4 3/4 1/4 
Difficulty with daily activities 0/4 3/4 0/4 
 
8.2.3.4 Medical Notes for PA032 PMP: Chart from the PA Hospital 
As seen in Table 8-6, PA032 PMP still experiences CIPN in the tips of the fingers and toes, which 
may now be a permanent effect. The peripheral neuropathy still present may represent the actual 
CIPN the patient developed. It is postulated that had the blood vitamin B12 levels been kept in normal 
range, the participant would have only experienced the neuropathy in the fingers and toes through the 
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effect of the chemotherapy. This is in comparison to the severe peripheral neuropathy reported by the 
patient in the arms and legs.  
Table 8-6: PA032 PMP Medical Notes from the PA Hospital Medical Charts 
 
Dates Medical Notes from patients chart at the PA 
29/05/2012 Presented to the breast cancer oncology and radiology clinic, weight 132.6 kg 
and 165 cm, age 53.   
06/06/2012 Commenced chemotherapy 
After first chemotherapy, cancer care coordinator noted the following: terrible 
joint and bone pain prescribed endone 10 mg. Diarrhoea bad from Sunday to 
Monday than settled. Nausea double positive so prescribed pramen. Has rash and 
possible fistulas and using clindamycin ointment. Has mouth ulcers and 
continues to use mouth washes.  
26/06/2012 Weight: 132.2 kg, bone pain/ myalgia, mouth ulcers, diarrhoea, hot flushes. 
Prescribed neulasta injection, gastro stop and endone and fentanyl 25 mcg.   
17/072012 Bone pain major issues. Fentanyl 25 mcg and endone.   
7/08/2012 Weight: 135.6 kg. Pain constant, vomiting, fluid retention, some CIPN, rash. 
Prescribed Lasix 2 g daily and Zofran (ondansetron) wafers. 
18/09/2012 Completed 4 cycles. CIPN noted, muscles sore, referred to physiotherapist. 
Physiotherapist noted CIPN refer to Appendix 11.   
02/10/2012 Holo TC 29 noted by oncologist, prescribed vitamin B12. Given by nurse on the 
2/10/12 as prescribed, 1000 mcg IM. CIPN noted as being severe. 
9/10/2012 Breast referral clinic: Osteopenia T-score -1.8 in right neck of femur. Rash has 
improved with antibiotics – seen dermatologist who prescribed hydrozole and 
advantin cream. Has lethargy, CIPN and taking vitamin B12. 
10/12/2012 Referred to neurologist as CIPN still present. BMD: oesteopenic. Prescribed 
Femara. 
22/01/2013    Rash resolved. CIPN improving, occasional partial PN.  Arthralgia, myalgia, 
increase in severity of psoriasis, increase weight gain, non-pitting oedema. BDM: 
left spine -0.6, right femur -1.8, and left femur -1.5. 
 
16/07/2013 Mammogram, no malignancy. Experiencing bone pain and stiffness, mild CIPN. 
Lymphedema still in arm and breast. 
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8.2.3.5 Chemotherapy Regime / Dates for PA032 PMP 
The subject was administered the complete dose of her chemotherapy with no reductions or cessations 
of treatment.  
Table 8-7: PA032 PMP Chemotherapy Regime and Administration 
 
Date 5/6/2012 26/6/2012 17/7/2012 7/8/2012 
Sodium chloride 100 ml IV 100 ml IV 100 ml IV 100 ml IV 
Granisetron (3mg) 3 mg IV 3 mg IV 3 mg IV 3 mg IV 
Dexamethasone 
(8mg) 
8 mg IV 8 mg IV 8 mg IV 8 mg IV 
Docetaxel (75mg/m2) 184 mg IV 184 mg IV 184 mg IV 184 mg IV 
Cyclophosphamide 
(600mg/m2) 
1480 mg IV 1480 mg IV 1480 mg IV 1480 mg IV 
Discharge Medication  
Ondansetron (oral) 8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 days 
Dexamethasone (oral) 8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 days 
Metolopramide (oral) 10-20 mg 4-6 
HRLY PRN x 5 
days 
10-20 mg 4-6 
HRLY PRN x 5 
days 
10-20 mg 4-6 
HRLY PRN 
x 5 days 
10-20 mg 4-6 
HRLY PRN x 5 
days 
Dexamethasone (oral) 
to be taken the day 
before next 
chemotherapy 
8 mg BD x 1 
day 
8 mg BD x 1 
days 
8 mg BD x 1 
days 
 
Pegfilgrastim INJ 
(6mg) subcutaneous 
 6 mg ONCE x 1 
day 
6 mg ONCE 
x 1 day 
6 mg ONCE x 1 
day 
 
8.2.3.6 Other Bloods Completed by PA Hospital for PA032 PMP 
8.2.3.6.1 Thyroid Function 
The participant has had a history of hypothyroidism and is currently taking thyroxin 100 mcg daily. 
These blood test results as seen in Table 8-8, were to monitor her thyroid function during and after 
radiation. The thyroid antibodies present still indicate the subject has Hashimoto’s disease.  
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Table 8-8: PA032 PMP Thyroid Function Blood Results 
Thyroid 13/6/2012 22/06/2013 Ref Range 
TSH 5 4.5 0.20- 4.00 mU/L 
Free thyroxine (fT4) 16  15-30 pmol/L 
Anti-thyroglobulin Ab  200 <60 U/ml 
Anti-Thyroid Peroxidase Ab  280 <60 U/ml 
 
8.2.3.6.2 Cholesterol 
This participant is not on cholesterol medication prior or after chemotherapy administration. The 
blood results for cholesterol are presented in Table 8-9. 
 
Table 8-9: PA032 PMP Cholesterol Blood Results 
Cholesterol 13/6/2012 13/07/2012 22/06/2013 Ref Range 
Total 
Cholesterol 
5.4 6.4 6.2 3.9-7.4 mmol/L 
Triglycerides 1.4 H 3.3 1.3 <1.5 mmol/L 
HDL 1.12   >1.0 mmol/L 
LDL H 3.24   <2.0 mmol/L 
Total/HDL ratio 4.8    
 
8.2.3.6.3 Full Blood Count 
PA032 PMP’s full blood count is fairly representative of a patient who has undergone chemotherapy 
with a low white cell count (WCC) and low neutrophils. The cumulative blood test results showed 
that the patient recovered well from the administration of chemotherapy in regards to red and white 
blood cell regeneration.  The blood pathology results are presented in Table 8-10. 
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Table 8-10: PA032 PMP Full Blood Count Results 
FBC 13/6/2012 13/7/2012 22/06/2013 Ref Range 
Hb 141 136 143 115-160 g/L 
RCC 4.5 4.5 4.6 3.6-5.2 x10 ˆ12/L 
Hct 0.43 0.41 0.42 0.33-0.46 
MCV 95 91 93 80-98 fL 
MCH 31 30 31 27-35 pg 
Platelets 304 172 261 150-450 x10 ˆ9/L 
WCC L 1.5 6.4 5.4 4.0-11.0 x10 ˆ9/L 
   Neuts L 0.1 3.1 3.0 2.0-7.5 x10 ˆ9/L 
   Lymphs 1.3 2.4 1.8 1.1-4.0 x10 ˆ9/L 
   Monos L 0.0 0.7 0.4 0.2-1.0 x10 ˆ9/L 
   Eos L 0.02 0.06 0.11 0.04-0.40 x10 ˆ9/L 
   Basos 0.02 0.06 0.05 <0.21 x10 ˆ9/L 
 
8.2.3.6.4 Serum Chemistry 
PA032 PMP’s full blood chemistry pathology results seen in Table 8-11 shows the participant is 
experiencing a number of other medical concerns. This includes borderline diabetes (blood glucose 
of 6), gout (uric acid 0.39 mmol/L), raised liver enzymes which could be from chemotherapy initially 
but has continued (GGT, ALT, AST, LD) and low calcium in July, 2012.  
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Table 8-11: PA032 PMP Serum Chemistry Results 
 
Serum 
Chemistry 
13/06/2012 
Fasting 
13/07/2012 
Random 
22/06/2013 
Fasting 
Ref Range 
Sodium 138 141 140 137-147 mmol/L 
Potassium 4.6 4.0 4.1 3.5-5.0 mmol/L 
Chloride 103 106 103 96-109 mmol/L 
Bicarbonate 29 27 28 25-33 mmol/L 
Other Anions 11 12 13 4-17 mmol/L 
     
Glucose  6.0 6.5 Random (3-6) 
     
Urea 4.6 3.3 4.3 2.5-7.5 mmol/L 
Creatinine 59 59 59 50-120 umol/L 
eGFR >90 >90 >90 Over 59 mL/min 
Uric acid  H 0.37 H 0.39 0.14-0.35 mmol/L 
     
Total Bilirubin 9 9 9 2-20 umol/L 
Alk. Phos 73 83 94 30-115 U/L 
Gamma GT H 69 H 91 H 75 0-45 U/L 
ALT H 56 45 H 60 0-45 U/L 
AST 32 33 H 56 0-41 U/L 
LD 188 H 277 202 80-250 U/L 
     
Calcium  L 2.24 2.29 2.25-2.65 mmol/L 
  Adjusted for 
albumin 
 2.34 2.33 2.25-2.65 mmol/L 
Phosphate  1.1 1.4 0.8-1.5 mmol/L 
Total Protein  66 73 60-82 g/L 
     
Albumins 39 39 41 35-50 g/L 
Globulins 32 27 32 20-40 g/L 
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8.2.3.6.5 Cumulative Serum Report 
No medical notes were documented as to the reason for testing her digestive enzymes, however results 
are all in range as seen in Table 8-12.  
 
Table 8-12: PA032 PMP Cumulative Serum Report Results 
 
 
8.2.3.6.6 Vitamin Levels 
The serum vitamin B12 as seen in Table 8-13, assists this case report in assessing the participant’s 
vitamin B12 status pre and post clinical trial. PA032 PMP was found deficient in vitamin B12 on the 
2/10/2012 (Holo TC 29 pmol/L), which is three months after the serum vitamin B12 test conducted 
on the 13/7/2012 (>1476). This serum vitamin B12 blood test was taken just before the participant’s 
third administration of chemotherapy (17/07/2012). It has been found that when the liver is damaged, 
vitamin B12 is released giving a reading of high serum vitamin B12 [401-403], however, tissue 
reserves are being depleted and the patient can result in a deficiency of vitamin B12 [404].  
The blood pathology tests for this participant showed raised liver enzymes and a raised serum vitamin 
B12 level that could represent the liver releasing stored vitamin B12. The Holo TC is the blood 
pathology assay for blood levels of vitamin B12 being released from the liver and transported to body 
tissues [62]. Holo TC blood results have also been found to be raised from liver damage [404], 
however, it has been reported that it can detect an early deficiency in vitamin B12 compared to serum 
vitamin B12 levels [62].  
PA032 PMP’s liver indicated possible damage as noted by raised liver enzymes, so it may be 
postulated that it was releasing stored vitamin B12 resulting in a vitamin B12 deficiency three-months 
post serum vitamin B12 test. This participant’s vitamin B12 deficiency was symptomatic displayed 
as peripheral neuropathy and possibly fatigue. The difficulty is differentiating between the patient’s 
symptoms being from chemotherapy and/or a vitamin B12 deficiency.  
According to the blood pathology tests, the medical doctors would normally not consider this patient’s 
presentation of CIPN as a possible vitamin B12 deficiency due to her serum vitamin B12 results from 
July, 2012. Had the subject not participated in this clinical trial, her vitamin B12 most likely would 
not have been re-tested as her previous tests indicate a saturated state. Therefore, this raises the 
Serum 13/07/2012 Ref Range 
Lipase 130 60-250 U/L 
Amylase 41 0-120 U/L 
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question of whether testing vitamin B12 during chemotherapy is worthwhile. Similarly, it is difficult 
to ascertain whether it gives an accurate reading of the patient’s vitamin B12 state.  
Testing vitamin B12 during chemotherapy may not give accurate results as the patient may be 
releasing stored vitamin B12 into the blood from liver damage. However, conducting a one off blood 
test for vitamin B12 during chemotherapy is different compared to conducting multiple vitamin B12 
tests. Adding serum vitamin B12 to blood pathology tests prior to every chemotherapy administration 
could provide an indication of the patient’s vitamin B12 status to the oncologist. If there is an 
increased risk of peripheral neuropathy from both the administration of chemotherapeutic agents and 
low vitamin B12, the oncologist would be able to ascertain this early before a vitamin B12 deficiency 
occurs.  Hence, vitamin B12 treatment can be started early before the patient is in a deficit state 
that may increase the risk of peripheral neuropathy.  
Is this a reasonable request for all patients undergoing chemotherapy with neurotoxic chemotherapy 
agents and is it cost effective? When is testing for vitamin B12 conducted if it was not conducted 
prior to chemotherapy commencement and what do the results indicate? Or should patients take a 
prophylactic vitamin B12 or B complex during chemotherapy? Patient comfort, quality of life and 
ability to complete the prescribed chemotherapy regime without dose reduction or cessation are 
clinically relevant points and important aspects to consider for ‘best patient care’. 
Intrinsic factor antibodies play an important role in a vitamin B12 deficiency. If a patient is 
continually found to be low or deficient in vitamin B12 after chemotherapy, then testing for intrinsic 
antibodies would be indicated. However, if a patient’s vitamin B12 level is in normal range without 
supplementation 6 to 12 months’ post-chemotherapy, then testing for intrinsic factor or parental cell 
antibodies would not be indicated. For PA032 PMP, the serum vitamin B12 was 411 pmol/L seven-
months’ post-chemotherapy administration which is in the reference range. The patient stated that 
during the seven months after the end of the B vitamin study, no oral vitamin B12 supplementation 
had been taken, nor had she been administered intramuscular vitamin B12. Therefore, it can be 
assumed that this participant does not have intrinsic factor antibodies. The subject was given a 
pathology request form for intrinsic factor antibody test but it was not performed. 
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Table 8-13: PA032 PMP Vitamin Level Blood Results 
 13/07/2012 22/06/2013 Ref Range 
Serum Vitamin B12 H >1476 411 162-811 pmol/L 
Red Cell Folate  1265 1290 545-3370 nmol/L 
Serum Ferritin H 743 H 395 15-290 ug/L 
Anti-tissue 
transglutaminase IgA 
<4  <4 U/mL 
 
8.2.3.6.7 Isotope Bone Scan 
Date: 11/02/2013 
History: Recent six weeks of pulsing pain down spine and more constant low back pain radiating 
through to hips bilaterally. Worse posterior left hip and worse with movement. Previous breast 
carcinoma.  
Findings: Diffuse activity throughout the right breast, noted on recent ultrasound commented on 
infected sebaceous cyst. The activity is out of proportion however these probably highlighted by the 
asymmetry and it is assumed that there is not a disuse breast carcinoma. This requires careful 
correlation with clinical history and clinical evaluation. There was little uptake in knees, ankles and 
feet which is likely to be degenerative and minimal asymmetry of uptake in the mid to lower lumbar 
spine is also degenerative. There is no evidence of metastatic disease or other focal bone process of 
note.  
8.2.4.2.8 Auto-antibody, Cancer Markers and Inflammatory Pathology 
The blood pathology results seen in Table 8-14 were requested and collected before PA032 PMP’s 
second administration of chemotherapy. Cancer markers and auto-immune markers are not 
commonly requested at this point of treatment. After the participant’s first chemotherapy 
administration, the cancer care coordinator recorded that the patient had experienced terrible joint 
and bone pain (not due from neulasta as it had not been administered yet), severe diarrhoea, nausea, 
mouth ulcers, had a rash and possible fistulas. The subject was prescribed endone for the pain. It is 
assumed that the blood pathology tests were conducted to elucidate what maybe causing the patient’s 
discomfort. From the blood test results, the subject was experiencing an inflammatory state (CRP = 
11 mg/L).  
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Table 8-14: PA032 PMP Auto-antibody, Cancer Markers and Inflammatory Blood Pathology 
Results 
Pathology 22/06/2013 Ref Range 
ANA (HEP-2) <80 <80 
Anti-CCP antibody <1 <5 
CRP +11 0-6 mg/L 
CA 15.3 13 <30 U/ml 
CEA 1.1 Up to  4.6 ug/L 
 
8.2.4 Discussion on PA032 PMP 
PA032 PMP baseline blood test indicated a normal vitamin B12 level, as measured by Holo TC assay 
107 pmol/L ref >35 pmol/L). Prior to the third cycle of chemotherapy, the subject’s serum vitamin 
B12 was found to be elevated >1476 pmol/L (162-811 pmol/L). Subsequently, PA032 PMP’s Holo 
TC assay after completion of the full chemotherapy regime indicated a deficiency in vitamin B12 (29 
pmol/L ref >35). No other B vitamin markers were found to be deficient. After two months of vitamin 
B12 administration (1,000 µg intramuscularly and 1,000 µg taken orally daily), the vitamin B12 levels 
from the Holo TC assay had risen to 106 pmol/L (ref >35 pmol/L). Seven months after the last blood 
pathology test in the clinical trial, the subject’s vitamin B12 levels were 411 pmol/L (162-811 
pmol/L) without vitamin B12 administration indicating normal vitamin B12 absorption and 
metabolism and possibly no intrinsic factor antibodies.  
PA032 PMP’s neurology test and patient neurological test showed no neuropathy at baseline, 
however displayed CIPN (Level 2 to 3) after chemotherapy. After two months of vitamin B12 
administration (one 1,000 µg intramuscularly and 1,000 µg taken orally daily) the subjects CIPN was 
reduced to the tips of her fingers and toes (Level 1). Therefore, a patient experiencing a vitamin B12 
deficiency while undergoing chemotherapy may display a severe CIPN. This presentation of 
peripheral neuropathy when a patient is undergoing chemotherapy may be diagnosed as CIPN by the 
oncologist without testing for a vitamin B12 deficiency. For this participant, the vitamin B12 status 
was tested and found to be deficient.  
After vitamin B12 administration both intramuscularly and orally, the participant’s peripheral 
neuropathy decreased from severe to mild. Hence, the patient was experiencing severe peripheral 
neuropathy from both a vitamin B12 deficiency and chemotherapy administration. This diagnosis 
would not have been elucidated without vitamin B12 blood pathology tests.  
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This case report indicates that chemotherapy administration can lower vitamin B12 status in certain 
patients and this may predispose them to the development of peripheral neuropathy, possibly of a 
severe nature. The development of peripheral neuropathy would then be from both a vitamin B12 
deficiency and the neurotoxic chemotherapy administration. The extent of the peripheral neuropathy 
from the chemotherapy agent cannot be ascertained until the patient’s vitamin B12 status has been 
resurrected into a normal range.  
The clinical relevance of this is very important as vitamin B12 is not a common pathology test 
conducted in patients presenting with CIPN.  
A vitamin B12 deficiency is medically acknowledged for causing peripheral neuropathy and has been 
identified as a potential risk factor for the development of CIPN in differential diagnosis tables [12]. 
The questions still to be answered are how and when should testing of vitamin B12 be conducted and 
when to intervene with treatment of vitamin B12. One limitation for cancer patients is the taste and 
smell of taking an oral B vitamin complex. Therefore, for some patients, taking a prophylactic oral 
vitamin B complex is not an option for them during chemotherapy. Intramuscular vitamin B12 
injections maybe the only option for certain patients who cannot tolerate a dose of an oral vitamin 
B12, or a B vitamin complex supplement.  
A further case report is documented below of a participant who was found deficient of vitamin B12 
before chemotherapy administration. The subject was followed throughout chemotherapy and or 
three-months’ post-chemotherapy treatment. Another perspective on the clinical relevance of vitamin 
B12 pathology testing for cancer patient is discussed. 
 
8.3 PA011 GMB - CASE REPORT 2 
The participant PA011 GMB was excluded from the clinical trial due to his baseline blood pathology 
results indicating 15 pmol/L (ref >35) for Holo TC. The participant was asked to consent to being 
followed throughout the chemotherapy regime and three-months’ post-chemotherapy. Consent was 
given and the results for this participant are documented below in 8.3.1, Table 8-15.  
 
8.3.1 PA011 GMB Details and Results 
PA011 GMB at recruitment had just been retrenched, so was unemployed at presentation at the 
hospital. The subject had recently separated and had two children under his care. Apart from the 
lymphoma, the patient was generally healthy. 
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Table 8-15: PA011 GMB Medical Details and Results 
PA011 GMB Details and Results 
DOB 07/06/1968 
Diagnosed Non-Hodgkin’s B-Cell Lymphoma in February, 2012 
Surgery PA Hospital:  Feb 2012 – lymphoma lump under right arm 
Previous surgery:  Ear to increase hearing (4 yo), twisted testicle (26 yo), 
car accident (9 yo) for related injuries and prescribed dilantin and tegretol 
for 6 years 
Recruited for study 03/02/2012 
Race Caucasian 
Gender Male 
Marital Status Separated 
Other medical 
considerations 
Mild asthma, borderline diabetes, glandular fever (EBV) 
Medications Panadol occasionally and an asthma puffer rarely 
Allergies Bee sting 
Diet history No history of being a vegan or vegetarian. Normally consumes red meat 
(beef, lamb, kangaroo) 3-4 times a week, chicken or pork 2-3 times a week 
and fish or seafood rarely. He does drink caffeine, approximately one cup 
a day, and doesn’t drink alcohol, smoke and or take recreational drugs. 
Height 187 cm 
Weight 117 kg 
BMI 33.5 
Chemotherapy 
regime 
R-CHOP every three weeks for 6 cycles. (Cylophosphamide, vincristine, 
doxorubicin, prednisone, rituximab)  
 
8.3.2 Blood Pathology Results for PA011 GMB 
On the receipt of PA011 GMB’s baseline blood results as seen in Table 8-16, the haematologist team 
at the PA hospital, Brisbane were informed of his results, noting his low Holo TC levels. An IM 
vitamin B12 injection (1,000 mg) was prescribed. After three cycles of chemotherapy, PA011 GMB 
organised further injections of vitamin B12 (three in total of 1,000 mg of vitamin B12 each) with the 
local general practitioner (GP). The blood taken from this patient for analysis of B vitamins after the 
cessation of chemotherapy was one week after a vitamin B12 injection. This information was 
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discovered by the researchers after the subject had the blood taken. The last blood test was taken 2 
weeks after receiving another vitamin B12 injection from the GP. 
 
Table 8-16: PA011 GMB Vitamin B Blood Pathology Results 
Blood Pathology Baseline 
03/02/2012 
After 
Chemo 
17/05/2012 
Last follow up 
19/10/2012 
Ref Range 
Vitamin B1 (TDP) 220 H 160 220 H 66-200 nmol/L 
Vitamin B2 (FAD) 340 240 290 180-470 nmol/L 
Vitamin B6 (P5P) 70 85 85 35-110 nmol/L 
Red cell folate 1430 2502 1808 >900 nmol/L 
Holo TC (Vitamin 
B12) 
15 L >128 88 >35 pmol/L 
 
8.3.3 Neurological Testing Results for PA011 GMB 
8.3.3.1 Total Neuropathy Score (TNS) 
PA011 GMB’s results shown in Table 8-17, indicates no peripheral neuropathy at baseline before 
chemotherapy administration, although the patient presented with sweating due to lymphoma. Testing 
post-chemotherapy regime, PA011 GMB presented with mild CIPN, with motor nerve function worse 
than sensory. PA011 GMB experienced a delayed CIPN as the follow-up neurology test conducted 
three-months’ post-chemotherapy cessation found severe (Level 4) sensory neuropathy. Level 4 
sensory peripheral neuropathy means numbness, tingling and/or pain above knees and elbows and is 
functionally debilitating. The sural nerve and tendon reflexes had decreased at three-months’ follow-
up, however pin sensibility improved. The pinprick test is for small nerve function therefore, 
indicating the severe sensory neuropathy diagnosed was due to large nerve damage rather than small 
nerve. 
A vitamin B12 deficiency damages large nerve fibres [12] therefore, it could be postulated that the 
patient’s vitamin B12 deficiency found at baseline may have previously damaged the large nerve 
fibres which the neurotoxic chemotherapy agent further affected. 
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Table 8-17: PA011 GMB TNS Scores 
Total Neuropathy Score (TNS) 
Item Baseline Score 
04/02/2012 
After 
Chemotherapy 
02/06/2012 
Three months later 
08/09/2012 
 
Sensory symptoms 0 1 4 
Motor symptoms 0 2 1 
Autonomic symptoms 2 (sweating from 
lymphoma) 
3 2 
Pin sensibility 0 1 0 
Vibration sensibility 0 2 1 
Strength 0 0 0 
Tendon reflexes 0 4 4 
Sural amplitude score 0 0 4 
Peroneal amplitude score 0 0 0 
Total 2 13 16 
 
8.3.3.2 Neurological Conduction Studies (NCS) 
The NCS for PA011 GMB indicates that the patient did experience nerve damage, particularly 
sensory after chemotherapy administration. The wrist and sural nerve showed nerve damage after 
chemotherapy, particularly the sural nerve, which was unable to be detected three-months after 
chemotherapy. The peroneal nerve also showed nerve damage three-months’ post-chemotherapy 
administration. Both the sural and peroneal nerve damage indicates delayed neuropathy from the 
vincristine. For motor function, the tibial nerve in the ankle showed nerve damage after chemotherapy 
but was restored to normal function after three months. The patient’s median nerve function seems to 
have been damaged or has low function before chemotherapy on the right hand and then on the left 
hand after chemotherapy. As the left hand was not tested prior to chemotherapy, it may not have been 
functioning ideally before chemotherapy. Overall, the patient does display nerve damage from 
chemotherapy, therefore has CIPN, particularly delayed peripheral neuropathy.  
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Table 8-18: PA011 GMB Nerve Conduction Study Results 
Sensory NCS 
Nerve/Sites Rec Site Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak Ampl 
µV 
 04/02/2012 02/06/2012 08/09/2012 
R MEDIAN  
   Palm 
III     1.75 8.8 
L MEDIAN 
    Palm 
III     1.70 5.8 
R ULNAR –  
    Wrist 
Dorsum of 
Hand 
    7.30 6.8 
R RADIALIS 
   Wrist 
 1.74 30.4     
L RADIALIS 
   Wrist 
Thumb   1.88 18.6 2.05 14.9 
L SURAL –  
    Calf 
Lat 
Malleolus 
2.42 11.0 3.32 11.8 absent  
R SURAL =  
     Calf 
Lat 
Malleolus 
3.00 10.9 3.29 11.3 absent  
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Motor NCS 
Nerve/Sites 
Rec Site 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak Ampl 
µV 
 04/02/2012 02/06/2012 08/09/2012 
R MEDIAN – APB 
    Wrist 
3.5 8.1     
    Elbow 7.52 6.5     
L MEDIAN – APB 
    Wrist 
  3.65 8.8   
L RADIAL – EIP 
  Forearm 
    3.95 7.7 
    Elbow     9.50 7.1 
R COMM PERONEAL – 
EDB 
     Ankle 
5.66 2.5   6.35 3.7 
     Bl knee-ankle 14.5 0.014   14.60 3.3 
L COMM PERONEAL – 
EDB 
     Ankle 
5.37 3.5 4.58 4.4 5.25 3.7 
     Fib Head     13.10 3.9 
R TIBIAL (KNEE) – AH 
     Ankle 
5.88 8.6 6.08 5.4 4.95 3.6 
L TIBIAL (KNEE) – AH 
     Ankle 
3.89 8.2 6.48 4.9 4.15 4.4 
 
8.3.4 Patient Neurotoxicity Questionnaire for PA011 GMB Results 
This is a linear scale and indicates the level of CIPN that the patient has experienced in the past week. 
The results are presented in Table 8-19. 
On the 19/04/12 PA011 GMB was diagnosed with grade 2 CIPN from the haematologist oncologist. 
The patient stated that their fingers felt burnt and were numb. The numbness was present in all fingers 
but not the palm of the hand and minimal sensation was present in the toes. The patient also 
experienced difficulty swallowing, buttoning clothes, picking up objects such as a wallet, was unable 
to work and had shortness of breath.  
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On the 08/09/2012 PA011 GMB was still experiencing CIPN, however in the patient’s opinion it was 
not as bad and located mainly in the fingers. The subject also stated that the feet felt different, which 
was affecting daily activity. The patient was still having difficulty with swallowing, experienced 
asthma and had shortness of breath in addition to anxiety. The neurologist’s examination diagnosed 
level 4 sensory neuropathy at three months’ post-chemotherapy administration, therefore a delayed 
CIPN had occurred (level 1 sensory neuropathy after chemotherapy). From the patient’s perspective, 
the CIPN was worse straight after chemotherapy in the PNQ (3/4) compared to three months’ post-
chemotherapy administration (1/4) which is completely opposite to the neurologist’s examinations.  
The difference between clinical examination and patient’s perspective highlights the importance of 
incorporating both aspects in examination and diagnosis of CIPN. The main confounder for 
chemotherapy patient’s perspective is their general feeling of well-being during and straight after 
chemotherapy administration versus three months’ post-chemotherapy. How the patient feels may 
influence their perspective of CIPN at the time of questioning. Therefore, the examination from an 
independent neurologist is important for an unbiased, quantitative medical diagnosis.   
 
Table 8-19: PA011 GMB Patient Neurotoxicity Questionnaire Results 
Items    
 04/02/12 19/04/12 08/09/2012 
Numbness, Pain, burning or tingling 1/4 (lymphoma under arm) 3/4 1/4 
Weakness in arms and legs 0/4 3/4 2/4 
Difficulty with daily activities 0/4 2/4 1/4 
 
8.3.5 Discussion on PA011 GMB 
PA011 GMB was excluded from the B vitamin clinical trial due to baseline blood vitamin B12 levels 
being below the reference range (15 pmol/L ref >35). The baseline neurology test indicated no signs 
of peripheral neuropathy even from a vitamin B12 deficiency. After administration of an IM vitamin 
B12 (1,000 µg), PA011 GMB consented to being followed throughout chemotherapy and post-
chemotherapy. Throughout the patient’s chemotherapy regimen, grade 2 CIPN developed mainly 
sensory neuropathy in fingers and toes. Half way through the chemotherapy regime, further IM 
vitamin B12 injections from his GP were administered. The researchers were unable to obtain an 
accurate list of how many IM vitamin B12 injections he had administered, other than the patient’s 
recollection of monthly injections for 3 months.  
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Immediately after chemotherapy cessation, PA011 GMB’s vitamin B12 level was at the highest 
recorded level (>128 in ref range >35) and the neurology test and patient’s perspective (although 
worse 3/4) indicated grade 2 CIPN. Three-months’ post-chemotherapy cessation, PA011 GMB’s 
blood test indicated the vitamin B12 level was in range (88 in ref range >35) however the neurology 
test from the neurologist identified a delayed severe sensory peripheral neuropathy, level 4.  
Results on record suggest that due to the subject’s vitamin B12 deficiency at baseline, the liver stores 
of vitamin B12 may have been depleted leaving no body reserves of vitamin B12. Chemotherapy can 
cause a temporary deficiency of vitamin B12 [62], which may have predisposed this patient to the 
development of CIPN. Alternatively, the patient’s large nerve fibres may have been damaged by the 
vitamin B12 deficiency prior to chemotherapy administration, although no peripheral neuropathy was 
present at baseline from the neurologist’s examination. The administration of neurotoxic 
chemotherapy may have caused further damage thereby increasing the development of CIPN. The 
vitamin B12 administered IM may not have been adequate in amount to repair the large nerve damage 
already present from the vitamin B12 deficiency before the neurotoxic chemotherapy agent 
(vincristine) was administered.  
The delayed severe sensory peripheral neuropathy may or may not be attributed to the patient’s 
vitamin B12 deficiency as PA011 GMB’s vitamin B12 level was in range. A delayed CIPN can occur 
with neurotoxic agents and this may be the case for PA011 GMB.  
Another participant PA002 KLB was not followed, nor had consented to being followed; however, 
from discussions with the cancer care coordinator and checking the patient’s hospital chart, the 
original chemotherapy regimen was down-graded from Hyper CVAD to R-CHOP due severe CIPN. 
Due to no consent, exact details cannot be obtained, therefore these results cannot be substantiated. 
 
8.4 PA016 GDT – CASE REPORT THREE 
8.4.1 PA016 GDT Details and Results 
PA016 GDT was a breast cancer patient diagnosed with invasive ductal carcinoma (IDC) and was 
triple positive (oestrogen, progesterone and HER2 positive). The patient underwent a chemotherapy 
regimen, AC-DT given every three weeks. PA016 GDT was administered four cycles of AC 
(Adriamycin and cyclophosphamide) and then four cycles of DT (docetaxel and Herceptin). The 
Herceptin was administered for a year. The patient was randomised to the B vitamin group.  
PA016 GDT had documented no CIPN during the chemotherapy regime. After the last administration 
of DT, the patient became very nauseous and was bed ridden for one week. In that week, the subject 
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was unable to take the clinical trial capsules and developed moderate CIPN. The CIPN did not 
dissipate after commencing the capsules again. The patient’s bloods and TNS scores are documented 
below in Table 8-20. 
Table 8-20: PA016 GDT Test Results 
 Vitamin  
B12 
Total TNS Vitamin 
B1 
Vitamin 
B2 
Vitamin 
B6 
Folate 
Baseline >128 6 180 380 300 1820 
After chemo >128 11 170 300 530 2790 
3 months follow up  12     
 
PA016 GDT’s vitamin B12 levels were at the maximum range both at baseline and after 
chemotherapy. The neuropathy, particularly sensory, was worse after chemotherapy and this 
continued at the three-months follow up. This case report has clinical relevance as CIPN development 
did not occur throughout the patient’s chemotherapy regimen until the B vitamin capsules were not 
taken for a week post last chemotherapy administration. Taking into consideration that her vitamin 
B12 level was at the maximum level pre and post-chemotherapy, the CIPN development may not be 
due to a decrease in vitamin B12. Therefore, it may be a consequence of a temporary decrease of 
other B vitamins or a change in vitamn B serum saturation. One B vitamin that has shown marked 
decrease and increase in blood levels as expressed in the absorption/interaction study is vitamin B6. 
In saying this, the patient’s vitamin B6 blood status was above reference range before and after 
chemotherapy.  
CIPN’s mechanism of action from the chemotherapy agents are still unknown however, it is known 
that it is an accumulation side effect [10]. It is possible that the patient’s development of CIPN was 
simply an accumulation of the chemotherapy agent. Therefore, vitamin B12 may only play a part in 
the development of CIPN for certain patients.  
 
8.5 DISCUSSION 
The main case report, PA032 PMP who was found deficient in vitamin B12 post-chemotherapy 
administration exemplifies that vitamin B12 status may be lowered to a point of deficiency during 
chemotherapy in certain individuals. This vitamin B12 deficiency may present itself as peripheral 
neuropathy and in conjunction with neurotoxic chemotherapy administration may be seen as severe 
CIPN when in fact it is partly due to a vitamin B12 deficiency. 
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This is clinically relevant as patients undergoing chemotherapy with neurotoxic agents who develop 
severe CIPN may be deficient in vitamin B12. If patients presenting with moderate to severe CIPN 
are found to be deficient in vitamin B12, it is possible that some of the severe neuropathy would be 
alleviated by the administration of vitamin B12. This is important for the patient as it decreases pain, 
discomfort, increases their physical ability to do daily activities and aids their quality of life.  
The second case study, PA011 GMB illustrated that a person deficient in vitamin B12 prior to 
chemotherapy administration can still develop CIPN, despite vitamin B12 administration 
intramuscularly. This may be due to the large nerves being damaged by the B12 deficiency and the 
neurotoxic chemotherapy agent, then accumulating and causing further damage that leads to CIPN 
establishment. Further research is required to substantiate this finding.   
The last case report illustrates that vitamin B12 may not be the only B vitamin that could be connected 
with the development of CIPN. It is possible that vitamin B6 may play more of a major role than 
previously thought. A journal article describing four children with vincristine induced peripheral 
neuropathy were treated with vitamin B6 and pyridostigmine with beneficial results [124]. An in vitro 
study with vitamin B6 and oxaliplatin demonstrated that vitamin B6 may protect cells from 
oxaliplatin-induced peripheral neuropathy without interfering with anti-tumour activity [17]. Further 
research is required, but the changes seen in vitamin B6 levels after the administration of 
chemotherapy as seen in chapter 6 (page 149-150) and the rise that occurs after 72 hours with 
supplementation of 40 mg of vitamin B6 is important to consider. Whether or not vitamin B6 actually 
provides a protection to nerve cells still needs to be elucidated.  
 
8.6 CONCLUSION 
Vitamin status, in particular vitamin B12, can play a role in the development of CIPN in certain 
patients. Patients experiencing moderate to severe CIPN should have their vitamin B12 levels 
pathologically tested and if serum vitamin B12 levels are found below 200 pmol/L or holo TC is 
below 35 pmol/L, then vitamin B12 should be administered. This can be achieved intramuscularly 
and orally for the duration of the chemotherapy administration and post-chemotherapy for a period 
of approximately three months, depending on the patient’s tolerance for oral supplementation.  
A protection from B vitamins, especially vitamin B12 and vitamin B6 may occur for CIPN 
development. Oral supplementation with a B complex may assist some patients is with the 
development of CIPN. This is the easiest method of administration, however, not all patients can 
tolerate the smell of the vitamin B capsule or they may struggle with the ingestion of the supplement. 
Also the pungent smell of their urine from the B vitamin supplementation is off putting for some 
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patients and may increase their feeling of being nauseous. As an alternative, intramuscular 
administration of vitamin B12 may be more appropriate for certain patients.   
Monitoring of vitamin B12 levels may also be implemented so early intervention with B12 
administration can occur before the patient is deficient. This could be through adding serum vitamin 
B12 to the blood pathology request forms for patients undergoing chemotherapy with neurotoxic 
agents before chemotherapy administration and on presentation of CIPN.  
These case reports outline the importance that vitamin B12 may play in CIPN development and the 
clinical relevance for medical practitioners.  
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9 CHAPTER 9 – DISCUSSION 
9.1 GENERAL DISCUSSION 
 
The study upon which this thesis was based assessed a posit that the administration of an oral B 
vitamin complex formulation could prevent CIPN when vincristine and the taxane class neurotoxic 
compounds were administered to patients diagnosed with a cancer. Oxaliplatin assessment was ceased 
due to poor recruitment. The primary outcome of the TNS showed that B vitamins did not statistically 
decrease the incidence of CIPN (p=0.22; t score=1.24). There was however, a trend toward a 
beneficial effect of B vitamins decreasing the onset and severity of CIPN. The patient’s perception 
that sensory peripheral neuropathy was decreased by B vitamins was statistically significant (12 
weeks p=0.03; 24 weeks p=0.005; 36 weeks p=0.021). The risk estimate for patient’s perception of 
sensory neuropathy was also statistically significant for both after chemotherapy cessation and at 
three-months follow up (OR=5.78, 95% CI = [1.63-20.5] and 36 weeks OR=.8.1, 95% CI=[1.23-
53.2]). 
Oncologists are aware that CIPN is a common and debilitating side effect from a variety of neurotoxic 
chemotherapy agents. Moreover, there is awareness of the negative impact CIPN may have on 
patients who are administered chemotherapy.   Important issues to patients and clinicians alike include 
treatment outcomes, quality of life and psychological wellbeing. To alleviate this debilitating side 
effect, a number of different agents have been prescribed by clinicians, or have been independently 
tried by patients, despite the availability of limited research for some of these interventions such as 
calcium and magnesium infusions, pregablin and gabapentin [249].  
The results from the clinical study demonstrated that participants inducted into the clinical trial and 
allocated to the B complex vitamin arm that developed CIPN, could not reverse the peripheral 
neuropathy with continued B complex vitamin supplementation.  In addition, B complex vitamin 
supplementation did not protect against small nerve damage or reflex loss.  Blood pathology results 
showed that B complex vitamin status increased (i.e., Vitamin B1, B6, B12 and folate) with 
supplementation except for vitamin B2. This data was not associated with CIPN prevention when 
correlated to the TNS results. A high blood level of vitamin B6 was detected in four participants 
(10.5%) who also had developed mild CIPN (as assessed by the independent neurologist through the 
TNS and nerve conduction studies). A statistically significant increase (p=0.001) in blood vitamin B6 
levels were found that indicated a good response to supplementation. This result though, warrants 
further research to establish whether an increased risk or protection relationship exists for B6 and 
CIPN. 
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The pilot study that assessed the absorption and interaction of B complex vitamin administration 
during chemotherapy, demonstrated that vincristine, docetaxel and oxaliplatin may induce a 
temporary decrease in vitamins B1, B2, B6 and B12 in patients receiving a B complex vitamin 
formulation.   
The projection of pain interference observed afforded to those participants administered a vitamin B 
complex supplement experienced significantly (p<0.05) less pain interference with daily activity 
compared to the subjects who were administered a placebo. No other differences were seen for quality 
of life or pain.  
When considering different cancer types, no benefit was found for breast cancer patients.  However, 
a possible sensory neuropathy benefit was found for lymphoma patients undergoing R-CHOP for 
eight cycles’ three weekly and lung cancer patients undergoing paclitaxel and carboplatin weekly. 
Furthermore, B complex vitamin supplementation did not protect patients with diabetes from the 
development of CIPN.  
The individual case study on PA032 PMP showed that patients that are deficient in vitamin B12 after 
chemotherapy cessation may present with moderate to severe CIPN. This adverse clinical outcome is 
due to the administration of neurotoxic chemotherapy as well as a B12 deficiency, which can also 
present as peripheral neuropathy. Therefore, monitoring a patient’s vitamin B12 levels throughout 
chemotherapy may assist clinicians in preventing moderate to severe development of CIPN that can 
progress from a vitamin B12 deficiency.  
Supplementation with an oral B vitamin may not be appropriate for certain patients due to difficulties 
in swallowing the capsules and/or the odour of the urine from the B vitamin excretion. When patients 
that are administered emetogenic chemotherapy regimens, unpleasant odours such as those produced 
by B vitamins may trigger further unpleasant behaviour that possibly can exacerbate chemotherapy-
induced nausea and vomiting. Therefore, the administration of intramuscular vitamin B12 would be 
the prudent option for patients undergoing chemotherapy and who have been also diagnosed with a 
blood vitamin B12 deficiency.  
If patients present with a blood vitamin B12 deficiency prior to chemotherapy administration, 
continual intramuscular injections of vitamin B12 may need to be administered throughout the 
chemotherapy cycles. Consensus of the how often an IM B12 should be administered requires further 
verification. In a study conducted in 2003 [174] it was suggested that daily IM administrations for 10 
days with a dose of 1,000 mcg, then weekly for four weeks and finally monthly was efficacious in 
maintaining blood B12 levels in those individuals diagnosed with low blood B12 levels. Such B12 
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dosing regimens could be adopted for patients with pathology verified blood B12 deficiencies prior 
to the administration of chemotherapy and post completion of treatment. 
An additional study that compared IM vitamin B12 to oral vitamin B12 supplementation reported that 
IM vitamin B12 given on study days 1, 3, 7, 10, 14, 21, 30, 60 and 90 was effective in restoring 
normal levels of serum cobalamin in all patients by 100% [406]. This study also provided evidence 
that a B12 supplementation regimen could be implemented for patients who are vitamin B12 deficient 
prior to chemotherapy administration throughout their entire chemotherapy cycles and three to six 
months’ post-treatment follow-up.  
It is important to note that further controlled studies are required to confirm the best vitamin B12 
administration for patients found to be deficient in blood vitamin B12 prior to and post-chemotherapy 
administration.  
9.2 CONCLUSION 
 
B vitamin supplementation throughout chemotherapy administration with neurotoxic agents was not 
superior to placebo (p>0.05) for the prevention of CIPN. Patient perception of reduced sensory 
peripheral neuropathy with B vitamin supplementation over placebo was statistically significant. 
Although not significant, a trend was observed for the prevention of the onset and severity of CIPN 
throughout chemotherapy and three-months’ post-chemotherapy cessation with B vitamins 
supplementation over placebo.. Patients with moderate to severe CIPN may have a vitamin B12 
deficiency that may lead to a worse symptomatic presentation. Monitoring of blood vitamin B12 
throughout chemotherapy administration may prove to be a prudent assessment in order to prevent 
the development of moderate to severe CIPN due to neurotoxic chemotherapy agents and a blood 
vitamin B12 deficiency.  
 
9.3 LIMITATIONS OF STUDY 
 
There were a number of limitations identified both during and after the completion of the study. 
These included:  
1. Number of participants recruited: As stated earlier, the aim of the main clinical trial was to 
obtain ninety participants plus fifty per cent attrition rate, equating to one hundred and thirty-
five participants. This was verified after completing a power analysis for sample size. Due to 
time of recruitment, the main clinical study was stopped following the recruitment of seventy-
one patients. Difficulty in recruitment and participant drop-out lowered the number of 
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participants recruited for the trial and consequently lowered the power of the study and 
affected achieving statistical significance for the primary outcome.  
2. Number of agents assessed: The majority of the clinical trials that have assessed CIPN have 
focused on one chemotherapy agent, to increase the statistical power of the study and the 
mechanism of action of that drug. However, due to the time required to complete this study, 
it was considered that including a variety of chemotherapy agents would increase the number 
of participants recruited and would allow for completion of the study. This was the case when 
the type of cancer and chemotherapy agents were separated from the combined results. 
However, in retrospect, this made the interpretation of the data difficult due to the fact that 
each chemotherapy agent has a different mechanism of action and each type of cancer has a 
variety of confounding factors.  
3. Assessment tools for CIPN: The assessment tools used for diagnosing CIPN as mentioned is 
a major limitation in all CIPN trials, as no one assessment tool is used consistently throughout 
all studies. There is no ‘Gold Standard’ assessment tool which makes it difficult to compare 
results to other studies completed. The TNS which was used as the primary outcome is both 
subjective and qualitative. The subjective nature of some of the criteria limits the quality of 
results from this assessment tool. However, the major benefit for this clinical study was the 
participation of only one neurologist who volunteered to assess all participants inducted into 
the study. Therefore, consistency was partly achieved by having an independent neurologist, 
blinded to treatment allocation assessing all patients at each time point. Extra neurological 
examinations were conducted to guarantee results.  
4. Interaction/absorption trial. The pilot clinical trial investigating blood B vitamin status after 
chemotherapy administration had several limitations. It may have been more judicious to have 
focussed on one chemotherapy agent only.   
5. Backwards power analysis: Re-analysis of the data calculating a backwards power calculation 
to assess the power of the completed study may assist in identifying statistical significant 
differences. 
6. Multiple statistical comparisons: A multiple statistical comparison was not completed and it 
would have allowed for statistical significant results by play of chance.  
9.4 CONTRIBUTIONS TO CURRENT KNOWLEDGE 
 
There are a number of provisions to current knowledge that this thesis has contributed. 1) This is the 
first clinical trial of its kind conducted to assess the efficacy of B complex vitamins administration 
for the prevention of CIPN.  2) Investigating different agents for the prevention of CIPN has been 
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identified, as a much needed area of research. 3) Although a not statistically significant result was 
reported for B complex vitamins over placebo, a trend in favour of the B complex formulation was 
achieved. This indicated that the study may have been under-powered. Therefore, supplementing with 
a B complex vitamin was found safe to use during chemotherapy with possible benefits in the 
prevention of CIPN. The patient’s perception of taking a B vitamin supplement was statistically 
significant in decreasing sensory CIPN. Hence, as no research to date has trialled a B group vitamin 
during chemotherapy, these results add to the current knowledge base on CIPN.  In addition, this 
study adds to research on vitamin interactions with chemotherapy administration.  
No research on blood B vitamin status and chemotherapy agents have been conducted since 1993 
where Vu et al. [62] looked at cancer patient’s blood vitamin B12 status during and after 
chemotherapy and radiation treatment. The absorption and interaction pilot trial and the main clinical 
trial’s blood pathology analysis was the first research conducted on vitamin B1, B2, B6, folate and 
vitamin B12. Although only a very small pilot trial, it provides insight into the fact that chemotherapy 
agent’s vincristine, docetaxel and oxaliplatin may decrease vitamin B1, B2, B6 and B12 in patients 
taking a B vitamin supplement within twenty-four hours of chemotherapy administration. The results 
of the main clinical trial indicated that a slight decrease in vitamin B1, B2, B6, folate and B12 were 
found post-chemotherapy in the placebo arm. Therefore, certain chemotherapy agents may potentially 
reduce B vitamin status in patients during and post-chemotherapy. 
One of the main contributions to current knowledge is the potential for patients with moderate to 
severe CIPN to be vitamin B12 deficient after chemotherapy administration. A deficiency in vitamin 
B12 may attribute to the presentation of moderate to severe CIPN. In patients with a vitamin B12 
deficiency, B12 supplementation or intramuscular injections of vitamin B12 may assist in decreasing 
the severity of their CIPN. Therefore, a patient who is found vitamin B12 deficient after 
chemotherapy may reduce their CIPN presentation from moderate to severe too mild with vitamin 
B12 administration. Currently, patients presenting with moderate to severe CIPN during treatment 
have their neurotoxic chemotherapy decreased or ceased. Pathology testing for vitamin B12 is not a 
traditional test that is conducted by oncologists on presentation of moderate to severe CIPN and the 
patient is treated for the CIPN with limited success in most cases.  
Further research on vitamin B12 status and CIPN development is required to identify trends in clinical 
presentation, and treatment predictors of a vitamin B12 deficiency that may develop during 
chemotherapy.  
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9.5 FURTHER RECOMMENDATIONS 
 
From the pilot trial conducted in this thesis, a number of further recommendations and future trials 
can be recommended. Firstly, the NMR and mass spectrometry analysis needs to be conducted to 
ascertain the results from the samples stored. As the NMR gives a wide spectrum analysis any peaks 
will be analysed to see if they correlate with B vitamin supplementation and CIPN development.  
Depending on results found in the NMR analyses, further research into vitamin B6 and its role in 
peripheral neuropathy and CIPN development or prevention is recommended. Further in vivo 
pathology tests on patients undergoing chemotherapy and their vitamin B6 status with or without 
supplementation in combination with neurological examination needs to occur. A focus on oxaliplatin 
and vitamin B6 supplementation looking at a dose range study and CIPN development would be of 
benefit.  
Introducing regular pathological testing of vitamin B12 for patients undergoing chemotherapy is 
recommended as prevention is better than treatment for CIPN. It is recommended that hospitals and 
clinicians set a protocol of incorporating testing vitamin B12 before each chemotherapy 
administration for all patients undergoing treatment. Therefore, a patient whose blood pathology is 
indicating a low vitamin B12 status can be administered vitamin B12 early preventing a vitamin B12 
deficiency in addition to decreasing the onset and severity of CIPN development.  
Lastly, several future trials are recommended incorporating statistically significant results from other 
agents: 
1. A pilot trial assessing B vitamins and omega 3-fatty acids for decreasing the incidence of 
taxane-induced peripheral neuropathy.  
2. A safety and efficacy trial assessing the dose range of vitamin B6 for oxaliplatin-induced 
peripheral neuropathy.  
3. A pilot trial assessing vitamin B12, B6 and omega 3-fatty acids for vincristine-induced 
peripheral neuropathy.  
4. In vitro work on Schwann cell cultures and the impact of inflammation on CIPN 
development. 
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9.6 FINAL STATEMENT 
 
The study upon which the research of this thesis was based reports that vitamin B 
complexadministration did not demonstrate efficacy (p>0.05) for reducing the total incidence of 
CIPN development for those patients administered neurotoxic compounds such as the taxanes and 
vincristine.  Notwithstanding, a trend was observed for vitamin B complex administration decreasing 
the onset and severity of CIPN development.  Moreover, patients administered a vitamin B complex 
supplement reported a reduced onset, severity and incidence of sensory peripheral neuropathy 
(p<0.05). 
One case study found that a deficiency in vitamin B12 during or after chemotherapy may also be a 
contributing factor for moderate to severe CIPN presentation in patients. Further research is warranted 
however, a prudent investigation prior to commencing chemotherapy administration may be to 
request a pathology blood test for vitamin B12.  
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11 APPENDICES 
11.1 APPENDIX 1. MOLECULAR WEIGHT AND BI-PRODUCTS OF B VITAMINS AND 
CHEMOTHERAPY AGENTS 
 
Molecule Molecular Weight  
(g mol-1) 
Pharmacology 
Chemotherapy Agents 
Oxaliplatin 397.301,7 Chemical name: oxalato(transl- 
1,2- diaminocyclohexane)7 
Pharmacology: dichloro(dach) is the active component.7  
There is no evidence of cytochrome P450-mediated 
metabolism in vitro. Up to 17 platinum-containing 
derivatives have been observed in plasma ultra-filtrate 
samples from patients, including several cytotoxic species 
e.g. monochloro DACH platinum, dichloro DACH 
platinum, and monoaquo and diaquo DACH platinum in 
addition to a number of noncytotoxic, conjugated species.1 
Paclitaxol 853.901 Chemical name: Paclitaxol1 
Pharmacology: Placlitaxol represents about 5% in faeces, 
however, it is metabolised in the liver by the cytochrome 
P450 isozymes CYP2C8 and CYP3A4 primarily to 
metabolites 6α-hydroxypaclitaxel with minor metabolites, 
3'-p-hydroxypaclitaxel and 6α, 3'-p-dihydroxypaclitaxel.1 
Vincristine 923.041 Chemical name: Vincristine sulfate 
Pharmacology: It has been found to be primarily 
metabolised by hepatic cytochrome P450 isoenzymes in 
the CYP 3A subfamily. Within 15-30 minutes after 
injection 90% of vincristine is distributed into tissues from 
the blood. Excretion is primarily through faeces 80% with 
10%-20% in urine. No metabolities have been named.1 
B Vitamins 
Vitamin B1 300.843 Chemical name: Thiamine8 
Pharmacology: Combines with adenosine triphosphate 
(ATP) for form thiamine pyrophosphate (TPP) and 
thiamine triphosphate (TTP)8 
 
Vitamin B2 376.402 Chemical name: Riboflavin8 
Pharmacology: Phosphorylated to flavin mononucleotide 
(FMN) in gastrointestinal mucosal cells, erythrocytes and 
the liver. FMN is than converted to flavin adenine 
dinucleotide (FAD) which are primarily protein bound.8 
Vitamin B3 122.133 Names:  Niacin, Nicotinamide, Nicotinic acid9 
Chemical name: Pyridine-3-Carboxyamide3 
Pharmacology:  Major metabolite NAD++ (nicotinamide 
adenine dinucleotide.3 Other metabolites include NADH, 
NADP and NADPH.6 
Vitamin B5 476.543 Chemical name: Pantothenic acid 
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Pharmacology:  Converted to major metabolites include 
CoA and 4’-phosphopantetheine. 9 
Vitamin B6 205.643 Chemical name: Pyridoxine, pyridoxal, pyridoxamine 
Pharmacology: Phosphorylated to pyridoxine phosphate, 
pyridoxal phosphate and pyridoxamine phosphate. In the 
liver they are than converted to pyridoxal phosphate 
(PLP). Excreted as pyridoxic acid.9 
Folate 441.406 Chemical name: Pteroylglutamate or 
pteroylmonoglutamate. Principal pteroylpolyglutamates 
components found in foods include 5-methyl 
tetrahydrofolate and 10-formyl tetrahydrofolate. 150 
different forms of folate have been reported.9 
Pharmacology: Within intestinal cells, folate is converted 
to dihydrofolate (DHF) and then tetrahydrofolate (THF). 
Folate is found in the blood as monoglutamate forms such 
as THF, 5-methy THF and 10-formyl THF plus other 
minor forms. 9 
Vitamin B12 1355.406 Chemical name: Cobalamin. Forms of vitamin B12 
include cyanocobalamin, hydroxocobalamin, 
aquocobalamin, nitritocobalamin, 5’-
deoxyadenosylcobalamin and methylcobalamin.9  
Pharmacology: In the blood, methylcobalamin comprises 
of about 60-80% and adenosylcobalamin around 20%. 
Other minor forms include cyanocobalamin and 
hydroxocobalamin.9  
Biotin 244.315 Chemical name: Biotin:  5-[(3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic 
acid.6,9 
Pharmacology: Biotin is found in plasma mostly in a free 
state with small amounts bound to proteins. Its activated 
form in the body is biotinyl adenosine monophosphate and 
pyrophosphate. This activated form is converted to 
Holocarboxylase synthetase which forms the basis for the 
four biotin-dependant enzymes which include pyruvate 
carboxylase, acetyl CoA carboxylase, propionyl CoA 
carboxylase and β-methylcrotonyl CoA carboxylase.9 
Choline 253.256 Chemical name: Choline 
Pharmacology: Choline can be found in the body as part 
of the neurotransmitter acetylcholine. It can also be found 
as the phospholipid phosphatidyl choline and 
spingomyelin.9 
Inositol 180.166 Chemical name: Cyclohexane-1,2,3,4,5,6-hexol6 
Pharmacology: Myo-inositol can be found in the body as 
structural basis for a number of secondary messengers 
such as inositol phosphates, phosphatidylinositol (PI) and 
phosphatidylinositol phosphate (PIP) lipids.6 
 
  
  
11-282 
 
 
References: 
1.  http://www.rxlist.com/script/main/hp.asp  
2.    http://www.druginfosys.com/index.aspx  
3.    http://www.greatvistachemicals.com/  
4. 
http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO
%7CBRAND_KEY&N4=C1629%7CSIGMA&N25=0&QS=ON&F=SPEC  
5.    http://www.chem.uwec.edu/Webpapers2001/barkacs/Pages/structure.html  
6.    http://en.wikipedia.org/wiki/Main_Page  
7. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr 
Oncol 2011 Jan:18(1):18-25 
8. http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-
%20Monographs/CPS-%20(General%20Monographs-%20V)/Vitamins  
9. Gropper S, Smith J, Groff J. Advanced Nutrition and Human Metabolism. 4th Edition. 
Thompson 2005 pp 191-192, 259-321 
 
  
11-283 
 
11.2 APPENDIX 2.  TOTAL NEUROPATHY SCORE (TNS) 
Item 0 1 2 3 4 Score 
Sensory symptoms 
(numbness, 
tingling, 
and neuropathic 
pain) 
None Limited to fingers 
or toes 
Extension to ankle 
or wrist 
Extension to knee 
or elbow 
Above knees or 
elbows 
or functionally 
disabling 
 
Motor symptoms None Slight difficulty Moderate difficulty Assistance required Paralysis  
Autonomic 
symptoms 
None One yes Two yes Three yes Four or five yes  
Pin sensibility Normal Reduced in fingers 
or toes 
Reduced to wrist or 
ankle 
Reduced to elbow 
or knee 
Reduced above elbow 
or knee 
 
Vibration 
sensibility 
Normal Reduced in fingers 
or toes 
Reduced to wrist or 
ankle 
Reduced to elbow 
or knee 
Reduced above elbow 
or knee 
 
Strength Normal Mild weakness Moderate weakness Severe weakness Paralysis  
Tendon reflexes Normal Ankle reflex 
reduced 
Ankle reflex absent Ankle reflex absent 
or others reduced 
All reflexes absent  
QST vibration 
threshold 
Normal to < 95 
percentile 
95–96 percentile 97 percentile 98 percentile > 99 percentile  
QST thermal 
threshold 
Normal to < 95 
percentile 
95–96 percentile 97 percentile 98 percentile > 99 percentile  
Sural amplitude 
score 
Normal or 
reduced < 5% 
76%–95% of LLN 51%–75% of LLN 26%–50% of LLN 0%–25% of LLN  
Peroneal 
amplitude 
Score 
Normal or 
reduced < 10% 
76%–95% of LLN 51%–75% of LLN 26%–50% of LLN 0%–25% of LLN  
Total   
LLN—lower limit of normal; QST—quantitative sensory testing 
Note. Based on information from Chaudhry et al., 1996, 2002. 
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11.3 APPENDIX 3.  PATIENT’S NEUROTOXICITY QUESTIONNAIRE – LONG VERSION (SHORT VERSION FOR PATIENT DIARIES DOES NOT INCLUDE 
ITEM 3.) 
In relation to chemotherapy induced peripheral neuropathy, indicate with a vertical line through the scales below (as shown on the example), the level 
of numbness, pain , tingling or weakness as indicated you have experienced over the PAST WEEK. 
Item 1:  Numbness, pain, burning or tingling in hands or feet and if this affects activities of daily living. 
 
l__________________________l__________________________l__________________________l__________________________l 
 
 
 
 
Item 2:   Weakness in arms and legs and if this interferes with activities of daily living. 
 
l__________________________l__________________________l__________________________l__________________________l 
 
 
 
 
 
 
Item 3:   Difficulty in swallowing, breathing, drinking or chewing food, or muscle spasms in my mouth/jaws, hands/fingers or feet/toes. 
 
l__________________________l__________________________l__________________________l__________________________l 
 
 
 
  
None Mild and no 
interference 
Moderate and no 
interference 
Moderate to 
severe and 
interference 
Severe and 
completely 
prevents you 
from doing 
activities 
None Mild and no 
interference 
Moderate and no 
interference 
Moderate to 
severe and 
interference 
Severe and 
completely 
prevents you 
from doing 
activities 
None Mild difficulty Moderate 
difficulty 
Moderate to 
severe difficulty 
Severe difficulty 
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If you have indicated a description that states ‘moderate to severe’ or ‘severe’ in one or more items above, please indicate by placing an X or 
writing in the space provided which activity or activities have been interfered with, as a result of therapy. 
  Button clothes      Use other eating utensils   Operate a remote control  
     
  Use a knife      Drive      Put on jewellery 
   
Use a fork      Fasten buckles    Knit 
   
Use a spoon      Sleep      Drinking liquids 
   
Swallowing      Climb stairs     Sew 
   
Open doors      Type on a keyboard    Work 
   
Zippers       Eating/chewing     Tie shoes 
   
Put in or remove contact lenses    Write      Shortness of breath 
   
Work or perform activities    Walk      Dial or use a telephone  
Of importance to me, specify 
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11.4 APPENDIX 4.  EORTC QUALITY OF LIFE QUESTIONNAIRE 
EORTC Quality of Life Questionnaire (QLQ)-C30 (version 3) 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number 
that best applies to you. There are no "right" or "wrong" answers. The information that you provide will remain strictly 
confidential 
_________________________________________________________________________________________________ 
  Not at       A        Quite    Very 
    All   Little          a Bit  Much 
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase?          1       2            3       4 
2. Do you have any trouble taking a long walk?          1       2            3       4 
3. Do you have any trouble taking a short walk outside of the house?           1       2            3       4 
4. Do you need to stay in bed or a chair during the day?         1       2            3       4 
5. Do you need help with eating, dressing, washing 
yourself or using the toilet?            1       2           3       4 
During the past week:       Not at      A         Quite   Very 
  All   Little         a Bit  Much 
6. Were you limited in doing either your work or other daily activities?       1       2            3       4 
7. Were you limited in pursuing your hobbies or other 
leisure time activities?             1       2            3       4 
8. Were you short of breath?            1      2           3       4 
9. Have you had pain?             1       2            3       4 
10. Did you need to rest?                 1      2            3       4 
11. Have you had trouble sleeping?           1       2            3       4 
12. Have you felt weak?             1       2            3       4 
13. Have you lacked appetite?            1       2            3       4 
14. Have you felt nauseated?            1       2            3       4 
15. Have you vomited?             1       2            3       4 
16. Have you been constipated?            1       2            3       4 
During the past week:       Not at       A         Quite    Very 
  All   Little          a Bit    Much 
 
17. Have you had diarrhoea?            1       2             3       4 
18. Were you tired?             1       2             3       4 
19. Did pain interfere with your daily activities?          1       2             3       4 
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television?           1       2             3       4 
21. Did you feel tense?             1       2             3       4 
22. Did you worry?             1       2             3       4 
23. Did you feel irritable?                   1      2             3       4 
24. Did you feel depressed?            1       2             3       4 
25. Have you had difficulty remembering things?          1       2             3       4 
26. Has your physical condition or medical treatment 
interfered with your family life?            1       2             3       4 
27. Has your physical condition or medical treatment 
interfered with your social activities?           1       2             3       4 
28. Has your physical condition or medical treatment 
caused you financial difficulties?            1       2             3       4 
 
For the following questions please circle the number between 1 and 7 that best applies to you 
29. How would you rate your overall health during the past week? 
1  2  3  4  5  6  7 
      Very poor             Excellent 
 
30. How would you rate your overall quality of life during the past week? 
1  2  3  4  5  6  7 
      Very poor              Excellent 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
Total Score: _____________ 
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11.5 APPENDIX 5. BRIEF PAIN INVENTORY 
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11.6 APPENDIX 6: ASSAYS USED BY SULLIVAN NICOLAIDES FOR B VITAMINS 
 
Test Principle for Sullivan Nicolaides Vitamin B1, B2, B6 Analysis 
 
1.1.1      Vitamin B11  
Traditionally, vitamin B1 status was measured using the erythrocyte transketolase test.  In that test, 
the formation of glyceraldehyde-3-phosphate by a TTP-dependent enzyme, transketolase, in 
haemolysed erythrocytes is taken as an index of patient’s thiamine store.  Although the test was 
indicative of only active vitamin (TPP), several interferences could result from certain disease 
conditions as well as interaction from thiamine-independent enzymes.   
The assay described in this procedure is a direct determination of TPP in whole blood via HPLC.  It 
allows rapid measurement of the physiologically active form of vitamin B1 in an isocratic HPLC 
system with fluorescent detection. 
1.1.2      Vitamin B22  
The described method allows for the separation and measurement of FAD, FMN and riboflavin in 
whole blood (though FAD is the only parameter reported at this time).  It uses simple protein 
precipitation and extraction followed by analysis on an Isocratic HPLC system with fluorescent 
detection.   
1.1.3      Vitamin B63 
The described method allows for specific determination of vitamin B6 (as pyridoxal-5’-phosphate 
or P5P).  P5P is extracted from whole blood samples.  The extracted samples are derivatised to form 
a stable P5P-fluorescent derivative, then run through an isocratic HPLC with fluorescent detection.   
  
35000) 
37000) 
tems Reagent kit For The Analysis Of Vitamin B6 In Whole Blood (Chromsystems Part# 
31000/WB) 
 
Sent by Sullivan Nicolaides 1st July, 2014 
 
 
The assay used for Folate is listed below: 
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11.7 APPENDIX 7: NHMRC DAILY DOSE AND UPPER LIMIT FOR EACH OF THE B 
VITAMINS IN THE INTERVENTION.  
Activated B Complex 
vitamin make-up 
Dose Dose we are 
administering 
daily 
NHMRC Nutrient Guidelines 2006 
reference ranges and safety limits  
Rationale  
Biotin 500mcg 1,000mcg Men RDI = 30mcg/day 
Female RDI = 25mcg/day 
 
Upper level: NHMRC found that there is 
insufficient evidence of adverse effects in 
human and animal studies to set an upper 
level.  
Calcium folinate (folinic 
acid)   
500mcg 1,000mcg Men RDI = 400mcg/day 
Women RDI = 400mcg/day 
 
Upper level: Men and Women = 
1,000mcg/day  
 
The dose we will be administering is 
equivalent to the upper level so is 
considered safe.  
Calcium pantothenate 
(vitamin B5) 
163.76mg 327.52mg Men RDI = 6mg/day 
Women RDI = 4mg/day 
 
Upper Level: NHMRC have set no upper 
level as there are no reports of adverse 
effects of oral pantothenic acid in either 
human or animal studies. Therefore, no 
upper level was set.  
Choline bitartrate 100mg 200mg Men RDI = 550mg/day 
Female RDI = 425mg/day 
 
Upper level: Adult male and females = 
3,500mg/day 
 
The amount we will be administering is less 
than the RDI’s for both men and women.  
Cyanocobalamin (vitamin 
B12) 
500mcg 1,000mcg Men RDI = 2.4mcg/day 
Women RDI = 2.4mcg/day 
 
Upper Level:  Currently there is no 
evidence that high amounts of vitamin B12 
represents a health risk as no adverse 
effects have been found with excess 
vitamin B12 intake or supplementation.  
 
Therefore, 1,000mcg a day is a safe level of 
intake for this study.  
Inositol 100mcg 200mcg Currently inositol is under review by the 
Therapeutics Goods Act. The NHMRC 
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does not mention inositol in its references 
ranges. 
 
A case report in 2010 (Kontoangelos K, eta 
al. 2010) found that administration of 3g of 
inositol for 4 years to a 62yo female 
suffering bipolor disorder for 30 years was 
effecetive and safe. The administration of 
inositol is still under review with no 
negative studies found on supplementation, 
the dose we are administrating would be 
considered safe.  
Nicotinamide (vitamin 
B3) 
80mg 160mg Men RDI = 16mg/day 
Women RDI = 14mg/day 
 
Upper Level:  For Niacin as nicotinamide 
Men and Women = 900mg/day 
The amount administered is below the 
upper level..  
Nicotinic acid (vitamin 
B3) 
20mg 40mg Men RDI = 16mg/day 
Women RDI = 14mg/day 
 
Upper Level:  For Niacin as nicotinic acid 
Men and Women = 35mg/day 
 
The upper level from the NHMRC was 
based on the flushing reaction. (FNB:10m 
1998) The upper level was 50mg/day set on 
the data from the study of Sebrell & Butler 
(1938) supported by Spies et al. (1938). An 
uncertainty factor of 1.5 was selected as the 
flushing is transient so after rounding, 
NHMRC decided on 35mg/day for adults. 
The amount that the patients will receive is 
just about this at 40mg. It is still under the 
50mg/day so patients could possibly 
experience some flushing, but it is only 
transient, no longer than 30mins. There are 
no negative effects from this and it is not 
considered to be unsafe.  
Pyridoxal-5-phosphate 
(vitamin B6) 
10mg 20mg Men RDI = 1.3mg for 19-50 years old 
                 1.7mg for 50-≥70 years old 
Women RDI = 1.3mg for 19-50 years old 
                     1.7mg for 50-≥70 years old 
 
Upper level: Adult men and women = 
50mg/day 
 
The upper level was set by the NHMRC 
using results of studies involving long-term 
oral administration of pyridoxine at doses 
Pyridoxial hydrochloride 
(vitamin B6) 
20mg 40mg 
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less than 1g/day (Berger & Schaumburg 
1984, Bernstein & Lobitz 1988, Dalton 
1985, Dalton & Dalton 1987, Del Tredici et 
al. 1985, FNB:IOM 1998, Parry & 
Bredesen 1985) The no observed adverse 
effect leve (NOAEL) is 200mg/day 
identified from the studies of Bernstein & 
Lobitz (1988) and Del Tredici et al. (1985) 
These studies had subjects taking 
supplements for 5-6 months or less, 
however Dalton and Dalton (1987) has 
suggested that symptoms might take 
substantially longer than this to appear.  
They found that subjects who had reported 
symptoms had been on supplementation on 
average for 2.9 years and those reporting no 
symptoms on supplements on average for 
1.9 years.  
 
The total amount we will be supplementing 
is 60mg which is just above the upper level 
but much lower than the NOAEL of 
200mg. They will be receiving this amount 
for 9 months which is also less than the 
average 2.9 years reported for subjects 
experiencing vitamin B6 toxicity side 
effects such as peripheral neuropathy.  
Riboflavin 5-phosphate 
(vitamin B2) 
20mg 40mg Men RDI = 1.2mg/day 
Women RDI = 1.1mg/day 
 
Upper level: No adverse events have been 
associated with vitamin B2 consumption in 
food or supplementation so no upper level 
can been set by the NHMRC. 
 
 
Thiamine hydrochloride 
(vitamin B1) 
50mg 100mg Men RDI = 1.2mg/day 
Women RDI = 1.2mg/day 
 
Upper levels: NHMRC decided that there is 
no upper level for Thiamin and it does not 
present a health risk.  
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11.8 APPENDIX 8. DIET FOR INITIAL ABSORPTION STUDY 
 
Date: ________________  Initials: _________  Gender:  Male / Female 
 Foods Amounts What was eaten 
Breakfast White bread toasted 
Butter 
Jam 
Banana or Apple 
2 -4 slices 
½  teaspoon per slice 
1 teaspoon per slice 
1 medium 
 
Morning Tea Grapes or Apple 
 
Herbal Tea 
1 bunch or medium 
apple 
1-2 cups 
 
Lunch Rice cakes 
Avocado 
Tomato 
Cucumber 
Boiled egg 
2-6 cakes 
1 tablespoon per cake 
2-3 slices per cake 
3-4 slices per cake 
1-2 medium  
 
Afternoon tea Grapes or Apple 
 
Or Yoghurt 
 
Herbal Tea 
1 bunch or medium 
apple 
1 small tub 
 
1-2 cups 
 
Dinner Fish – cod grilled 
White rice or white 
potato 
Carrot – raw, baked or 
boiled 
Sweet potato – baked or 
mashed 
Pumpkin – baked or 
mashed 
1 -2 fillets (120g each) 
½ - 1 cup 
 
¼  carrot 
2 pieces baked or 1 
tablespoon 
2 pieces baked or 1 
tablespoon 
 
 
Supper Yoghurt 1 small tub  
Beverages Water 
Herbal teas 
As much as you like 
As much as you like 
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11.9 APPENDIX 11: PHYSIOTHERAPY NOTES ON PA023 PMP 
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Abstract 
Chemotherapy-induced peripheral neuropathy [CIPN] is a common significant and debilitating side 
effect resulting from the administration of neurotoxic chemotherapeutic agents. These pharmaco–
chemotherapeutics can include taxanes, vinca alkaloids and others. Moderate to severe CIPN 
significantly decreases the quality of life and physical abilities of cancer patients and current 
pharmacotherapy for CIPN, for example, Amifostine and antidepressants have had limited efficacy 
and may themselves induce adverse side effects.  To determine the potential use of nutraceuticals i.e. 
vitamin E, acetyl-L-carnitine, glutamine, glutathione, vitamin B6, omega-3 fatty acids, magnesium, 
calcium, alpha lipoic acid and n-acetyl cysteine as adjuvants in cancer treatments a systematic 
literature review was conducted. Revised clinical studies comprised of randomized clinical trials that 
investigated the anti-CIPN effect of nutraceuticals as the adjuvant intervention in patients 
administered chemotherapy.  Twenty–four studies were assessed on methodological quality and 
limitations identified.  Studies were mixed in their recommendations for nutraceuticals. Currently no 
agent has shown solid beneficial evidence to be recommended for the treatment or prophylaxis of 
CIPN. The standard of care for CIPN includes dose reduction and/or discontinuation of chemotherapy 
treatment.  The management of CIPN remains an important challenge and future studies are warranted 
before recommendations for the use of supplements can be made.   
Key Words: Chemotherapy-induced peripheral neuropathy, Vitamin B6, Glutamine, 
Glutathione, Acetyl-L-Carnitine, Vitamin E, Alpha Lipoic acid, Magnesium, Calcium and N-
Acetyl Cysteine, Omega-3 Fatty Acids, CIPN.   
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Introduction 
Certain neoplastic agents can accumulate in the peripheral nervous system and the neurotoxicity may 
lead to CIPN.  The symptoms of CIPN can be numbness, tingling, burning, decreased touch sensation, 
decreased strength and movement and sometimes pain in the fingers, toes, hands or feet.1,2  These 
neurotoxic chemotherapy agents include the platinum compounds, anti-tubulin agents such as the 
taxane class and vinca alkaloids, epothilones, thalidomide, proteasome inhibitors and 5-fluorouracil 
(5FU).3-8  It is estimated that one third of all patients who undergo chemotherapy experience CIPN 
and of those, a third can have permanent nerve damage.3-5  Patients experiencing moderate to severe 
CIPN report a reduced quality of life,3 chronic discomfort4 and disruption of physical abilities for 
general life activities which can be temporary or permanent.3  Moreover, CIPN can lead to dose 
reduction of the chemotherapy agent or possible cessation of treatment which may have an adverse 
impact on cancer treatment and disease outcomes.5  
 
The Aetiology of CIPN 
A differential diagnosis of peripheral neuropathy in patients diagnosed with cancer has been reported 
(Table 1).2 Requisites for peripheral nervous system neurotoxicity include chemotherapy agent 
capacity to cross the blood-nerve barrier and nervous system sensitivity to the drug.  People with 
predisposing conditions such as type II diabetes mellitus (T2DM), HIV/AIDS, alcoholism or a 
vitamin B12 deficiency may be more prone to the agent’s adverse effects on the peripheral nervous 
system thereby increasing the prevalence of CIPN.2   
Peripheral nerve fibres are composed of small or large fibres. Small nerve fibres are unmyelinated 
and are comprised primarily of microtubules. They include nerves that sense pain and temperature. 
Large nerve fibres are myelinated and are composed mainly of neurofilaments that act as a framework 
for the axon.  These fibres sense position and vibration as well as motor control.2  Both fibres are 
targeted by neurotoxic chemotherapy agents that may explain why patients experience a variety of 
symptoms.   
Although each neurotoxic chemotherapy agent has a different mechanism of action on the nervous 
system, all induce a glove and stocking distribution. This means the point most distal from the trunk 
of the body is affected first (e.g. fingers and toes) and progression is then towards the trunk to hands 
and feet and then limbs.2  Each agent has been found to affect one nerve fibre more than others, for 
example,  cisplatin targets large fibres while paclitaxel and vincristine target small fibres.2 
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CIPN can be a temporary side effect which can take up to two years for full recovery. In 
approximately one third of cases it can be a permanent consequence of the drug neurotoxicity. 
Symptoms may occur within hours, days or weeks after the introduction of the chemotherapy agent, 
with cumulative doses increasing the severity and length of time the patient experiences this side 
effect.2 Cisplatin differs to other neurotoxic agents as it can induce a delayed CIPN several months 
after the drug has been administered rather than a more immediate response.4 
Mechanism of Action of Neurotoxic Chemotherapy Agents 
The neurotoxic chemotherapy agents can be divided into four main categories, alkylating and anti-
tubulin agents, thalidomide and proteasome inhibitors. A common feature of these drugs is that they 
are unable to cross the blood-brain barrier thereby protecting the central nervous system. The 
peripheral nervous system has no protective barrier making it susceptible to neurotoxicity3 and 
therefore neurotoxic chemotherapy agents can accumulate and target different regions of the neuron 
(Figure 1).6 
 
Methods 
A systematic search of the literature was conducted using PubMed, the Cochrane Library, Science 
Direct, Scopus, EMBASE, MEDLINE and CINAHL. 
Search Terms 
Articles were identified using the search terms, “chemotherapy” OR “Cisplatin” OR “Taxanes” OR 
“Paclitaxel” OR “Docetaxel” OR “Oxaliplatin” OR “Carboplatin” OR “Platinum compounds” OR 
“Proteasome inhibitors” AND “induced peripheral neuropathy” OR “CIPN” AND “nutrient” OR 
“vitamin” OR “mineral” OR “Acetyl-L-Carnitine” OR “Glutamine” OR “Vitamin E” OR “Alpha 
Lipoic acid” OR “Magnesium” OR “Calcium” OR “Vitamin B6” OR “B vitamins” OR “Omega-3 
fatty acids”. 
 
The Inclusion criteria for this review were: 1) An RCT and/or cross-over clinical trial that used either 
a placebo comparator or current anti–CIPN treatment as a control; 2) Human participants diagnosed 
with a cancer and administered chemotherapy; 3) The use of a nutraceutical supplement as the main 
intervention and specifically investigating its effects on reducing the primary outcome i.e., CIPN; and 
4) The clinical study was published in English.  
 
The overall body of evidence (based on a summary of the individual studies) ( See Supplemental 
Information: Clinical Studies Investigating the Efficacy of Selected Nutraceuticals for the 
Prevention of CIPN) evaluated within this review was assessed using a separate tool, the Australian 
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National health and Medical Research Council’s (NHMRC) body of clinical evidence assessment 
matrix. This is an assessment tool that assigns a level/grade (Level I: strongest evidence to level IV: 
weakest evidence) based on the strength of the published study.9  
 
Results 
Nutraceuticals and Peripheral Neuropathy 
The search strategy identified twenty-four studies (Supplemental Information) that provided Level II 
or III evidence and all had a positive quality rating.  All studies included in this review were analysed 
for common scientific characteristics / attributes consistent with rigorous methodologies, randomised 
group allocation and clear inclusion and/or exclusion criteria, major findings, and potential 
limitations.  
12.1.1  
12.1.2 Study characteristics  
The studies selected for this review included randomised controlled trials, open label trials and one 
retrospective study. The randomised controlled trials identified are divided into eleven double blind 
placebo controlled trials, five randomised controlled trials including a randomised open label with a 
blind assessment plus two non-randomised controlled trials. Four open label trials were identified 
which did not contain a placebo component. 
  
The results of the included studies were mixed. Several nutraceuticals showed initial positive results 
in reducing CIPN however further studies found that they were either not significant or indicated 
possible interference with the chemotherapy agents response rate. No nutraceutical currently has been 
found to significantly show protection or treatment for CIPN. 
 
Magnesium and Calcium 
Magnesium and calcium infusions with oxaliplatin also showed initial positive results in a 
retrospective study.10 Three clinical trials11-13 reported that efficacy was not enhanced with one trial 
(n=174) being terminated due to the treatment group reporting a significant lower response rate 
compared to placebo.11  
Vitamin E 
Vitamin E demonstrated positive results in three RCT’s showing a significant reduction in the relative 
risk of cisplatin induced PN, especially ototoxicity.14-18 However, a phase III multi-centre trial 
combining vitamin E with taxanes, cisplatin, carboplatin, oxaliplatin or combination concluded that 
vitamin E did not appear to reduce the incidence of sensory neuropathy.18   Vitamin E efficacy was 
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limited to those patients administered cisplatin (only 8 from the 207 cohort) during the phase III study.  
Previous studies have indicated that vitamin E seems to be more protective for cisplatin ototoxicity 
compared to other neurotoxic agents.19  
 
Lipoic acid  
One open label study was conducted with alpha lipoic acid (n=15) co-administered with oxaliplatin.20  
This treatment combination showed a trend toward a reduction in the severity of oxaliplatin induced 
CIPN in 8 out of 15 patients but the trend was not statistically significant.20  
 
N-Acetyl Cysteine 
N-acetyl cysteine (NAC) administration to cancer patients has been based on the assumption that 
NAC can increase glutathione production, an effect that may decrease cyto-toxicity.21 In a further 
study conducted with NAC no significant changes on electrophysiological testing on both sensory 
and motor nerves were found between the two groups.21 
 
Glutathione 
Glutathione has been reported to show positive results in reducing CIPN.22 Intravenous glutathione 
administered before cisplatin administration reported promising outcomes for the prevention of 
cisplatin induced PN without reducing the anti-tumour activity of the chemotherapeutic agent.23-25 A 
positive result was also found in two studies with oxaliplatin.26,27  Both studies reported a significant 
reduction in oxaliplatin induced PN, mainly relevant to sural sensory nerve reduction. These results 
present clinical data that indicates that glutathione administration may aid in the prevention of CIPN.  
However, additional higher quality studies are required, as these trials were limited due to a high 
participant dropout rate and without long-term follow–up.  
 
Glutamine 
Two almost identical clinical studies28,29 that have been published on the administration of glutamine 
with paclitaxel are the results from the early study25 that was merged / extended into a second trial.26  
Both studies were conducted at the same institution over the same period of time but with slightly 
different numbers of participants and authors, presenting similar results. These studies reported that 
the patients on glutamine tended to have fewer symptoms than those on placebo however the trend in 
the nerve conduction studies was not statistically significant. There was a drift in the results that 
indicated that glutamine decreased the severity of dysesthesias in the fingers and toes. An additional 
study30 with glutamine and oxaliplatin co-administration reported that glutamine may reduce the 
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incidence and severity of oxaliplatin induced CIPN.30 No significant differences were found between 
the two groups.30  
 
Acetyl–L–Carnitine 
Two open label studies reported that acetyl–L–carnitine (ALC) may be a treatment option for 
paclitaxel and cisplatin induced CIPN.31,32  A phase III trial demonstrated that ALC did not provide 
a positive benefit for the prevention of CIPN.33  The study concluded that patients should be 
discouraged from using ALC during treatment with taxane therapy.  Notwithstanding this 
recommendation it may be an option for the treatment of CIPN rather than prevention in patients that 
already may be experiencing CIPN. 
 
Vitamin B6 
One DBRCT with vitamin B6 found that it significantly reduced CIPN from cisplatin and 
hexamtheylmelamin administration.34 Furthermore the results indicated that the high dose vitamin B6 
(100 mg) administered may affect response duration and that it requires further investigation.34 
12.1.3 Omega–3 Fatty Acids 
A recent DBRCT investigating the effect of omega–3 fatty acids on paclitaxel induced peripheral 
neuropathy found that it significantly reduced the incidence of CIPN from paclitaxel by 70%.35  The 
sural nerve conduction test was also significant for omega–3 fatty acids compared to placebo. Further 
testing in larger randomised clinical trials is required but omega–3 fatty acids do show promise for 
protection against paclitaxel induced peripheral neuropathy.35 
12.1.4  
12.1.5 Adverse Events and Adherence 
The nutraceuticals trialled were generally well tolerated according to the clinical trials reported.  
Hence, there were limited adverse events noted from the nutraceuticals trialled for the prevention of 
CIPN.  Adverse events were reported for the use of acetyl-l-carnitine only. These included two 
patients that reported mild nausea associated with acetyl-l-carnitine administration29 and one patient 
reported insomnia following supplementation with acetyl-l-carnitine.30 One additional study 
described two participants who stopped their vitamin E supplementation after one month.18 No 
interpretation of the result was given as to why the participants had stopped taking the vitamin E.  
Confounding Factors 
The main confounding factors reported in the clinical studies investigated for this review are 
presented in Table 2. All studies from the supplemental information table indicated that confounding 
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factors were controlled in the study but were not individually listed in the clinical trials examined. 
They were itemised under why patients did not complete the trial, why they withdrew their 
participation or experienced chemotherapy administration toxicity. The confounding factors 
mentioned may importantly influence the decisions to administer nutraceuticals to cancer patients 
who are about to undergo chemotherapy treatments. Such decisions may be dependent on those 
factors that could affect drug absorption, metabolism and or compliance.  One study reported the 
difficulty in reproducing or quantifying peripheral neuropathy as a confounding factor.25  
Possible Drug-Interactions with High Doses of Nutraceuticals 
Three studies have reported that there could be possible drug interactions with the administration of 
high dose nutraceuticals.11,25,32 The intravenous administration of magnesium and calcium trial with 
FOLFOX regime was terminated due to the treatment group reporting a significant lower response 
rate compared to placebo.11  The study concluded that a possible drug interaction had occurred 
between the chemotherapy regime and the magnesium and calcium infusions however no further 
investigations were continued to determine the mechanism of action.  A further study with 
glutamine25 indicated that there could have been a protective effect on the tumour from the 
administered glutamine thereby leading to reduced cytotoxicity from the paclitaxel administered. 
Moreover, no decrease in response rate was reported in the trial and no further testing was undertaken 
to ascertain the mechanism of action.25 The third clinical study that administered vitamin B6 showed 
a significant decrease in the response rate with cisplatin and HMM.32 The study concluded that this 
effect was directly due to vitamin B6 supplementation as it occurred in all participants administered 
the high dose of vitamin B6. However, it also was noted that vitamin B6 reduced response rate. No 
investigations were undertaken to determine how this occurred or the possible mechanism of action. 
Further investigations on the vitamin B6 effect are warranted. 
12.1.6  
12.1.7 Clinical Implications 
The current scientific literature demonstrates that there is limited evidence for the concurrent 
administration of nutraceuticals with neurotoxic agents in the prevention or treatment of CIPN.  
Nutraceuticals that may be considered include oral vitamin E with cisplatin administration, omega–3 
fatty acids with paclitaxel and possibly the intravenous administration of glutathione with oxaliplatin.  
Although unvaryingly these may not prevent the development of CIPN they may assist in some cases 
depending on the severity of the diagnosed cancer and the commencement of medical treatment. 
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Vitamin B6 also warrants further investigation as a potential protective agent of CIPN. A recent in 
vitro experiment with vitamin B6 and oxaliplatin reported that vitamin B6 showed protection against 
oxaliplatin induced peripheral neuropathy without compromising drug anti-tumour efficacy.36  
 
Review Limitations 
The exclusion of unpublished literature may significantly affect this review by introducing a 
publication bias.  In addition, several restraints have been identified with this review namely within 
the selected studies. The low participant numbers in most studies was a significant limitation.  The 
retrospective study10 was included because it allowed the formulation of a biologically plausible 
hypothesis for the efficacy of nutraceuticals to prevent CIPN, even though it presented as a low–level 
evidence study.  Furthermore, no objective markers were used in the assessment of the signs and 
symptoms of CIPN.  
Studies reported using a variety of assessment tools to quantify CIPN development and severity. 
These included the National Cancer Institute Common Toxicity Criteria (NCI-CTC), total neuropathy 
score (TNS), nerve conduction studies and/or electrophysiological investigations and quality of life 
questionnaires.   The NCI-CTC is a clinician-based grading scale whereby the assessor may mix 
impairment, disability and quality of life measures which can lead to different interpretations of 
results and demonstrates observer objectivity and possible bias.37 The NCI-CTC is the most 
commonly used assessment tool in the selected studies. The TNS is stated to be the most 
comprehensive assessment tool available at this time37,38 with only two studies using this assessment 
tool as their main measurement of results.17,35 The nerve conduction studies and electrophysiological 
investigations are the other main assessment tool used within these studies. These provide information 
on compound action potential amplitude and conduction velocity but do not provide information 
regarding ion channel function or resting membrane potential and are still dependent on the skill of 
the neurologist conducting the assessment.39 Hence assessment of CIPN was not uniform among the 
clinical studies examined. This makes comparisons difficult to evaluate when comparing study 
results.  Moreover, it is therefore possible that researchers may have underestimated the nutraceutical 
efficacy to prevent CIPN, resulting in significant study design bias.  
 
An additional secondary study limitation involves the assessment of the activities of daily living.  
Activities of daily living is an important factor in CIPN as it may provide a marker of the level of 
disability experienced from symptoms by interference of daily activity. Hence activities of daily 
living are generally subjective and signs on a physical examination may not always be predictive of 
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whether activities of daily living is affected or if it is important for the participant entering a CIPN 
clinical trial.  
 
Measurement of CIPN 
The measurement/grading or assessment of CIPN is critical for accurate clinical and instrumental 
monitoring. Currently there is no accurate measurement tool that has been used in either clinical trials 
or in a clinical setting that monitors CIPN.40 The lack of standardization and reporting mechanisms 
has resulted in contentious reporting of CIPN data and consequently CIPN has become an under-
diagnosed problem.41 
CIPN is most commonly graded by clinicians by using common toxicity scales such as the National 
Cancer Institute – Common Toxicity Criteria (NCI-CTC). However, these scales rarely provide a 
detailed profile on clinical and pathological aspects of peripheral neuropathy that is a requisite for 
inclusion into clinical trial methodology. However, other measurement tools such as the Total 
Neuropathy Score [TNS] provide more detailed information pertaining to motor, sensory and 
autonomic signs and symptoms, determination of vibration perception thresholds and 
electrophysiological examination.37,42  
Of the studies evaluated, there were a variety of measurement tools used that makes comparing results 
difficult. The majority of studies n=19 used the NCI-CTC as their measurement tool.10-14,21-31,33-34 Of 
the studies that used the NCI-CTC six also included electrophysiological tests such as nerve 
conduction tests,14,23,26,28,29,31 two included a self-reported perception of peripheral neuropathy18,33 
and one included a quality of life questionnaire.25 Two studies used the TNS as their measurement 
tool,17,35 two used modified versions of the Neurologic symptom score (NSS) and the Neurologic 
Disability Score (NDS) in addition to patient symptom experience15,16 and one used the World Health 
Organisation (WHO) toxicity grading list.32 
Given that the measurement of CIPN remains difficult due to the use of a number of different 
measurement tools the ideal recommendation is that a variety of standardized tools be used that 
include a peripheral neuropathy scale i.e. [TNS], quality of life questionnaire, pain scale and patient’s 
perspective questionnaire.37,42,43 This however, is impractical due to the very time consuming nature 
of the combined interventions for clinicians, therefore a more realistic recommendation would be the 
use the NCI-CTC.  Hence when patients report experiencing grade 2 or higher neuropathy occurrence 
during or after chemotherapy they can then be referred to a neurologist for further testing.  
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Discussion 
Currently there are no established neuroprotective nutraceuticals for the prevention or treatment of 
CIPN. Results are inconsistent requiring further clinical investigations to confirm efficacy and safety 
or obtained from relatively small sample sizes.  Several nutraceuticals have shown promise for 
selective neurotoxic chemotherapy agents such as vitamin E (dose 300-600mg) with cisplatin, 
intravenous glutathione (dose 1.5gm/m2) for oxaliplatin administration, vitamin B6 (dose 100mg 
TID) with HMM and cisplatin although interference with response rate was reported, and omega–3 
fatty acids (dose 640mg TID) for paclitaxel. Acetyl–L–carnitine (dose 3 grams) has also demonstrated 
potential for efficacy as a treatment option for CIPN.  Further research with large scale randomised 
controlled trials are warranted.   
 
Conclusion 
The overall survival from cancer, free from disease progression has increased in cancer patients, 
making quality of life an important factor for cancer survivors.  CIPN is a major side effect that can 
interfere with a patient’s quality of life, daily activities and also with medical treatments.  The 
disruption of medical therapy for cancer patients that is due to the development of CIPN can affect 
chemotherapy dose and continuation of treatment that is of clinical importance. Investigating agents 
that could assist with CIPN prevention and treatment has significant scientific merit.  Scientific 
evidence for nutraceuticals in the prevention and treatment of CIPN is limited. The analysis of the 
evidence presented according to the NHMRC grading scale of clinical evidence indicates that at the 
present time there can be no explicit recommendations that can be given for the prevention or 
treatment of chemotherapy induced peripheral neuropathy. Future clinical studies investigating 
natural compounds as neuro–protective agents should constitute a priority for this clinically relevant 
side effect.  
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Clinical Studies Investigating the Efficacy of Selected Nutraceuticals for the Prevention of CIPN. 
 
Table 1: A differential diagnosis of peripheral neuropathy in patients with cancer.2 
Cause Neurotoxic Effect on Peripheral Nerves 
Vitamin B12 deficiency Large fibre injury, Dorsal root ganglia damage 
Cachexia Diffuse weakness and muscle wastage 
Chemotherapy Small and/or large fibre injury 
Charcot–Marie–Tooth Disease Large fibre injury 
Diabetes Mellitus Type 2  Small fibre injury, slow development 
Atherosclerotic Ischemic Disease Sensory neuropathy in lower extremities 
Para–Neoplastic Syndrome Distal sensory or sensori-motor deficit 
Thyroid Dysfunction Proximal and distal weakness; carpal tunnel syndrome 
Alcoholic Neuropathy Numbness, parasthesias 
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Table 2: Reported Confounding Factors. 
 
Confounding Factors n 
Disease progression 5 
Grade 3 or 4 nausea and vomiting 4 
Metastasis (liver, abdomen, peritoneum, lymph 
nodes, lung, other) 
4 
Sudden patient death 4 
Grade 3 or 4 diarrhoea 3 
Patients refused any further treatment 3 
Heamatological toxicity (including transient 
hepatic failure) 
2 
Severe neutropenia 2 
Stomatitis 2 
If the treatment was first, second or third line 
treatment 
2 
Lethal toxicity from the chemotherapy agent 2 
Cardiac and/or neurocerebellar adverse events 2 
Grade 3 or 4 allergic reactions to the 
chemotherapy drugs 
2 
Thrombocytopenia 1 
If the patient had resectable or unresectable 
lesions 
1 
Wrong diagnosis 1 
Change to treatment protocol 1 
Use of Alternative treatments 1 
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Figure 1: Site of chemotherapy-induced neurotoxicity.7 
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Supplemental Information: 
 
Clinical Studies Investigating the Efficacy of Selected Nutraceuticals for the Prevention of CIPN. 
Nutraceuticals Study Type / 
Level of 
Evidence 
[No. 
Participants] 
Duration Results 
Magnesium / 
Calcium 
Retrospective 
study10  
Level III-2  
[161 
participants]  
3 cycles of FOLFOX 
(oxaliplatin) given 
every 2 weeks 
  96 participants received ca gluconate and mg sulphate (1g) before and 
after oxaliplatin. 65 participants did not  
 20% of Ca/Mg group had CIPN versus 45% in control group with tumour 
response rates similar 
 Participants with grade 3 or 4 in the Ca/Mg group recovered significantly 
quicker than the controls 
 4% in Ca/Mg group withdrew due to neurotoxicity compared to 31% in 
control group 
 DBRCT11 
Level II 
[174 
participants] 
 
8 cycles of FOLFOX 
plus bevacizumab given 
every two weeks 
 First 140 participants were randomised to Ca/Mg before and after 
oxaliplatin 
 Trial was terminated due to the findings that the Ca/Mg group reported a 
significantly lower response rate than placebo 
 Open label12 
Level III-3 
[14 
participants] 
FOLFOX 12 cycles 
given every two weeks 
 All participants received an infusion of Ca/Mg before and after 
oxaliplatin 
 CIPN occurred in 8 participants (57.1%) with no neurotoxicity with 
functional impairment 
 Limited sensory neuropathy before the fourth cycle.  
 DBRCT13 
Level II 
[35 
participants] 
FOLFOX6 12 cycles 
given every two weeks 
 Ca/Mg group n=17 and placebo n=16 given before and after oxaliplatin 
 The incidence of CIPN after 6 cycles was not significant between the two 
groups 
 Blood platinum and the area under the curve were also not significantly 
different between the two groups 
Vitamin E DBRCT14 
Level II 
Cisplatin 6 cycles and 3 
months after 
 27 participants completed the 6 cycles of cisplatin 
 N=13 were randomised to vitamin E (300 mg/d) 
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[47 
participants] 
chemotherapy 
completion 
 The incidence of CIPN was significantly lower in vitamin E group 
(30.7%) compared to control group (85.7%) using a comprehensive 
neurotoxicity score based on clinical and neurophysiological parameters 
 No differences were observed in tumour weight inhibition, tumour growth 
delay or life span. 
 RCT15  
Randomised 
open label with 
blind 
assessment 
Level III-1  
[40 
participants] 
6 cycles of cisplatin, 
paclitaxel or 
combination plus 3 
months after 
chemotherapy cessation 
 
 31 participants finished 6 cycles of chemotherapy 
 Vitamin E group (n=16) received 600mg/d compared to a control group 
(n=15)  
 CIPN developed in 4/16 (25%) of vitamin E group compared to 11/15 
(73.3%) of control group. 
 RCT16 
Randomised 
open label with 
blind 
assessment  
Level III-1 
[35 
participants] 
6 cycles of cumulative 
cisplatin based regimes 
 30 participants finished 6 cycles of chemotherapy 
 Vitamin E group (n=16) received 600mg/d compared to a control group 
(n=19) 
 CIPN developed in 3/14 (21.4%) of participants assigned to the vitamin E 
group compared to 11/16 (68.5%) of controls 
 This study includes the final results of the published 2005 paper from 
Argyriou6.  Therefore the study above involves the results incorporated 
into this journal article as disclosed by the authors. 
 DBRCT17 
Level II 
[108 
participants] 
Cisplatin – intervention 
given before 
chemotherapy (from 3 
days before), during 
and 3 months after 
chemotherapy cessation 
 Vitamin E group (n=54) were given 400mg/d compared to placebo group 
(n=54) 
 If participants received <300mg cumulative dose they were excluded 
which left vitamin E group (n=17) and placebo group (n=24) 
 The incidence of CIPN was significantly lower in vitamin E group (5.9%) 
compared to placebo group (41.9%) as measured by TNS. 
 Authors stated that these results provided Class II evidence that vitamin E 
supplementation significantly reduces the relative risk of developing signs 
for symptoms of neurotoxicity (relative risk _0.14)(95% confidence 
interval_0.02-1.00,p_0.05) 
 DBRCT18 
Multi-centre 
Administered within 4 
days of chemotherapy, 
 N=189 evaluable cases, oral vitamin E 300mg/d bd (n=96) compared to 
oral placebo (n=93) 
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Level II 
[207 
participants] 
given during and 1 
month after cessation of 
chemotherapy 
 Cytotoxic agents included taxanes (n=109), cisplation (n=8), carboplatin 
(n=2), oxaliplatin (n=50) or combination (n=20) 
 No difference was found in the incidence of grade 2+ sensory neuropathy 
between the two arms (vitamin E 34% compared to placebo 29%; P=0.43) 
 No significant differences was found between treatment arms for time to 
onset of neuropathy (P=0.58), chemotherapy dose reduction due to 
neuropathy (P=0.21) or secondary endpoints derived from patient-
reported neuropathy symptom assessment. 
 Concluded vitamin E did not appear to reduce the incidence of sensory 
neuropathy in this studied group 
Alpha Lipoic Acid Open label20 
Level III-3 
[15 
participants] 
Administered after 6 
cycles of oxaliplatin in 
participants with ≥grade 
2 CIPN till full 
recovery of 
neurological symptoms 
or for a maximum 
duration of 6 months 
 N=12 participants had grade 2 CIPN, n=3 participants had grade 3 CIPN 
 Administration included 600mg IV alpha lipoic acid was given once a 
week for 3-5 weeks followed by 600mg TDS (total=1800mg/d) orally 
until full recovery or maximum duration of 6 months. 
 Neurologic symptoms improved by at least 1 grade in 7 participants with 
grade 2 CIPN and in 1 patient with grade 3.  
 Medium time to respond was 4 weeks with median duration of treatment 
being 2 months (range 1-4 months) 
 Seven participants did not respond 
 Concluded that alpha lipoic acid reduced the severity of oxaliplatin CIPN 
in 8 out of 15 participants (53%)  
N-acetyl cysteine 
(NAC) 
RCT21 
Level III-1 
[14 
participants] 
Oxaliplatin (FOLFOX) 
12 cycles administered 
every 2 weeks – 
monitored until 2 weeks 
after last administration 
 N=5 (1200mg NAC) versus N=9 placebo given 1 ½ hours before each 
oxaliplatin administration 
 After 4 cycles 2 participants (40%) in NAC group compared to 7 
participants (77.8%) in placebo had clinical grade 1 CIPN 
 After 8 cycles 3 participants (60%) in NAC group had grade 1 CIPN 
compared to 4 participants (44.4%) with grade 1 and 5 participants 
(55.6%) with grade 2-4 CIPN.  
 After 12 cycles, 3 participants (60%) had grade 1 CIPN and 1 patient 
(20%) had grade 2-4 CIPN in NAC group compared to 1 patient (11.1%) 
with grade 1 and 8 participants (88.9%) with grade 2-4 CIPN in placebo 
group 
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 No significant change on electrophysiological testing including sensory 
and motor nerve studies after 4,8 and 12 cycles were found between the 
two groups. 
Glutathione DBRCT23 
Level II 
[50 
participants] 
Weekly cisplatin for 15 
weeks 
 Glutathione was administered immediately before cisplatin at a dose of 
1.5g/m2 in 100ml of saline solution over 15 minutes and after at a dose of 
600mg by intramuscular injection on days 2 and 5.  
 Normal saline solution was administered to placebo-randomised 
participants 
 Clinical neurologic evaluation and electrophysiologic investigations were 
performed at baseline, after 9 cycles and 15 cycles 
Results:  
At 9th week – no participants showed clinically evident CIPN in 
glutathione arm compared to 16 participants in placebo arm 
At 15th week 4/24 participants in glutathione arm displayed CIPN     
compared to 16/18 in placebo arm (P=0.0001) 
 Reduced haemotransfusions occurred in glutathione arm (32 v 62) 
 Treatment delay was reduced in glutathione arm (55 v 94 weeks) 
 Response rate was 76% (20% complete response) in glutathione group 
and 52% (12% complete response) in placebo arm 
 Concluded that glutathione is a promising and effective drug for the 
prevention of cisplatin induced neuropathy and does not reduce the 
clinical activity. 
 RCT24 
Level III-1 
[33 
participants] 
Weekly cisplatin for 9 
weeks 
 High risk CIPN participants with relapsed ovarian cancer who had at least 
a one year disease free interval and prior cisplatin administration 
 Administration was 50mg/m2 of cisplatin weekly with +/- 2.5g of 
glutathione 
 Response rate in 31 participants was 9/15 in glutathione group and 12/16 
in control group including 4/15 vs 7/16 complete responses.  
 Administered dose intensity was higher in the glutathione arm (100% 
dose intensity was received by 56% vs 27%) 
 A trend in neuro-protection was detected in the glutathione treated group 
with no major differences in other observed toxicities. 
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 Possible benefits of concomitant glutathione administration with cisplatin 
can be expected in high risk neurotoxicity participants without decreasing 
the anti-tumour activity 
 DBRCT25 
Level II 
[151 
participants] 
Cisplatin every 3 weeks 
for 6 cycles 
 Cisplatin alone (n=77) versus cisplatin + glutathione (n=74) 
 Administration of 3g/m2 of either glutathione or saline was given for 20 
minutes before cisplatin administration 
 CIPN was observed in 42% of cisplatin alone and 39% of cisplatin + 
glutathione arms which is not significant 
 58% of glutathione arm vs 39% of cisplatin alone (P=0.04) were able to 
receive 6 cycles of cisplatin at any dose 
 A significant difference was found between the reduction in creatinine 
clearance for the glutathione treated arm compared to control (74% vs 
62%; P=0.006) 
 QoL scores demonstrated that participants in the glutathione arm were 
statistically significant for improvement in depression, emesis, peripheral 
neurotoxicity, hair loss, shortness of breath and difficulty concentrating. 
They were found to be able to undertake housekeeping and shopping 
more easily.  
 DBRCT26 
Level II 
[52 
participants] 
Oxaliplatin every 2 
weeks for 12 cycles 
 Administration of either glutathione 1,500mg/m2 (N=21) or saline (N=19) 
was given before oxaliplatin over a 15 minute infusion period. 
 Clinical neurologic evaluation and electrophysiologic investigations were 
performed at baseline, after 4, 8 and 12 cycles of oxaliplatin 
 After 4th cycle, 7 glutathione and 11 placebo participants showed 
clinically evident neuropathy 
 After 8th cycle, 9/21 glutathione and 15/19 placebo showed CIPN 
 After 12th cycle, grade 2-4 NCIC-TC was observed in 3 glutathione and 8 
placebo arm (P=0.004) 
 The neurophysiologic investigations showed a statistically significant 
reduction in the sural sensory nerve conduction in the placebo arm but not 
in the glutathione arm. 
 Response rate was 26.9% in glutathione arm and 23.1% in placebo arm 
indicating no reduction in activity of oxaliplatin. 
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 RCT27 
Level III-1 
[27 
participants] 
Oxaliplatin every 2 
weeks for 12 cycles 
 Administration of either glutathione 1,500mg/m2 (n=14) or saline (n=13) 
was given before oxaliplatin  
 Evaluations were conducted at 5, 9 and 12 cycles of oxaliplatin 
 After 12 cycles 7/14 (50%) had grade 1 CIPN and 7/14 (50%) had grade 2 
CIPN in gluthione group. 
 After 12 cycles 9/13 (69%) had grade 2 CIPN and 4/13 (31%) had grade 3 
CIPN in placebo group. 
 At the end of all cycles the glutathione arm showed a statistically 
significant reduction of neurotoxicity (P=0.0037) compared to placebo 
arm. 
 No significant differences were noted in the main pharmacokinetic 
parameters between the two arms except a lower area under the plasma 
concentration-time curve and a smaller apparent steady-state volume of 
distribution when glutathione was co-administered. 
Glutamine NRCT28,29 
Level III-2 
[47 
participants] 
Given orally for 4 days 
starting 24 hours after 
paclitaxel completion 
 Stage 4 breast cancer participants undergoing high-dose chemotherapy 
with stem cell support - In intensification high dose paclitaxel 
(825mg/m2) was administered continuously IV over 24 hours on day 24 
prior to stem cell infusion 
 N= 33 non-glutamine, n=12 glutamine (10g orally 3 times a day for 4 
days) with neurological examinations completed at baseline and 2 weeks 
after paclitaxel administration 
 Results: participants who received glutamine had fewer symptoms than 
those who did not 
 8% versus 40% of participants receiving glutamine compared to those 
who did not had moderate to severe dysesthesias in fingers or toes 
 The frequency of moderate to severe numbness was observed less often in 
the glutamine group to non-glutamine group for both fingers and toes 
(P=0.016 and 0.009 respectively) 
 Less loss of vibration (P=0.04), reflexes and motor weakness was 
observed in the glutamine group although not significant except vibration 
 All signs and symptoms in both groups were reversible 
 Nerve conduction studies were not statistically significant 
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RCT30 
Level III-1 
[88 
participants] 
6 cycles of Oxaliplatin 
given in FOLFOX 
regime over 6 months 
 N=44 received glutamine and N=44 were control 
 Dose of glutamine was 15g bd orally for 7 consecutive days every 2 
weeks starting on the day of oxaliplatin administration 
 16.7% glutamine group versus 38.6% control displayed grade 1-2 CIPN 
after 2 cycles 
 4.8% glutamine group versus 18.2% control displayed grade 3-4 CIPN 
and 11.9% versus 31.8% after 6 cycles 
 The glutamine group also had less interference with daily activities 
(16.7% versus 40.9%) 
 Need for oxaliplatin dose reduction was lower (7.1% versus 27.3%). 
 No significant differences between the groups in response to 
chemotherapy, electrophysiological abnormalities and grade 3-4 non-
neurological toxicities or survival. 
 Glutamine may reduce the incidence and severity of CIPN with 
oxaliplatin 
Acetyl-L-Carntine 
(ALC) 
Open label31 
Level III-2 
[25 
participants] 
8 weeks   Participants with CIPN ≥3 (Common toxicity criteria – CTC) during 
paclitaxel or cisplatin therapy or grade ≥2 persisting for at least 3 months 
after discontinuing drugs were selected 
 1gram tid of ALC orally was administered for 8 weeks 
 All participants except 1 reported symptomatic relief 
 2 reported grade 1 nausea 
 Sensory neuropathy improved in 15 participants (60%) 
 Motor neuropathy in 11out of 14 participants (79%) and total neuropathy 
score (TNS) improved in 23 participants (92%) 
 Symptomatic improvement persisted in 12 of 13 participants 13 months 
after ALC administration 
 ALC may be a treatment option for paclitaxel and cisplatin CIPN 
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 Open label32 
Level III-2 
[26 
participants] 
10 days  CIPN participants were enrolled: N=5 cisplatin, N=11 paclitaxel, N=11 
combination of both cisplatin and paclitaxel 
 ALC 1gram IV infusion over 1-2 hours was administered for at least 10 
days 
 A decrease in at least 1 WHO grade improvement in CIPN severity was 
noted in 73% of participants 
 1 case of insomnia related to ALC treatment was reported 
 ALC may be an effective and well tolerated agent for the treatment of 
CIPN but results need to be confirmed by a DBRTC 
 DBRCT33 
multi-centre 
Level II 
[409 
participants] 
24 weeks  N=208 ALC participants (1000mg TID) versus N=201 placebo 
participants in women with stage I-III breast cancer undergoing adjuvant 
taxane therapy 
 At 12 weeks, the mean FACT-NTX score was 5.2 points lower in ALC 
arm versus 4.5 points lower in placebo group. 
 At 12 weeks in a linear regression adjusting for baseline score, planned 
treatment and age, score were 0.9 points lower in the ALC arm versus 
placebo (95%CI:-2.2 to 0.4, p=0.17) 
 At 24 weeks the mean FACT-NTX score was lower for ALC arm (5.3 vs 
3.6) compared to placebo arm 
 At 24 weeks the multivariate models were 1.8 points lower in the ALC 
arm (95%CI: -3.2 to 0.4, p=0.01), indicating more self-reported CIPN 
 At 24 week more Grade 3 to 4 CIPN was found in the ALC arm (p=0.04), 
in addition to 38% in ALC arm having a >5 point decrease score 
compared to 28% in placebo group (OR=1.57, p=0.05) and the FACT-
TOI scores were 3.5 points lower in the ALC (95%CI: -6.5 to -0.4, 
p=0.03) 
 No differences between arms were observed for fatigue or other toxicities 
 Concluded that ALC has no evidence of a positive impact at 12 weeks of 
treatment and may increase CIPN by 24 weeks of treatment.  
 Correlative studies are being conducted to explain this unexpected result 
and participants should be discouraged from using ALC. 
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Vitamin B6 DBRCT34 
Level II 
[248 
participants] 
Multicentre 
Between 1-70 months 
(median duration of 
response was 8.3 
months) 
 Participants with stages III-IV ovarian epithelial cancer (114 with and 134 
without prior chemotherapy) were randomized to 4 groups:  
Group A: Cisplatin (DDP) 37.5mg/m2  day 1 Hexamethylmelamin 
(HMM) 200mg/m2 day 8-21 repeat on 21 day cycle 
Group B: DDP 37.5mg/m2  day 1HMM (HMM) 200mg/m2 day 8-21 
repeat on 21 day cycle Vitamin B6 100mg TID day 1-21 repeat 
Group C: Cisplatin (DDP) 75mg/m2  day 1 Hexamethylmelamin (HMM) 
200mg/m2 day 8-21 repeat 21 day cycle 
Group D: DDP 75mg/m2  day 1 HMM 200mg/m2 day 8-21 repeat on 21 
day cycle Vitamin B6 100mg TID day 1-21 repeat 
 Participants with higher dose cisplatin experienced more severe nausea, 
vomiting and CIPN 
 Study demonstrated that the combination of cisplatin and HMM was an 
effective regimen for advanced ovarian carcinoma 
   B6 was found to significantly reduce CIPN however it was found to 
adversely affect response duration. The mechanism by which vitamin B6 
may unfavourably affect response duration requires further investigation. 
Omega 3 Fatty 
Acids (Omega 
3FA) 
DBRCT35 
Level II 
[69 
participants] 
 
During chemotherapy 
of paclitaxel (dose 175 
mg/m2 ) IV every 3 
week for 4 cycles and 
one month after 
 
 Breast cancer participants randomized to N=35 allocated to receive 
Omega 3FA (dose 640mg t.i.d)  and n=34 placebo (sunflower oil t.i.d) 
with 57 participants finishing the trial 
 Primary outcome was based on rTNS evaluated pre-chemotherapy and on 
month after the end of chemotherapy 
 Omega 3FA group: 21 participants (70%) did not develop CIPN 
compared to 11 participants (40.7%) in the placebo group.  
 In the Omega 3FA group 9 participants (30%) had CIPN with 4 
participants with mild CIPN (13.3%) and 5 participants with moderate 
CIPN (16.7%) with no severe CIPN compared to 16 participants (59.3%) 
had CIPN with 10 participants with mild CIPN (37%) , 5 participants 
(18.5%) with moderate CIPN and 1 patient (3.7%) with severe CIPN.  
 A statistically significant difference was seen in the incidence of the 
Omega 3 FA group compared to the placebo [OR=0.3, 0.95% C = (0.10-
0.88), p = 0.029] therefore the omega 3 FA group had a 70% lower risk of 
developing CIPN. 
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 A statistically significant difference was also seen in the nerve conduction 
test for sural a-SAP for omega 3FA group (p=0.015) 
 No other significant differences found 
DBRCT: Double Blind Randomized Controlled Trial; SBRCT: Single Blinded Randomized Controlled Trial; RCT: Randomized Controlled Trial; 
NRCT: Non Randomised Clinical Trial; CS: Case Study; TNS: Total Neuropathy Score 
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Abstract 
Chemotherapy-induced peripheral neuropathy [CIPN] is a significant and debilitating side 
effect resulting from the administration of neurotoxic chemotherapeutic agents. Moderate to 
severe CIPN significantly decreases the quality of life and physical abilities of patients 
diagnosed with cancer and current pharmacotherapy for CIPN with agents such as Amifostine, 
anticonvulsants, and antidepressants have had limited efficacy and may themselves induce 
additional adverse side effects. Each class of chemotherapeutic agent has a particular 
mechanism of action in cancer treatment and the neuropathy that develops from these drugs is 
treatment and dose duration dependent. Currently, there are two studies that have investigated 
vitamin B6 and CIPN with no research data available on B vitamin complex administration 
and CIPN.  Furthermore, a B vitamin deficiency or temporary deficiency may predispose a 
patient to the development of CIPN as deficits in this vitamin group can target the same focal 
points in a peripheral neuron. We hypothesize that B group vitamin administration has the 
potential to assist in the prevention and treatment of CIPN. 
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Introduction 
Particular neoplastic agents can accumulate in the peripheral nervous system and the 
neurotoxicity may lead to chemotherapy induced peripheral neuropathy [CIPN]. The 
symptoms of CIPN can be numbness, tingling, burning, decreased touch sensation, decreased 
strength and movement and sometimes pain in the fingers, toes, hands or feet (1, 2).  These 
neurotoxic chemotherapy agents include the platinum compounds, anti-tubulin agents such as 
the taxane class and vinca alkaloids, epothilones, thalidomide, proteasome inhibitors and 5-
fluorouracil (5FU) (3-8).  It is estimated that one third of all patients who undergo 
chemotherapy experience CIPN and of those, a third can have permanent nerve damage (3-5).  
Patients experiencing moderate to severe CIPN report a reduced quality of life (3), chronic 
discomfort (5) and disruption of physical abilities for general life activities which can be 
temporary or permanent (3). Moreover, CIPN can lead to dose reduction of the chemotherapy 
agent or possible cessation of treatment which may have an adverse impact on cancer treatment 
and disease outcomes (4).  
Aetiology of CIPN 
Requisites for peripheral nervous system neurotoxicity include chemotherapy agent capacity 
to cross the blood-nerve barrier and nervous system sensitivity to the drug.  People with 
predisposing conditions such as type II diabetes mellitus (T2DM), HIV/AIDS, alcoholism or a 
vitamin B12 deficiency may be more prone to the agent’s adverse effects on the peripheral 
nervous system thereby increasing the prevalence of CIPN (2).  Given that cancer is multi-
factorial, a differential diagnosis of the types of peripheral neuropathies experienced by cancer 
patients is necessary to ascertain peripheral neuropathy from chemotherapy agents [Table 1].  
Peripheral nerve fibres are composed of small or large fibres. Small nerve fibres are 
unmyelinated and are comprised primarily of microtubules. They include nerves that sense pain 
and temperature. Large nerve fibres are myelinated and are composed mainly of neurofilaments 
that act as a framework for the axon.  These fibres sense position and vibration as well as motor 
control (2). Both fibres are targeted by neurotoxic chemotherapy agents that may explain why 
patients experience a variety of symptoms.   
Although each neurotoxic chemotherapy agent has a different mechanism of action on the 
nervous system, all induce a glove and stocking distribution. This means the point most distal 
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from the trunk of the body is affected first (e.g. fingers and toes) and progression is then 
towards the trunk to hands and feet and then limbs (2).  Each agent has been found to affect 
one nerve fibre more than others, for example, cisplatin targets large fibres while paclitaxel 
and vincristine target small fibres (2). 
CIPN can be a temporary side effect which can take up to two years for full recovery. In 
approximately one third of cases it can be a permanent consequence of the drug neurotioxicity. 
Symptoms may occur within hours, days or weeks after the introduction of the chemotherapy 
agent, with cumulative doses increasing the severity and length of time the patient experiences 
this side effect (2). Cisplatin differs to other neurotoxic agents as it can induce a delayed CIPN 
several months after the drug has been administered rather than a more immediate response 
(5). 
Mechanism of action of Neurotoxic Chemotherapy Agents 
The neurotoxic chemotherapy agents can be divided into four main categories, alkylating and 
anti-tubulin agents, thalidomide and proteasome inhibitors [Table 2]. A common feature of 
these drugs is that they are unable to cross the blood-brain barrier thereby protecting the central 
nervous system however the peripheral nervous system has no protective barrier making it 
susceptible to neurotoxicity (3) and neurotoxic chemotherapy agents can accumulate and target 
different regions of the neuron (6) [Figure 1]. 
Mechanism of Action of B vitamins 
The vitamin B complex [vitamins B1, 2, 3, 5, 6, 12, folate, choline and biotin] function as 
coenzymes in several intermediary metabolic pathways for energy generation, blood cell 
formation and metabolism.  Deficiencies in one or more of these B group vitamins may 
promote nerve dysfunction and nerve damage that can lead to peripheral neuropathy (20). 
Research has demonstrated that administration of B vitamins can assist in regenerating nerve 
fibres and myelination (3, 5, 21-25). 
To date, no research on B group vitamins and CIPN has been undertaken.  However, two 
studies using only vitamin B6 and the development of CIPN have been reported (26, 27).  
Research on vitamin B6 and CIPN has been conducted in vitro with oxaliplatin (26) and in 
vivo with cisplatin (27). Garg MB and Ackland SP (2010) administered vitamin B6 to a range 
  
343 
 
of cell lines with induced cytotoxicity from oxaliplatin. It was demonstrated that vitamin B6 
did not affect the oxaliplatin’s anti-cancer effect.  Although no direct testing on peripheral 
neuropathy induced from oxaliplatin was conducted, this research demonstrated safety 
information for the use of vitamin B6 with oxaliplatin administration as it is unlikely that it 
will reverse the anti-tumour effect of the drug (26).  
Wiernik RH et al. (1992) conducted a clinical trial on Hexamethylmelamine and low or 
moderate dose cisplatin with or without vitamin B6. Two hundred and forty-eight patients with 
stage III-IV ovarian epithelial cancer were randomised into four groups. Results found that 
vitamin B6 administration reduced neurologic toxicity from cisplatin administration however, 
it was also found to have an adverse effect on response duration. The dose administered was 
100mg three times a day (total 300mg) of vitamin B6 from day 1-21 (27). Considering the 
CIPN was reduced, further studies with a lower dose of vitamin B6 are warranted to confirm if 
the response duration result is vitamin B6 dose dependent. 
Furthermore, research has demonstrated that certain chemotherapeutic agents can induce a 
temporary deficiency in vitamin B12 which may predispose a patient to CIPN development 
(28). Additional studies on 5 Fluorouracil (5FU), an agent that also exhibits neurotoxicity was 
shown to induce Wernicke’s encephalopathy, an acute neuropsychiatric syndrome that results 
from a vitamin B1 deficiency (8, 29-33). Hence, it is possible to hypothesize that specific 
chemotherapy agents may induce a temporary B vitamin deficiency which could then be a 
major causal contributor to the development of CIPN in patients undergoing treatment with 
neurotoxic chemotherapy agents. Moreover, deficits in B group vitamins can biochemically 
affect the health of nerve fibres and ganglia that neurotoxic chemotherapy agents can adversely 
modulate.  
The mechanism of action of how the B vitamins may prevent CIPN is still to be elicited. 
However, from research, we can surmise certain actions which may assist in preventing CIPN 
with B vitamins. Firstly, a vitamin B1 deficiency has been found to cause an axonal 
degeneration that is comparable to that seen from vincristine (34). As a result of axonal 
degeneration from a vitamin B1 deficiency, chromatolysis of dorsal root ganglia neurons and 
anterior horn cell neurons can occur which again is very similar to that seen from vincristine 
administration (35,36).  Active regeneration of peripheral nerves was found in patients with a 
vitamin B1 deficiency receiving thiamine supplementation (34). Therefore it is possible that 
vitamin B1 may play a key role in the prevention of CIPN from vincristine administration 
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through decreasing axonal degeneration, chromatolysis of dorsal root ganglia neurons and 
regeneration of peripheral nerves. 
Research has also demonstrated that vitamin B1 administration suppresses thermal 
hyperalgesia  [increased sensitivity to pain] by reducing hyper-excitability and lessening 
alterations of sodium currents in injured dorsal root ganglia neurons in rats (24).  This maybe 
correlated to the injury incurred by oxaliplatin in the dorsal root ganglia as it affects voltage-
gate sodium currents and causes axonal degeneration without evidence of primary 
demyelination (3, 5). Therefore thiamine administration potentially regenerates axons, reduces 
pain and aids in balancing sodium currents in cancer patients receiving oxaliplatin. 
Vitamin B12 may also aide in preventing CIPN although no direct connection has yet been 
reported. Research has found that a deficiency in vitamin B12 results in an imbalance of 
cytokines and growth factors that directly affect glial cells and nerve myelination. Abnormally 
high levels of TNF-α and abnormally low levels of epidermal growth factor (EGF) have been 
found in vitamin B12 deficiencies which can cause demyelination resulting in nerve damage 
(39,40). Other cytokines and end products reported from vitamin B12 deficiencies include 
increased NF-κB, accumulation of Nέ-Carboxymethyllysine (CML) in sural nerves and 
activation of the receptors for advanced glycation end products (RAGE) pathway (38). These 
are all related to an inflammatory response (38). 
Furthermore, an in-vitro study found that neuroblastoma cells that were deficient in vitamin 
B12 showed slower proliferation but faster differentiation. This was through interacting 
signalling pathways related to an increased expression of catalytic protein phosphatase 2A 
(PP2A), pro-nerve growth factor (proNGF) and two tumor necrosis factor alpha converting 
enzymes (TACE) (41). Nerve regeneration, myelinogenesis, reduction in inflammatory 
cytokines such as TNF-α and up-regulation of neural IGF-1 gene expression has been shown 
to reverse or markedly improve peripheral neuropathy by administration of vitamin B12 (21, 
22, 37, 42-47). Hence, vitamin B12 has the potential in conjunction with other B vitamins to 
assist in preventing CIPN development. 
Discussion 
CIPN can affect chemotherapy dose and continuation of treatment which is of clinical 
importance. Investigating agents that can assist with CIPN treatment and prevention has 
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significant scientific merit.  Several different substances hypothesised for pharmacological 
neuroprotection (e.g. Amifostine) have been trialled however neither prophylactic strategies 
nor symptomatic treatments have proven useful at this stage (5, 48). 
B group vitamins have the potential to decrease the onset and severity of CIPN as a deficiency 
of B vitamins biochemically affects the health of nerve fibres and ganglia that neurotoxic 
chemotherapy agents can further adversely modulate. Reducing this chemotherapy induced 
side effect is clinically relevant for disease outcome and quality of life.  
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Table 1: A differential diagnosis of peripheral neuropathy in patients with cancer [2] 
Cause Neurotoxic Effect on Peripheral Nerves 
Vitamin B12 deficiency Large fibre injury, Dorsal root ganglia damage 
Cachexia Diffuse weakness and muscle wastage 
Chemotherapy Small and/or large fibre injury 
Charcot-Marie-Tooth disease Large fibre injury 
Diabetes Mellitus  Small fibre injury, slow development 
Atherosclerotic ischemic 
disease 
Sensory neuropathy in lower extremities 
Paraneoplastic syndrome Distal sensory or sensori-motor deficit 
Thyroid dysfunction Proximal and distal weakness; carpal tunnel 
syndrome 
Alcoholic neuropathy Numbness, parasthesias 
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Table 2: Neurotoxic Chemotherapy agents 
 
Chemotherapy 
Category 
Mechanism of 
Action 
Chemotherapeutic 
Drug 
Incidence of 
Peripheral 
Neuropathy 
Cancers 
Treated 
Sensory Symptoms Motor 
Symptoms 
Other common 
side effects 
 
Alkylating 
Agents 
Bind and cross 
link DNA strands, 
impairing cell 
division and 
inducing 
apoptosis. 
Neurotoxicity 
mechanism due 
to 
intracytoplasmati
c protein binding 
and ion channel 
interactions 
inducing neuronal 
apoptosis of the 
DRG. 
PLATINUM 
COMPOUNDS:  
 
 
59-92% 
[2,10,11] 
 
25% [4] 
 
 
Acute 80-90 % 
Chronic 15-
25% [2,4,8]   
 
Breast 
Colon 
Lung 
Testicles 
Bladder 
Ovaries [4] 
Mild to moderate 
numbness and 
tingling of hands 
and feet can occur 
after prolonged (4-
6 months) of 
therapy and may 
develop weeks 
after last dose.  
Symptoms can 
become severe 
with high 
cumulative doses.  
Reduced or absent 
Achilles tendon 
reflex. [2,4,8] 
Weakness is 
rare but can 
occur with 
high doses 
of Cisplatin 
and 
Oxaliplatin. 
[2,4]  
Ototoxicity, 
vestibular 
toxicity, anemia, 
neutropenia, 
leukocytopenia, 
thrombocytopeni
a, nausea, 
mucositis, 
vomiting, 
granulocytopenia, 
hypochromia 
[11,12] 
 
Cisplatin 
(Platinol®) 
 
Carboplatin 
(Paraplatin®)  
 
Oxaliplatin 
(Eloxatin®) 
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Chemotherapy 
Category 
Mechanism of 
Action 
Chemotherapeutic 
Drug 
Incidence of 
Peripheral 
Neuropathy 
Cancers 
Treated 
Sensory Symptoms Motor 
Symptoms 
Other common 
side effects 
 
 
 
 
 
Anti-Tubulin 
Agents 
 
Microtubule 
depolymerisation 
which inhibits 
mitosis resulting 
in apoptosis in 
rapidly dividing 
cells. 
Soluble tubulin 
exists in a cell as a 
heterodimer. 
During 
polymerisation, 
these 
heterodimers link 
together to form 
protofilaments 
which form a 
hollow cylinder 
that makes up the 
backbone of the 
microtubule. 
Anti-tubulin 
agents bind to 
the tubulin and 
TAXANE CLASS:  
Paclitaxel (Taxol®)  
 
Docetaxel  
(Taxotere®)  
 
Abraxane™  
 
60% [3,8,14] 
50% [3,8] 
71% [15] 
 
Breast 
Ovaries 
Prostate 
Non-small cell 
lung cancers 
[13] 
Mild to moderate 
numbness, tingling, 
burning/stabbing 
pain of hands and 
feet are common 
which can become 
severe with 
increased doses. 
Reduced or absent 
achilles tendon 
reflex [2,13] 
Weakness 
of distal 
muscles has 
been 
documente
d with high 
cumulative 
doses of 
paclitaxel 
and 
docetaxel. 
[2,13] 
Neutropenia, 
anemia, 
myalgia/arthralgi
a, nausea, 
alopecia, 
hypersensitivity 
reactions (allergic 
reactions) [16] 
VINCA ALKALOID 
CLASS:  
 
Vincristine 
(Onkovin®)  
Vinorelbine 
(Navelbine®)  
Vindesine  
Vinorelbine. 
 
 
75% [3,4,17] 
25% [3,4] 
 
 
25% [3,4] 
25% [3,4] 
Lymphomas 
Leukaemia 
Neuroblastoma 
Rhabdomyo-
sarcoma 
Ewing’s 
sarcoma 
Wilm’s tumour 
Multiple 
myeloma [18] 
Mild to moderate 
numbness, tingling, 
burning/stabbing 
pain of hands and 
feet are common 
and can become 
severe with 
increased doses. 
Reduced or absent 
Achilles tendon 
reflex [2,4] 
 
Weakness 
of distal 
muscles, 
decreased 
deep 
tendon 
reflexes, 
and foot 
drop have 
been noted 
with high 
doses [2,4] 
Granulocytopenia
, leukcytopenia, 
anemia, fatigue, 
nausea, alopecia, 
constipation, 
mouth ulcers [18] 
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 interfere with the 
heterdimerisation 
disrupting the 
microtubule 
dynamics (failure 
of alignment of 
the daughter 
chromosomes 
and their bipolar 
attachment to 
mitotic spindles)  
 
Epothilones: 
Ixabepilone 
Patupilone 
MBS-310705 
Epothilone D (KOS-
862) 
Sagopilone (ZK-EPO) 
 
 
 
60-71% 
[2,13] 
 
Breast 
Gastric 
Soft tissue 
sarcomas 
Prostate 
Ovaries 
Colon 
Lymphomas 
[13] 
 
Mild to moderate 
numbness, tingling, 
burning/stabbing 
pain of hands and 
feet are common 
which can become 
severe with 
increased doses. 
Reduced or absent 
achilles tendon 
reflex [2,13] 
Weakness 
of distal 
muscles 
with high 
doses [2,13] 
Neutropenia, 
leukopenia, 
nausea, 
stomatitis, 
pharyngitis, 
diarrohea, 
fatigue. [19] 
Proteasome 
inhibitors 
Inhibition of 
protein 
degradation 
through the 
ubiquitin-
proteasome 
pathway which 
carries out the 
regulated 
degradation of 
damaged cellular 
proteins. 
 
 
Bortezomib 
 
 
35-50% [5,6] 
 
Multiple 
myeloma 
Mantle-cell 
lymphoma [6] 
Can induce severe 
pain. Small-fibre, 
axonal, sensory 
neuropathy 
manifesting as 
burning, hyper- or 
hypo-esthesia and 
paresthesias 
affecting both 
hands and feet. [6] 
Severe CIPN 
results in 
vibration 
sense and 
ankle jerks.  
Muscle 
weakness is 
uncommon. 
[6] 
Tiredness, 
diarrhoea, rashes, 
skin 
discolouration, 
sore mouth, loss 
of appetite, 
decreased blood 
counts, swelling, 
fluid retention 
[20] 
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Chemotherapy 
Category 
Mechanism of 
Action 
Chemotherapeutic 
Drug 
Incidence of 
Peripheral 
Neuropathy 
Cancers 
Treated 
Sensory Symptoms Motor 
Symptoms 
Other common 
side effects 
Thalidomide A glutamic acid 
derivative that 
induces the 
production of 
interferon-  and 
interleukin-2, and 
inhibits tumour 
necrosis factor-α 
production and 
angiogenesis. It 
also inhibits the 
migration of both 
immune and 
phagocytic cells, 
reduces tumour-
associated 
macrophage 
infiltration and 
suppresses the 
proliferation of 
human myeloma 
cells 
 
 
Thalidomide 
 
 
50-83% [6] 
 
 
Multiple 
myeloma 
Myeloma [2,6] 
 
Mild to moderate 
numbness, tingling, 
burning hands and 
feet are common 
which can become 
severe with 
increased doses. 
Pain is uncommon 
[2,6] 
None noted Nausea, vomiting, 
blood clots, birth 
defects, fatigue, 
loss of appetite, 
dizziness, rashes, 
ankle swelling, 
fluid retention [6] 
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Figure 1: Site of chemotherapy-induced neurotoxicity. [6] 
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12.3 HERBAL MEDICINE AND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY 
(ACCEPTED BY CLINICAL REVIEWS IN FOOD SCIENCE AND NUTRITION IN 
JANUARY 2014 – AWAITING PUBLICATION) 
 
 
Herbal Medicines and Chemotherapy Induced Peripheral Neuropathy (CIPN): 
a Critical Literature Review. 
 
Abstract 
Background: Chemotherapy-induced peripheral neuropathy [CIPN] is a common significant and 
debilitating side effect resulting from the administration of neurotoxic chemotherapeutic agents. 
These pharmaco–chemotherapeutics can include taxanes, vinca alkaloids, platinum analogues and 
others. Moderate to severe CIPN significantly decreases the quality of life and physical abilities of 
cancer patients and current pharmacotherapy for CIPN (e.g. Amifostine and antidepressants) have 
had limited efficacy and may themselves induce adverse side effects.   
Methods: To determine the potential use of herbal medicines as adjuvants in cancer treatments a 
critical literature review was conducted by electronic and manual search on nine databases. These 
include PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, Google 
Scholar and two Chinese databases CNKI and CINAHL. Thirty-four studies were selected from 5614 
studies assessed and comprised of animal studies, case reports, retrospective studies and minimal 
randomized clinical trials investigating the anti-CIPN effect of herbal medicines as the adjuvant 
intervention in patients administered chemotherapy.  The thirty-four studies were assessed on 
methodological quality and limitations identified.   
Results: Studies were mixed in their recommendations for herbal medicines as an adjuvant treatment 
for CIPN.   
Conclusion: Currently no agent has shown solid beneficial evidence to be recommended for the 
treatment or prophylaxis of CIPN. Given that the number of cancer survivors is increasing, the long-
term side effects of cancer treatment, is of major importance.  
 
Key Words: Chemotherapy-induced peripheral neuropathy, herbal medicines, peripheral 
neuropathy, herbs. 
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Abbreviations 
AC  Acorus calamus 
CIPN  Chemotherapy-Induced Peripheral Neuropathy 
CAPEOX Chemotherapy regime comprising of: Capecitabine and Oxaliplatin 
DBRCT Double Blind Randomised Controlled Trial 
FOLFOX Chemotherapy regime comprising of: Folinic acid (leucovorin), Fluorouracil and 
Oxaliplatin 
GB  Ginkgo biloba 
GJG  Gohsajinkigan 
HIV  Human Immunodeficiency virus 
IPN  Induced Peripheral Neuropathy 
IV  Intravenous 
MC  Matricaria chamomilla 
NHMRC National Health and Medical Research Council 
PN  Peripheral Neuropathy 
PNQ  Peripheral Neuropathy Questionnaire 
RCT  Randomised Controlled Trial 
SO  Salvia officinalis 
TCM  Traditional Chinese Medicine 
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Herbal Medicines and CIPN 
Introduction 
Chemotherapy-induced peripheral neuropathy [CIPN] is major dose limiting side effect of certain 
chemotherapy agents including taxanes, platinum compounds, epothilones, vinca alkaloids, 
thalidamide and newer agents such as bortezomib and lenolidamide [Wolf et al., 2008]. The incidence 
of CIPN varies depending on the chemotherapy agent but can range from 20% to 75% [Caveletti et 
al., 2011]. The symptoms of CIPN can be numbness, tingling, burning, decreased touch sensation, 
decreased strength and movement and sometimes pain in the fingers, toes, hands or feet [Armstrong 
et al., 2005; Visovsky et al., 2008]. 
 
Mechanism of Action for CIPN 
Currently, the exact mechanism of action underlying the neurotoxic activity of the chemotherapy 
agents that can cause CIPN is largely incomplete and data is frequently based on poorly supported 
assumptions. There are similarities between the cytotoxicity mechanism of action of the 
chemotherapy agent and their action on the peripheral nervous system cells. However, if the amount 
of DNA damage or cellular damage exceeds the cells ability to repair, the cell will undergo apopotosis 
or cell death. This damage does not explain the sensory, possible motor involvement and pain 
associated with CIPN [Caveletti et al., 2011]. These neoplastic agents have been found to accumulate 
in the peripheral nervous system and its this accumulation that is said to cause the neurotoxicity 
leading to CIPN however, the mechanism of action is still relatively unknown.  [Bhagra et al, 2007; 
Cavaletti et al., 2008; Cavaletti et al, 2004; Park et al., 2008; Pirzada et al., 2000; Schiff et al., 2009]. 
 
Justification for conducting a literature review on herbal medicine and CIPN 
 It is estimated that one third of all patients who undergo chemotherapy experience CIPN and of those, 
a third can have permanent nerve damage [Bhagra et al, 2007; Cavaletti et al., 2008; Cavaletti et al., 
2004].  Patients experiencing moderate to severe CIPN report a reduced quality of life [Cavaletti et 
al., 2008], chronic discomfort [Cavaletti et al., 2004] and disruption of physical abilities for general 
life activities, which can be temporary or permanent [Cavaletti et al., 2008].  Moreover, CIPN can 
lead to dose reduction of the chemotherapy agent or possible cessation of treatment, which may have 
an adverse impact on cancer treatment and disease outcomes [Bhagra et al., 2007]. 
 
Currently no pharmaceutal or neutraceutical agent has shown solid beneficial evidence to be 
recommended for the treatment or prophylaxis of CIPN. Given that the number of cancer survivors 
is increasing, the long-term side effects of cancer treatment, is of major importance. Herbal medicine 
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may have the potential to provide prevention or treatment for CIPN. Hence, examining the current 
literature to assess studies conducted on herbal medicine and CIPN may provide information to its 
possible benefit.  
 
Herbal treatments may offer a different aspect to assisting CIPN however the main problem with 
research involving herbal extracts or medicinal herbs is the understanding of the mechanism of 
actions and the fact that the herbs contain a number of active compounds. Moreover, Asian herbal 
therapies contain a combination of multiple herbs, which adds to the complexity of study analysis, 
data interpretation and an assessment of benefit. Isolation of one extract which is common in scientific 
research is unable to be conducted with herbal medicine research in most situations as the 
combination of compounds or combination of herbs such as Asian herbal therapies are seen to work 
in synergy. 
 
The Aetiology of CIPN 
A differential diagnosis of peripheral neuropathy in patients diagnosed with cancer includes a vitamin 
B12 deficiency, cachexia, chemotherapy, Charcot-Marie-Tooth disease, diabetes mellitus type II, 
atherosclerotic ischemic disease, para-neoplastic syndrome, thyroid dysfunction and alcoholic 
neuropathy  [Armstrong et al., 2005]. Requisites for peripheral nervous system neurotoxicity include 
chemotherapy agent capacity to cross the blood-nerve barrier and nervous system sensitivity to the 
drug.  People with predisposing conditions such as type II diabetes mellitus (T2DM), HIV/AIDS, 
alcoholism or a vitamin B12 deficiency may be more prone to the agent’s adverse effects on the 
peripheral nervous system thereby increasing the prevalence of CIPN [Armstrong et al., 2005].   
 
Peripheral nerve fibres are composed of small or large fibres. Small nerve fibres are unmyelinated 
and are comprised primarily of microtubules. They include nerves that sense pain and temperature. 
Large nerve fibres are myelinated and are composed mainly of neurofilaments that act as a framework 
for the axon.  These fibres sense position and vibration as well as motor control [Armstrong et al., 
2005]. Both fibres are targeted by neurotoxic chemotherapy agents, and that may explain why patients 
experience a variety of symptoms.   
 
Although each neurotoxic chemotherapy agent has a different mechanism of action on the nervous 
system, all induce a glove and stocking distribution. This means the point most distal from the trunk 
of the body is affected first (e.g. fingers and toes) and progression is then towards the trunk to hands 
and feet and then limbs [Armstrong et al., 2005]. Each agent has been found to affect one nerve fibre 
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more than others, for example, cisplatin targets large fibres while paclitaxel and vincristine target 
small fibres [Armstrong et al., 2005].   
 
CIPN can be a temporary side effect, which can take up to two years for full recovery. In 
approximately one third of cases it can be a permanent side effect of the drug’s neurotoxicity action. 
Symptoms may occur within hours, days or weeks after the introduction of the chemotherapy agent, 
with cumulative doses increasing the severity and length of time the patient experiences this side 
effect [Armstrong et al., 2005]. Cisplatin differs to other neurotoxic agents as it can induce a delayed 
CIPN several months after the drug has been administered rather than a more immediate response 
[Cavaletti et al., 2004]. 
 
Mechanism of Action of Neurotoxic Chemotherapy Agents 
The neurotoxic chemotherapy agents can be divided into four main categories, alkylating and anti-
tubulin agents, thalidomide and proteasome inhibitors. A common feature of these drugs is that they 
are unable to cross the blood-brain barrier thereby protecting the central nervous system. The 
peripheral nervous system has no protective barrier making it susceptible to neurotoxicity [Cavaletti 
et al., 2008] and therefore neurotoxic chemotherapy agents can accumulate and target different 
regions of the neuron [Ferrier et al., 2013]. 
 
Methodology 
Selection Criteria 
The Inclusion criteria for this review were:  
1) Any type of human trial e.g. RCT, retrospective, case study;  
2) Animal studies;  
3) The use of a herb or combination of herbs as the main intervention and specifically investigating 
its effects on reducing the primary outcome i.e. CIPN; and  
4) The journal article or abstract must be written in English (a number of Asian journal articles 
had the abstract in English but the journal article in their language i.e. Japanese or Chinese.) 
 
Databases 
The following databases were used to retrieve journal articles: PubMed, the Cochrane Library, 
Science Direct, Scopus, EMBASE, MEDLINE, and Google Scholar. 
Chinese databases included CNKI and CINAHL. 
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Search Terms 
Electronic databases were searched using the following  search terms, “chemotherapy-induced 
peripheral neuropathy” OR “Cisplatin” OR “Taxanes” OR “Paclitaxel” OR “Docetaxel” OR 
“Oxaliplatin” OR “Carboplatin” OR “Platinum compounds” OR “Proteasome inhibitors” AND 
“peripheral neuropathy” OR “CIPN” AND “herb” OR “cannabis” OR “chamomile” OR “ginkgo” 
OR “sweet bee venom” OR “turmeric” OR “sage” OR “hypericum” OR “herbal medicines” OR 
“Chinese herbal medicines” OR “ayurvedic herbal medicines”. 
 
The overall body of evidence (based on a summary of the individual studies: See Table 1 and 2) 
evaluated within this review was primarily assessed using a separate tool, the Australian National 
Health and Medical Research Council’s (NHMRC) body of clinical evidence assessment matrix. This 
is an assessment tool that assigns a level/grade (Level I: strongest evidence to level IV: weakest 
evidence) based on the strength of the published study [NHMRC, 2009]. Supportive evidence was 
obtained from animal studies. 
 
Risk bias assessment 
The risk bias of both animal and human studies was assessed using the Cochrane Risk of Bias 
Assessment tool (http://handbook.cochrane.org/ , part 2, Chapter 8). All studies were reviewed by 
two reviewers (JS, LV).  
 
Data Synthesis 
All human clinical trial data (excluding case studies) was analysed using RevMan version 5.2.7 to 
quantify and compare the efficacy outcomes of the intervention versus control.  
 
 
Results 
A total of 5614 journal articles were identified. These were retrieved through electronic search and 
examination of references in reviews. Dissemination of the articles and abstracts decreased the total 
of articles from 5614 to 34 relevant journal articles. These results found 6 single herbs [Abad et al., 
2011a, 2011b; Al Moundhri et al., 2013; Cakil, 2012; Huang et al., 2007; Lim et al., 2013; Marshall 
et al., 2004; Muthuraman A et al., 2011; Ozturk et al., 2004; Park et al., 2011; Xu O, et al., 2004; 
Yoon et al., 2012;], one extract [Xu F, et al., 2011], one receptor agonist [Rahn et al., 2007; Rahn et 
al., 2008] and 8 combinations of herbs [Bahar et al., 2013; Deng and Zou, 2007; Fujii et al., 2004; 
Hashimoto et al., 2004, 2006; Hidaka et al., 2009; Hosokawa et al., 2012; Kaku et al., 2012; Kono et 
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al., 2011, 2013; Nishioka et al., 2011; Pan et al., 2012; Shindo et al., 2008; Sima et al., 2009; Sun et 
al., 2008; Tatsumi et al., 2009; Ushio et al., 2012; Yamada et al., 2012; Yamamoto et al., 2009;].  
 
All studies included in this review were analysed for common scientific characteristics however lower 
levels of evidence was used as rigorous randomised clinical trials were limited. The flow chart of 
study selection can be seen on figure 1.  Of the journal articles identified n=18 were animal studies 
(see table 1) with human clinical studies consisting of one multi-centre, randomised double-blind 
placebo-controlled trial, six randomised trials, six retrospective studies, one uncontrolled study and 
three case reports found, [n=17] (see Table 2).  
 
Animal Studies (See table 1 ) 
 
Single Herbal Medicines in Animal Studies and CIPN 
1. Acorus calamus rhizome 
Acorus calamus (AC) is an Ayurvedic herb traditionally used to treat or manage pain and 
inflammation. This study investigated if AC had protective effects for vincristine-induced painful 
neuropathy in rats. Acorus calamus was compared to pregabalin (Lyrica) and was found to be 
comparable as both attenuated the vincristine-induced painful neuropathy [Muthuraman et al., 2011].  
 
2. Curcumin longa  
Curcumin, an extract from turmeric has been reported to have strong anti-inflammatory, anti-cancer 
and antioxidant activity [Al Moundhri et al., 2013].  This study looked at curcumin’s potential 
protective effect on cisplatin and oxaliplatin induced behavioural, biochemical and histopathological 
changes in rats. Rats were randomly divided into five groups (six rats per group): 1) IV glucose and 
distilled water; 2) IV oxaliplatin and distilled water; 3) IV oxaliplatin and curcumin in water; 4) IV 
cisplatin and distilled water; 5) IV cisplatin and curcumin in water. Results found that oral curcumin 
reversed the alterations in the plasma neurotensin and sciatic nerve platinum concentrations and 
markedly improved sciatic nerve histology. This study doesn’t provide complete evidence for 
neuroprotection however it does give evidence warranting further research.  
 
3. Ginkgo biloba (EGb 761) 
Ginkgo biloba (GB) has been found in in-vivo and in-vitro studies to have potential as a 
neuroprotective agent [Mills, 1991]. Four studies on animals have been conducted to test GB as a 
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neuroprotective agent against cisplatin-induced peripheral neuropathy particularly focusing on 
ototoxicity [Cakil et al., 2012; Huang et al., 2007; Ozturk et al., 2004; Xu O, et al., 2004].  
 
Cakil B, et al (2012) tested twenty rats with normal hearing to cisplatin exposure with one group 
receiving 100mg/kg of GB for 10 days. Results indicated that ginkgo could protect against inner ear 
cisplatin-induced ototoxicity. Huang X, et al. (2007) also tested GB on rats to investigate its protective 
effect for ototoxicity by cisplatin administration. Results from this investigation also found GB to be 
protective against cisplatin-induced ototoxicity.  
 
Xu O, et al. (2004) investigated the combination of GB and deferoxamin (DFO, a chelating agent) on 
guinea pigs again focusing on the ototoxicity induced by cisplatin. They concluded that the combined 
use of GB and DFO reduced cisplatin-induced ototoxicity and that the combination was better than 
using just GB alone. The fourth animal study was conducted on mice by Ozturk G, et al. (2004) who 
investigated the neuroprotective effects of GB for cisplatin-PN, not just ototoxicity. They evaluated 
the neuropathy by conducing nerve conduction velocity (NCV) tests on the mice. Results indicated 
that GB was effective in preventing some functional and morphological peripheral nerve 
deteriorations induced by cisplatin administration.   
 
4. Matricaria chamomilla (chamomile) 
Matricaria chamomilla (MC) is traditionally used for sedation, pain management, spasms, 
inflammation and wound healing [Berry, 1995; Hosokawa et al., 2012]. This study’s aim was to 
investigate the effects of MC hydro-alcoholic extract on cisplatin-induced peripheral neuropathy 
compared to morphine in mice. Mice were divided into 6 groups which received: 1) normal saline; 2) 
MC hydro-alcoholic extract; 3) cisplatin; 4) MC hydro-alcoholic extract and cisplatin; 5) morphine; 
6) morphine and cisplatin. The results found that cisplatin caused significant pain (P<0.05) and that 
MC given before cisplatin decreased the pain response significantly (P<0.05) in the first and second 
phase. In comparison to morphine, morphine had analgesic effects in the first phase while MC had 
anti-inflammatory effects in the second phase [Abad et al., 2011a].   
 
5. Salvia officinalis 
Salvia officinalis (SO) or sage is a traditional culinary herb that has been found to have analgesic and 
anti-inflammatory activity [Howes et al., 2003, Wang et al., 2001]. One study investigated an SO 
hydro-alcoholic extract on vincristine-induced peripheral neuropathy in mice compared to morphine 
[Abad et al., 2011b]. Sixty mice were divided into six groups similar to the chamomile study [Abad 
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et al., 2011a]. Results found that SO could be effective as a treatment for vincristine-induced 
peripheral neuropathy [Abad et al., 2011b]. 
 
6. Sweet bee venom (pharmacopuncture) 
Sweet bee venom treatment is a part of a normal oriental medical practice in Korea for the treatment 
of various pain and neurological symptoms [Yoon et al., 2012]. Pharmacopuncture is a treatment by 
which pharmaceuticals and acupuncture are joined by injecting pharmaceutical derivatives into 
acupuncture points chosen for each patient’s diagnosis and symptoms based on TCM [Yoon et al., 
2012].  
 
A recent article looked at bee venom acupuncture for cold allodynia induced from oxaliplatin in rat 
[Lim et al., 2013]. It found that it was effective in alleviating the oxaliplatin-induced cold allodynia 
in rats which was partly due to the activation of the noradrenergic system.  
 
Herbal Medicine Extracts in Animal Studies and CIPN 
 
1. Verticinone (Extract from Bulbus Fritillaria) 
Verticinone is an isosteroidal alkaloid, which has been extracted from the Bulbus Fritillaria [Xu F, et 
al., 2011]. It has been used in China for more than 2000 years as an antitussive, expectorant and anti-
asthmatic [Lee et al., 2006]. Recently, verticinone has demonstrated in pharmacological studies more 
diverse bioactivities such as inhibiting angiotensin I converting enzyme [Li et al., 2006], antagonizing 
M-receptor (the muscarinic acetylcholine receptor) activity and significantly elevating cAMP 
concentrations in HEK cells [Oh et al., 2003].  
 
This study aimed to investigate verticinone’s effect on paclitaxel induced neuropathic pain compared 
to morphine. The authors concluded that verticinone seemed to exert good analgesic effects for the 
inflammatory pain and the CIPN pain. The hypothesised this could be through both the central and 
peripheral nervous system and that further studies are warranted [Xu F et al., 2011]. 
 
Herbal Medicines with Receptor Agonist Activity in Animal Studies and CIPN 
 
1. Cannabis (Cannabis sativa L.) 
Cannabinoids have been tested for nerve suppression and two studies have examined the cannabinoids 
suppression potential for CIPN from vincristine [Rhan et al., 2007] and paclitaxel [Rahn et al., 2008] 
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in rats.  The two main cannabinoids tested include 1) CB1/CB2 receptor agonist WIN55,212-2  and; 
2) receptor-inactive enantiomer WIN55,212-3, a CB2-selective agonist (R,S)-AM1241 [Rahn et al., 
2007]. 
 
For the vincristine experiment, WIN55,212-2 was administered intrathecally (in the spine) or locally 
into the hind paw of rats. Results found that WIN55,212-2 not WIN55,212-3 suppressed vincristine 
evoked mechanical allodynia. The authors concluded that cannabinoids can suppress the maintenance 
of vincristine-induced mechanical allodynia through the activation of CB1 and CB2 receptors and 
this was mediated partly at the spinal cord level [Rahn et al., 2007].  For the paclitaxel experiment, 
they concluded that cannabinoid CB(2) receptors maybe a potential treatment for paclitaxel CIPN 
[Rahn et  al., 2008].  
 
Combination Herbal Medicines in Animal Studies and CIPN 
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1. Geramii herba plus Aconiti radix 
The combination of Geramii herba and Aconiti radix herbs was used as an external application in a 
rat model of oxaliplatin CIPN. The results showed that mechanical allodynia and thermal 
hyperalgesia were alleviated, nerve growth factor (NGF) was increased and substance P was 
decreased in the treated rat group compared to oxaliplatin alone [Sima et al., 2009]. 
 
2. Goshajinkigan (Japan), Niu Che Sen Qi Wan (Chinese), Pilula renales plantaginis et 
achyranthis (Lat.) 
Nine trials on both animals and humans have been conducted on this formula [Bahar et al., 2013; 
Hashimoto et al., 2004, 2006; Kaku et al., 2012; Kono et al., 2011, 2013; Nishioka et al., 2011;  
Shindo et al., 2008;  Ushio et al., 2012; Yamamoto et al., 2009]. This formula contains ten herbs: 
Rehmannia viride radix, Achyranthis bidentatae radix, Corni fructus, Dioscorea opposite rhizome, 
Plantaginis semen, Alismatis rhizome, Moutan cortex, Cinnamomi cortex, Aconiti lateralis 
praeparata tuber, and Poria alba [Japan Society of Oriental Medicine, 2005]. A rat study tested this 
formula (GJG) on paclitaxel-IPN in three different studies.  
 
The first trial found no neuroregeneration in histological examination [Hashimoto et al., 2004] 
however the second trial found that it showed a positive effect on cold allodynia [Hashimoto et al., 
2006]. A recent trial on mice found that GJG was effective for mechanical allodynia from paclitaxel 
but not for tumour allodynia [Akbar Bahar et al., 2013].  Another rat study tested GJG on oxaliplatin-
IPN and found that it prevented cold hyperalgesia but not mechanical allodynia or axonal 
degeneration in rat sciatic nerves. However, after CIPN had developed, a single administration of 
GJG reduced both cold hyperalgesia and mechanical allodynia [Ushio et al., 2012]. 
 
3. Shakuyakukanzoto (Japanese), Shao Yao Gan Cao Tang (Chinese), Formula glycyrrhizae et 
paeonia (Lat), Peony and Licorice Decoction (English) 
This herbal formula is a combination of Peony and Licorice in a decoction. Three studies have been 
conducted on this herbal combination, one mouse study [Hidaka et al., 2009], a retrospective case 
analysis [Fujii et al., 2004] and a retrospective clinical trial comparison [Hosokawa et al., 2012]. The 
mouse study invested paclitaxel-IPN and found that this combination significantly relieved the 
allodynia and hyperalgesia induced by paclitaxel [Hidaka et al., 2009].  
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Human Studies on CIPN and Herbal Medicine (see Table 2) 
 
Single Herbal Medicines on Human Studies and CIPN 
 
1. Ginkgo biloba (EGb 761) 
One retrospective study has been conducted on human beings administered oxaliplatin [Marshall et 
al. 2004]. The retrospective analysis was conducted on 17 colorectal patients who were being treated 
with either FOLFOX or CAPEOX chemotherapy regimes for either adjuvant or metastatic treatment 
[Marshall et al., 2004]. GB 120mg b.i.d was given orally either after cycle 1 or 2 of treatment. They 
concluded that GB appeared to decrease the intensity and duration of the acute dysethesias caused by 
oxaliplatin and have initiated a phase II RCT to confirm results. To date, no results have been 
published from this phase II trial which apparently started in 2004. [Marshall et al., 2004] 
 
2. Sweet bee venom (pharmacopuncture) 
Two journal articles outlining case studies using sweet bee venom for CIPN have been found with 
the agent used being identified as melittin, an extracted active ingredient from the bee venom that 
has the allergens removed such as phospholipase A2 (PLA2), hyaluronidase and histamine. Melittin 
is a low molecular weight peptide and is reported to have analgesic, anti-inflammatory and anti-
cancer effects [Choi et al., 2006; Kwon et al., 2006; Wang et al., 2001]. 
The first article outlined 5 case reports receiving a one week course of treatment with sweet bee 
venom pharmacopuncture. No side effects were experienced and results indicated clinical 
improvement of CIPN [Park et al., 2011]. Another case series on 11 patients were treated for three 
weeks with six sweet bee venom pharmacopuncture treatments. Results showed a reduction in the 
WHO CIPN grade and PNQ score indicating a reduction in CIPN [Yoon et al., 2012]. Further studies 
are required to confirm their findings. 
 
Combination Herbal Studies on Human Studies and CIPN 
 
1. Bu Yang Huan Wu (Chinese) 
This formula consists of Astragulus membranaceus radix, Angelica sinesis radix, Prunus persicae 
semen, Paeoniae rubra radix, Ligustici chuanxiong rhizome, Lumbricus terrestris, Spatholobi caulis, 
Curcuma radix, Chaenomeles lagenaria fructus and Achyranthes bidentatae radix. In traditional 
Chinese medicine (TCM) it is said to tonify the yang and restore the five-tenths decoction [Zhou et 
al., 2006]. This decoction was used in an RCT of 84 participants (intervention n=44, control n=40) 
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for the treatment of CIPN after oxaliplatin administration. Results indicated that Bu Yang Huan Wu 
reduced the development of CIPN in the treatment group tested by standardized clinical tests [Sun et 
al., 2008]. 
 
2. Modified Bu yang Huan Wu (Chinese) 
The modified formula used was Bu Yang Huan Wu plus Liuwei Di Huang which contains the herbs: 
Astragulus membranaceus radix, Ligustrum lucidum fructus, Paeoniae rubra radix, Lumbricus 
terrestris, Prunus persicae semen, Rehmanniae viride radix, Corni officinalis fructus, Dioscorea 
opposite radix, Alismatis rhizome, Poria alba, Spatholobi caulis, Scolopendra, Mori fructus, 
Glycyrrhizae radix, Dipsaci fructus, Lycii fructus, Coicis semen, Atractylodis Rhizome, Phellodendri 
cortex, Scorpio, Moi ramulus and Cyathula officinalis. A RCT was conducted using this decoction 
on 32 patients with existing CIPN from various chemotherapy agents. The treatment was compared 
to 32 patients who were treated daily with 2500µg of vitamin B1 orally in addition to intramuscular 
injections of 100mg of vitamin B1. The Chinese herbal formula was found to be significantly more 
effective compared to the vitamin B1 treatment (P<0.05) [Deng et al., 2007]. 
 
3. Modified Chai Hu Long Gu Mu Li Wan (Chinese) 
This modified Chinese oral combination of herbs consists of Psuedostellaria heterophylla,Pinelliae 
rhizome, Glycyrrhizae radix, Scutellaria baicalensis radix, Bupleuri radix, Fossiliaossis mastoid, 
Ostreae concha, Rubia cordifolia radix, Scutellariae barbatae herba and Fritillariae thunbergia 
bulbi. This combination was used in a RCT of 48 patients with ovarian cancer undergoing paclitaxel 
administration. They were divided into a control group of paclitaxel only or a treatment group of 
paclitaxel plus a combination of the oral Chinese herbal decoction and an external washing of the feet 
with Chinese herbs (Astragulus membranaceus radix, Angelica sinensis radix, Paeoniae radix, 
lumbricus terrestris, Ligustici chuanxiong Rhizome, Prunus persicae semen and Carthami flos.) 
Results indicated that the incidence rate of CIPN in the treatment group was nearly half compared to 
the paclitaxel only group. Therefore this Chinese formula may help in preventing paclitaxel CIPN 
[Pan et al., 2012]. 
4. Geramii herba plus Aconiti radix 
A RCT was conducted on 58 patients experiencing CIPN from oxalipatin, taxol or capecitabine. 30 
patients were assigned to the treatment group and 28 to the control group. After one week of 
treatment, the external application of the two herbs was found to reduce pain, paraesthesia and 
swelling. The authors concluded that Geramii herba plus Aconiti radix may relieve neuropathy and 
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improve quality of life. No species of these two herbs were mentioned in the abstract [Sima et al., 
2009]. 
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5. Goshajinkigan (Japan), Niu Che Sen Qi Wan (Chinese), Pilula renales plantaginis et 
achyranthis (Lat.) 
Six human trials have been conducted on Goshajinkigan [GJG].. Firstly, GJG was invested in a non-
controlled trail on 14 patients receiving oxaliplatin. GJG was administered every day after the first 
oxaliplatin infusion and results indicated that it seemed to prevent acute oxaliplatin-IPN [Shindo et 
al., 2008]. Two retrospective studies were conducted on FOLFOX (oxaliplatin) and GJG [Kono et 
al., 2011; Nishioka et al., 2011]. The first trial was conducted on 45 patients with 22 patients receiving 
GJG with their FOLFOX regime compared to 23 who did not receive GJG. They found that the 
incidence of grade 3 CIPN in the GJG group was significantly lower than in the control group 
(P<0.01, log-rank test) [Nishioka et al., 2011].  
 
The second study investigated 90 patients undergoing FOLFOX for metastatic colorectal cancer. 
There were four groups: 1) FOLFOX plus GJG; 2) FOLFOX plus GJG plus Ca2+/Mg2+; 3) FOLFOX 
plus Ca2+/Mg2+; 4) FOLFOX only. Results included the incidence rate for each group which were 
91% for FOLFOX only, 100% in FOLFOX plus Ca2+/Mg2+, 79% in FOLFOX plus GJG plus 
Ca2+/Mg2+ and 50% in FOLFOX plus GJG. The authors concluded that GJG reduced the 
neurotoxicity of oxaliplatin without affecting the response rate [Kono et al., 2011].  
 
In another retrospective trial, GJG was investigated for paclitaxel-IPN in 82 breast and 
gynaecological cancer patients. The investigators concluded that GJG was possibly effective for the 
treatment and the prevention of paclitaxel-IPN was seemed more effective if administered at the 
beginning of chemotherapy treatment [Yamamoto et al., 2009]. Another human trial on GJG involved 
a prospective RCT on paclitaxel/carboplatin treatment for 29 ovarian or endometrial cancer patients. 
They were divided into two groups; 1) 14 patients received vitamin B12; 2) 15 patients received 
vitamin B12 and GJG and were given treatment for six weeks. Grade 3 CIPN was observed in 2/14 
patients receiving vitamin B12 compared to 0/15 receiving vitamin B12/GJG. It was concluded that 
GJG inhibits the progression of CIPN but further trials are warranted [Kaku et al., 2012]. 
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A recent phase II multi-centre, randomised, double-blind, placebo-controlled trial was conducted and 
published on GJG and oxaliplatin-induced PN [Kono et al., 2013]. In this trial, patients undergoing 
FOLFOX for colorectal cancer was randomised to either receive oral GJG (7.5g) or matching placebo 
daily. The severity of CIPN was assessed using the common toxicity criteria for adverse events every 
two weeks until the 8th cycle, and then every 4 weeks thereafter. The primary endpoint was the 
incidence of grade 2 CIPN or greater before the 8th cycle. The incidence of grade 2 or greater CIPN 
was 39% in the GJG arm and 51% in the placebo arm. The authors concluded that GJG shows promise 
in delaying the onset of grade 2 or greater CIPN without impairing FOLFOX efficacy [Kono et al., 
2013]. 
 
6. Keishikajutsubuto (Jananese), Gui Zhi Jia Shu Fu Tang (Chinese), Decoctum ramulorum 
cassia cum atractylodis macrocephae et aconite (Lat) 
This oriental formula contains Cinamomi cortex, Aconiti lateralis praeparata tuber, Zingiberis 
rhizome, Jujubae fructus, Glycyrrhizae radix and Atracylodis macrocephalae rhizome. A non-
controlled trial was conducted investigating this herbal formula on 11 patients with metastatic 
colorectal cancer undergoing FOLFOX administration. A reduction of CIPN was observed in 5 cases 
(45.5%) after cessation of chemotherapy [Yamada et al., 2012].  
 
7. Ogikeishigomotsuto (Japanese), Huang Qi Wu Wu Tang (Chinese), Decotum quinque 
medicamentorum cum astragalo (Lat.), Astragulus and Cinnamon Five herb combination 
(English) 
This oriental herbal combination contains Astragalus membranaceus radix, cinnamomi cortex, 
Paeonia alba radix, Jujubae fructus and Zingiberis 12-371hizome. A single case study was 
published using this formula for neuropathic pain induced by oxaliplatin. It showed a positive effect 
in reducing the pain and the patient was allowed to continue chemotherapy treatment with 
oxaliplatin [Tatsumi et al., 2009]. 
 
8. Shakuyakukanzoto (Japanese), Shao Yao Gan Cao Tang (Chinese), Formula glycyrrhizae et 
paeonia (Lat), Peony and Licorice Decoction (English) 
Two studies human studies have been conducted on this formula, a retrospective case analysis [Fujii 
et al., 2004] and a retrospective clinical trial comparison [Hosokawa et al., 2012]. 
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The retrospective case analysis investigated 23 patients with paclitaxel-IPN and observed that this 
combination had a positive effect on the neuropathic pain experienced by these ovarian cancer 
patients [Fujii et al. 2004]. Lastly the retrospective clinical trial compared Shakuyakukanzoto (peony 
and licorice) to Goshajinkigan (GJG). This was a preventive study and investigated 20 metastatic 
colorectal cancer patients administered Shakuyakukanzoto in conjunction with FOLFOX compared 
to 24 patients administered GJG. The Shakuyakukanzoto group was found to prevent 65% CIPN 
compared to 50% in the GJG group. It was concluded that both formulas may prevent oxaliplatin-
IPN [Hosokawa et al., 2012]. 
 
Discussion 
Current improvements in detection and treatment strongly correlate with increases survival rates of 
those patients diagnosed with cancer [Coleman et al., 2011].  With an increased survival rate, long-
term side effects from chemotherapy and other medical treatments has raised significant awareness 
as it can affect quality of life and clinical outcomes [Bhagra et al., 2007; Cavaletti et al., 2008; 
Takenaka et al., 2012]. CIPN is an important side effect that can affect quality of life and can be a 
permanent consequence of treatment [Bhagra et al., 2007; Caveletti et al., 2004, 2008]. Currently, 
there are no standard recommended treatments or prophylactic options that employ pharmacological, 
nutraceutical or herbal medicines.  Agents that have shown promise such as duloxetine [Takenaka et 
al., 2012; Smith et al., 2013], vitamin E [Argyriou et al., 2005, 2011; Pace et al., 2003, 2010], omega 
3 fatty acids [Ghoreishi et al., 2012], and Asian herbal medicines in particular Goshajinkigan [Bahar 
et al., 2013; Hashimoto et al., 2004, 2006; Kaku et al., 2012; Kono et al., 2011, 2013; Nishioka et al., 
2011;  Shindo et al., 2008;  Ushio et al., 2012; Yamamoto et al., 2009] require further research, 
however, in order to assess the strength of efficacy.  
 
Traditional scientific research is based on a single agent or active compound; herbal medicines though 
can be comprised of numerous active compounds with synergistic efficacy. For example in the use 
of Asian herbal medicines, a combination of herbs can be employed [Kono et al., 2013]. This 
combination may give a multi-targeted approach that complicates the identification and elucidation 
of the active compound and the mechanism of action. Nevertheless warranted research on single 
herbal extracts and compounds through validated clinical studies can still provide useful data.  
 
Investigations carried out with herbal medicines for CIPN found no neuroprotection or treatment 
when a single compound or herb was studied. Animal models provide basic research for further 
studies but do not guarantee that the herb or compound will be efficacious in human clinical trials. 
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Herbal medicines such as Ginkgo biloba [Marshall et al., 2004] and curcumin [Al Moundhri et al., 
2013] warrant further research as they have reported a positive clinical likelihood from animal studies.  
 
An important and common mechanism of action within the identified medicinal herbs trialled for 
CIPN is their anti-inflammatory activity [Al Moundhri MS et al., 2013; Berry, 1995; Choi et al., 2006; 
Ghoreishi et al., 2012; Howes et al., 2003; Kwon et al., 2006;  Lee et al., 2006; Mills, 1991; 
Muthuraman et al., 2011; Wang et al., 2001]. The anti-inflammatory activity of the herbs may be a 
plausible mechanism of action that assists with the protection and treatment of CIPN. Medical 
treatment of peripheral neuropathy has involved non-steroidal anti-inflammatory drugs for the 
inflammation and pain associated with this condition [Kaley and Deangelis, 2009]. This potential 
mechanism of action warrants further research which may attribute to other herbal remedies, nutrients 
or pharmaceuticals being trialled for CIPN. 
 
The Asian herbal combination remedies investigated for CIPN were difficult to analysis as a number 
of the journal articles were written in their Asian language rather than English. Therefore the 
information obtained for twelve out of the nineteen herbal combinations journal articles was extracted 
from abstracts. From these Asian herbal combinations, Goshajinkigan (GJG) is the herbal medicine 
that has been trialled extensively through animal and human clinical trials [Bahar et al., 2013; 
Hashimoto et al., 2004, 2006; Kaku et al., 2012; Kono et al., 2011, 2013; Nishioka et al., 2011;  
Shindo et al., 2008;  Ushio et al., 2012; Yamamoto et al., 2009]. Of the clinical trials, three were 
retrospective studies using controls for Folfox and paclitaxel administration [Kono et al., 2011; 
Nishioka et al., 2011; Yamamoto et al., 2009], one RCT [Kaku et al., 2013] comparing vitamin B12 
administration with the herbal combination and a recent phase II multi-centre, randomised, double-
blind, placebo-controlled trial conducted as an adjuvant treatment with FOLFOX [Kono et al., 2013]. 
All studies concluded that this herbal combination may provide neuroprotection however, as this is a 
Japanese combination and has been trialled in Japan, it may be difficult to transfer into other countries 
depending on their National regulatory body. Another limitation with GJG is that not all details of its 
mechanism of action have been clearly identified and for certain herbs, their effects are unknown 
[Schroder et al., 2013].  
 
All other trials with the Asian combination herbs were animal models, case studies, retrospective 
studies and limited RCT’s so the quality of evidence is very low. Without further randomised clinical 
trials that are written in English and well established, they are not recommended for use.  
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Two herbal treatments have been investigated for peripheral neuropathy that may be considered for 
use in CIPN. These include St John’s wort and capsaicin cream. St John’s Wort (Hypericum 
perforaturn) was selected to trial for PN as tricyclic antidepressant medication is used medically for 
its treatment. In a crossover DBRCT, 54 patients with or without diabetes were investigated for 
treatment with St John’s Wort (SJW) for diabetic PN. Participants were randomly assigned to either 
SJW (900mcg hypericin/tablet) or placebo for five weeks. They were then crossed over to the other 
treatment for an additional five weeks. No statistical significant was found in pain indexes however 
a trend was noted for an improved overall pain score [Sindrup et al., 2001].  
 
Capsaicin has been investigated as a topical application for diabetic [Biesbroeck et al., 1995; Chad et 
al., 1990; Low, et al., 1995; No authors listed, 1991; Tandan et al., 1992] and HIV peripheral 
neuropathy [Brown et al., 2013; Clifford et al., 2012; Simpson et al., 2103]. The majority of studies 
have been conducted on diabetes PN with most resulting in statistical significance [Biesbroeck et al., 
1995; Chad et al., 1990; Low, et al., 1995; No authors listed, 1991; Tandan et al., 1992]. The results 
indicate that capsaicin cream may provide relief for chronic, intractable pain and reduce dependence 
on opioids however the main side effect of burning at the site of application may be of concern [No 
authors listed, 1991].  It is recommended that it is not used as a monotherapy but in combination with 
oral medication to assist this condition.  
 
Clinical Relevance 
We have previously reported in a systematic review, that there was limited evidence for the 
administration of nutraceuticals in the treatment or prevention of CIPN [Schloss, et al., 2013]. 
Herewith we again report that the current scientific literature demonstrates that there is limited 
evidence for the concurrent administration of herbal remedies as adjuvants to neurotoxic agents for 
the prevention or treatment of CIPN.  The clinical studies conducted with single or combination 
herbal medicines identified in this review do not provide a clear recommendation for clinical use.  
Goshajinkigan has shown the most promise in preventing severe CIPN but maybe limited in use 
depending on national governing body guidelines.  Other herbs that may be considered after further 
research include Ginkgo biloba, curcumin and capsaicin cream.  
 
Conclusions 
Investigations into the research on herbal medicine and CIPN have not yet yielded clinical evidence 
to support the standard use of herbal medicine as a prevention or treatment of CIPN. However, data 
does suggest that herbal medicine may provide potential benefits with further research required. More 
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extensive scientific research into the mechanism of action of not only the herbal extracts but the 
neurotoxic activity of the chemotherapeutic agents may provide a key in identifying remedies that 
may help prevent or treat this side effect.  
 
Tables and Figures: 
 
1. Figure 1: Flow chart of study selection 
2. Table 1: Animal Studies with Herbal Medicines for the Prevention and or Treatment of 
CIPN  
3. Table 2: Human Clinical Studies with Herbal Medicines for the Treatment and or 
Prevention of CIPN   
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Table 1: Animal Studies with Herbal Medicines for the Prevention and or Treatment of CIPN  
Medicinal Herb Study Type Chemotherapy Agent  Results 
Single Medicinal Herbs 
Acorus calamus rhizome  Rat model (Muthuraman et al., 
2011) 
Vincristine  Improvement in neuropathic pain 
Curcumin Mouse model (Al Moundhri et al., 
2013) 
Oxaliplatin and cisplatin  Possible neuroprotection 
Gingko biloba Rat model (Cakil et al., 2012) Cisplatin  Protection of ototoxicity 
Rat model (Huang et al., 2007) Cisplatin Protection of ototoxicity 
Mice model (Ozturk et al., 2004) Cisplatin Some functional and morphological 
protection against CIPN 
Guinea pigs (Xu O, et al., 2004) Cisplatin Protection of ototoxicity 
Matricaria chamomilla 
(chamomile) 
Mouse model (Abad et al., 2011) Cisplatin  Improvement of neuropathic pain 
Salvia officinalis Mouse model (Abad et al., 2011) Vincristine  Improvement in neuropathic pain 
Sweet Bee Venom  Rat model (Lim et al., 2013) Oxaliplatin  Alleviated cold related pain 
Extract 
Verticinone (Extract from 
Fritillaria bulbus) 
Mouse and rat model (Xu F et al., 
2011) 
Paclitaxel  Decreased inflammation and neuropathic 
pain 
Receptor agonist 
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Cannabis-Receptor agonists Rat model (Rahn et al., 2008) Paclitaxel  
 
Reduced pain and sensitivity to stimuli 
Rat model (Rahn et al., 2007) Vincristine Reduced pain and sensitivity to stimuli 
Combination Herbal Studies 
Geramii herba plus Aconiti 
radix 
Rat model (Sima et al., 2009) 
 
Oxaliplatin, taxol or 
capecitabine  
Reduced neuropathic  pain and paraesthesia 
Goshajinkigan (Japan) 
 
Mice model (Bahar et al., 2013) Paclitaxel  Prevents paclitaxel-IPN without interfering 
with the anti-cancer action of paclitaxel. 
Rat model (Hashimoto et al., 
2004) 
Paclitaxel Improvement in neuropathic pain 
Rat model (Hasmimoto et al., 
2006) 
Paclitaxel Improves paclitaxel-IPN without affecting 
anti-tumour efficacy  
Rat/mouse model (Ushio et al., 
2012) 
Oxaliplatin  Improvement in neuropathic pain, no 
neuroregeneration 
Shakuyakukanzoto (Japanese) Mouse model (Hidaka et al., 
2009) 
Paclitaxel  Reduced neuropathic pain and hyperalgesia 
 
DBRCT: Double Blind Randomized Controlled Trial; SBRCT: Single Blinded Randomized Controlled Trial; RCT: Randomized Controlled Trial; 
NRCT: Non Randomised Clinical Trial; CS: Case Study; TNS: Total Neuropathy Score 
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Table 2: Human Clinical Studies with Herbal Medicines for the Treatment and or Prevention of CIPN 
  
Medicinal Herb Study Type No 
of 
Pts
26 
T27 C28 NHMRC 
Rating 
Chemotherapy 
Agent  
Results 
Single Medicinal Herbs 
Ginkgo biloba RS (Marshall et 
al., 2004) 
17 N/A
29 
N/A Level IIIb Oxaliplatin  Possible neuroprotection 
Sweet bee venom 
(pharmacopuncture) 
Case series 
(Park et al., 
2011) 
5 N/A N/A Level IV Taxol, 
carbo/taxol30  
Injecting into the acupoint decreased 
pain and neuropathy (treatment) 
Case series 
(Yoon et al., 
2012) 
11 N/A N/A Level IV Taxol, carbo/taxol  Injecting into the acupoint decreased 
pain and neuropathy (treatment) 
Combination Herbal Studies 
Bu Yang Huan Wu 
(Chinese)  
RCT (Sun et al., 
2008) 
84 44 40 Level II Oxaliplatin  Reduced development of CIPN 
Modified Bu yang 
Huan Wu (Chinese)  
RCT (Deng, et 
al, 2007) 
64 32 32 Level IIIa Different 
chemotherapies  
Reduced development of CIPN 
 
                                                 
26 Pts: Participants 
27 T: Treatment group 
C: Control group or placebo 
29 N/A: Not applicable 
30 Carbo/Taxol: Carboplatin and Paclitaxol chemotherapy combination 
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Modified Chai Hu 
Long Gu Mu Li Wan 
(Chinese) 
RCT (Pan et al., 
2012) 
48 N/A N/A Level II Paclitaxel  Possible neuroprotection 
Geramii herba plus 
Aconiti radix 
RCT 
prospective  
(Sima et al., 
2009) 
58 30 28 Level II Oxaliplatin  Reduced neuropathic pain 
Goshajinkigan (Japan) 
 
NRCT (Shindo 
et al., 2008) 
14 N/A N/A Level IIIb Oxaliplatin  Reduced acute neurotoxicity 
RS (Nishioka et 
al., 2011) 
45 22 23 Level IIIa Folfox  Possible neuroprotection 
RS (Kono et al., 
2011) 
90 11 44 Level IIIa Folfox  Possible neuroprotection, no change of 
anticancer activity 
Plus 
CaMg
31 = 21 
CaMg 
= 14 
RS (Yamamoto 
et al., 2009) 
82 N/A N/A Level IIIb Paclitaxel  Possible neuroprotection, better when 
administered early 
RCT 
prospective 
study (Kaku et 
al., 2012) 
29 Vit 
B12 + 
I = 15 
Vit 
B12 
= 14 
Level IIIa Carbo/Taxol  Less severe neurotoxicity, better in 
combined group 
DBRCT (Kono 
et al., 2013) 
89 44 45 Level II Folfox  Acceptable safety margin and indicates 
a delay in onset of grade 2 or higher 
CIPN without impairing FOLFOX 
efficacy. 
Keishikajutsubuto 
(Jananese) 
Uncontrolled 
study (Yamada 
et al., 2012) 
11 N/A N/A Level IIIb Folfox  76.6% mean improvement 
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Ogikeishigomotsuto 
(Japanese) 
Case report 
(Tatsumi et al., 
2009) 
1 N/A N/A Level IV Oxaliplatin  Reduced neuropathic pain 
Shakuyakukanzoto 
(Japanese) 
Peony and Licorice 
Decoction (English) 
Retrospective 
case analysis 
(Fujii et al., 
2004) 
23 N/A N/A Level IV Paclitaxel  
 
Reduced neuropathic pain 
RS comparison 
(Hosokawa et 
al., 2012) 
44 
 
20 
(SKK) 
24 
(GJG) 
Level IIIa Folfox  50% response in Shakuyu-kanzoto and 
65% in Goshajinkigan on prevention of 
neurotoxicity. 
 
DBRCT: Double Blind Randomized Controlled Trial; SBRCT: Single Blinded Randomized Controlled Trial; RCT: Randomized Controlled Trial; 
NRCT: Non Randomised Clinical Trial; CS: Case Study; TNS: Total Neuropathy Score; RS: Retrospective Study 
 
 
 
                                                 
31 CaMg: Calcium and magnesium infusion 
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Dear Editor,  
We are submitting this interesting case report as a letter to the editor to identify an important issue in 
supportive cancer care. 
Abstract 
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common significant and 
debilitating side effect resulting from the administration of neurotoxic chemotherapeutic agents. 
Moderate to severe CIPN can significantly decrease the quality of life and physical abilities of cancer 
patients.  Nervous system dysfunction can include sensory, sensorimotor and autonomic nervous 
system damage and a third of all patients who experience this side effect have permanent 
consequences. Currently, early termination of treatment or dose reduction of the chemotherapy agent 
is the standard treatment.  
Case Report: A clinical report on a cancer patient who underwent chemotherapy administration and 
was diagnosed with severe grade 3 CIPN is presented.  The patient was a participant in a clinical trial 
testing B vitamins for CIPN.  
Results: The patient was found to be vitamin B12 deficient after chemotherapy administration. Within 
months of oral vitamin B administration and a vitamin B12 intramuscular (IM) injection, the patient’s 
CIPN was significantly reduced to grade 1. 
Conclusion: Cancer patients who experience severe CIPN may have their chemotherapy dose reduced 
or terminated due to this side effect. Treatment may involve anti-depressants, gabapentin or 
pregabalin for CIPN pain. Differential diagnosis needs to include vitamin B12 testing involving 
holotranscobalamin (active B12) as an early marker of a vitamin B12 deficiency. Treatment with 
vitamin B12 in CIPN patients found to be low or deficient in vitamin B12 may reduce the severity of 
CIPN experienced and allow the continuation of chemotherapy treatment if required which can 
benefit patient outcomes. Quality of life may also improve in addition to physical abilities.  
 
Introduction 
Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a major concern for 
oncological practise considering the increasing number of cancer survivors and the lack of 
standardised prevention or treatment [1]. The incidence of CIPN depends on the chemotherapy agent 
administered but is estimated to occur in one third of all patients undergoing chemotherapy [2,3]. The 
prevalence of CIPN has been estimated to be 68.1% the first month after the administration of 
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neurotoxic chemotherapy agents and 60% three months post chemotherapy treatment. Patients were 
found to still have 30% prevalence six months or more after chemotherapy  according to the results 
published in a systematic review conducted in 2014 [4].  Patients experiencing moderate to severe 
CIPN report a reduced quality of life [5], chronic discomfort [6], and disruption of physical abilities 
for general life activities which can be temporary or permanent [5].  
Currently in clinical practise, CIPN is assessed using the common toxicity scales however, these rely 
heavily on the patient’s subjective reports rather than quantitative testing [7]. CIPN is a potentially 
rescindable side effect although reversibility may be dependent on early detection or identification 
and modification of chemotherapy treatment [7]. Permanent CIPN has still been reported, especially 
sensory symptoms in the lower extremities among patients treated with oxaliplatin up to 11 years 
after treatment [8]. Early differential diagnosis and prevention of permanent CIPN needs to be a 
priority for extending the quality of life of cancer patients. 
Patients with a previous history of a vitamin B12 deficiency has been identified as a predisposing 
condition that may increase the risk of developing CIPN [5]. However, patients who have had no 
previous history of a vitamin B12 deficiency may not be tested before chemotherapy commences for 
vitamin B12 status. Moreover, a potential vitamin B12 deficiency may develop during chemotherapy 
administration [9] that can therefore potentially predispose the patient to developing and/or delaying 
the development of CIPN.  
We present a clinical case of a cancer patient who developed CIPN and was found to be vitamin B12 
deficient after completing a chemotherapy regimen. Upon vitamin B12 administration, the severity 
of CIPN decreased that allowed the patient increased functional ability in daily activities including 
the ability to walk.  
 
Case Study 
A 53 year old female was enrolled in a randomised clinical trial and was randomised to the placebo 
arm. Initial B group vitamin status pathology bloods, a neurological exam involving the Total 
Neurology Score (TNS) and electro-neurological examination in addition to other history and 
questionnaires was conducted prior to the commencement of chemotherapy. The same independent 
neurologist following chemotherapy administration conducted the neurological examination and 
TNS. Blood vitamin B group pathology and questionnaires were assessed at post chemotherapy and 
at a three-month follow up visit.  This patient’s case report details and results are documented in 
Table 1.  
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The patient was overweight and generally healthy. The patient had been diagnosed with osteoarthritis 
with increased difficulty in walking, adding to this patient’s weight issue. The patient worked in an 
office and had a generally sedentary lifestyle.  
Blood Pathology Results  
The blood pathology tests for this patient before chemotherapy was in the reference range, 107 
pmol/L (ref range >35 pmol/L) presented in Table 2. After chemotherapy administration (Table 3 
documents the chemotherapy regime) the vitamin B12 status decreased and was deemed as deficient 
as presented in Table 2 and Figure 1. After supplementation with a B group vitamin complex 
(equivalent to 1,000 µg/day of vitamin B12) and receiving one intramuscular vitamin B12 injection 
(dose 1,000 µg), the blood vitamin B12 level reverted back to baseline (106 pmol/L). Other blood 
pathology conducted for B vitamin status including vitamin B1, B2, B6 and folate were found to be 
equivalent to baseline blood levels. The exception was vitamin B6, which had increased after 
supplementation with the oral B vitamin complex (95 nmol/L at baseline to 250 nmol/L reference 
range 35-110 nmol/l). Therefore as vitamin B12 was the only B vitamin found deficient after 
chemotherapy administration, changes in the patient’s neuropathy symptoms were correlated by 
administration of vitamin B12.  
Results of the Neurological Testing 
Total Neuropathy Score (TNS) used in the Clinical Trial 
The neurological test results presented in Table 4 showed that the patient’s peripheral sensory and 
motor nerve function had decreased after chemotherapy administration compared to baseline. The 
neurologist’s examination of the patient found no numbness, tingling or pain in the hands or feet at 
baseline. There was however noted interference to the electrical testing for the patient at baseline that 
occurred due to the application of copious amounts of a moisturiser just prior to testing. This 
interference with the electronic testing showed a mild impairment in motor function and interference 
with the baseline assessment of the sural nerve. The neurologist noted through assessment that despite 
the application of the moisturiser and impairment to ambulatory walking due to osteoarthritis, the 
motor nerves examined for the patient’s hands and feet were all functioning within the normal 
reference ranges.    
Following chemotherapy administration, the neurologist’s examination and electronic testing of 
sensory and motor peripheral nerves reported a notable reduction in function. The patient was 
identified as exhibiting Level 2 CIPN that confirmed numbness, tingling and neuropathic pain up to 
the ankle and the wrist of her lower and upper extremities respectively.  The pin sensibility is the test 
from the TNS that examines small nerve damage, and the patient’s score after chemotherapy 
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administration indicated that nerve damage was evident proximal to the wrist and ankle. Furthermore 
there was loss of tendon reflexes a hallmark representative of nerve damage. The sural nerve was not 
detectable by electronic testing at baseline or after chemotherapy administration.  
Following the administration of an intramuscular injection of vitamin B12 (dose 1,000 µg) with a 
concomitant oral administration of a vitamin B group complex (equivalent to 1,000 µg per day of 
vitamin B12), sensory nerve function was restored to the fingers and toes (level 1 CIPN) after 60 
days.  Motor function remained unchanged and pin sensibility still indicated nerve damage in the 
wrists and ankles. The sural nerve was positively detected. The patient’s menopause triggered severe 
hot flushes complicated the clinical neurological picture; this being indicative of autonomic nerve 
function involvement.  
Neurological Conduction Studies (NCS) 
The neurologist conducted extra nerve conduction tests in addition to the tests required for the TNS. 
These electrical tests assessed large nerve activity. The nerve conduction study (NCS) normal values 
used were ascertained from the University of Michigan Medical School [10]. The NCS conducted on 
this patient indicated that nerve damage occurred after chemotherapy administration, of which the 
data is presented in Table 5. The main areas affected post chemotherapy administration were the 
hands (palms), wrists, sural nerve and in part the peroneal nerve.  The sural nerve at baseline as 
discussed was unable to be found due to a large amount of moisturiser applied by the patient prior to 
testing. This made it difficult to ascertain if damage had occurred or if the sural activity was low 
before chemotherapy administration. Considering the fact that the activity of the sural nerve had 
improved by the last neurological test, it can be postulated that there may have been some activity 
prior to chemotherapy.  
The main nerves affected as demonstrated by the NCS tests were sensory nerves. The amplitude of 
the peroneal nerve was the only motor nerve identified as demonstrating decreased nerve function 
after chemotherapy administration. This is congruent with the symptoms displayed by the patient.  
Results of Patient Neurotoxicity Questionnaire 
Throughout the clinical trial, patients were asked to complete a patient neurotoxicity questionnaire 
(PNQ).  This is a linear scale and indicates the level of CIPN that the patient has experienced in the 
past week. The results of this patient’s PNQ were 0 out of 4 at baseline for any numbness, pain, 
burning or tingling as well as difficulties with daily activities. At the three-month follow-up visit, the 
patient registered 3 out of 4 for numbness, pain, burning or tingling in the arms and legs. Weakness 
in the arms and legs was 1 out of 4 at baseline and 3 out of 4 at the three-month follow-up visit.  
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Two months after the intervention with an IM injection of B12 and B vitamin supplement the 
numbness, pain, burning, tingling and weakness of the arms and legs was ranked 1 out of 4 by the 
patient. The inference with daily activities was ranked 0 out of 4.  
The results documented post chemotherapy administration (25th August 2012) indicated that the 
patient had difficulties with buttoning clothes, zippers, typing on a keyboard, writing, walking, 
putting on jewellery, knitting, sewing, working and dialling or using a telephone. At the six month 
follow up (17th November 2012) which is three months post administration of B12 and B group 
vitamins, all of the identified daily issues were resolved and no further difficulties were reported aside 
from some shortness of breath.  
On the 2nd October, 2012 the patient presented at the Princess Alexandra hospital breast cancer clinic 
following receipt of blood results.  The patient’s Holo TC (vitamin B12) result was reported as 29 
(ref >35 results reported on 25/9/2012) indicating a deficiency in blood vitamin B12. The patient’s 
oncologist was informed and requested administration of vitamin B12 intramuscularly (dose 1,000 
µg). The patient was also provided with 3 bottles of a vitamin B complex from the manufactures that 
supplied the active supplement for the clinical trial that the patient had been enrolled in. The patient 
was advised to take 1 capsule twice daily with food, morning and night. At the oncology appointment 
on the 2nd October, 2012 the patient reported that numbness was present up to the hips in both legs 
and from the wrists to the elbows (Grade 3 to 4 CIPN on the NCI-CTC scales as assessed by the 
oncologist). The patient was referred to a physiotherapist for the numbness (CIPN) and 
lymphoedema.  
The patient reported one week later on the 9th October, 2012 significant improvement in CIPN 
symptoms which had reduced dramatically to the feet and hands. On the 17th November, 2012 which 
was the patients six month follow up, the patient described numbness in the toes and on the tips of 
the fingers to be approximately 50%.  
Other Medical Notes 
The patient presented to the breast cancer oncology and radiation public clinic at the Princess 
Alexandra Hospital in Brisbane, Australia on 29th May, 2012. After the first administration of the 
chemotherapy regime on the 6th June, 2012 the cancer care coordinator reported the patient had 
experienced terrible joint and bone pain, severe diarrhoea and nausea. In addition, the patient had a 
rash and possible fistulas and mouth ulcers. Throughout the chemotherapy administration regimen, 
the patient reported severe joint and muscle pain; nausea and vomiting; fluid retention; CIPN; 
diarrhoea and a rash. 
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The patient had a history of hypothyroidism, which was medicated with 100 mcg of thyroxin daily as 
documented in Table 1. The patient’s thyroid function was monitored throughout the chemotherapy 
administration regimen (TSH = 5 and 4.5 mU/L).  The full blood count and serum chemistry was 
representative of a patient undergoing chemotherapy with a low white cell count (WCC) and was 
neutrophilic, which recovered after chemotherapy cessation (WCC = 1.5 to 5.4 ref range 4-11 
x10ˆ9/L, Neutrophils 0.1 to 3 ref range 2-7.5 x10ˆ9/L). The patient throughout chemotherapy regimen 
was borderline type 2 diabetic (blood glucose = 6), experienced gout (uric acid 0.39 mmol/L ref range 
0.14-0.35 mmol/L), had raised liver enzymes (GGT=75 U/L, ALT= 60 U/L, AST=56 U/L) and 
borderline calcium (2.24 ref range 2.24-2.65 mmol/L). 
Discussion 
The serum vitamin B12 as seen in Table 2 assists this case report in assessing the participant’s vitamin 
B12 status pre- and post- chemotherapy administration. The patient was found deficient in vitamin 
B12 on the 2nd October, 2012 (Holo TC 29 pmol/L) which is three months after the serum vitamin 
B12 test conducted on the 13th July, 2012 (>1476). This serum vitamin B12 blood test was taken the 
day before the patient’s third administration of chemotherapy (17th July, 2012). The raised serum 
vitamin B12 level found could be representative of liver damage. It has been found that when the 
liver is damaged, vitamin B12 is released giving a reading of high serum vitamin B12  [11-12] 
however, tissue reserves are being depleted and the patient can result in a deficiency of vitamin B12 
[11].  
The blood pathology tests for this patient showed raised liver enzymes and a raised serum vitamin 
B12 level which could represent the liver releasing stored vitamin B12. The Holo TC is the active 
vitamin B12 blood pathology assay for blood levels of vitamin B12 being released from the liver and 
transported to body tissues [9]. Holo TC blood results have also been found to be raised from liver 
damage [11] however, it has been reported that it can detect an early deficiency in vitamin B12 
compared to serum vitamin B12 levels [9].  
The patients liver results indicated possible damage as noted by raised liver enzymes so it may be 
postulated that it was releasing stored vitamin B12 resulting in a vitamin B12 deficiency three months 
post serum vitamin B12 test. This patient’s vitamin B12 deficiency was symptomatic as displayed by 
the peripheral neuropathy and fatigue. Therefore the differential diagnosis of the patient’s symptoms 
included chemotherapy and a vitamin B12 deficiency.  
According to the blood pathology tests, clinicians would normally not consider this patient’s 
presentation of CIPN as a possible vitamin B12 deficiency in addition to the neuropathy from the 
chemotherapy due to the serum vitamin B12 results from July, 2012. Had the patient not participated 
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in a clinical trial assessing B vitamin status, the vitamin B12 most likely would not have been re-
tested as the previous tests indicated a saturated state. Therefore, this raises the question of whether 
testing vitamin B12 during chemotherapy is worthwhile. Similarly, it is difficult to ascertain whether 
it gives an accurate reading of the patient’s vitamin B12 state.  
Intrinsic factor antibodies play an important role in a vitamin B12 deficiency. If a patient is 
continually found to be low or deficient in vitamin B12 after chemotherapy, then testing for intrinsic 
antibodies would be indicated. However, if a patient’s vitamin B12 level is in normal range without 
supplementation 6 to 12 months post chemotherapy, then testing for intrinsic factor or parental cell 
antibodies would not be indicated. For this patient, the serum vitamin B12 was 411 pmol/L seven 
months post chemotherapy administration, which is in the reference range. The patient stated that 
during the seven months post last neurological exam, no oral vitamin B12 supplementation was 
consumed nor had an intramuscular vitamin B12 injection been administered. Therefore, it can be 
assumed that this participant does not have intrinsic factor antibodies. The patient was given a 
pathology request form for intrinsic factor antibody test but it was not performed. 
The patient’s baseline blood test indicated a normal vitamin B12 level as measured by Holo TC assay 
107 pmol/L ref >35 pmol/L). Prior to the third cycle of chemotherapy, the patient’s serum vitamin 
B12 was reported as elevated >1476 pmol/L (162-811 pmol/L). Subsequently, the patient’s Holo TC 
assay after completion of the full chemotherapy regime indicated a deficiency in vitamin B12 (29 
pmol/L ref >35). No other B vitamin markers were found to be deficient. After two months of vitamin 
B12 administration (1,000 µg intramuscularly and 1,000 µg taken orally daily) the vitamin B12 levels 
from the Holo TC assay had risen to 106 pmol/L (ref >35 pmol/L). Seven months post last blood 
pathology test, the patients’s vitamin B12 levels was 411 pmol/L (162-811 pmol/L) without vitamin 
B12 administration indicating normal vitamin B12 absorption and metabolism and possibly no 
intrinsic factor antibodies.  
The patient’s neurological test showed no neuropathy at baseline, however displayed CIPN (Grade 2 
to 3 on NCI-CTC scales) after chemotherapy. After two months of vitamin B12 administration (1,000 
µg intramuscularly and 1,000 µg taken orally daily) the patient’s CIPN was reduced to the tips of the 
fingers and toes (Grade 1 on NCI-CTC scales). Therefore a patient experiencing a vitamin B12 
deficiency while undergoing chemotherapy may display a severe CIPN. This presentation of severe 
CIPN is normally attributed to the administration of the neurotoxic chemotherapy agent and vitamin 
B12 may not be tested. For this patient, the vitamin B12 status was tested and found to be deficient 
therefore the severe CIPN presentation was due to both the administration of the neurotoxic 
chemotherapy agent and a vitamin B12 deficiency. This diagnosis / presentation would have gone 
un-noticed without a request for vitamin B12 pathology blood test.  
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This case report indicates that chemotherapy administration may lower vitamin B12 status in certain 
patients and that this may predispose them to the development of peripheral neuropathy, possibly of 
increased severity. The development of peripheral neuropathy would then be causal due to both the 
neurotoxicity of chemotherapy administration and a concomitant vitamin B12 deficiency. The extent 
of the peripheral neuropathy from the chemotherapy agent cannot be ascertained until the patient’s 
vitamin B12 status has been recovered toward a normal range.  
The clinical relevance of this case study is of significant importance to clinicians as vitamin B12 
is not a common pathology test requested in those patients presenting with moderate to severe 
CIPN due to Vitamin B12 deficits following the administration of certain chemotherapeutic 
agents.  
A vitamin B12 deficiency is medically acknowledged as causal for peripheral neuropathy and has 
been identified as a potential risk factor for differentially diagnosing the development of CIPN [3]. 
This then questions as to how and when should a request for testing the blood level of vitamin B12 
be conducted and when to intervene with treatment for those diagnosed with a deficiency of vitamin 
B12. One of the confounding factors for cancer patients is the taste and smell of taking an oral B 
vitamin complex. For some patients, taking a prophylactic oral vitamin B complex is not an option 
during chemotherapy administration therefore intramuscular vitamin B12 injections may be the only 
option for certain patients. 
One option for clinical application may be to request vitamin B12 blood levels with every pathology 
test conducted before the administration of neurotoxic chemotherapy agents. Identifying those 
patients who are at increased risk of a vitamin B12 deficiency may lead to better patient management 
by reducing the risk of developing CIPN during chemotherapy administration with neurotoxic agents. 
The blood pathology level of serum vitamin B12 or Holo TC at which vitamin B12 treatment would 
be implemented would need to be determined. Neurological symptoms can be experienced by patients 
not undergoing chemotherapy at 200 pmol/L [11] hence the intervention range of vitamin B12 maybe 
250 pmol/L for serum vitamin B12 and 35 pmol/L for Holo TC. Therefore prevention of neurological 
side effects from a vitamin B12 deficiency would be avoided and the development of CIPN would 
only be from the neurotoxic chemotherapy agent.  
The cost analysis of conducting vitamin B12 pathology tests for each patient being administered a 
neurotoxic chemotherapy agent is prohibitive. Hence, it is proposed that a vitamin B12 pathology test 
be conducted before chemotherapy administration and when the patient presents with moderate to 
severe CIPN. Patients may be advised to take an oral B vitamin complex or vitamin B12 supplement 
prophylactically through chemotherapy administration. Alternatively, a prophylactic IM injection of 
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vitamin B12 may be administered to those patients deemed at risk of a vitamin B12 deficiency through 
chemotherapy administration.  
Conclusion 
Vitamin status, in particular vitamin B12, can play a role in the development of CIPN in certain 
patients. Patients experiencing moderate to severe CIPN should have their vitamin B12 levels 
pathologically tested and if serum vitamin B12 levels are found below 200 pmol/L or holo TC is 
below 35 pmol/L, then vitamin B12 should be administered intramuscularly and orally for the 
duration of the chemotherapy administration. Administration post chemotherapy for a period of 
approximately three months should be continued depending on the patient’s tolerance for oral 
supplementation.  
A protection from vitamin B12 may be inferred for CIPN development. Oral supplementation with a 
B vitamin complex or vitamin B12 supplement may reduce the risk of CIPN development in certain 
patients. However, some patients may not tolerate the smell of the vitamin B capsule or may have 
difficulty with ingestion of the supplement. Also the pungent smell of their urine from the B vitamin 
supplementation can be off putting for some patients and may increase their feeling of nauseousness. 
As an alternative, intramuscular administration of vitamin B12 may be more appropriate for certain 
patients.   
Monitoring of vitamin B12 levels may also be implemented so early intervention with B12 
administration can occur before the patient is found deficient. This could be through adding serum 
vitamin B12 to the blood pathology request forms for patients that will undergo chemotherapy with 
neurotoxic agents before chemotherapy cycles commence and at presentation of moderate to severe 
CIPN.  
This case report outlines the importance vitamin B12 may play in CIPN development and the clinical 
relevance for medical practitioners.  
Further clinical trials looking at vitamin B12 levels in patients with neurotoxic agents will be 
undertaken. The next study which is being designed is a clinical trial aimed at taxol agents only. One 
arm will be a control monitoring CIPN and vitamin B12 status with no intervention and the other arm 
will be administered intramuscular vitamin B12 monthly during chemotherapy and three months post-
chemotherapy. This clinical trial is aimed at gathering further information pertaining to vitamin B12 
levels during chemotherapy administration and possible prevention of CIPN. 
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Figure 1: Vitamin B12 results (Holo TC) for Case study before and after chemotherapy 
 
Table 1: Medical Details of Participant PMP 
PA 032 PMP Details 
DOB 17/06/59 
Diagnosed Breast Cancer in March, 2012 
Surgery PA Hospital 27/3/2012 – right breast lumpectomy and axillary 
clearance. 
Previous surgery:  Appendectomy, cholecystectomy, basal cell 
carcinoma on nose    (flap repair)  
Results Grade II IDC and DCIS – Oestrogen and Progesterone positive, 
HER2 negative 
Nodes positive / removed:   0/9 
Recruited for study 2/6/2012 
Race Caucasian 
Marital Status Married 
Other medical 
considerations 
Psoriasis, hypothyroidism, osteoarthritis, reactive arthritis, 
asthma (late onset), osteopenia, obesity 
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Medications Thyroxin 100 mcg daily 
Allergies Codeine, pethidine 
Diet history No history of being a vegan or vegetarian. Normally consumes 
red meat (beef, lamb, kangaroo) 3-4 times a week, chicken or 
pork 2-3 times a week and fish or seafood approximately 3-4 
times a week. She does drink caffeine, approximately 4-5 cups 
a day (tea), rarely drinks alcohol, doesn’t smoke or take 
recreational drugs. 
Height 162cm 
Weight 129kg 
BMI 49.2 
Chemotherapy regime Carboplatin and docetaxel (TC) 4 times every three weeks 
 
Table 2: Blood Pathology Results 
Blood Pathology 
from Clinical Trial 
Baseline 
5/6/2012 
After 
Chemo 
25/09/2012 
Last follow up 
8/12/2012 
Ref Range 
Vitamin B1 (TDP) 140 140 180 66-200 nmol/L 
Vitamin B2 (FAD) 280 310 230 180-470 nmol/L 
Vitamin B6 (P5P) 95 90 250 H 35-110 nmol/L 
Red cell folate 2249 2163 2170 >900 nmol/L 
Holo TC (Vitamin 
B12) 
107 29 L 106 >35 pmol/L 
Results from the PA Hospital 13/07/2012 22/06/2013 Ref Range 
Serum Vitamin B12 H >1476 411 162-811 pmol/L 
Red Cell Folate  1265 1290 545-3370 nmol/L 
Serum Ferritin H 743 H 395 15-290 ug/L 
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Table 3: Chemotherapy Regime and Administration 
Date 5/6/2012 26/6/2012 17/7/2012 7/8/2012 
Sodium chloride 100 ml IV 100 ml IV 100 ml IV 100 ml IV 
Granisetron (3mg) 3 mg IV 3 mg IV 3 mg IV 3 mg IV 
Dexamethasone 
(8mg) 
8 mg IV 8 mg IV 8 mg IV 8 mg IV 
Docetaxel (75mg/m2) 184 mg IV 184 mg IV 184 mg IV 184 mg IV 
Cyclophosphamide 
(600mg/m2) 
1480 mg IV 1480 mg IV 1480 mg IV 1480 mg IV 
Discharge Medication  
Ondansetron (oral) 8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 
days 
Dexamethasone 
(oral) 
8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 
days 
8 mg BD x 2 
days 
Metolopramide (oral) 10-20 mg 4-6 
HRLY PRN x 
5 days 
10-20 mg 4-6 
HRLY PRN x 5 
days 
10-20 mg 4-
6 HRLY 
PRN x 5 
days 
10-20 mg 4-6 
HRLY PRN x 5 
days 
Dexamethasone 
(oral) to be taken the 
day before next 
chemotherapy 
8 mg BD x 1 
day 
8 mg BD x 1 
days 
8 mg BD x 1 
days 
 
Pegfilgrastim INJ 
(6mg) subcutaneous 
 6 mg ONCE x 
1 day 
6 mg ONCE 
x 1 day 
6 mg ONCE x 1 
day 
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Table 4: Total Neuropathy Score Results  
Total Neuropathy Score (TNS) 
Item Baseline Score 
02/06/2012 
After 
Chemotherapy 
25/08/2012 
 
Three months later 
17/11/2012  
(2 months after 
beginning of B12 
supplementation) 
Sensory symptoms 0 2 1 
Motor symptoms 1 (right hand 
sweating reduced 
testing) 
2 2 
Autonomic symptoms 1 (sweating) 1 2 (menopause post 
chemo) 
Pin sensibility 0 2 2 
Vibration sensibility 0 0 0 
Strength 0 0 0 
Tendon reflexes 0 4 2 
Sural amplitude score 4 4 2 
Peroneal amplitude 
score 
0 0 0 
Total 7 15 11 
 
Table 5: NCS Study Results 
 Sensory NCS 
Nerve/Sites Rec Site Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl 
µV 
 2/6/2012 25/08/2012 17/11/2012 
R MEDIAN  
   Palm 
III 1.30 4.3 2.8 10.2 2.85 4.9 
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L MEDIAN 
   Palm 
III   2.70 12.0 3.30 5.0 
L ULNAR –  
   Wrist 
Digit V 1.95 19.5     
R ULNAR –  
     Wrist 
Dorsum of 
Hand 
1.30 26.1 1.65 1.5 1.85 3.1 
L ULNAR –  
     Wrist 
Dorsum of 
Hand 
1.65 13.2 1.70 3.6 1.65 3.9 
R SURAL –  
     Calf 
Lat Malleolus   2.65 6.7 2.35 5.1 
NB: First baseline tests were difficult due to moisturiser used by patient 
Motor NCS 
Nerve/Sites 
Rec Site 
Latency 
Ms 
Peak 
Ampl 
µV 
Latency 
Ms 
Peak 
Ampl µV 
Latency 
Ms 
Peak Ampl 
µV 
 2/6/2012 25/08/2012 17/11/2012 
L MEDIAN – APB   
    Wrist  
5.10 7.7 4.45 8.0 3.80 7.7 
    Elbow 9.45 7.8 9.05 7.3 9.35 7.8 
R COMM PERONEAL – 
EDB 
    Ankle 
4.05 2.9 3.15 3.3 4.05 2.2 
    Fib Head 9.65 4.8 10.55 0.7 10.15 2.3 
R TIBIAL (KNEE) – AH 
     Ankle 
5.05 10.4 3.55 8.3 4.65 3.7 
 
 
 
 
